<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005653" GROUP_ID="BEHAV" ID="057003071813214204" MERGED_FROM="" MODIFIED="2010-05-12 16:23:19 +0200" MODIFIED_BY="Chris Champion" REVIEW_NO="F0025" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2010-05-12 16:23:19 +0200" MODIFIED_BY="Chris Champion">
<TITLE MODIFIED_BY="[Empty name]">Pharmacological interventions for borderline personality disorder</TITLE>
<CONTACT MODIFIED="2010-05-12 16:23:19 +0200" MODIFIED_BY="Chris Champion"><PERSON ID="2FCEA65C82E26AA2000C5DBB20C47907" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Klaus</FIRST_NAME><LAST_NAME>Lieb</LAST_NAME><POSITION>Chair</POSITION><EMAIL_1>klaus.lieb@ukmainz.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>University Medical Center Mainz</ORGANISATION><ADDRESS_1>Untere Zahlbacherstr 8</ADDRESS_1><CITY>Mainz</CITY><ZIP>D-55131</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 6131 17-7335</PHONE_1><PHONE_2>+49 6131 17-7336</PHONE_2><FAX_1>+49 6131 229974</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-05-12 16:23:19 +0200" MODIFIED_BY="Chris Champion"><PERSON ID="2FE6F4A782E26AA2000C5DBB80392281" ROLE="AUTHOR"><FIRST_NAME>Jutta</FIRST_NAME><LAST_NAME>Stoffers</LAST_NAME><EMAIL_1>jutta.stoffers@uniklinik-freiburg.de</EMAIL_1><MOBILE_PHONE>+49 151 12 705 894</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy, Freiburg</DEPARTMENT><ORGANISATION>&amp; Department of Psychiatry and Psychotherapy</ORGANISATION><CITY>Mainz</CITY><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON><PERSON ID="2FDDC59482E26AA2000C5DBBC4F767BD" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Birgit</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Völlm</LAST_NAME><POSITION>Clinical Associate Profesor</POSITION><EMAIL_1>birgit.vollm@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Section of Forensic Mental Health</DEPARTMENT><ORGANISATION>Institute of Mental Health</ORGANISATION><ADDRESS_1>University of Nottingham, Duncan Macmillan House</ADDRESS_1><ADDRESS_2>Porchester Road</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG3 6AA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 9535373</PHONE_1></ADDRESS></PERSON><PERSON ID="0CFB145382E26AA2005EE6A627852244" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Gerta</FIRST_NAME><LAST_NAME>Rücker</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>ruecker@imbi.uni-freiburg.de</EMAIL_1><ADDRESS><DEPARTMENT>German Cochrane Centre</DEPARTMENT><ORGANISATION>Department of Medical Biometry and Statistics</ORGANISATION><ADDRESS_1>University Medical Center Freiburg</ADDRESS_1><ADDRESS_2>Stefan-Meier-Str. 26</ADDRESS_2><CITY>Freiburg</CITY><ZIP>79104</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 761 203 6673</PHONE_1><FAX_1>+49 761 203 6680</FAX_1></ADDRESS></PERSON><PERSON ID="C3DB143C82E26AA2014A559479172D27" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Antje</FIRST_NAME><LAST_NAME>Timmer</LAST_NAME><SUFFIX>MD, MSc.</SUFFIX><EMAIL_1>antje.timmer@helmholtz-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Epidemiology</DEPARTMENT><ORGANISATION>Helmholtz Zentrum München Research Center for Health and Environment</ORGANISATION><ADDRESS_1>Ingolstädter Landstrasse 1</ADDRESS_1><CITY>München</CITY><ZIP>85764</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 89 3187 4578</PHONE_1></ADDRESS></PERSON><PERSON ID="9E912AD582E26AA201B8424E499187D4" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nick</FIRST_NAME><LAST_NAME>Huband</LAST_NAME><POSITION>Clinical Research Fellow</POSITION><EMAIL_1>nick.huband@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Section of Forensic Mental Health</DEPARTMENT><ORGANISATION>Institute of Mental Health</ORGANISATION><ADDRESS_1>Nottinghamshire Healthcare Trust, Room B06, The Gateway Building</ADDRESS_1><ADDRESS_2>University of Nottingham, Innovation Park, Triumph Road</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)115 823 1264</PHONE_1></ADDRESS></PERSON><PERSON ID="2FCEA65C82E26AA2000C5DBB20C47907" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Klaus</FIRST_NAME><LAST_NAME>Lieb</LAST_NAME><POSITION>Chair</POSITION><EMAIL_1>klaus.lieb@ukmainz.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>University Medical Center Mainz</ORGANISATION><ADDRESS_1>Untere Zahlbacherstr 8</ADDRESS_1><CITY>Mainz</CITY><ZIP>D-55131</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 6131 17-7335</PHONE_1><PHONE_2>+49 6131 17-7336</PHONE_2><FAX_1>+49 6131 229974</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-05-12 14:44:23 +0100" MODIFIED_BY="Chris Champion">
<UP_TO_DATE>
<DATE DAY="25" MONTH="1" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="18" MONTH="9" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="18" MONTH="9" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2010-05-10 10:22:30 +0100" MODIFIED_BY="Chris Champion">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-05-10 10:22:30 +0100" MODIFIED_BY="Chris Champion">
<DATE DAY="10" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>Substantive amendment undertaken by a new author team</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-05-10 10:21:50 +0100" MODIFIED_BY="Chris Champion">
<DATE DAY="10" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>This is an update of the review of the same title published first in 2006</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="30" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Research Committee of the University Hospital Freiburg</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>German Federal Ministry of Education and Research, grant no. 01KG0609</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-05-12 12:28:35 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-05-12 09:04:46 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-01-13 17:00:36 +0000" MODIFIED_BY="[Empty name]">Drug treatment for borderline personality disorder</TITLE>
<SUMMARY_BODY MODIFIED="2010-05-12 09:04:46 +0100" MODIFIED_BY="[Empty name]">
<P>Many people with borderline personality disorder (BPD) receive medical treatment. However, there are no drugs available for BPD treatment specifically. A certain drug is most often chosen because of its known properties in the treatment of associated disorders, or BPD symptoms that are also known to be present in other conditions, such as depressive, psychotic, or anxious disorders. BPD itself is characterised by a pervasive pattern of instability in affect regulation (with symptoms such as inappropriate anger, chronic feelings of emptiness, and affective instability), impulse control (symptoms: self-mutilating or suicidal behaviour, ideation, or suicidal threats to others), interpersonal problems (symptoms: frantic efforts to avoid abandonment, patterns of unstable relationships with idealization and depreciation of others), and cognitive-perceptual problems (symptoms: identity disturbance in terms of self perception, transient paranoid thoughts or feelings of dissociation in stressful situations). This review aimed to summarise the current evidence of drug treatment effects in BPD from high-quality randomised trials.</P>
<P>Available studies tested the effects of antipsychotic, antidepressant and mood stabiliser treatment in BPD. In addition, the dietary supplement omega-3 fatty acid (commonly derived from fish) which is supposed to have mood stabilising effects was tested. Twenty-eight studies covering 1742 study participants were included.</P>
<P>The findings tended to suggest a benefit from using second-generation antipsychotics, mood stabilisers, and omega-3 fatty acids, but most effect estimates were based on single study effects so repeat studies would be useful. Moreover, the long-term use of these drugs has not been assessed. The small amount of available information for individual comparisons indicated marginal effects for first-generation antipsychotics and antidepressants.</P>
<P>The data also indicated that there may be an increase in self-harming behaviour in patients treated with olanzapine. In general, attention must be paid to adverse effects. Most trials did not provide detailed data of adverse effects and thus could not be considered within this review. We assumed their effects were similar to those experienced by patients with other conditions. Available data of the studies included here suggested adverse effects included weight gain, sedation and change of haemogram parameters with olanzapine treatment, and weight loss with topiramate. Very few beneficial effects were identified for first-generation antipsychotics and antidepressants. However, they may be helpful in the presence of comorbid problems that are not part of BPD core pathology, but can often be found in BPD patients.</P>
<P>There are only few study results per drug comparison, with small numbers of included participants. Thus, current findings of trials and this review are not robust and can easily be changed by future research endeavours. In addition, the studies may not adequately reflect several characteristics of clinical settings (among others, patients' characteristics and duration of interventions and observation periods).</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-05-12 12:28:15 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-05-12 08:44:54 +0100" MODIFIED_BY="[Empty name]">
<P>Drugs are widely used in borderline personality disorder (BPD) treatment, chosen because of properties known from other psychiatric disorders ("off-label use"), mostly targeting affective or impulsive symptom clusters.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-01-13 16:42:08 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of drug treatment in BPD patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-05-12 08:50:05 +0100" MODIFIED_BY="[Empty name]">
<P>We searched bibliographic databases according to the Cochrane Developmental, Psychosocial and Learning Problems Group strategy up to September 2009, reference lists of articles, and contacted researchers in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-05-12 08:45:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised studies comparing drug versus placebo, or drug versus drug(s) in BPD patients. Outcomes included total BPD severity, distinct BPD symptom facets according to DSM-IV criteria, associated psychopathology not specific to BPD, attrition and adverse effects.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-05-12 08:45:39 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors selected trials, assessed quality and extracted data, independently. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-05-12 12:28:15 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-eight trials involving a total of 1742 trial participants were included. First-generation antipsychotics (flupenthixol decanoate, haloperidol, thiothixene); second-generation antipsychotics (aripirazole, olanzapine, ziprasidone), mood stabilisers (carbamazepine, valproate semisodium, lamotrigine, topiramate), antidepressants (amitriptyline, fluoxetine, fluvoxamine, phenelzine sulfate, mianserin), and dietary supplementation (omega-3 fatty acid) were tested. First-generation antipsychotics were subject to older trials, whereas recent studies focussed on second-generation antipsychotics and mood stabilisers. Data were sparse for individual comparisons, indicating marginal effects for first-generation antipsychotics and antidepressants. </P>
<P>The findings were suggestive in supporting the use of second-generation antipsychotics, mood stabilisers, and omega-3 fatty acids, but require replication, since most effect estimates were based on single studies. The long-term use of these drugs has not been assessed.</P>
<P>Adverse event data were scarce, except for olanzapine. There was a possible increase in self-harming behaviour, significant weight gain, sedation and changes in haemogram parameters with olanzapine. A significant decrease in body weight was observed with topiramate treatment. All drugs were well tolerated in terms of attrition.</P>
<P>Direct drug comparisons comprised two first-generation antipsychotics (loxapine versus chlorpromazine), first-generation antipsychotic against antidepressant (haloperidol versus amitriptyline; haloperidol versus phenelzine sulfate), and second-generation antipsychotic against antidepressant (olanzapine versus fluoxetine). Data indicated better outcomes for phenelzine sulfate but no significant differences in the other comparisons, except olanzapine which showed more weight gain and sedation than fluoxetine. The only trial testing single versus combined drug treatment (olanzapine versus olanzapine plus fluoxetine; fluoxetine versus fluoxetine plus olanzapine) yielded no significant differences in outcomes.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-05-12 09:00:32 +0100" MODIFIED_BY="[Empty name]">
<P>The available evidence indicates some beneficial effects with second-generation antipsychotics, mood stabilisers, and dietary supplementation by omega-3 fatty acids. However, these are mostly based on single study effect estimates. Antidepressants are not widely supported for BPD treatment, but may be helpful in the presence of comorbid conditions. Total BPD severity was not significantly influenced by any drug. No promising results are available for the core BPD symptoms of chronic feelings of emptiness, identity disturbance and abandonment. Conclusions have to be drawn carefully in the light of several limitations of the RCT evidence that constrain applicability to everyday clinical settings (among others, patients' characteristics and duration of interventions and observation periods).</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-05-12 12:28:35 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-05-12 09:39:57 +0100" MODIFIED_BY="[Empty name]">
<P>The disorder is a condition first recognised in the 19th century. The term 'Borderline Personality Disorder' (BPD) was coined by A. Stern describing a condition in the "borderland" between psychosis and neurosis (<LINK REF="REF-Stern-1938" TYPE="REFERENCE">Stern 1938</LINK>). Subsequent psychoanalytic contributions (especially that of <LINK REF="REF-Kernberg-1975" TYPE="REFERENCE">Kernberg 1975</LINK>) have reaffirmed this distinction emphasising that the capacity to test reality remains grossly intact but is subject to subtle distortions, especially under stress.</P>
<P>According to current diagnostic criteria, BPD is characterised by a pervasive pattern of instability in affect regulation, impulse control, interpersonal relationships, and self-image. Clinical hallmarks include emotional dysregulation, impulsive aggression, repeated self-injury, and chronic suicidal tendencies (<LINK REF="REF-Lieb-2004" TYPE="REFERENCE">Lieb 2004</LINK>). Whereas some authors have suggested that it is a variant of affective disorders (<LINK REF="REF-Akiskal-2004" TYPE="REFERENCE">Akiskal 2004</LINK>), others claim only partially overlapping etiologies (<LINK REF="REF-Paris-2007" TYPE="REFERENCE">Paris 2007</LINK>). Despite the difficulties in defining the condition, borderline personality disorder is the focus of great interest. Its importance stems from the huge suffering of the persons concerned, functional impairment (<LINK REF="REF-Skodol-2002" TYPE="REFERENCE">Skodol 2002</LINK>), and from the significant impact it has on mental health services (<LINK REF="REF-Zanarini-2004a" TYPE="REFERENCE">Zanarini 2004a</LINK>).</P>
<P>The definition of BPD in the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV, also DMS-IV-TR; <LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>; <LINK REF="REF-APA-2000a" TYPE="REFERENCE">APA 2000a</LINK>) comprises nine criteria that cover the above features, with a definite diagnosis requiring that five criteria are met, and probable diagnosis requiring four. The competing International Classification of Diseases in its 10th edition (ICD-10) refers to the condition of Emotionally Unstable Personality Disorder (F60.3) of which there is an impulsive type (F60.30) and a borderline type (F60.31) (<LINK REF="REF-WHO-1993" TYPE="REFERENCE">WHO 1993</LINK>). The latter essentially overlaps with the DSM-IV definition. A significant problem with this type of polythetic definition is that it is possible for two people to satisfy the criteria and yet have very different personalities. This heterogeneity is a major problem in assessing the impact of an intervention. In addition to the specific BPD criteria, DSM-IV and ICD-10 provide general diagnostic criteria for personality disorders that also must be met.</P>
<P>The prevalence of BPD is estimated to be about 1.5% in the general population (most recent data: <LINK REF="REF-Lenzenweger-2007" TYPE="REFERENCE">Lenzenweger 2007</LINK>; for a survey of epidemiologic studies see <LINK REF="REF-Torgersen-2005" TYPE="REFERENCE">Torgersen 2005</LINK>), but higher (up to 20%) among psychiatry inpatients, and predominantly diagnosed in women (75%; <LINK REF="REF-APA-2000a" TYPE="REFERENCE">APA 2000a</LINK>). There are particular problems in its diagnosis in adolescents and young adults where existential dilemmas may be mistakenly classified as BPD (DSM-IV). BPD commonly co-occurs with mood disorders, substance misuse, eating disorders, post-traumatic stress disorder (PTSD) and is also associated with other personality disorders (<LINK REF="REF-McGlashan-2000" TYPE="REFERENCE">McGlashan 2000</LINK>). Suicidal behaviour is reported to occur in up to 84% of patients with BPD (<LINK REF="REF-Soloff-2002" TYPE="REFERENCE">Soloff 2002</LINK>), comorbid mood disorders or substance use being the most relevant risk factors for completion (<LINK REF="REF-Black-2004" TYPE="REFERENCE">Black 2004</LINK>).</P>
<P>Although the short to medium-term outcome of BPD is poor - similar to that of schizophrenia - there is some evidence that long term follow-up shows a more favourable course, with remission rates of about 88% within ten years (<LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). However, remission here only means that diagnostic criteria are not fulfilled and doesn't indicate the absence of any symptoms. Indeed, whereas acute symptoms such as self-mutilation, help-seeking suicide threats or attempts and impulsivity in most cases decrease with time, affective symptoms reflecting areas of chronic dysphoria, such as chronic feelings of emptiness, intense anger or profound abandonment largely remain (<LINK REF="REF-Zanarini-2007" TYPE="REFERENCE">Zanarini 2007</LINK>). Therefore, the majority of people with BPD still have significant levels of symptoms. Risk factors for a poorer long term outcome are comorbid substance use disorders, PTSD, and anxious cluster disorders (<LINK REF="REF-Zanarini-2005" TYPE="REFERENCE">Zanarini 2005</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>), and also a family history of psychiatric disorder (especially mood disorders and substance use disorders), demographic issues, such as older age, longer treatment history, pathological childhood experiences, temperament issues, and adult psychosocial functioning (<LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). It is estimated that about 60% to 78% of BPD patients make suicide attempts (<LINK REF="REF-Links-2009" TYPE="REFERENCE">Links 2009</LINK>), but the rate of completed suicides is far less. Zanarini and colleagues found suicide rates of 4% during follow-up of ten years (<LINK REF="REF-Zanarini-2007" TYPE="REFERENCE">Zanarini 2007</LINK>), whereas <LINK REF="REF-Stone-1993" TYPE="REFERENCE">Stone 1993</LINK> reported a suicide rate of 8.5% after 16.5 years. Study estimates of the lifetime risk of suicide among patients with BPD range from 3% to 10% (<LINK REF="REF-Links-2009" TYPE="REFERENCE">Links 2009</LINK>).</P>
<P>The direct costs of BPD are considerable in that many people so affected make major demands on health professionals. The problem of deliberate self-harm is a particular issue in this group (<LINK REF="REF-Linehan-1997" TYPE="REFERENCE">Linehan 1997</LINK>). In medical settings, people with BPD often present after self-harming behaviour or in suicidal crisis and are treated in emergency settings, often involving repeated psychiatric hospitalizations. Additionally, more than 80% of BPD patients are in individual psychotherapy for at least half of a six year period, and the same number is taking standing medication (<LINK REF="REF-Zanarini-2004a" TYPE="REFERENCE">Zanarini 2004a</LINK>). Treatment settings and provisions for BPD patients may vary across different countries. Nevertheless, pharmacological interventions are increasingly being used to treat different facets of the BPD pathology spectrum, such as affective instability, impulsivity, dissociative states, or cognitive-perceptual symptoms. Associated pathology, such as depression, can likewise be the target of psychopharmacological interventions. Therefore, different classes of agents are used in the treatment of BPD patients, such as mood stabilisers, antipsychotics, or antidepressants (<LINK REF="REF-Lieb-2004" TYPE="REFERENCE">Lieb 2004</LINK>).</P>
<P>In summary, BPD is a condition that has been extensively studied. It has a major impact on health facilities as those affected often present in crisis. Its long-term course leads to improvement but people continue to have considerable problems. The polythetic nature of the diagnosis is likely to lead to heterogeneity making it difficult to assess treatment efficacy.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the effects of pharmacological interventions in BPD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-05-12 09:52:35 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-05-12 09:48:12 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-05-12 09:43:21 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised comparisons testing pharmacological interventions in BPD were included. Likewise, data from randomised cross-over studies up to the point of first cross-over (first period only) were eligible. We excluded outcomes of following periods since carry-over effects of the preceding treatments were likely. Furthermore, since BPD characteristically has no stable course but comprises rapid mood shifts, it seemed inappropriate for subjects to serve as their own controls (i.e. within-subject comparisons). Thus, we decided to use first period data only (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>).</P>
<P>At least 70% of study participants had to have a formal diagnosis of BPD. Studies including BPD patients as a subsample were included as well, if separate data on these patients were available. Studies were eligible if they stated both provider and recipient blinding. The adequacy of relevant arrangements was judged subsequently.
<BR/>

</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-05-12 09:47:34 +0100" MODIFIED_BY="[Empty name]">
<P>Adult patients with a formal diagnosis of BPD according to DSM criteria (see table below).<B> </B>Since its introduction in 1980, the criteria have only changed marginally.<B> </B>
</P>
<TABLE COLS="2" ROWS="12">
<TR>
<TD>
<P>
<B>DSM-III (</B>
<LINK REF="REF-APA-1980" TYPE="REFERENCE">APA 1980</LINK>
<B>)</B>
</P>
<P>
<B>301.83 Borderline Personality Disorder</B>
</P>
</TD>
<TD>
<P>
<B>DSM-IV-TR (</B>
<LINK REF="REF-APA-2000a" TYPE="REFERENCE">APA 2000a</LINK>
<B>)</B>
</P>
<P>
<B>301.83 Borderline Personality Disorder</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>
<I>Diagnostic criterion A (5 of the following are required)</I>
</B>
</P>
</TD>
<TD>
<P>
<B>
<I>Diagnostic criterion A: A pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts, as indicated by five (or more) of the following:</I>
</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>(6) intolerance of being alone, e.g., frantic efforts to avoid being alone, depressed when alone</P>
</TD>
<TD>
<P>(1) frantic efforts to avoid real or imagined abandonment - note: do not include suicidal or self-mutilating behavior covered in criterion 5</P>
</TD>
</TR>
<TR>
<TD>
<P>(2) a pattern of unstable and intense interpersonal relationships, e.g., marked shifts of attitude, idealization, devaluation, manipulation (consistently using others for one's own ends)</P>
</TD>
<TD>
<P>(2) a pattern of unstable and intense interpersonal relationships characterized by alternating between extremes of idealization and devaluation</P>
</TD>
</TR>
<TR>
<TD>
<P>(4) identity disturbance manifested by uncertainty about several issues relating to identity, such as self-image, gender identity, long-term goals or career choice, friendship patters, values, and loyalties, e.g., 'Who am I', 'I feel like I am my sister when I am good'</P>
</TD>
<TD>
<P>(3) identity disturbance: markedly and persistently unstable self-image or sense of self </P>
</TD>
</TR>
<TR>
<TD>
<P>(1) impulsivity or unpredictability in at least two areas that are potentially self-damaging, e.g., spending, sex, substance use, shoplifting, overeating, physically self-damaging acts</P>
</TD>
<TD>
<P>(4) impulsivity in at least two areas that are potentially self-damaging (e.g., spending, sex, substance abuse, reckless driving, binge eating) - note: do not include suicidal or self-mutilating behavior covered in criterion 5</P>
</TD>
</TR>
<TR>
<TD>
<P>(7) physically self-damaging acts, e.g., suicidal gestures, self-mutilation, recurrent accidents or physical fights</P>
</TD>
<TD>
<P>(5) recurrent suicidal behavior, gestures, or threats, or self-mutilating behavior </P>
</TD>
</TR>
<TR>
<TD>
<P>(5) affective instability: marked shifts from normal mood to depression, irritability, or anxiety, usually lasting a few hours and only rarely more than a few days, with a return to normal mood</P>
</TD>
<TD>
<P>(6) affective instability due to a marked reactivity of mood (e.g., intense episodic dysphoria, instability, or anxiety usually lasting a few hours and only rarely more than a few days)</P>
</TD>
</TR>
<TR>
<TD>
<P>(8) chronic feelings of emptiness or boredom</P>
</TD>
<TD>
<P>(7) chronic feelings of emptiness</P>
</TD>
</TR>
<TR>
<TD>
<P>(3) inappropriate, intense anger or lack of control of anger, e.g., frequent displays of temper, constant anger</P>
</TD>
<TD>
<P>(8) inappropriate, intense anger or difficulty controlling anger (e.g., frequent displays of temper, constant anger, recurrent physical fights)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>(9) transient, stress-related paranoid ideation or severe dissociate symptoms</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>
<I>Diagnostic criterion B: If under 18, does not meet the criteria for Identity Disorder</I>
</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<P/>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-05-12 09:47:43 +0100" MODIFIED_BY="[Empty name]">
<P>Any drug or a defined combination of drugs administered on a long-term basis (i.e. not only in case of crisis only) with the intention to treat BPD pathology.</P>
<P>Comparison treatments were classified in four categories:</P>
<UL>
<LI>placebo;</LI>
<LI>active comparator drug;</LI>
<LI>combination of drugs;</LI>
<LI>combined treatment, i.e. drug plus concomitant psychotherapeutic treatment or counselling.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-05-12 09:48:12 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes could either be self-rated by patients or interviewer-assessed. Only adequately validated measures were included. Studies were only included if they provided data that could be used for effect size calculation for at least one of the primary or secondary outcomes defined below.</P>
<P>If a trial provided more than one measure for the same outcome construct (e.g. several questionnaires for the assessment of depression) the one most often used in the whole pool of included studies was used for effect size calculation, in order to minimise heterogeneity of outcomes in form and content. If a study reported the data of two assessment instruments that were equally frequently used, two reviewers (JS, BV) discussed the issue and chose the one which was in its content most appropriate for assessing BPD patients. Self-rated measures were preferred.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-05-12 09:48:05 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Overall BPD severity.</LI>
<LI>Severity of single BPD criteria according to DSM (avoidance of abandonment, dysfunctional interpersonal patterns, identity disturbance, impulsivity, suicidal ideation, suicidal behaviour, self-mutilating behaviour, affective instability, feelings of emptiness, anger, psychotic paranoid symptoms, dissociative symptoms).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-05-12 09:48:12 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Depression.</LI>
<LI>Anxiety.</LI>
<LI>General psychiatric pathology: comprehensive measures.</LI>
<LI>Mental health status.</LI>
<LI>Attrition.</LI>
<LI>Adverse effects.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-05-12 09:48:30 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-05-12 09:48:27 +0100" MODIFIED_BY="[Empty name]">
<P>A qualified librarian searched the following electronic databases:<BR/>
</P>
<UL>
<LI>CENTRAL (<I>The Cochrane Library</I>, 2009, issue 3);</LI>
<LI>MEDLINE (January 1966 to 11 September 2009);</LI>
<LI>CINAHL (1982 to September 2009);</LI>
<LI>EMBASE (1980 to 37th week 2009);</LI>
<LI>BIOSIS (1985 to 16 September 2009);</LI>
<LI>PsycINFO (1872 to 2nd week September 2009);</LI>
<LI>Sociological Abstracts (1963 to September 2009);</LI>
<LI>ASSIA (1987 to June 2008);</LI>
<LI>WEB OF SCIENCE (1981 to 12 September 2009);</LI>
<LI>SIGLE (1980 to April 2006);</LI>
<LI>COPAC (September 2009);</LI>
<LI>Dissertation Abstracts (September 2009);</LI>
<LI>ASSIA (1987 to September 2009).</LI>
</UL>
<P>For detailed search strategies and periods searched, see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> to <LINK REF="APP-13" TYPE="APPENDIX">Appendix 13</LINK>.</P>
<P>The following trial registers were searched via the WHO International Clinical Trials Registry Platform (ICTRP), using "borderline personality disorder" as search term:</P>
<UL>
<LI>ISRCTN (International Standard Randomised Controlled Trial Number);</LI>
<LI>ClinicalTrials.gov;</LI>
<LI>ACTR (Australian Clinical Trials Registry).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-05-12 09:48:30 +0100" MODIFIED_BY="[Empty name]">
<P>Relevant journals such as the Journal of Personality Disorders, the American Journal of Psychiatry, the Archives of General Psychiatry, the British Journal of Psychiatry and the Journal of Clinical Psychiatry were surveyed on a regular basis. Additionally, researchers in the field were contacted by e-mail and asked for unpublished data. Cross-references from relevant literature were also traced.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-05-12 09:52:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-05-12 09:48:33 +0100" MODIFIED_BY="[Empty name]">
<P>On the basis of publication abstracts, a first estimation of study eligibility was made. After that, the studies were critically appraised by two reviewers (JS, BV), independently, in order to decide about inclusion or exclusion of studies according to the above mentioned criteria. The RefMan bibliography management software was used in order to keep track of appraised trials and decisions. If the reviewers' judgements did not match, a third person (KL) was called upon to finally discuss inclusion or exclusion. To ensure transparency of study selection, flow charts were provided according to the QUOROM statement, showing how many hits had been excluded for a certain reason (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-05-12 09:48:45 +0100" MODIFIED_BY="[Empty name]">
<P>Data were independently extracted by two reviewers (JS, BV). For this purpose, standardized data extraction forms were used, and data were double entered into the Review Manager software. If discrepancies arose that were not due to oversights, they were again resolved by discussion and adjudication by a third person (KL). In case of incomplete data reporting in publications, or where relevant subsample data were lacking, we contacted the study authors for more information.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-05-12 09:48:57 +0100" MODIFIED_BY="[Empty name]">
<P>Again, two reviewers (JS, BV) independently rated the included trials in terms of their risk of bias. A standardized rating form was used in order to judge the probability of different risks of bias. Using The Cochrane Collaboration's tool for assessing risk of bias, the following questions were judged: Was the allocation sequence adequately generated? Was allocation adequately concealed? Was knowledge of the allocated intervention adequately prevented during the study (this question was judged separately for observer- and self-rated outcomes)? Were incomplete outcome data adequately addressed? Are reports of the study free of suggestion of selective outcome reporting? Was the study apparently free of other problems that could put it at a high risk of bias? Relevant text passages were quoted and, if necessary, commented upon. After that, the overall risk of bias was rated either as low (question answered 'Yes') or high (question answered 'No'). If insufficient detail was reported, or sufficient detail was known but the actual risk of bias was unknown, the judgement was 'Unclear'. Both reviewers (JS, BV) tried to reach a concerted estimation taking into account the information available. In case of disagreement, a third person (KL) was called in again.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-05-12 09:50:28 +0100" MODIFIED_BY="[Empty name]">
<P>Standardized mean differences (SMDs) were calculated on the basis of post-treatment results and follow-up data, respectively. Follow-up data were to be subsumed in 6 month steps. In case the direction of a scale was opposite to most of the other scales, the corresponding mean values were multiplied by -1 to ensure adjusted values.</P>
<P>For some trials, effect sizes could not be calculated as intended, i.e. as SMDs as described above, because relevant information was lacking. However, we decided to include these data by calculating alternative estimates, and discussed the peculiar risk of over- or underestimating the effects.</P>
<P>The following effect sizes were used alternatively:</P>
<UL>
<LI>Pre-standardized mean differences (MDs): The effects were calculated by using the post-treatment means as intended, but the standard deviations (SDs) of pre-treatment means. This may have led to an overestimation of effect sizes, as the pre-SDs are commonly smaller than post-SDs. This kind of effect size had to be used for the <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK> outcome data.</LI>
<LI>Standardised mean changes: The effects were calculated by using the pre-post mean change scores and their SDs. This is also a common method for preparing standardized effect sizes, but these data cannot be pooled with the common SMDs due to statistical assumptions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). Standardized mean changes were calculated for <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK> (partly) and <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK> (partly).</LI>
<LI>Mean change differences: For some outcomes of <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK> and <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>, data allowed only for the calculation of the differences in mean baseline changes experienced by the two groups. Its standard errors (SE) were derived from the pair-wise P-values of the ANCOVA, as provided in the study reports. This is, therefore, a non-standardized measure reflecting the mere difference in reduction of assessment instrument scores. Both studies used the same assessment instrument.</LI>
</UL>
<P>Effect sizes were preferably calculated on the basis of intention-to-treat (ITT) data. If means and standard deviations from intention-to-treat analysis with missing values replaced were available, we used these data. In other cases we used analysis based on available data.<B> </B>Regarding dichotomous outcomes, the risk ratio (RR) was computed on an intention-to-treat basis. We acted on the conservative assumption that all participants who were lost to post-treatment assessment had an unfavourable outcome, e.g. they had left because the treatment had not been acceptable for them. We specified in the Characteristics of included studies risk of bias tables if continuous data of a certain study referred to the intention-to-treat or per-protocol sample.</P>
<P>All calculations were done using the latest release of the Review Manager software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-05-12 09:51:20 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>We planned to included data from randomised cross-over studies up to the point of first cross-over (first period only). We decided not to consider outcomes of following periods due to the likelihood of carry-over effects of the preceding treatment(s).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Repeated observations</HEADING>
<P>We did not plan to combine repeated observations on participants in one meta-analysis. Data from different points of measurement (i.e. post-treatment, catamnestic data of 6-months-steps) were subject to separate analyses. Interim observations were not used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Studies with multiple treatment groups</HEADING>
<P>If a trial compared more than two intervention groups, all pair-wise comparisons were included as long as they were not subject to the same meta-analysis. If, for example, two different doses of a certain drug were tested against placebo, only the one comparison of placebo to the group with the dosage most similar to either recommended dosage standards or (if available) other trials testing this comparison was included. Thus, we avoided including the same group of participants twice in the same meta-analysis. If the experimental groups received different treatments with regard to contents, such as different drugs or combinations of drugs, and were not subject to the same meta-analysis, we included all comparisons.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-05-12 09:51:24 +0100" MODIFIED_BY="[Empty name]">
<P>Where there was incomplete reporting of outcomes stated as having been assessed, we contacted the study authors. If data were not reported in an immediately usable way but required processing before being analysed, a statistician (GR) was consulted. Results derived from processed data were reported in sensitivity analyses.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-05-12 09:52:16 +0100" MODIFIED_BY="[Empty name]">
<P>Both visual inspection of the graphs and the I<SUP>2</SUP> statistics (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>) were used to investigate statistical heterogeneity within a certain comparison. Besides the I<SUP>2 </SUP>statistic, the number of studies and study characteristics such as duration, dose, and participants were taken into account to judge if heterogeneity was more probable due to clinical, i.e. explainable factors, or to unknown factors. In case of substantial heterogeneity, we made up subgroups, depending on study characteristics such as study size, duration, dose, or participants, and discussed the most apparent sources of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-11-07 12:11:31 +0000" MODIFIED_BY="[Empty name]">
<P>Funnel plots were to be provided for comparisons with sufficient primary studies. However, the poor numbers of study effects per comparison did not allow for constructing interpretable figures.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-05-12 09:52:19 +0100" MODIFIED_BY="[Empty name]">
<P>If data pooling seemed feasible, the primary studies effects were pooled and their 95% confidence interval (CI) was calculated. A random-effects model was used, as some degree of clinical heterogeneity was present in most cases, though confined by study inclusion criteria and not regarded as preventing from pooling in principle.</P>
<P>As a basic rule, I<SUP>2</SUP> scores of up to 75% were regarded as indicating possibly substantial, but accountable degrees of heterogeneity permitting statistical pooling. In case of I<SUP>2</SUP> scores exceeding 75%, we discussed if diversity of specific study characteristics (dose, duration, participants, outcome assessment, size) was likely to cause heterogeneity and tried to investigate this by setting up subgroups, the number of effect estimates permitting. If heterogeneity could not be explained, the estimates were not pooled.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-05-12 09:52:35 +0100" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses for the primary outcomes were planned to be performed as follows:</P>
<UL>
<LI>trials requiring patients to have a certain psychiatric comorbidity in addition to BPD were to be excluded;</LI>
<LI>only ITT data based outcomes were to be included.</LI>
</UL>
<P>Given the small numbers of effect estimates per comparison and outcome, we did not conduct sensitivity analyses, as this would only have led to omitting results. Instead, we strived to make all potential shortcomings of methodological quality explicit (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables and the "Risk of bias in included studies" section of the <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>) and to critically discuss all findings.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-05-12 12:28:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-05-12 09:57:37 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-05-12 09:52:44 +0100" MODIFIED_BY="[Empty name]">
<P>The study searches were re-run several times for updates. Due to overlaps in time periods covered and the use of sensitive search strategies (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> to <LINK REF="APP-13" TYPE="APPENDIX">Appendix 13</LINK>), a large number of references was retrieved during preparation of this review. Study searches generated 13,972 references, 3723 of which were identified as duplicates. After screening of titles and abstracts of the remaining 10,249 hits, 489 citations merited closer inspection, and the full texts were ordered and scrutinized by two reviewers (JS, BV). Of these, 425 citations were excluded because they did not meet the inclusion criteria. Seven references referred to currently ongoing trials (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>). A total of 57 different citations were included, relating to 28 RCTs.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-05-12 09:57:37 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Setting of studies/study sample</HEADING>
<P>Included studies were published between the years 1979 and 2009, with 20 of the 28 included trials dating from 2000 or later. The studies were conducted in either the USA (14 studies; <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>) or in Western European countries (12 studies; 5 in Germany and/or Austria (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>), two each in the UK (<LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>) and Spain (<LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>), and one each in Belgium (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>), Ireland (<LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>) and the Netherlands (<LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>)). There were two international multicentre trials: The <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK> trial was carried out in 39 study centres located in the USA and Western European countries. The RCT by <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK> took place in 13 study centres in the USA, South America, and Eastern Europe.</P>
<P>Study samples ranged from N = 16 (<LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>) to N = 314 (<LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>) in size. In the <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK> trial, even more patients had been involved altogether but there were three treatment groups, only two of which could be included in this meta-analysis, leaving 301 patients (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. In total, the included studies provided data from 1742 patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Characteristics of participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Demographic data</HEADING>
<P>Most studies were not restricted to any gender, but nine studies included female patients only (<LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>). The study of Nickel and colleagues reported the study data of a female (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>) and a male sample (<LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>) in separate publications. Patients were at least 18 years of age with the exception of two studies (<LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>) where participants had to be at least 16 years old. The mean participants' age ranged from 21.7 (<LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>) to 38.6 (<LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>) years, with 14 of the 28 studies having a mean age below 30 years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment settings</HEADING>
<P>Study participants were mostly outpatients. The participants of only one trial were inpatients (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>), while in two others participants were initially treated as inpatients for a minimum of two and three weeks, respectively (<LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>), but could continue as outpatients afterwards.<BR/>Five trials dating from before 1990 diagnosed the participants according to DSM-III (<LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK> <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK> <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>), three studies used DSM-III-R criteria (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>
<LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>). Diagnoses of all 20 remaining studies were based on DSM-IV or DSM-IV-TR.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Psychiatric comorbidity</HEADING>
<P>Most study samples were clearly defined as BPD patients with a formal diagnosis of BPD as the main inclusion criterion<B> </B>(<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>).<B> </B>However, there were a few exceptions: The <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK> study required patients to have a diagnosis of BPD and/or schizotypal personality disorder (PD). Of the 50 patients included, 17 were diagnosed as having BPD, 13 as having schizotypal PD, and 20 as satisfying both sets of criteria. Hence, 74% of the study sample were BPD patients. The <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK> and <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK> studies included patients admitted to a general hospital after a suicidal act, who had a history of two or more previous documented suicidal acts. BPD patients constituted 76.6% and 78.9%, respectively, of all included participants of the two studies. Similarly, all patients of the <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK> trial were recruited from the accident and emergency department, where they had presented acutely with self-harm. Additionally, all had to to have a lifetime history of at least one other episode. Of all participants, 71% were diagnosed as having BPD. Only one trial required patients to satisfy another diagnosis besides BPD: All patients of the <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK> study additionally had a bipolar II disorder.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Exclusion criteria</HEADING>
<P>Exclusion criteria varied between studies. Commonly, patients particularly prone to pharmacotoxic effects (i.e. pregnant or breastfeeding women, persons with known allergic reactions or intolerances) were excluded, as were patients with severe somatic illnesses, or neurological disorders (especially seizure disorders). Organic brain syndrome or mental retardation were also listed as exclusions by most studies.<BR/>The most common exclusion criteria relating to psychiatric conditions were schizophrenia, bipolar disorders, major depressive disorder and substance related disorders. Patients with any comorbid Axis-I disorder were excluded in two studies (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>), as were patients with any unstable Axis-I disorder in another trial (<LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>).<BR/>In the remaining 25 trials, patients suffering from schizophrenia were excluded in 15 trials (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>). Another nine trials specified that even the lifetime diagnosis of schizophrenia was an exclusion criterion (<LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). Eight studies also excluded patients with current (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>) or lifetime schizoaffective disorder (<LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>).<BR/>Patients with the diagnosis of any bipolar disorder were excluded in 20 of all 28 included trials. However, <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK> and <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK> did not exclude bipolar patients. Additionally, all patients of the <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK> study sample had a bipolar II disorder as an inclusion criterion (here, patients with bipolar I disorder were excluded). In the <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK> trial, bipolar patients could be included if they were in a stable condition.<BR/>Patients with current major depressive disorder were not allowed in the majority of trials (besides the <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK> and <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK> trials that excluded any Axis-I disorder, and <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK> that excluded any unstable Axis-I disorder): <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). The <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK> trial excluded patients with melancholia, and <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK> excluded patients currently suffering from major depressive disorder with psychotic features.<BR/>Another frequent exclusion criterion was substance related disorder. Besides the two aforementioned trials that did not include patients with any Axis-I disorder (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>), and the one trial that excluded patients with any unstable Axis-I condition (<LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>), there were ten trials (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>) that did not include patients who currently satisfied criteria for alcohol or drug dependence. Another eight trials did not even include patients abusing alcohol or drugs at the time of recruitment (<LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). Therefore, only seven of the 28 trials did not state any substance related disorder as hindering patients from entering the trial (<LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>).<BR/>Current suicidality was an explicit exclusion criterion in 13 trials (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). Eleven trials did not explicitly specify suicidality as an exclusion criterion (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>). However, all patients of the <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK> and <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK> trials were recruited following admittance to hospital due to a suicidal act, so these patients can be assumed to have been acutely suicidal when entering the trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Severity of illness at baseline</HEADING>
<P>The study participants' baseline severity of illness varied between studies. Seven studies used the Global Assessment scale (GAS; <LINK REF="REF-Endicott-1976" TYPE="REFERENCE">Endicott 1976</LINK>) to assess individuals' level of functioning, and seven used the Global Assessment of Functioning scale (GAF; <LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>). Both are 100-point single item rating scales used to rate functioning; on a hypothetical continuum from intact mental health to mental illness. The scale values range from 1, which represents the hypothetically most impaired individual, to 100, the hypothetically healthiest individual (<LINK REF="REF-APA-2000b" TYPE="REFERENCE">APA 2000b</LINK>). The GAS and GAF scores ranged from 42.2 to 72.4 and were, therefore, typical for psychiatric outpatients (<LINK REF="REF-APA-2000b" TYPE="REFERENCE">APA 2000b</LINK>). The average functioning in one study (<LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>) was located at the lower end of the interval range or 71 to 80 ("slight impairment in functioning"), while the average level of functioning of the <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK> study participants was rated between 61 and 70 ("some mild symptoms"). The participants of most studies (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>) were located in the interval range from 51 to 60, defined as "having moderate symptoms or generally functioning with some difficulty". The samples of four other studies (<LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>) had a lower level of functioning and were rated between 41 and 50, i.e. as having "any serious symptomatology or impairment in functioning that most clinicians would think obviously requires treatment or attention".</P>
<P>The Clinical Global Impressions Severity of Illness Scale (CGI-S; <LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) was used in two trials to estimate participants' severity of illness. This scale covers seven items from 1 "not ill at all" to 7 "among the most extremely ill". Here, the average ratings ranged from 4.2 to 5.14. The average CGI-S ratings of <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK> (4.3) was closest to item 4, "moderately ill", while the participants of the <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK> trial were rated with an average of 5.14, which fits best with item 5, "markedly ill". A similar estimation was found by <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>, who used the Clinical Global Impressions Borderline Peronsality Disorder (CGI-BPD) scale specifically referring to the rating of BPD severity (<LINK REF="REF-Perez-2007" TYPE="REFERENCE">Perez 2007</LINK>). These patients had an average CGI-BPD severity of illness of 4.8.</P>
<P>
<LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK> provided data specifically concerning BPD severity of illness. On average, the participants met 6.95 (SD = 1.3) DSM BPD criteria. Additionally, the BPDSI (Borderline Personality Disorder Severity Index; <LINK REF="REF-Arntz-2003" TYPE="REFERENCE">Arntz 2003</LINK>) was used to assess BPD severity. The BPDSI is a fully structured interview measuring the frequency of occurrence of all DSM-IV BPD criteria during the last three months. Each of the nine DSM criteria is operationalized as a subscale, and the sum of all subscales constitutes the BPDSI-total, with a possible range of 0 (no occurrence) to 90 (most severe). A BPDSI total score above 15 signifies BPD pathology (<LINK REF="REF-Arntz-2003" TYPE="REFERENCE">Arntz 2003</LINK>). For inclusion, a BPDSI total score of 20 was required, and the average baseline mean of all participants was 32.9 (SD = 7.7), indicating moderate severity.</P>
<P>For the samples of the <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK> and <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK> trials, the t-transformed baseline SCL-90-R global severity index scores (SCL-90-R-GSI) were reported. The SCL-90-R scale is a measure of the status of psychopathology along nine symptom constructs: somatization, obsessive-compulsive symptoms, interpersonal sensitivity, depression, anxiety, hostility, phobic-anxiety, paranoid ideation, and psychoticism. The GSI is essentially a mean of all scores. With t-transformed baseline GSI scores above 70 (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>: mean GSI at baseline 72.25; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>: mean GSI at baseline: 74.7), the participants of these trials can be considered as having "high to very high mental stress" (<LINK REF="REF-Franke-2002" TYPE="REFERENCE">Franke 2002</LINK>). For the participants of the <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK> trial it is reported that the 'mean scores for all psychometric instruments [i.e. concerning depression, impulsivity, perceived stress] were well in excess of published normative data'.</P>
<P>Concerning the trials of <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; and <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>, there were no psychometric data available relating to the overall severity of illness, psychopathologic burden or impairment. All samples were described as "moderately ill", and treatment histories were given (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>: 10.3% had previously been hospitalized for psychiatric reasons, 58.6% had a history of psychotherapeutic treatment, and 69.0% had received pharmacotherapeutic treatment previously; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>: 7.1% had previously been hospitalized for psychiatric reasons, 23.8% had been in psychotherapeutic treatment, and 57.1% had received pharmacotherapeutic treatment; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>: 18.5% had previously been hospitalized for psychiatric reasons, 44.4% had been in psychotherapeutic treatment, and 71.1% had received pharmacotherapeutic treatment; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>: 14.3% had previously been hospitalized for psychiatric reasons, 82.1% had been in psychotherapeutic treatment, and 64.3% had received pharmacotherapeutic treatment). Treatment use may depend on availability and health care system specifics, though. However, all three trials excluded patients with bipolar disorders, substance-related disorders, schizophrenia, and especially acutely suicidal patients.</P>
<P>No psychometric data concerning the patients' severity of illness were available concerning the <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK> and <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK> studies. However, all participants were included after admission to hospital following a suicidal act, and had a history of at least two more documented suicidal acts. Therefore, the severity of illness can be considered very serious.</P>
<P>Concerning the <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK> trial sample, the only information available was that participants had to meet four or more of the diagnostic BPD characteristics described by Gunderson and Kolb, and two of these had to be rated as severe, two as at least moderate. Therefore, patients with rather lower levels of pathology may have been included.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Comparisons</HEADING>
<P>Older studies focused mainly on first-generational antipsychotics and antidepressants. Since the mid 1990s, second-generation antipsychotics, mood stabilisers, and selective serotonin reuptake inhibitor (SSRI) antidepressants have gained more attention.</P>
<P>The majority of studies involved two comparison groups. However, there were some studies with three comparison groups: <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK> tested two active groups, i.e. haloperidol and amitriptyline, against placebo, and <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK> tested haloperidol and phenelzine sulfate against placebo. <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK> compared two active drugs in three different combinations, i.e. fluoxetine alone versus olanzapine alone versus fluoxetine plus olanzapine. Therefore, each of the three comparison groups was involved twice within this review. The different testings belonged to different comparison categories, and were therefore not pooled.</P>
<P>Additionally, <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK> also compared three conditions, i.e. olanzapine in two different dosages, to placebo. Since the comparison of each of the two olanzapine groups to placebo would have belonged to the same comparison category, and would have led to pooling dependent data, we decided to include only one of the two olanzapine groups. Therefore, we chose the one olanzapine group with the dosage most closely matching the remaining olanzapine versus placebo comparisons.</P>
<P>In total, included studies comprised the following comparisons.</P>
<SUBSECTION>
<HEADING LEVEL="6">Active drug versus placebo</HEADING>
<OL>
<LI>First-generation antipsychotics: thiothixene (<LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>), flupenthixol decanoate (<LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>), haloperidol (<LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>).</LI>
<LI>Second-generation antipsychotics: aripiprazole (<LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>), olanzapine (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>;<B> </B>
<LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>;<B> </B>
<LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>), ziprasidone (<LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>).</LI>
<LI>Mood stabilisers: carbamazepine (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>), valproate semisodium (<LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>), lamotrigine (<LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>), topiramate (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>).</LI>
<LI>Antidepressants: amitriptyline (<LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>), fluoxetine (<LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>), fluvoxamine (<LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>), phenelzine sulfate (<LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>), mianserin (<LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>).</LI>
<LI>Miscellaneous: omega-3 fatty acids (<LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Active drug versus active comparator drug</HEADING>
<OL>
<LI>First-generation antipsychotic versus first-generation antipsychotic: loxapine versus chlorpromazine (<LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>).</LI>
<LI>First-generation antipsychotic versus antidepressant: haloperidol versus amitriptyline (<LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>), haloperidol versus phenelzine sulfate (<LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>).</LI>
<LI>Second-generation antipsychotic versus antidepressant: olanzapine versus fluoxetine (<LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Active drug versus combination of drugs</HEADING>
<OL>
<LI>Second-generation antipsychotic versus second-generation antipsychotic plus antidepressant: olanzapine versus olanzapine plus fluoxetine (<LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>).</LI>
<LI>Antidepressant versus antidepressant plus second-generation antipsychotic: fluoxetine versus fluoxetine plus olanzapine (<LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>).</LI>
</OL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Study duration</HEADING>
<P>The intervention times ranged from 32 days to 24 weeks, with a mean duration of 84.0 days (SD = 43.6), i.e. approximately 12 weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Concomitant medication</HEADING>
<P>In 13 of the 28 studies, patients were not taking any concomitant psychotropic medication (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>). Four studies did not specify whether psychotropic medication was allowed or not (<LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>). Two trials gave no details on permissible drug treatment, but there was a washout period for tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) in one (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>) and a one week placebo run-in, probably without any other psychotropic treatment, in the other (<LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>). Some studies specified permissible drugs that could be taken in order to manage adverse effects, or to address certain symptoms that were not addressed by the study drugs. Mostly, these were drugs with sedative or anxiolytic effects.</P>
<P>In the <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK> study, nighttime sedatives (flurazepam and chloral hydrate) could be taken. In the case of insomnia, participants of the <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK> study were allowed to take 50 to 100 mg/day of Trazodone. In cases of extrapyramidal reactions, participants of the <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK> study could take 2 mg/day of biperiden hydrochloride. Patients of both the <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK> and <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK> studies could continue treatment with benzodiazepines, antidepressants or mood stabilisers, if initiated prior to study inclusion, but doses could not be modified. Participants of the <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK> study were allowed to take one antidepressant but had to have been on a stable dose for at least one month. Patients of the <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK> and the <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK> trials were allowed to take benzodiazepines and hypnotics.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Concomitant psychotherapeutic treatment</HEADING>
<P>Concerning the permission of concomitant psychotherapy, six studies gave no details at all on this (<LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>;<B> </B>
<LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>;<B> </B>
<LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>;<B> </B>
<LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>;<B> </B>
<LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>;<B> </B>
<LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>). In eight trials, psychotherapeutic treatment was an exclusion criterion (<LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>). Although not cited as a reason for exclusion in two trials, no participants of the <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK> and <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK> studies received psychotherapy at the time. In two further studies, very few patients received concomitant psychotherapy (<LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>: two out of 22; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>: 10 out of 415). The <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK> trial allowed patients to continue psychotherapeutic treatment if initiated more than three months prior to randomization, but there was no specification as to how many subjects actually did. Four trials provided supportive non-specific psychotherapeutic treatment to all their participants (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>: "supportive atheoretical psychotherapy"; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK> and <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>: follow-up with support from social workers, community nurses and a crisis intervention team after admission due to a suicidal act; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>: weekly two hour, non-specific group psychotherapy). There were three trials (<LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>) in which all participants received specific psychotherapeutic treatment, i.e. Dialectic Behavioural Therapy. All patients of the <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK> and <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK> studies started as inpatients for three and two weeks, respectively, but it was not specified whether they received psychotherapeutic treatment during this time and thereafter.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome measures</HEADING>
<P>As a rule, higher scores indicate more severe pathology. There are only two exceptions: GAF and GAS scores (mental health status assessments) are oppositely directed, i.e. higher scores indicate higher or better levels of functioning.</P>
<P>Some trials reported several measures relating to the same outcome, as defined for this review (e.g. for depression there were both Beck Depression Inventory (BDI) and Hamilton Depression Scale (HAM-D) scores available). To avoid an unnecessary inflation of type-I error, only one relevant result out of each study was used for effect size calculation. BPD-specific assessment instruments were first choice for primary outcome assessment. If none was available, the measure most often used in the whole pool of included studies was chosen for effect size calculation, in order to minimise the heterogeneity of outcomes in form and content. If there was no difference in the frequency of use, we chose the measure that we thought was in its contents most adequately reflecting the particular outcome in BPD patients. Self-rated measures were also preferred.</P>
<P>Concerning adverse events, objective data were preferred (i.e. weight increase in kg was used instead of the ratio of patients with perceived weight gain). The ratios of patients experiencing a certain adverse event in each group were only statistically compared if the event occurred more than once in at least one of the two groups. <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> (FGAs versus placebo), <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> and <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> (SGAs versus placebo), <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>; and <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK> (mood stabilisers versus placebos), <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK> and <LINK REF="TBL-09" TYPE="TABLE">Table 9</LINK> (antidepressants versus placebo), <LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK> (miscellaneous active agents versus placebo); <LINK REF="TBL-11" TYPE="TABLE">Table 11</LINK> (FGAs versus FGAs); <LINK REF="TBL-12" TYPE="TABLE">Table 12</LINK> (FGAs versus antidepressants); <LINK REF="TBL-13" TYPE="TABLE">Table 13</LINK> (SGAs versus antidepressants); <LINK REF="TBL-14" TYPE="TABLE">Table 14</LINK> (SGAs versus SGA+antidepressant) and <LINK REF="TBL-15" TYPE="TABLE">Table 15</LINK> (antidepressants versus antidepressant+SGA) specify the measures the effect sizes were calculated from for each comparison category. If there were several measures available for the same outcome, the reasons for choosing a particular one were<I> </I>indicated.   </P>
<P>In the following, a survey of the assessment instruments finally used in the review is given. Measures used in the included studies to assess outcomes that were not relevant to this review are not considered, as are data that were of relevance but could not be used for effect size calculation due to the format of reporting.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(1) BPD severity</HEADING>
<P>(a) Borderline Syndrome Index (BSI): <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>.<BR/>(b) Clinical Global Impression (CGI) scale for use in borderline personality disorder patients (CGI-BPD), global: <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>.<BR/>(c) Schedule of Interviewing Schizotypal Personalities (SIB), subscale "borderline score": <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>.</P>
<P>(d) Zanarini Rating Scale for borderline personality disorder (Zan-BPD) total score: <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(2) Avoidance of abandonment</HEADING>
<P>(a) CGI-BPD, subscale "abandonment": <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>.<BR/>(b) ZAN-BPD, subscale "frantic efforts to avoid abandonment": <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(3) Interpersonal problems</HEADING>
<P>(a) Atypical Depression Inventory, subscale "rejection sensitivity": <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>.<BR/>(b) CGI-BPD, subscale "unstable relationships": <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>.<BR/>(c) Hopkins Symptom Checklist (HSCL), Symptom Checklist-90 (SCL-90) or Symptom Checklist-90-Revised (SCL-90-R), subscale "interpersonal sensitivity": <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>.<BR/>(d) ZAN-BPD, subscale "unstable interpersonal relationships": <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(4) Identity disturbance</HEADING>
<P>(a) CGI-BPD, subscale "identity disturbance": <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>.<BR/>(b) ZAN-BPD, subscale "identity disturbance": <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(5) Impulsivity</HEADING>
<P>(a) Acting out-Scale, ratio of patients with status quo or worsened after treatment: <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>.<BR/>(b) Barrett Impulsiveness Scale (BIS): <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>.<BR/>(c) Behavioural reports of numbers of episodes of impulsivity/aggressive behaviour: <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>.<BR/>(d) Borderline Personality Disorder Severity Index (BPDSI), subscale "impulsivity": <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>.<BR/>(e) CGI-BPD, subscale "impulsivity": <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>.<BR/>(f) Modified Overt Aggression Scale (MOAS), total score: <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>.<BR/>(g) Overt Aggression Scale-Modified (OAS-M), subscale "aggression": <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>.<BR/>(h) Stait-Trait Anger Expression Inventory (STAXI), subscale "anger out": <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK> and <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>.<BR/>(i) ZAN-BPD, subscale "impulsivity that are self-damaging": <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(6) Suicidal behaviour/suicidal ideation</HEADING>
<P>(a) Behavioural reports of numbers of episodes of self-injuring behaviour/suicide attempts: <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>.</P>
<P>(b) CGI-BPD, subscale "recurrent suicidal ideation": <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>.</P>
<P>(c) OAS-M, subscale "suicidality": <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>.</P>
<P>(d) OAS-M, subscale "suicidality": number of patients with high suicidality, i.e. frequent suicide ideation and/or planning or behaviour: <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>.</P>
<P>(e) Ratio of patients with suicidal act during treatment: <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>.</P>
<P>(f) ZAN-BPD, subscale "suicidal or self-mutilating behaviour": <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(7) Self-injurious behaviour</HEADING>
<P>(a) Ratio of patients with self-injury during treatment period: <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>.<BR/>(b) OAS-M, subscale "auto aggression": <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(8) Affective instability</HEADING>
<P>(a) BPDSI, subscale "rapid mood shifts": <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>.<BR/>(b) CGI-BPD, subscale "affective instability": <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>.<BR/>(c) ZAN-BPD, subscale "affective instability": <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(9) Chronic feelings of emptiness</HEADING>
<P>(a) CGI-BPD, subscale "chronic feelings of emptiness": <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>.<BR/>(b) ZAN-BPD, subscale "chronic feelings of emptiness": <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(10) Inappropriate anger</HEADING>
<P>(a) BPDSI, subscale "anger": <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>.<BR/>(b) CGI-BPD, subscale "inappropriate anger": <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>.<BR/>(c) HSCL, SCL-90 or SCL-90-R, subscale "hostility": <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>.<BR/>(d) OAS-M, subscale "irritability": <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>.<BR/>(e) Profile of Mood States (POMS), subscale "anger": <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>.<BR/>(f) STAXI, subscale "trait anger": <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK> and <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>.<BR/>(g) ZAN-BPD, subscale "intense anger": <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(11) Psychotic/paranoid symptoms or dissociation</HEADING>
<P>(a) CGI-BPD, subscale "transient paranoia or dissociation": <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>.<BR/>(b) Dissociative Experiences Scale (DES): <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>.<BR/>(c) HSCL, SCL-90 or SCL-90-R, subscale "paranoid ideation": <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>.</P>
<P>(d) SIB, subscale "suspicious/paranoid": <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>.<BR/>(e) ZAN-BPD, subscale "paranoid ideation of dissociation": <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">(1) Depression</HEADING>
<P>(a) BDI: <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>.<BR/>(b) HAM-D: <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>.<BR/>(c) HSCL, SCL-90 or SCL-90-R, subscale "depression": <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>.<BR/>(d) Montgomery-Asberg Depression Rating Scale (MADRS): <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(2) Anxiety</HEADING>
<P>(a) Hamilton Anxiety Rating Scale (HARS): <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>.<BR/>(b) HSCL, SCL-90 or SCL-90-R, subscale "anxiety": <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(c) State-Trait Anxiety Inventory (STAI), trait score: <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(3) General psychiatric pathology</HEADING>
<P>(a) HSCL, SCL-90 or SCL-90-R, Global Severity Index (GSI): <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(4) Mental health status</HEADING>
<P>(a) Clinical Global Impressions Scale (CGI), subscale "severity of illness": <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>.<BR/>(b) Global Assessment Scale (GAS): <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>.<BR/>(c) Global Assessment of Functioning (GAF): <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(d) Ratio of patients with Clinical Global Impressions Scale - improvement (CGI-I) score of 3 or more (i.e. minimally improved to very much worse): <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(5) Attrition</HEADING>
<P>(a) Ratio of patients lost after randomisation in each group: <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(6) Adverse events - body weight change</HEADING>
<P>(a) Total weight at endpoint (kg): <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>.<BR/>(b) Baseline to endpoint weight change (kg): <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(c) Atypical Depression Inventory (ADS), subscale "weight gain": <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(7) Patient-reported adverse events (AE)</HEADING>
<P>(a) Any AE: <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
<P>(b) Akathisia: <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>.<BR/>(c) Anxiety: <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>.<BR/>(d) Constipation: <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>.<BR/>(e) Disturbed attention: <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(f) Dizziness: <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>.<BR/>(g) Dry mouth: <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(h) Fainting spells: <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>.<BR/>(i) Fatigue: <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(j) Headache: <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(k) Increased appetite: <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(l) Insomnia: <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(m) Memory problems: <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>.<BR/>(n) Menstrual pain: <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>.<BR/>(o) Muscle spasms: <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>.</P>
<P>(p) Nausea: <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
<P>(q) Paraesthesia: <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>.
<BR/>
(r) Restlessness: <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>.
<BR/>
(s) Sedation: <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>.</P>
<P>(t) Sleepiness/drowsiness: <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>.<BR/>(u) Somnolence: <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(v) Trouble in concentrating: <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">(8) Laboratory values</HEADING>
<P>(a) Lipids: High-density lipoprotein (HDL) cholesterol baseline to endpoint mean change (mmol/L): <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(b) Lipids: Low-densitiy lipoprotein (LDL) cholesterol baseline to endpoint mean change (mmol/L): <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>.<BR/>(c) Lipids: total cholesterol baseline to endpoint mean change (mmol/L): <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(d) Lipids: triglycerides, fasting, baseline to endpoint mean change (mmol/L): <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(e) Liver function: gamma-glutamyl transferase (GGT) baseline to endpoint mean change Units per litre (U/L): <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(f) Liver function: Alanine transaminase (ALT)/serum glutamic pyruvic transaminase (SGPT) baseline to endpoint mean change (U/L): <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(g) Liver function: Aspartate transaminase (AST)/serum glutamic oxaloacetic transaminase (SGOT) baseline to endpoint mean change (U/L): <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(h) Liver function: total bilirubin baseline to endpoint mean change (&#956;mol/L): <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>.<BR/>(i) Liver function: direct bilirubin baseline to endpoint mean change (&#956;mol/L): <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>.<BR/>(j) Prolactin: baseline to endpoint mean change (&#956;g/L): <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(k) Blood values: leukocyte count baseline to endpoint mean change (GI/L): <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(l) Blood values: monocytes baseline to endpoint mean change (GI/L): <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(m) Blood values: neutrophils, segmented, baseline to endpoint mean change (GI/L): <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.<BR/>(n) Blood values: platelet count baseline to endpoint mean change (GI/L): <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-05-12 09:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>The assessment of the risk of bias caused several problems, mainly because about one third of trials dated from before publication of the CONSORT statement, and may, therefore, have paid less attention to reporting all relevant issues. However, we tried to be consistent in judging methodological quality throughout all included trials, old or not, which may have resulted in a more 'liberal' judgment.</P>
<P>The judgments for each single study can be found in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables, and are summarised in <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK> and <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>.</P>
<ALLOCATION MODIFIED="2010-05-12 09:59:46 +0100" MODIFIED_BY="[Empty name]">
<P>All included trials stated treatment allocation as "randomised". Some trials (<LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>) reported the use of a randomised number sequence. Participants of the <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK> trial were randomised "blocked on the presence of a diagnosis of major depressive disorder or post-traumatic stress disorder (PTSD)", which seems justifiable in the light of an overall small sample size. In the <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK> trial, allocation was carried out "in blocks of four generated using the SPSS software". The <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK> and <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK> trials were both carried out in parallel multicentre studies by sponsorship of EliLilly and Company. The publications only make mention of the use of a randomisation code. However, as one of the reviewers (KL) had been involved at one of the study centres, we know that randomisation was carried out centrally, and investigators were strictly kept blinded to the patients' allocation. These trials were rated 'Yes' with regard to adequacy of sequence generation.</P>
<P>
<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK> and <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK> specified that randomisation had been performed confidentially by the clinic administration, but there were no further details of how this was actually done. <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK> stated that "subjects [...] were selected randomly", but in the light of the identical numbers of men and women in the two groups, the use of some matching procedure seems probable. All remaining trials were only described as having used a randomisation procedure, without giving further details. Thus, it remains unclear if sequence generation was adequate or not.</P>
<P>The actual concealment of allocation was judged adequate for twelve trials where relevant details were given, such as involvement of a third, independent person to disperse medication or to adjust dosages (especially in case of agents with very peculiar adverse effects that could disclose treatment allocation to the clinician) or the use of numbered tablet boxes (<LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). In the <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK> trial, the actual numbers of participants in each group were not concordant with the intended group sizes (45 participants should be allocated "in equal numbers" to three groups, but the group sizes differed in an irreproducible way). <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK> stated that "although the planned patient assignment ratio was 2:1 [...], the ratio was actually 3:1". Here, allocation seems not to have been conducted adequately. For the remaining 14 trials, no information was given how adequate allocation concealment was ensured, but there were also no indications for inadequate concealment (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-05-12 09:59:53 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Self-rated outcomes</HEADING>
<P>All trials were stated as "double-blind" by their authors. In cases where details were given to assure that patients were kept blind, e.g. by using opaque capsules, blinding was judged as adequate. The majority of trials either did so, or there was no risk of bias since there were no self-rated outcomes assessed (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). The remaining nine trials gave no details, but there were also no indications for non-blindness of participants (e.g. by possibly experiencing very peculiar adverse effects, or by joining the same therapy groups as other participants; <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of outcome assessors</HEADING>
<P>The majority of trials reported that outcome observers were blinded or did not use observer-rated outcomes, so the risk of bias was rated as improbable in this regard (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). For the remaining trials, it was not apparent if the person who actually assessed outcomes was blinded, and the risk of bias was judged unclear (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>).</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-05-11 14:14:19 +0100" MODIFIED_BY="[Empty name]">
<P>Incomplete outcome data were rated as adequately handled for the trials of <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>. In these cases, only data referring to the intention-to-treat (ITT) sample were used. Mostly, a last-observation-carried-forward (LOCF) approach was used in primary studies. This item was also judged 'Yes' if the primary study reported on completers only but drop-outs could be imputed ex post as having the negative outcome for the purpose of this review.</P>
<P>The risk of bias due to inadequate handling of incomplete outcome data was judged 'unclear' for studies that used a LOCF approach but had a total drop-out of more than 20% of the initial sample (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). Two trials used a LOCF approach, but it was not clear how the trial participants were chosen out of eligible subjects<B> </B>(<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>).<B> </B>For another three trials it was not clear if continuous data referred to the ITT or completer samples (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>). The risk of bias due to incomplete outcome data was therefore judged 'unclear'. The item was also judged 'unclear' for studies that reported on completers only, but the overall drop-out rate did not exceed 10%, and reasons for dropping out were specified, not related to treatments and balanced across groups. This was the case for<B> </B>
<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>
<B>. </B>
</P>
<P>One trial that both had high drop-out rates (i.e. more than 10%) and excluded non-completers from analyses were judged 'No', i.e. as having a high risk of bias due to incomplete outcome data (<LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>). Two trials with very high attrition rates (i.e. more than 50%) plus unclear selection of study participants out of eligible patients were judged 'No' as well (<LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-05-11 14:14:56 +0100" MODIFIED_BY="[Empty name]">
<P>For the majority of cases no study protocols were available, so there was not enough information to judge if selective reporting was present or not. These trials were rated as 'Unclear' in terms of being biased due to selective reporting (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>). Four studies that protocols were available for with no major differences of final reporting to the pre-specified way were judged 'Yes', i.e. as having a low risk of bias with this regard (<LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>;<B> </B>
<LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>;<B> </B>
<LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>;<B> </B>
<LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). In one case reported outcomes and the study protocol differed (<LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>), for another study the authors said they only reported significant findings (<LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>), and a third one provided data from one assessment instrument only, but it seems implausible that in such a complex trial only one assessment instrument had been used (<LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>). These three trials were rated 'No'.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-05-11 14:53:12 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Carry-over effects from previous pharmacological treatment</HEADING>
<P>To avoid carry-over effects from additional psychotropic medication, concomitant psychotropic treatment was not allowed during the experimental treatment, and, in the main part, a washout-phase or placebo run-in preceded the experimental phase. Internal validity was judged as not threatened by concomitant medication for the trials of <LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>.</P>
<P>The risk of bias due to co-medication was judged unclear for 10 studies because of the following reasons: no details were given whether concomitant psychotropic drug use was allowed or not, or if there was a drug washout (<LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>); participants were allowed to continue previous psychotropic treatment if initiated prior to study participation (<LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>); participants were allowed to take sedatives/hypnotics concomitantly<B> </B>(<LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>). For the case of <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>, bias seemed to be probable, as concomitant medication was allowed without restrictions, and changes could also be made anytime.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bias due to sponsoring</HEADING>
<P>Two studies (<LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>) declared financial support solely from national non-profit organisations. Another study (<LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>) claimed that there was no funding at all. <LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK> explicitly declared that the active preparation and placebo were provided by a certain company, but that it was not otherwise involved in the study. These four trials were rated as having a low risk of bias due to sponsoring.</P>
<P>For six studies (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>) the authors declared support by pharmaceutical companies, seven studies were supported in part by pharmaceutical companies (<LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>; <LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>). Another two studies were sponsored by a pharmaceutical company, and the company's trial reports were used in this review (<LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). These 15 studies were rated 'No' in terms of bias to sponsoring being unlikely.</P>
<P>No sufficient information about funding and sponsoring was available for the remaining nine studies (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>; <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>; <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>). These were rated 'unclear'.</P>
<P>In summary, 14 out of 28 included trials were at least partly supported by pharmaceutical companies, with no further specification of the companies' roles in conducting and evaluating. For these, bias due to sponsoring cannot be ruled out.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-05-12 12:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>Generally, SMDs with a negative value indicate a greater reduction of pathology by the first treatment in line (mostly: verum treatment) in contrast to the alternate treatment (mostly: placebo). Should the opposite be the case, i.e. positive values favour the first mentioned treatment, this will be indicated.<BR/>Risk ratios (RRs) with a value lower than one indicate that the risk of a certain event in the first treatment (mostly: active agent) group is lower than that in the comparison treatment (mostly: placebo) group.</P>
<P>For a survey of all outcomes and assessment instruments, see the <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>/Outcome measures section. In addition, tables are provided showing per comparison which assessment instruments were used for assessment of the results that the final effect estimates are based upon, and in case several measures were available for a certain outcome, why the definite one was chosen (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> to <LINK REF="TBL-10" TYPE="TABLE">Table 10</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Drug versus placebo comparisons</HEADING>
<P>For corresponding analyses of drug versus placebo comparisons, refer to <LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK> to <LINK REF="CMP-065.01" TYPE="ANALYSIS">Analysis 65.1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 BPD severity</HEADING>
<P>There were two single study estimates for first-generation antipsychotics, one comparing haloperidol to placebo, the other one thiothixene. Both indicated less favourable results for the groups receiving first-generation antipsychotics (haloperidol: N = 58, 1 RCT, SMD 0.30, 95% confidence interval (CI) -0.22 to 0.82; thiothixene: N = 50, 1 RCT, SMD calculated on basis of post-means and pre-SD 0.28, 95% CI -0.28 to 0.83).</P>
<P>Two large RCTs assessed the impact of olanzapine treatment on BPD severity. The pooled SMDs, based on change scores, indicated olanzapine treated patients to be slightly better-off, but not significantly (N = 596, 2 RCTs, SMD calculated on basis of changes scores -0.15, 95% CI -0.41 to 0.10, I<SUP>2</SUP> = 60%). For ziprasidone, data also indicated better results for verum treated patients, but the effect was not significant (N = 60, 1 RCT, SMD -0.47, 95% CI -0.98 to 0.05).</P>
<P>Data for mood stabiliser treatment were provided by one RCT (N = 27) that tested lamotrigine. There was a non-significant effect estimate of moderate size (SMD calculated on basis of change scores -0.43, 95% CI -1.20 to 0.34).</P>
<P>For treatment with antidepressants, only one RCT provided data for BPD severity. Here, the group with phenelzine sulfate treatment had slightly better results, but the difference was, again, not significant (N = 62, 1 RCT, SMD -0.15, 95% CI -0.65 to 0.35).</P>
<P>In summary, none of the investigated agents (i.e. first- and second-generation antipsychotics, one MAOI antidepressant) yielded a significant effect on overall BPD severity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Avoidance of abandonment</HEADING>
<P>Data were available for second-generation antipsychotics only. There was almost no difference between ziprasidone and placebo treated patients (N = 60, 1 RCT, SMD -0.08, 95% CI -0.58 to 0.43) and neither did data indicate a substantial impact for olanzapine treatment (N = 631, 3 RCTs, SMD calculated on basis of change scores -0.01, 95% CI -0.22 to 0.21, I<SUP>2</SUP> = 35%).</P>
<P>In summary, the data did not suggest substantial effects of second-generation antipsychotics for this outcome. The outcome was not assessed for any other agent.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3 Interpersonal problems</HEADING>
<P>First- and second-generation antipsychotics, mood stabilisers and antidepressants were investigated with regard to possible amelioration of interpersonal problems (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for SMDs, and <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> to <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK> for additional effect sizes).</P>
<P>As can be seen, most estimates favoured drug treatment, with exception of phenelzine sulfate, for which less favourable results were reported. Significant effects were found for the second-generation antipsychotic aripiprazole (SMD -0.77, N = 52, 1 RCT, 95% CI -1.33 to -0.20) and the mood stabilisers valproate semisodium (SMD -1.04, N = 30, 1 RCT, 95% CI -1.85 to -0.23) and topiramate (SMD -0.91, N = 56, 1 RCT, 95% CI -1.46 to -0.35). All significant effects were derived from one single study each.</P>
<P>In summary, there were significant effects of medium to large size for aripiprazole, valproate semisodium, and topiramate, but all were based on single studies only.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4 Identity disturbance</HEADING>
<P>The pooled mean change SD for olanzapine was -0.06 (N = 631, 3 RCTs, 95% CI -0.21 to 0.10, I<SUP>2</SUP> = 0%). The single study estimate (SMD) for ziprasidone was -0.38 (N = 60, 1 RCT, 95% CI -0.90 to 0.13).</P>
<P>In summary, data for this outcome were only available for the second-generation antipsychotics olanzapine and ziprasidone, with no significant results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5 Impulsivity</HEADING>
<P>Impulsivity had been assessed in trials investigating first- and second-generation antipsychotics, mood stabilisers, antidepressants, and omega-3 fatty acids. SMDs are displayed in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, additional effect sizes were calculated for olanzapine and carbamazepine (see <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK> to <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</P>
<P>Again, most findings were based on single study estimates. Large, significant effects were found for the second-generation antipsychotic aripiprazole (N = 52, 1 RCT, SMD -1.84, 95% CI -2.49 to -1.18), and the mood stabilisers lamotrigine (two RCTs the estimates of which could not be pooled: N = 27, 1 RCT, SMD -1.62, 95% CI -2.54 to -0.69; N = 27, 1 RCT, SMD on basis of baseline to post mean changes -1.41, 95% CI -2.27 to -0.55) and topiramate (N = 71, 2 RCTs, SMD -3.36, 95% CI -4.44 to -2.27, I<SUP>2</SUP> = 51%). Available data indicated no beneficial effects for the first-generation antipsychotic haloperidol, the second-generation antipsychotics olanzapine and ziprasidone, the mood stabiliser valproate semisodium, the antidepressants amitriptyline, fluoxetine, fluvoxamine, and phenelzine sulfate, or omega-3 fatty acids.</P>
<P>In summary, data consistently indicated significant beneficial effects for mood stabilisers, and the second-generation antipsychotic aripiprazole. The direction of study estimates indicates no beneficial effects for first-generation antipsychotics and antidepressants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6 Suicidal ideation</HEADING>
<P>Usable data concerning the effect of the second-generation antipsychotic olanzapine on suicidal ideation were provided by four RCTs (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>). Due to different formats of data reporting, only two of these could be pooled, and several kinds of effect sizes had to be calculated. There was a small effect for one RCT in terms of mean change difference (N = 291, 1 RCT, MCD -0.10, 95% CI -0.20 to -0.00). However, the remaining three RCTs indicated more suicidal ideation in olanzapine treated patients, resulting in one non-significant effect (RR of having high suicidality scores 1.20, N = 24, 1 RCT, 95% CI 0.50 to 2.88), and even another significant one: the pooled mean change SD of the remaining two trials was 0.29 (N = 340, 2 RCTs, 95% CI 0.07 to 0.50, I<SUP>2</SUP> = 0%). For ziprasidone, another second-generation antipsychotic, there was a single study estimate of SMD -0.27 (N = 60, 1 RCT, 95% CI -0.78 to 0.23), indicating a tendency of better outcomes in verum than placebo treated patients.</P>
<P>For mood stabilisers and antidepressants, there were two single estimates of small studies available. Both tended to suggest a worse outcome following drug treatment, but neither was significant (valproate semisodium: SMD 0.52, N = 16, 1 RCT, 95% CI -0.63 to 1.67; fluoxetine: SMD 0.44, N = 20, 1 RCT, 95% CI -0.46 to 1.33).</P>
<P>The impact of omega-3 fatty acids on suicidal ideation was assessed by one RCT. There, significantly less patients who had received omega-3 fatty acids reported at least slight or more severe suicidal tendencies (RR 0.52, N = 49, 1 RCT, 95% CI 0.28 to 0.95).</P>
<P>In summary, the findings indicate that drug treatment may not only have no substantial effect of decreasing suicidal ideation but may even result in worsening of suicidal ideation, or at least in less favourable outcomes, as compared to placebo treatment. However, this estimation is only based on single study findings for valproate semisodium and fluoxetine. For olanzapine, several estimates are available, with one small significant effect in favour of olanzapine and a medium significant effect against it, and yet another study supporting this tendency. There was a significant beneficial effect for omega-3 fatty acids as reported by one study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7 Suicidal behaviour</HEADING>
<P>There was a significant single study estimate for the reduction of suicidal behaviour by the first-generation antipsychotic flupenthixol decanoate (RR of suicidal behaviour 0.49, N = 37, 1 RCT, 95% CI 0.26 to 0.92).</P>
<P>Another RCT of olanzapine assessed the frequency of suicidal episodes. Again, olanzapine treated patients had unfavourable results as compared to placebo, resulting in a non-significant SMD of 0.15 (N = 60, 1 RCT, 95% CI -0.36 to 0.65). No significant effect was found for the antidepressant mianserin sulfate (RR of suicidal behaviour 1.00, N = 58, 1 RCT, 95% CI 0.71 to 1.41).</P>
<P>In summary, there was a significant reduction in suicidal behaviour during flupenthixol decanoate treatment, a first-generation antipsychotic given as a long acting depot. Additionally, there was another study effect supporting by its direction the possible unfavourable effects of olanzapine for self-damaging tendencies in general, as previously seen for suicidality (cf. to 1.6 Suicidal ideation, above). The prevalence of suicidal behaviour was reported to be lower in mianserin treated patients, but not significantly.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8 Self-mutilating behaviour</HEADING>
<P>There were two single study estimates for the second-generation antipsychotics aripiprazole and olanzapine, respectively. Both were non-significant but had opposite directions. Data indicated that patients treated with aripiprazole were less likely to engage in self-mutilating behaviour (RR 0.29, N = 52, 1 RCT, 95% CI 0.07 to 1.25), whereas olanzapine treated patients were not (RR 1.20, N = 24, 1 RCT, 95% CI 0.50 to 2.88). A comparable effect size was found for omega-3 fatty acids by one study (RR 1.23, N = 49, 1 RCT, 95% CI 0.51 to 2.97).</P>
<P>For the SSRI antidepressant fluoxetine, a SMD of 0.03 was found (N = 20, 1 RCT, 95% CI -0.85 to 0.92), indicating almost no difference between experimental and control group.</P>
<P>In summary, none of the available single study estimates yielded a significant effect. However, the possibility of more self-damaging behaviour in general under olanzapine treatment was, again, fortified (cf. to 1.6 Suicidal ideation and 1.7 Suicidal behaviour). Self-mutilating behaviour also occurred more often under omega-3 fatty acid supplementation as compared to placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.9 Affective instability</HEADING>
<P>There was a significant decrease in affective instability by olanzapine treatment (mean change SD -0.16, N = 631, 3 RCTs, 95% CI -0.32 to -0.01, I<SUP>2</SUP> = 0%), but the effect was small in size. Another small but non-significant effect was found by one RCT for the second-generation antipsychotic ziprasidone (SMD -0.10, N = 60, 1 RCT, 95% CI -0.61 to 0.41).</P>
<P>One trial indicated a medium to large effect of the mood stabiliser lamotrigine (mean change SD -0.61, N = 27, 95% CI -1.39 to 0.17) and another trial showed a moderate to large effect of fluvoxamine, (SMD -0.64, N = 38, 1 RCT, 95% CI -1.30 to 0.01).</P>
<P>In summary, data indicated a significant (but small) effect of olanzapine in ameliorating affective instability, but no substantial effect for ziprasidone. Available data suggest that both lamotrigine and fluvoxamine may also be effective, but there are only single study effect estimates in each case with possibly too low power to detect statistical significance.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.10 Chronic feelings of emptiness</HEADING>
<P>This outcome was only assessed in RCTs of second-generation antipsychotics, i.e. olanzapine and ziprasidone. For olanzapine, there was a minimal non-significant difference between olanzapine and placebo in terms of mean change SDs (-0.03, N = 631, 3 RCTs, 95% CI -0.22 to 0.16, I<SUP>2</SUP> = 23%). Ziprasidone treated patients felt slightly worse compared to patients who had been given placebo (SMD 0.18, N = 60, 1 RCT, 95% CI -0.32 to 0.69).</P>
<P>In summary, the evidence available for this outcome suggests no substantial effect of second-generation antipsychotics for this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.11 Anger</HEADING>
<P>SMDs are provided in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. For additional effect sizes, see <LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK> and <LINK REF="CMP-011.03" TYPE="ANALYSIS">Analysis 11.3</LINK>.</P>
<P>There was a significant effect for haloperidol treatment (SMD -0.46, N = 114, 2 RCTs, 95% CI -0.84 to -0.09, I<SUP>2</SUP> = 0%). Another first-generation antipsychotic, thiothixene, yielded no significant effect, as investigated by one RCT (SMD on basis of post-means and pre-SDs -0.07, N = 50, 1 RCT, 95% CI -0.63 to 0.48).</P>
<P>Usable data were also available for the second-generation antipsychotics aripiprazole, olanzapine, and ziprasidone. There was a large, significant effect for aripiprazole (SMD -1.14, N = 52, 1 RCT, 95% CI -1.73 to -0.55), and another significant effect for olanzapine (mean change SD -0.27, N = 631, 3 RCTs, 95% CI -0.43 to -0.12, I<SUP>2</SUP> = 0%). For ziprasidone, data suggested no beneficial effect (SMD 0.08, N = 60, 1 RCT, 95% CI -0.43 to 0.58).</P>
<P>For mood stabilisers, data indicated significant beneficial effects for any agent investigated here, with the exception of carbamazepine, where there was a positive but non-significant effect. Two RCTs tested valproate semisodium, but we did not pool the study estimates due to considerable heterogeneity (I<SUP>2 </SUP>= 78%). Both RCTs indicated better results for their experimental groups as compared to placebo, but the difference was only significant in one case (<LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>: SMD -1.83, N = 16, 1 RCT, 95% CI -3.17 to -0.48). There was another large effect for lamotrigine treatment (SMD -1.69, N = 27, 1 RCT, 95% CI -2.62 to -0.75). For topiramate, there were three RCTs available, two including women only, and one men. Each of the three study estimates favoured topiramate treatment significantly, but the size of effects varied. Therefore, all three estimates were considerably heterogeneous (I<SUP>2</SUP> = 93%), and we decided not to pool them. Instead, the two female samples were pooled, yielding a large overall effect estimate of SMD -3.00 (N = 85, 2 RCTs, 95% CI -3.64 to -2.36, I<SUP>2 </SUP>= 0%). The effect of topiramate in the remaining male sample was smaller, but also significant (SMD -0.65, 1 RCT, 95% CI -1.27 to -0.03).</P>
<P>There were no significant effects for antidepressant treatment, i.e. the TCA amitriptyline, the SSRIs fluoxetine and fluvoxamine, and the MAOI phenelzine sulfate. Each estimate was based on one single study, though. Effect sizes were small to moderate in size (SMD -0.26 for amitriptyline to -0.65 for fluoxetine, see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>In summary, data were available for first- and second-generation antipsychotics, mood stabilisers, and antidepressants. Significant effects were found for mood stabilisers (topiramate, valproate semisodium, lamotrigine) and second-generation antipsychotics (aripiprazole, olanzapine).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.12 Psychotic symptoms</HEADING>
<P>Findings indicated no significant beneficial effects for first-generation antipsychotics, mood stabilisers or antidepressants. With exception of haloperidol, all estimates were derived from single studies. However, all suggest better results for the experimental groups (see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>), except of one trial of thiothixene (see <LINK REF="CMP-012.02" TYPE="ANALYSIS">Analysis 12.2</LINK>).</P>
<P>There were significant effects for the second-generation antipsychotics aripiprazole (SMD -1.05, N = 52, 1 RCT, 95% CI -1.64 to -0.47) and olanzapine (mean change SD -0.18, N = 631, 3 RCTs, 95% CI -0.34 to -0.03, I<SUP>2</SUP> = 0%), but not for ziprasidone (see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="CMP-012.03" TYPE="ANALYSIS">Analysis 12.3</LINK>).</P>
<P>In summary, data indicated significant benefits for second-generation antipsychotics only, i.e. for aripiprazole and olanzapine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.13 Dissociation</HEADING>
<P>This outcome was only assessed by one RCT investigating the SSRI antidepressant fluoxetine. The study estimate indicated unfavourable results for fluoxetine treated patients, but the effect was not significant (SMD 0.42, N = 20, 1 RCT, 95% CI -0.47 to 1.32).</P>
<P>In summary, data for treatment of dissociative symptoms are scarce. Available data suggest that the antidepressant fluoxetine may not be beneficial in this regard.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.14 Depression</HEADING>
<P>SMDs are provided in <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>. For additional effect sizes concerning thiothixene and olanzapine, see <LINK REF="CMP-014.02" TYPE="ANALYSIS">Analysis 14.2</LINK> to <LINK REF="CMP-014.04" TYPE="ANALYSIS">Analysis 14.4</LINK>.</P>
<P>No significant effects were found for the first-generation antipsychotics haloperidol and thiothixene.</P>
<P>There was a large significant effect for the second-generation antipsychotic aripiprazole (SMD -1.25, N = 52, 1 RCT, 95% CI -1.85 to -0.65). No significant effects were found for olanzapine or ziprasidone.</P>
<P>Another significant effect was found for the mood stabiliser valproate semisodium (SMD -0.66, N = 46, 2 RCTs, 95% CI -1.31 to -0.01, I<SUP>2</SUP> = 0%). Single study estimates indicated better results for carbamazepine and topiramate as compared to placebo, but none yielded a significant effect.</P>
<P>Among antidepressant agents, a significant effect was only found for the TCA amitriptyline (SMD -0.59, N = 57, 1 RCT, 95% CI -1.12 to -0.06). For phenelzine sulfate, a MAOI, the direction of effect pointed to better outcomes for the experimental group as well, but not to a significant effect. The pooled estimate for the SSRI fluoxetine, however, indicated worse results for fluoxetine treated patients as compared to placebo (SMD 0.12, N = 42, 2 RCTs, 95% CI -1.13 to 1.36, I<SUP>2</SUP> = 74%).</P>
<P>Omega-3 fatty acids were found to have beneficial effects by two trials. A non-significant yet favourable difference between the active treatment and placebo of SMD -0.34 (N = 30, 1 RCT, 95% CI -1.11 to 0.42) was found by one RCT. This finding was supported by another RCT reporting a significantly lower risk of non-responding in terms of a 50% reduction of depressive pathology if having received omega-3 fatty acids (RR 0.48, N = 49, 1 RCT, 95% CI 0.28 to 0.81).</P>
<P>In summary, agents of different classes of drugs were found to be effective in the treatment of depression (second-generation antipsychotic aripiprazole, mood stabiliser valproate semisodium, TCA amitriptyline, omega-3 fatty acids).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.15 Anxiety</HEADING>
<P>SMDs are given in <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>, for additional effect size calculations see <LINK REF="CMP-015.02" TYPE="ANALYSIS">Analysis 15.2</LINK>.</P>
<P>No significant beneficial effects were found for the first-generation antipsychotic haloperidol or the antidepressant agents amitriptyline, fluoxetine, or phenelzine sulfate. Of the second-generation antipsychotics, aripiprazole was found to be significantly beneficial (SMD -0.73, N = 52, 1 RCT, 95% CI -1.29 to -0.17) as was olanzapine (mean change difference -0.22, N = 274, 1 RCT, 95% CI -0.41 to -0.03).</P>
<P>Additionally, a large significant effect was found for topiramate (SMD -1.40, N = 56, 1 RCT, 95% CI -1.99 to -0.81). Data indicated favourable results for carbamazepine treatment as well, with an effect of medium size, but this was not significant (SMD -0.51, N = 19, 1 RCT, 95% CI -1.43 to 0.41).</P>
<P>In summary, significant effects were found for second-generation antipsychotics (aripiprazole and olanzapine), and the mood stabiliser topiramate. These estimates are single study findings only.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.16 General psychiatric pathology</HEADING>
<P>SMDs are given in <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>, for additional effect size calculations see <LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>.</P>
<P>No significant beneficial effects were found for the first-generation antipsychotic haloperidol or the antidepressant agents amitriptyline and phenelzine sulfate. Of second-generation antipsychotics, aripiprazole was found to be significantly beneficial with a large effect of SMD -1.27 (N = 52, 1 RCT, 95% CI -1.87 to -0.67), but not so for olanzapine and ziprasidone. For these, the direction of effect did favour drug treatment though.</P>
<P>Additionally, another large significant effect was found for topiramate (SMD -1.19, N = 56, 1 RCT, 95% CI - 1.76 to -0.61). Data indicated favourable results for carbamazepine treatment as well, with an effect of medium size, but this was not significant (SMD -0.57, N = 19, 1 RCT, 95% CI -1.49 to 0.36).</P>
<P>Small and non-significant effects were found for the antidepressant agents amitriptyline and phenelzine sulfate.</P>
<P>In summary, significant effects were found for the second-generation antipsychotic aripiprazole and the mood stabiliser topiramate. These estimates were derived from single studies each.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.17 Mental health status</HEADING>
<P>SMDs are given in <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>, for additional effect size calculations see <LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK> to <LINK REF="CMP-017.04" TYPE="ANALYSIS">Analysis 17.4</LINK>. For this outcome, positive values of effect sizes indicate an amelioration, i.e. an increase of functioning by drug treatment.</P>
<P>Data were available for first-generation antipsychotics haloperidol and thiothixene, the second-generation antipsychotic olanzapine, the mood stabilisers carbamazepine and valproate semisodium, and the antidepressant agents amitriptyline, fluoxetine, and phenelzine sulfate. The effect sizes were small to medium in size but none was significant.</P>
<P>In summary, available data do not suggest a significant increase of overall functioning by any of the investigated drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.18 Attrition</HEADING>
<P>Overal tolerability was assessed in terms of the risk of not completing the study per protocol. Risk ratios of leaving the study early are given in <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>.</P>
<P>Attrition did not differ significantly between experimental and control groups for any other drug versus placebo comparison. Lower drop-out rates for active drug treatment as compared to placebo were found for olanzapine, valproate semisodium, lamotrigine, topiramate, amitriptyline, fluvoxamine, phenelzine sulfate, and omega-3 fatty acids. No usable data of attrition were available for the comparison of aripiprazole versus placebo.</P>
<P>In summary, available data indicated that none of the active drugs was less well tolerated than placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.19 Adverse effects</HEADING>
<P>Adverse effects outcomes will be reported separately by drug classes.</P>
<SUBSECTION>
<HEADING LEVEL="6">1.19.1 First-generation antipsychotics</HEADING>
<P>There was a non-significant effect of haloperidol reducing body weight (SMD -0.18, N = 58, 1 RCT, 95% CI -0.70 to 0.34). For thiothixene or flupenthixol decanoate treatment, no adverse effects data were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.19.2 Second-generation antipsychotics</HEADING>
<P>No usable data were available for aripiprazole treatment.</P>
<P>Detailed data were available for olanzapine. There was a significant effect of weight gain (SMD 1.05, N = 752, 6 RCTs, 95% CI 0.90 to 1.20, I<SUP>2 </SUP>= 0%). The ratio of study participants reporting any adverse event was not significantly increased among olanzapine treated patients as compared to placebo (RR 1.13, N = 615, 2 RCTs, 95% CI 1.00 to 1.28, I<SUP>2</SUP> = 0%), but single events were: increased appetite was significantly more often reported in olanzapine groups (RR 2.78, N = 615, 2 RCTs, 95% CI 1.75 to 4.34, I<SUP>2 </SUP>= 0%) as was somnolence (RR 2.97, N = 215, 2 RCTs, 95% CI 1.75 to 5.03, I<SUP>2</SUP> = 0%) and mouth-dryness (RR 2.24, N = 615, 2 RCTs, 95% CI 1.08 to 4.67, I<SUP>2</SUP> = 0%). Sedation had been assessed by two trials (<LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>), but we decided not to pool the two estimates because of considerable statistical heterogeneity (I<SUP>2</SUP> = 82%), that may have been due to the different observation periods (12 weeks versus 24 weeks) and sample sizes (N = 314 versus N = 28). <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK> reported sedation as significantly more often experienced by olanzapine treated patients (RR 9.23, N = 314, 1 RCT, 95% CI 2.18 to 39.12), while <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>'s findings supported the direction of effect (RR 1.26, N = 27, 1 RCT, 95% CI 0.44 to 3.66). The following adverse events were also reported but not found to occur significantly more often under olanzapine treatment: headache (RR 0.91, N = 615, 2 RCTs, 95% CI 0.43 to 1.92, I<SUP>2</SUP> = 67%), disturbed attention (RR 11.37, N = 301, 1 RCT, 95% CI 0.63 to 203.81), fatigue (RR 2.04, N = 615, 2 RCTs, 95% CI 0.79 to 5.23, I<SUP>2</SUP> = 54%), insomnia (RR 0.68, N = 615, 2 RCTs, 95% CI 0.33 to 1.37, I<SUP>2</SUP> = 15%), anxiety (RR 0.90, N = 314, 1 RCT, 95% CI 0.33 to 2.42), nausea (RR 0.83, N = 615, 2 RCTs, 95% CI 0.43 to 1.59, I<SUP>2</SUP> = 1%), constipation (RR 6.50, N = 28, 1 RCT, 95% CI 0.41 to 104.20), and nasopharyngitis (RR 0.62, N = 301, 1 RCT, 95% CI 0.23 to 1.66).</P>
<P>Detailed data were also available for laboratory value and vital sign changes. Therefore, all following effect estimates are based on baseline to endpoint change data. Significant changes were found for liver function tests, blood lipids, the haemogram, and calcium. For liver function parameters, the following effect estimates were found (all significant): AST/SGOT change: SMD 0.35, N = 526, 2 RCTs, 95% CI 0.18 to 0.52, I<SUP>2</SUP> = 0%; ALT/SGPT change: SMD 0.46, N = 530, 2 RCTs, 95% CI 0.29 to 0.63, I<SUP>2</SUP> = 0%; GGT (GGPT/SGGT/YGGT) change: SMD 0.26, N = 268, 1 RCT, 95% CI 0.02 to 0.50; total bilirubin change: SMD -0.29, N = 264, 1 RCT, 95% CI -0.53 to -0.05; direct bilirubin change: SMD -0.35, N = 158, 1 RCT, 95% CI -0.60 to -0.11). The following blood lipid changes were reported (all significant): total cholesterol change: SMD 0.42, N = 327, 2 RCTs, 95% CI 0.20 to 0.64, I<SUP>2</SUP> = 0%; LDL cholesterol change: SMD 0.35, N = 259, 1 RCT, 95% CI 0.10 to 0.59; HDL cholesterol change: SMD -0.28, N = 269, 1 RCT, 95% CI -0.52 to -0.04; triglycerides (fasting) change: SMD 0.37, N = 203, 1 RCT, 95% CI 0.09 to 0.64. There was also a significant effect for prolactin change (SMD 0.41, N = 528, 2 RCTs, 95% CI 0.23 to 0.59, I<SUP>2</SUP> = 10%). There were some significant differences in changes of haemogram parameters: leukocyte count change: SMD -0.40, N = 262, 1 RCT, 95% CI -0.65 to -0.16; neutrophils (segmented) change: SMD -0.39, N = 262, 1 RCT, 95% CI -0.63 to -0.14; basophils change: SMD -0.28, N = 262, 1 RCT, 95% CI -0.53 to -0.04; monocytes change: SMD -0.28, N = 262, 1 RCT, 95% CI -0.53 to -0.04. No significant differences in baseline to endpoint change were found for the following: erythrocyte count change: SMD -0.18, N = 262, 95% CI -0.42 to 0.06; haemoglobin change: SMD -0.21, N = 262, 1 RCT, 95% CI -0.45 to 0.03 and mean cell haemoglobin concentration change: SMD 0.03, N = 260, 1 RCT, 95% CI -0.22 to 0.27). For the platelet count change, conflicting results were reported, and effect estimates were not pooled because of considerable heterogeneity (I<SUP>2</SUP> = 90%). Despite having the same treatment durations, participants characteristics, and treatment doses, <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK> found a significant increase in the platelet count (SMD 0.32, N = 257, 1 RCT, 95% CI 0.07 to 0.56), whereas <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK> reported a significant decrease (SMD -0.26, N = 260, 1 RCT, 95% CI -0.50 to -0.01). There was a significant effect for calcium change (SMD -0.33, N = 268, 1 RCT, 95% CI -0.57 to -0.09), but not for albumin change (SMD -0.21, N = 269, 1 RCT, 95% CI -0.45 to 0.03). There were no significant effects of olanzapine concerning kidney function parameters (creatine phosphokinase change: SMD -0.21, N = 268, 1 RCT, 95% CI -0.45 to 0.03; urea nitrogen change: SMD -0.14, N = 269, 1 RCT, 95% CI -0.38 to 0.10) or vital signs changes (pulse, standing: SMD 0.08, N = 290, 1 RCT, 95% CI -0.15 to 0.31; pulse, supine: SMD 0.02, N = 290, 1 RCT, 95% CI -0.21 to 0.25; diastolic blood pressure, standing: SMD -0.03, N = 290, 1 RCT, 95% CI -0.26 to 0.20; diastolic blood pressure, supine: SMD -0.01, N = 290, 1 RCT, 95% CI -0.24 to 0.22; systolic blood pressure, standing: SMD 0.03, N = 290, 1 RCT, 95% CI -0.20 to 0.26; systolic blood pressure, supine: SMD -0.04, N = 290, 1 RCT, 95% CI -0.27 to 0.19).</P>
<P>For ziprasidone, data on single adverse events as reported by patients were available. There was no increased risk of experiencing any adverse event under ziprasidone treatment (RR 2.75, N = 60, 1 RCT, 95% CI 0.99 to 7.98). In detail, the following symptoms were reported more frequently by participants who had received ziprasidone, with no significant differences of frequency: dizziness (RR 9.00, N = 60, 1 RCT, 95% CI 0.51 to 160.17), sedation (RR 6.00, N = 60, 1 RCT, 95% CI 0.77 to 46.87), "uneasy feeling" (RR 7.00, N = 60, 1 RCT, 95% CI 0.38 to 129.93).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.19.3 Mood stabilisers</HEADING>
<P>For carbamazepine, no detailed data were available concerning adverse effects. For valproate semisodium and lamotrigine, body weight changes were given. No significant changes of body weight were observed for valproate semisodium (SMD 0.68, N = 30, 1 RCT, 95% CI -0.10 to 1.47) or lamotrigine (SMD -0.13, N = 27, 1 RCT, 95% CI -0.93 to 0.67).</P>
<P>There was a significant effect of body weight change by topiramate treatment, indicating significant weight loss (SMD -0.55, N = 127, 3 RCTs, 95% CI -0.91 to -0.19, I<SUP>2</SUP> = 0%). The following single adverse events were reported, with no significantly increased risk: memory problems (RR 2.00, N = 56, 1 RCT, 95% CI 0.55 to 7.22), trouble in concentrating (RR 2.00, N = 56, 1 RCT, 95% CI 0.55 to 7.22), headache (RR 1.00, N = 56, 1 RCT, 95% CI 0.15 to 6.61), fatigue (RR 2.00, N = 56, 1 RCT, 95% CI 0.40 to 10.05), dizziness (RR 1.50, N = 56, 1 RCT, 95% CI 0.27 to 8.30), menstrual pain (RR 1.67, N = 56, 1 RCT, 95% CI 0.44 to 6.31), and paraesthesia (RR 3.00, N = 56, 1 RCT, 95% CI 0.33 to 27.12).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.19.4 Antidepressants</HEADING>
<P>No detailed data of adverse effects were available for amitriptyline, fluoxetine, fluvoxamine, and mianserin. For phenelzine sulfate, a non-significant effect of weight gain was reported (SMD 0.11, N = 62, 1 RCT, 95% CI -0.39 to 0.61).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.19.5 Miscellaneous active agents</HEADING>
<P>No detailed data were available for the remaining active agent that had been included in this review, i.e. omega-3 fatty acids.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Drug versus drug comparisons</HEADING>
<P>For corresponding analyses to drug versus drug comparisons, see <LINK REF="CMP-066.01" TYPE="ANALYSIS">Analysis 66.1</LINK> to <LINK REF="CMP-082.01" TYPE="ANALYSIS">Analysis 82.1</LINK>.</P>
<P>In the following, results will be reported by comparison category.</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 First-generation antipsychotic versus first-generation antipsychotic</HEADING>
<P>One RCT compared two first-generational antipsychotics, i.e. loxapine versus chlorpromazine (<LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>).</P>
<P>The participants of this trial were administered either loxapine (N = 40; mean daily dose 14.5 mg) or chlorpromazine (N = 40; mean daily dose 110 mg) for six weeks. Both male and female outpatients were included. Their mean age was 30.8 years. Severity of illness was rather low, as participants had to fulfil only four of the diagnostic BPD characteristics of Gunderson et al. (<LINK REF="REF-Gunderson-1981" TYPE="REFERENCE">Gunderson 1981</LINK>). Two of them had to be rated as severe and two as at least moderate.</P>
<P>Only tolerability and adverse events data were usable for effect size calculation. The ratio of patients who did not complete at least three weeks of treatment or were removed due to side effects did not differ significantly between either of the groups (RR of loxapine treated patients as compared to chlorpromazine treated patients 1.14, N = 80, 95% CI 0.46 to 2.85). Neither did the frequency of any adverse events differ significantly between the two groups (RR 1.14, N = 80, 95% CI 0.46 to 2.85), nor did any of the most frequent adverse events in particular (sleepiness/drowsiness: RR 0.80, N = 80, 95% CI 0.23 to 2.76; restlessness: RR 1.50, N = 80, 95% CI 0.26 to 8.50; muscle spasms: RR 3.00, N = 80, 95% CI 0.33 to 27.63; fainting spells: RR 0.14, N = 80, 95% CI 0.01 to 2.68).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 First-generation antipsychotic versus antidepressant</HEADING>
<P>Two RCTs compared haloperidol, a first-generational antipsychotic agent, with antidepressant medication. In the <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK> trial, the comparison treatment was the TCA amitriptyline, in the <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK> trial it was the MAOI phenelzine sulfate..</P>
<P>Patients in the <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK> trial received 4 to 16 mg/day of haloperidol (mean daily dose 4.8 mg/day, average plasma level 8.66 ng/ml, SD 3.7 ng/mL) or 100 to 175 mg/day of amitriptyline (mean daily dose 149.1 mg/day, average plasma level of 240.4 ng/mL amitriptyline + nortriptyline, SD 99.4). Patients (N = 61, both male and female, mean age 25.1 years) started as inpatients and were allowed to leave the hospital after two weeks. Nevertheless, almost two thirds (62%) completed as inpatients. Study duration was five weeks. With average GAS scores of 42.2 at baseline, the severity of illness was serious.</P>
<P>Data were available for interpersonal problems, impulsivity, anger, and psychotic paranoid symptoms. There were no significant effects for any primary outcome. Results indicated that patients tended to profit more from haloperidol treatment concerning interpersonal problems (SMD -0.14, N = 57, 95% CI -0.66 to 0.38), anger (SMD -0.36, N = 57, 95% CI -0.89 to 0.16), and psychotic paranoid symptoms (SMD -0.35, N = 57, 95% CI -0.87 to 0.18); and more from amitriptyline concerning impulsivity (SMD 0.20, N = 57, 95% CI -0.32 to 0.72). Neither drug proved to be significantly superior to the other one for any other pathology related outcome. Favourable results were found for haloperidol concerning anxiety (SMD -0.18, N = 57, 95% CI -0.70 to 0.34) and general psychiatric pathology (SMD -0.07, N = 57, 95% CI -0.59 to 0.45) as well as for amelioration of mental health status (SMD 0.29, N = 57, 95% CI -0.23 to 0.81). Depressive pathology responded slightly better in amitriptyline treated patients (SMD 0.08, N = 57, 95% CI -0.44 to 0.59). The risk of dropping out was higher in the haloperidol treated group (RR 2.90, N = 61, 95% CI 0.32 to 26.38), but again this was not statistically significant.</P>
<P>
<LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK> tested up to 4 mg of haloperidol (average dose 3.93 mg/day, SD 0.65, mean plasma level 5.29 ng/mL, SD 5.05) against up to 90 mg/day of the MAOI phenelzine sulfate (average dose 60.45 mg/day, SD 9.55, 77.54% mean platelet MAO inhibition after three weeks) in male and female BPD patients (N = 64, mean age: 26.7 years, SD = 7.2) for a duration of five weeks. All patients started as inpatients and remained in hospital for at least two weeks. With average GAS scores of 43.9 at baseline, the severity of illness was serious.</P>
<P>There were no significant differences between the two drugs concerning primary outcomes. The results indicated a tendency for haloperidol treated patients to suffer less from interpersonal problems as compared to phenelzine sulfate treated patients (SMD -0.46, N = 64, 95% CI -0.96 to 0.04). In all other cases, i.e. concerning BPD severity (SMD 0.46, N = 64, 95% CI -0.03 to 0.96), impulsivity (SMD 0.09, N = 64, 95% CI -0.04 to 0.58), anger (SMD 0.08, N = 64, 95% CI -0.41 to 0.57), and psychotic/paranoid symptoms (SMD 0.15, N = 64, 95% CI -0.34 to 0.64), phenelzine sulfate treated patients were better off.</P>
<P>Significant effects were found in favour of phenelzine sulfate treatment for depression (SMD 0.68, N = 64, 95% CI 0.17 to 1.19), anxiety (SMD 0.66, N = 64, 95% CI 0.15 to 1.16), general psychiatric pathology (SMD 0.53, N = 64, 95% CI 0.03 to 1.03) and mental health status (SMD -0.51, N = 64, 95% CI -1.01 to -0.01), with medium effect sizes. The risk of dropping out was higher in the haloperidol group (RR 1.58, N = 74, 95% CI 0.49 to 5.15), but the effect was not significant. Haloperidol treated patients experienced less weight gain than amitriptyline treated patients did (SMD -0.29, N = 64, 95% CI -0.78 to 0.21), but the effect was not significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Second-generation antipsychotic versus antidepressant</HEADING>
<P>One RCT (<LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>) compared the second-generation antipsychotic olanzapine to the SSRI antidepressant fluoxetine. All participants were female outpatients (N = 30, mean age: 23.0 years, SD = 5.7), receiving either 2.5 mg/day of olanzapine or 10.0 mg/day of fluoxetine for a duration of eight weeks. With average GAF scores of 52.5 (SD = 6.9), the patients were moderately ill.All SMD effect sizes were calculated on the basis of mean baseline change scores. Dichotomous data were calculated on basis of the ITT sample as intended.</P>
<P>There were no significant differences between the two drugs for any pathology-related outcome. Usable data were provided for impulsivity, with a small, non-significant effect favouring olanzapine (mean change SMD -0.20, N = 29, 95% CI -0.93 to 0.53). Olanzapine treated patients also experienced a greater decrease in depressive pathology (SMD -0.73, N = 29, 95% CI -1.49 to 0.03), but the effect was, again, not significant. Attrition did not differ significantly between the groups (RR 0.29, N = 30, 95% CI 0.20 to 1.76). The only significant findings referred to adverse effects of treatment, with higher weight gain (SMD 0.98, N = 29, 95% CI 0.20 to 1.76) and more cases of mild sedation (RR 3.50, N = 30, 95% CI 1.23 to 9.92) in olanzapine treated patients. Akathisia was also more often reported by olanzapine treated patients, but the effect estimate was not significant (RR 0.70, N = 30, 95% CI 0.23 to 2.11).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Drug versus combination of drugs</HEADING>
<P>The <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK> RCT comprised three experimental groups. One group received the second-generation antipsychotic olanzapine (2.5 mg/day; N = 16), another group received the SSRI antidepressant fluoxetine (10 mg/day; N = 14), and the third group received both drugs (2.5 mg/day of olanzapine plus 10.0 mg/day; N = 15) for eight weeks. All participants were female outpatients (mean age: 23.0 years, SD = 5.7). With average GAF scores of 52.5 (SD = 6.9), they were moderately ill.<BR/>All SMD effect sizes were calculated on basis of mean baseline change scores. Dichotomous data were calculated on basis of the ITT sample as intended.</P>
<P>Only small and non-significant differences were found between olanzapine treatment alone and combined treatment with fluoxetine (impulsivity: mean change SMD 0.02, N = 29, 95% CI -0.71 to 0.76, "favouring" combined treatment; depression: mean change SMD -0.26, N = 29, 95% CI -1.00 to 0.47, favouring olanzapine alone). Neither attrition (RR 0.19, N = 31, 95% CI 0.01 to 3.63), nor weight gain (SMD 0.70, N = 29, 95% CI -0.05 to 1.46) differed significantly between the two groups . There were no significant differences in the ratio of participants reporting sedation (RR 1.61, N = 31, 95% CI 0.87 to 2.96) or akathisia (RR 0.75, N = 31, 95% CI 0.25 to 2.28) between the groups.</P>
<P>For the comparison of fluoxetine versus combined treatment with olanzapine, again there were no significant differences. However, both effect estimates of pathology-related outcomes indicated better results for combined treatment than fluoxetine alone (impulsivity: mean change SMD 0.25, N = 26, 95% CI -0.53 to 1.02; depression: mean change SMD 0.54, N = 26, 95% CI -0.24 to 1.33). For tolerability, body weight change and sedation, data indicated better results for the group that had received fluoxetine alone (attrition: RR 0.54, N = 29, 95% CI 0.05 to 5.28; body weight change: SMD -0.54, N = 29, 95% CI -1.32 to 0.25; sedation: RR 0.46, N = 29, 95% CI 0.15 to 1.44). Akathisia was more often experienced by the participants with single treatment (RR 1.07, N = 29, 95% CI 0.39 to 2.92).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-05-12 10:57:53 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2010-05-12 10:45:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Drug versus placebo</HEADING>
<P>The following placebo comparisons were investigated in the identified RCTs.</P>
<P>(1) First-generation antipsychotics:<BR/>(a) thiothixene (<LINK REF="STD-Goldberg-1986" TYPE="STUDY">Goldberg 1986</LINK>, N = 50);<BR/>(b) flupenthixol (<LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK>, N = 30);<BR/>(c) haloperidol (<LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>, N=60; <LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>, N = 58).</P>
<P>(2) Second-generation antipsychotics:<BR/>(a) aripiprazole (<LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>, N = 52);<BR/>(b) olanzapine (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>, N = 40; <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>, N = 24; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>, N = 314; <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK>, N = 60; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>, N = 28; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>, N = 301);<BR/>(c) ziprasidone (<LINK REF="STD-Pascual-2008" TYPE="STUDY">Pascual 2008</LINK>, N = 60).</P>
<P>(3) Mood stabilisers:<BR/>(a) carbamazepine (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>, N = 20);<BR/>(b) valproate semisodium (<LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>, N = 30; <LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>, N = 16);<BR/>(c) lamotrigine (<LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>, N = 27);<BR/>(d) topiramate (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>, N = 56; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK> and <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>, N = 31 + N = 44).</P>
<P>(4) Antidepressants:<BR/>(a) amitriptyline (<LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>, N = 59);<BR/>(b) fluoxetine (<LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>, N = 22, <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>, N = 25);<BR/>(c) fluvoxamine (<LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>, N = 38);<BR/>(d) phenelzine sulfate (<LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>, N = 72);<BR/>(e) mianserin (<LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>, N = 38).</P>
<P>(5) Miscellaneous:<BR/>(a) omega-3 fatty acid (<LINK REF="STD-Hallahan-2007" TYPE="STUDY">Hallahan 2007</LINK>, N = 49; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>, N = 30).</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Pathology related outcomes</HEADING>
<P>Of the first-generation antipsychotics under investigation, haloperidol had a significant effect concerning the reduction of anger, and flupenthixol treated patients were significantly less likely to get engaged in suicidal acts. No proof of efficacy was found for thiothixene.</P>
<P>Of the second-generation antipsychotics, aripiprazole had significant effects in the reduction of interpersonal problems, impulsivity, anger, psychotic paranoid symptoms, depression, anxiety, and general psychiatric pathology. For olanzapine, no significant effects were found for any pathology related outcome in primary analyses. Secondary analyses indicated significant decreases in affective instability, anger, psychotic paranoid symptoms, and anxiety. A significantly greater decrease in anxiety by olanzapine was found by one trial. Concerning suicidal ideation and self-mutilating behaviour, only two of the five relevant study results could be pooled due to different formats of reporting. The pooled effect of these two estimates suggests that the olanzapine-treated group experienced a significantly lower degree of amelioration of recurrent suicidal ideation as compared to the placebo group. Of the remaining three trials reporting on self-harming behaviour, two also found non-significant tendencies of unfavourable outcomes for olanzapine. No significant effects were found for ziprasidone treatment.</P>
<P>There were also significant effects for the mood stabilisers valproate semisodium, lamotrigine, and topiramate. Valproate semisodium had significant effects concerning the reduction of interpersonal problems and depression. A significant effect in the reduction of anger was found by one study, and the positive direction of effect was supported by the findings of another study. Lamotrigine was significantly superior to placebo concerning impulsivity and anger. Topiramate had significant effects concerning interpersonal problems, impulsivity, anger (as assessed by three single, significant study effects, only two of which could be pooled), anxiety, and general psychiatric pathology. No significant effects were found for carbamazepine treatment.</P>
<P>For antidepressants, there was only a significant effect for the TCA amitriptyline concerning the reduction of depression. No significant effects were found for mianserin, the SSRI agents fluoxetine and fluvoxamine, nor for the MAOI agent phenelzine sulfate.</P>
<P>Omega-3 fatty acid was found to have a significant effect on suicidality. For depression, a significant effect was found by one study, with the second study (that could not be pooled with the first one due to different formats of data reporting) supporting the direction of effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Adverse effects</HEADING>
<P>Tolerability did not differ for any drug placebo comparison, i.e. drug treatment was not associated with a higher rate of non-completers than was placebo treatment.</P>
<P>Most trials did not provide numerical data on specific adverse effects, with the exception of body weight changes. Haloperidol and phenelzine treatment had no significant effects on body weight, nor did valproate semisodium or lamotrigine. However, olanzapine treatment was associated with significant weight gain, and topiramate treatment with significant weight loss. The ratio of olanzapine, ziprasidone and lamotrigine treated patients reporting any adverse event did not differ significantly as compared to the placebo groups.<BR/>Numerous data on additional specific adverse effects were only available for a few trials. For the placebo comparisons of ziprasidone and topiramate, single adverse events were reported, with no significant differences in occurrence between the groups. Detailed data were available for olanzapine, including even changes in laboratory values. Here, the ratio of participants reporting any adverse event in each group did not differ significantly between olanzapine and placebo treatment. However, olanzapine treated patients reported significantly more often increased appetite, somnolence, and mouth-dryness. One trial reported significantly more sedation in olanzapine treated patients, and another one (that could not be pooled with the first one due to substantial heterogeneity) supported this direction of effect. Additionally, significant effects on liver values, blood lipids, prolactin levels, and full blood counts were found, but there were no significant effects on kidney function values or cardiovascular system parameters.<BR/>
</P>
<P>However, little is known about adverse events increasing the risk of patients not completing treatment or experiencing body weight changes, except for olanzapine treatment. Therefore, the above cited significant effects should be regarded with caution. Known adverse effects of the remaining drugs have certainly also to be considered when choosing a treatment option for a certain patient, though the data were too sparse to calculate effect sizes in this review for most drugs.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Drug versus drug</HEADING>
<P>The following drug versus drug comparisons were investigated (numeration as in results section for ease of comparison).</P>
<P>(6) First-generation antipsychotic versus first-generation antipsychotic:<BR/>(a) loxapine versus chlorpromazine (<LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>, N = 40).</P>
<P>(7) First-generation antipsychotic versus antidepressant:<BR/>(a) haloperidol versus amitriptyline (<LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>, N = 61);<BR/>(b) haloperidol versus phenelzine sulfate (<LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>, N = 74).</P>
<P>(8) Second-generation antipsychotic versus antidepressant:</P>
<P>(a) olanzapine versus fluoxetine (<LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>, N = 30).</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Pathology related outcomes</HEADING>
<P>Concerning the comparison of the two first-generation antipsychotics loxapine versus chlorpromazine, there were no usable data available regarding any pathology related outcome.<BR/>The first-generation antipsychotic haloperidol and the antidepressant amitriptyline did not differ significantly concerning any primary or secondary outcome. The antidepressant phenelzine sulfate proved to be superior to haloperidol in reducing depression, anxiety, general psychiatric pathology, and improving the overall mental health status.</P>
<P>No significant differences were found for the comparison of the second-generation antipsychotic olanzapine with the antidepressant fluoxetine for any pathology related outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Adverse effects</HEADING>
<P>Tolerability, i.e. attrition, did not differ significantly for any of the investigated drug versus drug comparisons.<BR/>The comparison of the frequencies of adverse events (i.e. any adverse event, sleepiness, restlessness, muscle spasms, fainting spells) in loxapine and chlorpromazine treated patients yielded no significant differences.</P>
<P>No data of adverse effects were available for the comparison of haloperidol versus amitriptyline. For the haloperidol versus phenelzine sulfate comparison, weight change was reported, with no significant difference between the two treatments.</P>
<P>However, olanzapine and fluoxetine treatment differed significantly concerning weight gain, with more weight gain in the olanzapine treated group. Additionally, a higher ratio of olanzapine treated patients reported mild sedation, as compared to the fluoxetine group.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Active drug versus combination of drugs</HEADING>
<P>The following comparisons were investigated (numeration following on from 2. Drug versus drug, above).</P>
<P>(9) Second-generation antipsychotic versus second-generation antipsychotic plus antidepressant:<BR/>(a) olanzapine versus olanzapine plus fluoxetine (<LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>, N = 31).</P>
<P>(10) Antidepressant versus antidepressant plus second-generation antipsychotic:<BR/>(a) fluoxetine versus fluoxetine plus olanzapine (<LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>, N = 29).</P>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Pathology related outcomes</HEADING>
<P>For both the comparisons olanzapine versus olanzapine plus fluoxetine as well as fluoxetine versus fluoxetine plus olanzapine, data on impulsivity and depressive pathology were available. There were no significant differences indicating any benefits from combined treatment versus treatment with olanzapine or fluoxetine alone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Adverse effects</HEADING>
<P>There were no significant differences for both comparisons in terms of tolerability, body weight change, and the frequency of restlessness or mild sedation.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-05-12 10:46:43 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>As described earlier (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table), most study participants exhibited mild to moderate levels of illness. However, there was a broad range from seriously ill (e.g. <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>: mean GAS value pre-treatment 42.2, reflecting "serious symptomatology or impairment in functioning") to very mildly impaired patients (e.g. <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>: "patients [...] leading active social and vocational lives"). Acutely suicidal patients were not included in most trials, with the exception of <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK> and <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK>, including patients immediately following a severe suicidal act that had led to hospital admission.</P>
<P>Of concern regarding applicability to clinical settings might be the psychiatric exclusion criteria of most studies. Besides acutely suicidal patients, people with comorbid schizophrenia or schizoaffective disorders, bipolar disorders, alcohol or drug dependence and sometimes even alcohol or drug abuse were often not eligible for study participation. What is more, a current major depressive episode or severe depression was also a criterion of exclusion in the majority of trials. As comorbid axis-I disorders are highly prevalent in BPD patients, especially mood disorders (96.9%) and substance use disorders (62.1%; <LINK REF="REF-Zanarini-2004b" TYPE="REFERENCE">Zanarini 2004b</LINK>), the exclusion of those participants renders applicability difficult. However, eating disorders, which are highly prevalent in BPD patients as well (53%, <LINK REF="REF-Zanarini-2004b" TYPE="REFERENCE">Zanarini 2004b</LINK>), were no reason for exclusion in any study (with the exception of <LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>; <LINK REF="STD-Salzman-1995" TYPE="STUDY">Salzman 1995</LINK>, who excluded patients with any comorbid axis-I disorder). Anxiety disorders, which are prevalent in 89.0% of BPD patients (<LINK REF="REF-Zanarini-2004b" TYPE="REFERENCE">Zanarini 2004b</LINK>), were only excluded in two trials (i.e. current PTSD, panic disorder, or obsessive-compulsive disorder; <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>).</P>
<P>One third of trials was restricted to female patients (nine out of 27), one trial was restricted to men (<LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>), and within the remaining samples, women were always predominant. Thus, women constituted the majority of all participants involved within this review. This reflects the overall higher prevalence of BPD diagnosis in women as compared to men (although the "real" prevalence is supposed to be even; <LINK REF="REF-Torgersen-2005" TYPE="REFERENCE">Torgersen 2005</LINK>), but may make the applicability to male patients difficult.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>Study duration ranged from 32 days to 24 weeks, with a mean duration of approximately 12 weeks. These observation periods may be sufficient to judge treatment efficacy in the single patient. However, drug treatment often lasts longer in clinical settings. Therefore, especially adverse effects must be monitored cautiously. Since most BPD patients are taking psychotropic medication continuously, future RCTs on this topic should cover appropriate observation periods of longer duration (e.g. six months as a rough navigation) to allow for better applicability to clinical settings.</P>
<P>Catamnestic data are only available for <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK> (all: topiramate versus placebo), <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK> (lamotrigine versus placebo in female patients), and <LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK> (aripiprazole versus placebo in both male and female patients) studies. As blinding was broken after the initial 8- and 10-week treatment phases in each of these trials, we decided not to include the catamnestic data here, as the break of blinding is likely to introduce bias on efficacy findings, especially on self-rated or self-reported data. For aripiprazole and lamotrigine, all significant findings of the post-treatment comparisons were still present after an additional 18 months of open treatment. Significant changes throughout the whole observation period were reported for all topiramate trials. All findings at post-treatment were corroborated by the catamnestic data, with exception of two outcome variables: There was no significant change for general psychiatric pathology concerning the overall observation period, and a significant change for depressive pathology emerged at the end of the 18-month follow-up.</P>
<P>Another difference to clinical settings may be that patients often receive several psychotropic drugs at a time. Polypharmacy is the rule rather than the exception (<LINK REF="REF-Zanarini-2004a" TYPE="REFERENCE">Zanarini 2004a</LINK>). With the exception of the comparison of combined olanzapine and fluoxetine treatment to olanzapine and fluoxetine treatment alone (<LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>; no beneficial effects for combined treatment), there are no data from RCTs available supporting or even investigating polypharmacological treatment. As combined drug treatment cannot be considered as having the additional effect to that of each single drug treatment, it should always be considered that the administration of several drugs is not empirically supported by any RCT, and, to our knowledge, not by any trial of lower evidence level either.</P>
<P>With the exception of the <LINK REF="STD-Linehan-2008" TYPE="STUDY">Linehan 2008</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK> and <LINK REF="STD-Soler-2005" TYPE="STUDY">Soler 2005</LINK> trials, all patients of whom were in DBT treatment, the study participants did not receive specific concomitant psychotherapy, either because it was not allowed by the study protocol, or patients were allowed to receive psychotherapy but did not. However, mental health service treatment options vary internationally, i.e. receiving psychotherapy may be more characteristic for some countries and out of character for others.</P>
<P>There are some more substances that are currently discussed for use in BPD patients (especially second-generation antipsychotics), that could not be included in this review as RCTs are currently not available. However, there are some ongoing trials (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>), the results of which will hopefully be included in subsequent versions of this review. Additionally, there are findings from lower-evidence studies on further second-generation antipsychotics (clozapine, quetiapine, risperidone), mood stabilisers (divalproex-extended release, lithium, oxcarbazepine), antidepressants (MAOI tranylcypromine, NRI reboxetine, SNRI venlafaxine, the SSRIs sertraline and paroxetine, the TCAs desipramine and imipramine), anxiolytics (alprazolam), and miscellaneous drugs (clonidine, opioid antagonists naloxone and naltrexone, riluzole, and trifluoperazine).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>Unfortunately, there was little consensus between primary studies on which outcome variables are crucial to rate therapy efficacy upon, even for those testing the same drug comparisons. Additionally, the use of different assessment instruments for one outcome variable renders comparability more difficult than necessary, and increases heterogeneity.<BR/>Mostly, outcome assessment was restricted to target variables that were not assessed with BPD-specific assessment instruments. For example, psychotic pathology was a common outcome, and common unspecific assessment instruments were used (i.e. SCL-90-subscale "psychoticism"), but BPD-specific psychotic pathology, i.e. stress-related paranoid ideation and dissociation, was not assessed. Hence, some domains of BPD core pathology were almost completely neglected, e.g. affective instability, dissociation, or chronic feelings of emptiness. Fortunately, relevant assessment instruments have been developed lately, reflecting each of the BPD core criteria (e.g. the BPDSI scale by <LINK REF="REF-Arntz-2003" TYPE="REFERENCE">Arntz 2003</LINK>, the CGI-BPD scale by <LINK REF="REF-Perez-2007" TYPE="REFERENCE">Perez 2007</LINK>, or the ZAN-BPD scale by <LINK REF="REF-Zanarini-2003a" TYPE="REFERENCE">Zanarini 2003a</LINK>).<BR/>Additionally, there were very few numerical data provided concerning adverse events. Some studies reported no details at all beyond attrition and body weight changes, whereas others only stated that adverse events were few and comparably frequent in all groups. We therefore appreciate the detailed reporting of adverse effects allowing for the calculation of treatment effects, and warn against regarding the other drugs, where relevant data are lacking, as safe, especially with regard to long-term therapy. We strongly recommend considering known adverse effects of all drugs when choosing a certain treatment option, although we were not able to report them here because of incomplete assessment or reporting of the primary studies investigated here.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Specificity of treatment effects</HEADING>
<P>We cannot exclude that unspecific sedating effects, e.g. of valproate semisodium or olanzapine, may have contributed to study results. However, effects were also seen with non-sedating substances such as aripiprazole or lamotrigine questioning the broad conclusion that sedating effects are central for treatment effects.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-05-12 10:47:03 +0100" MODIFIED_BY="[Empty name]">
<P>Altogether, 28 RCTs have been included, covering 22 different comparisons in ten comparison categories (see "Description of studies"). In the presence of the multitude of different comparisons and outcome variables, most results are based on single study findings only. The study sample sizes were rather small, and ranged, with exception of two large trials (<LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>; N = 314; <LINK REF="STD-Zanarini-2007" TYPE="STUDY">Zanarini 2007</LINK>; N of patient data used here: 301), between 16 (<LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>) and 108 (<LINK REF="STD-Soloff-1993" TYPE="STUDY">Soloff 1993</LINK>; divided into three groups). Depending on the randomisation algorithm, i.e. if study groups were equal in size or one group twice as large as the other, and the overall number of treatment groups, the minimum group size was N = 4 (<LINK REF="STD-Hollander-2001" TYPE="STUDY">Hollander 2001</LINK>) and the maximum group size was N = 43 (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>). Therefore, the power to detect significant effects was quite low.<BR/>In addition, the overall robustness of findings must be considered low for the majority of comparisons. Because the current evidence embraces only one single RCT effect, further findings would be likely to affect the actual results, especially if including larger study samples. However, the influence of further trials cannot definitely be predicted: On the one hand, further primary studies would enhance power and therefore make the detection of significant effects more likely. On the other hand, the actual data are based on very few to single observations, so it is impossible to judge about publication biases (e.g. by depicting funnel plots as intended), even if the concealment of negative, non-significant findings is much more likely. In <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>, a funnel plot was drawn for the comparison category with most single study effects (comparison 11.1, SMDs of active drug versus placebo comparisons for the outcome "anger"). It is most difficult to draw definite conclusions from that figure, as it embraces a heterogeneous sample of effect sizes for diverse drug-placebo comparisons. On the one hand, there seems to be an overall tendency of lacking non-significant findings (no effect estimates at bottom right corner). On the other hand, the publication of additional RCTs matching the comparisons already investigated here is rather unlikely, as we are only aware of ongoing trials testing different drugs (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>).</P>
<P>Summary of findings tables including ratings of the evidence quality are provided for all drug versus placebo comparisons (see<B> </B>
<LINK REF="APP-14" TYPE="APPENDIX">Appendix 14</LINK> to <LINK REF="APP-29" TYPE="APPENDIX">Appendix 29</LINK>).<B> </B>
</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-05-12 10:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>We strived to identify all relevant published and unpublished evidence (see <LINK TAG="SEARCH_METHODS" TYPE="SECTION">Search methods for identification of studies</LINK>). The search was not restricted to any language. In spite of the great efforts to avoid publication bias, we were not able to include any unpublished data.<BR/>As relating to our inclusion criteria, we tried to retain a most homogeneous pool of primary studies. However, there were some inconsistencies between studies particularly pertaining to psychiatric comorbidity of study participants. For example, bipolar disorders were a common exclusion criterion, whereas one study (<LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>) required its participants to have a diagnosis of bipolar II disorder. Also, acute suicidal patients were not eligible for most studies, but the participants of the <LINK REF="STD-Montgomery-1979_x002f_82" TYPE="STUDY">Montgomery 1979/82</LINK> and <LINK REF="STD-Montgomery-81_x002f_82_x002f_83" TYPE="STUDY">Montgomery 81/82/83</LINK> trials were recruited immediately following a suicidal act that had led to hospital admission. In nine studies, only women were included (<LINK REF="STD-Frankenburg-2002" TYPE="STUDY">Frankenburg 2002</LINK>; <LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>; <LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>; <LINK REF="STD-Rinne-2002" TYPE="STUDY">Rinne 2002</LINK>; <LINK REF="STD-Simpson-2004" TYPE="STUDY">Simpson 2004</LINK>; <LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>; <LINK REF="STD-Zanarini-2001" TYPE="STUDY">Zanarini 2001</LINK>; <LINK REF="STD-Zanarini-2003" TYPE="STUDY">Zanarini 2003</LINK>; <LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>), whereas the remaining study samples consisted of both male and female patients. The severity of illness also varied between studies, mostly from mild to moderate. However, we tried to exactly specify and describe all studies with regard to their crucial characteristics (see <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>), in order to let the reader decide about applicability of relevant study characteristics to his or her decisive situation.</P>
<P>Another point of concern is reporting bias. Most studies provide only a fragmentary outcome pattern, making the concealment of non-significant findings likely. We tried to deal with this by first defining all patient-relevant outcome variables that are directly (primary outcomes) or indirectly (secondary outcomes) associated with BPD treatment, i.e. all outcome variables that a consumer and his or her therapist are likely to be interested in. We have tried not only to stress reported findings but also outcome gaps, such as outcome variables for which the effects of a certain treatment cannot be judged due to a lack of data.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-05-12 10:57:53 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Other reviews</HEADING>
<P>This is an update and new citation version of the preceding Cochrane Collaboration review 'Pharmacological interventions for BPD' by <LINK REF="REF-Binks-2006" TYPE="REFERENCE">Binks 2006</LINK>. Its literature searches covered the period up to October 2002, and the latest included study dates from 2001. Since then, there have been further research activities, and new substances have been investigated in BPD. The preceding review included ten RCTs, whereas we were aware of 28 includable studies at the point of last literature search updates (September 2009).</P>
<P>As concerns other systematic reviews and meta-analysis on the topic of pharmacotherapy for BPD, we did not review this type of evidence systematically. However, there are three recent works, each with a similar focus, that should be referred to at this point (<LINK REF="REF-Duggan-2008" TYPE="REFERENCE">Duggan 2008</LINK>; <LINK REF="REF-Ingenhoven-2010" TYPE="REFERENCE">Ingenhoven 2010</LINK>; <LINK REF="REF-Nos_x00e8_-2006" TYPE="REFERENCE">Nosè 2006</LINK>).<LINK REF="REF-Nos_x00e8_-2006" TYPE="REFERENCE">Nosè 2006</LINK> <LINK REF="REF-Duggan-2008" TYPE="REFERENCE">Duggan 2008</LINK>; <LINK REF="REF-Ingenhoven-2010" TYPE="REFERENCE">Ingenhoven 2010</LINK>
</P>
<P>Both <LINK REF="REF-Nos_x00e8_-2006" TYPE="REFERENCE">Nosè 2006Nosè 2006</LINK> and <LINK REF="REF-Ingenhoven-2010" TYPE="REFERENCE">Ingenhoven 2010Ingenhoven 2010</LINK> included placebo-controlled RCTs. Mixed study samples with primarily BPD patients were includable in the <LINK REF="REF-Nos_x00e8_-2006" TYPE="REFERENCE">Nosè 2006Nosè 2006</LINK> review, participants with both BPD and/or schizotypal PD were includable in the <LINK REF="REF-Ingenhoven-2010" TYPE="REFERENCE">Ingenhoven 2010Ingenhoven 2010</LINK> review, and people with any PD were included in the <LINK REF="REF-Duggan-2008" TYPE="REFERENCE">Duggan 2008Duggan 2008</LINK> review. The most recent literature searches were done in June 2006, December 2007 and December 2006, respectively. Due to different inclusion criteria and different search periods, the study pools differ from ours. Mainly, these reviews had less RCTs of antipsychotic drugs available, but included more RCTs of antidepressants since these drugs have been tested in mixed samples that were not includable in this review (if less than 70% of participants had a diagnosis of BPD, see <LINK TAG="CRIT_STUDIES" TYPE="SECTION">Types of studies</LINK>). Outcomes were, by and large, comparable to those of our review. All three reviews conducted meta-analyses across classes of drugs, i.e. effect estimates referring to a certain class of drugs (any antipsychotic, any antidepressant, or any mood stabiliser) were pooled. In this review, study effects were only pooled if referring to the same substance.</P>
<P>Both reviews report several findings of effectiveness for antidepressants. This differs from our findings that are only based on RCTs conducted in study samples of more than 70% BPD patients, and were not derived from accumulation of findings from different (antidepressant) substances.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Guidelines</HEADING>
<P>This systematic review is not a guideline, which provides treatment recommendations. It is meant to help providers, practitioners and patients make informed decisions. However, we will now comment on the main guidelines that give recommendations for pharmacotherapy treatment of BPD in light of the results of this systematic review.</P>
<P>The American Psychiatric Association Practice Guidelines (<LINK REF="REF-APA-2001" TYPE="REFERENCE">APA 2001</LINK>; updated in 2005, <LINK REF="REF-APA-2005" TYPE="REFERENCE">APA 2005</LINK>) are commonly cited when recommending pharmacological treatment strategies for BPD. However, these are based on literature searches covering the literature up to 1998. Since then, 20 RCTs have been published, investigating mood stabilisers (valproate semisodium, lamotrigine, topiramate), antidepressants (fluvoxamine, fluoxetine), second-generation antipsychotics (aripiprazole, olanzapine, ziprasidone), and omega-3 fatty acids.</P>
<P>Taking the findings of this review into account with regard to the APA guidelines, some differences are apparent: The up-to-date RCT evidence presented here does not support the recommendation of SSRIs as first-line treatment for affective dysregulation and impulsive-behavioural dyscontrol symptoms. Instead, beneficial effects were found for mood stabilisers (topiramate, valproate semisodium, lamotrigine) and second-generation antipsychotics (aripiprazole, olanzapine) for affective dysregulative symptoms. Beneficial effects indicating a reduction of impulsive-behavioural dyscontrol symptoms are available for mood stabilisers (topiramate, lamotrigine) or second-generation antipsychotics (aripiprazole). The APA guidelines recommend low-dose antipsychotics in general for the treatment of cognitive-perceptual symptoms, whereas our findings support the use of SGA (aripirazole, olanzapine) in particular. This development, a shift towards second-generation antipsychotics, has been foreshadowed by John M. Oldham in his guideline watch of 2005 (<LINK REF="REF-APA-2005" TYPE="REFERENCE">APA 2005APA 2005</LINK>), butto our knowledge, the original guideline recommendations have not been modified since.</P>
<P>The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders (<LINK REF="REF-Herpertz-2007" TYPE="REFERENCE">Herpertz 2007</LINK>), that are based upon RCTs, open trials and individual clinical experiences, refer to all evidence that was identified in MEDLINE searches up to June 2007. Although their aim was to grade the evidence for the use of drugs in BPD treatment, and to give recommendations based not only on RCT but also lower-level evidence, they conclude that there is no evidence at either level of evidence that any drug improves BPD psychopathology in general. In addition, they did not find any beneficial evidence for the use of a the combination of several drugs. In contrast to this review, the WFSBP guidelines conclude that SSRIs "are best shown to influence emotional dysregulation such as depressive mood, anxiety and mood swings and [...] appear to extend the improvement of comorbid conditions of mood and anxiety disorders." (<LINK REF="REF-Herpertz-2007" TYPE="REFERENCE">Herpertz 2007</LINK>, p. 214). This recommendation is not corroborated by the RCT evidence, as investigated in this review. Additionally, some trials were included in the WFSBP guidelines as randomised controlled trials, that were not included in this review due to stricter inclusion criteria (see <LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK> and <LINK TAG="EXCLUDED_STUDIES" TYPE="SECTION">Excluded studies</LINK>).</P>
<P>The NICE guideline on treatment and management of BPD (<LINK REF="REF-NICE-2009" TYPE="REFERENCE">NICE 2009</LINK>) is based on a similar pool of RCTs, even if the NICE literature searches were last updated in May 2008 (<LINK REF="REF-NICE-2009" TYPE="REFERENCE">NICE 2009</LINK>, p. 56). The guideline developers recommend that "Drug treatment should not be used specifically for borderline personality disorder or for the individual symptoms or behaviour associated with the disorder (for example, repeated self-harm, marked emotional instability, risk-taking behaviour and transient psychotic symptoms)." (<LINK REF="REF-NICE-2009" TYPE="REFERENCE">NICE 2009</LINK>, p. 297). This seems somehow contradictory to the findings of this review. However, the scope of NICE and this Cochrane Collaboration review differ in asking different questions and using different means and methods to answer them. In relation to the question or topic, this Cochrane review aims at reviewing all of the available valid RCT evidence concerning pharmacotherapy of BPD treatment, whereas NICE aims at providing specific recommendations for a defined clinical setting, with pharmacotherapy being only one component within a comprehensive framework of possible health care provisions. Regarding methods, NICE considers somewhat different sources of evidence and applies additional criteria to weigh the costs and benefits of treatments ("NICE has always been focused on providing guidance on the most effective way to use NHS resources", <LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>) and it is consensus-based. In contrast, the aim of this review is, according to Cochrane Collaboration standards, "to present information, rather than to offer advice" (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>, p. 67).</P>
</SUBSECTION>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-05-12 12:28:35 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-05-12 12:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>The current RCT evidence supporting the use of pharmacotherapy for BPD is very sparse when compared to its widespread usage. Despite the remarkable growth in RCT evidence (this review includes 18 more RCTs than its previous version of 2006, with 9 different substances under test), the conclusion that pharmacotherapy in BPD "is not based on good evidence from trials" (<LINK REF="REF-Binks-2006" TYPE="REFERENCE">Binks 2006</LINK>, p. 19) still stands. There are only a few study results per comparison, with small numbers of included participants. However, it is important to remember that no evidence of an effect is not evidence of no effect. Current findings from RCTs presented in this review are not robust and can easily be changed by future research.</P>
<P>The findings suggest there is support for the use of second-generation antipsychotics, mood stabilisers, and omega-3 fatty acids, but these require replication since most effect estimates were based on single study effects. The small amount of available information for individual comparisons indicated marginal effects for first-generation antipsychotics and antidepressants.</P>
<P>Notably, avoidance of abandonment, chronic feelings of emptiness, identity disturbance, and dissociation were not found to be affected significantly by any drug. This finding may be the result of the use of non-BPD specific assessment instruments that do not reproduce these very specific outcomes, but it also reflects that these symptoms are broadly not regarded treatable by pharmacotherapeutic interventions and remain subject to non-pharmaceutical treatments such as psychotherapy.</P>
<P>It is important to consider the adverse effects for these interventions. Most trials did not provide detailed data of adverse effects, but these can be assumed to be similar to those experienced by patients with other conditions. However, the data available suggest an increase in self-harming behaviour when using olanzapine. In addition, toxic effects in case of overdosing (e.g. TCA antidepressants) and the potential for misuse or substance dependence (e.g. hypnotics and sedatives) need special attention in BPD treatment. In the presence of a comorbid eating disorder, possible effects on body weight changes (especially weight gain by olanzapine treatment and weight loss by topiramate treatment) should be taken into accountand discussed between the treating physician and the patient ("shared decision making").</P>
<P>Currently, there is no evidence from RCTs that any drug reduces overall BPD severity, but there are distinct pathology facets. Therefore, pharmacotherapeutic treatment of BPD should be targeted at defined symptoms. Drug treatment should last a sufficient period of time (according to pharmacokinetic and dynamic properties of a certain substance) to judge if there are any benefits, and should be stopped or changed if there are none. Polypharmacy is not supported by the up-to-date evidence and should be avoided wherever possible.</P>
<P>As discussed above, the evidence is not robust. The studies may not adequately reflect several characteristics of clinical settings (among others, patients' characteristics and duration of interventions and observation periods). Further research is urgently needed to provide reliable recommendations. Furthermore, there are some difficulties stemming from the polythetic nature of BPD. Different patients with BPD are likely to experience different facets of the disorder, and clinicians working with these patients are acquainted with different subtypes. The question "What works for whom?" remains broadly unanswered. Consequently, there is little consensus among researchers about a common battery of outcome variables and measures, even for primary studies testing the same drugs with putatively the same treatment targets and effects. Thus, we have a fragmentary view on drug effects, and it remains uncertain how the modulation of one symptom affects another.</P>
<P>People with BPD and their carers should lobby for and facilitate good research.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-05-12 12:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>In recent years, a shift of attention in BPD treatment research has been observed towards SGAs and mood stabilisers, which may be a consequence of study sponsoring by pharmaceutical companies.</P>
<P>Some other classes of drugs have been paid much less attention to than their actual importance in clinical settings suggests. For example, antidepressants, especially SSRIs, play a major role in everyday practice but currently only three placebo-controlled RCTs exist that tested SSRIs in BPD. These drugs urgently need further attention in future placebo-controlled RCTs of BPD treatment. However, replicative studies for all comparisons would be desirable in order to enhance the robustness of findings. On the other hand, placebo-controlled RCTs testing different mood stabilisers (such as oxcarbazepine) and SGAs (e.g. clozapine, quetiapine, risperidone) that have lately been investigated in several non-randomised studies with promising results would be of interest. Currently, there is no RCT evidence-based "gold standard", so any future research endeavour should comprise a placebo condition. Longer observation periods would be sensible, this would enhance external validity and the applicability of findings to primary care settings. Additionally, patients with comorbid axis-I disorders should not be excluded, as psychiatric comorbidities are common in BPD patients. Another point for future research may be the update of popular algorithms to follow in this patient group, e.g. the "Soloff-algorithm" (<LINK REF="REF-Soloff-1998" TYPE="REFERENCE">Soloff 1998Soloff 1998</LINK>) or the APA guidelines algorithm (<LINK REF="REF-Oldham-2004" TYPE="REFERENCE">Oldham 2004Oldham 2004</LINK>).</P>
<P>There is a huge heterogeneity of outcome variables and assessment instruments. A consensus on a minimum set of therapy outcome variables that are most likely to be of interest for any BPD patient would be desirable. Outcome assessment should be more specific and sensitive to BPD relevant pathology. For example, psychotic pathology should be assessed in terms of BPD relevant symptoms, i.e. stress-related paranoid ideation. Fortunately, several assessment instruments have been developed lately to reflect BPD core pathology as described precisely by the DSM-IV criteria (e.g. the BPDSI scale by <LINK REF="REF-Arntz-2003" TYPE="REFERENCE">Arntz 2003</LINK>, the CGI-BPD scale by <LINK REF="REF-Perez-2007" TYPE="REFERENCE">Perez 2007</LINK>, or the ZAN-BPD scale by <LINK REF="REF-Zanarini-2003a" TYPE="REFERENCE">Zanarini 2003a</LINK>). However, some DSM-IV BPD criteria embrace several symptoms, e.g. the criterion of "stress-related paranoid ideation OR dissociation". The possibility of more differentiated outcome assessment may stimulate further research on drugs that may affect BPD core symptoms but have been neglected in the existing RCTs. In particular, drugs targeting affective instability, an important hallmark of BPD pathology, would be of interest. Outcome assessment should also embrace a thorough, standardized assessment of adverse events. Spontaneous reporting of patients may not be as valid and comprehensive as would be desirable.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-05-11 17:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank the previous authors of this review, Claire Binks, Mark Fenton, Lucy McCarthy, Tracy Lee, Clive Adams, and Conor Duggan. Additionally, we thank the editorial team of the Cochrane Developmental, Psychosocial and Learning Problems Group (CDPLPG), Bristol, especially Chris Champion, Jane Dennis, Jo Abbott, and Geraldine Macdonald, and the German Cochrane Centre for supporting this work. We are grateful to Gerd Antes, director of the German Cochrane Centre, who made contact with CDPLPG and helped in gaining grants for financing this work. We are also grateful to Martin Schumacher, director of the Institute of Biostatistics and Medical Informatics at the University Medical Center Freiburg, who gave support in application submission. Thanks also to Nicolas Rüsch, who helped translating studies during the study selection phase.<BR/>We are grateful to the German Ministry of Education and Research (BMBF; grant no. 01KG0609), and the research committee of the University Medical Center Freiburg for supporting this work.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-05-12 09:59:05 +0100" MODIFIED_BY="[Empty name]">
<P>We are not aware of any personal, political, academic or financial conflicts. KL was involved in the <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK> trial by recruiting and assessing participants as one of the 39 study sites. KL and JS have been involved in the process of preparation of the WFSBP guidelines for the treatment of personality disorders (<LINK REF="REF-Herpertz-2007" TYPE="REFERENCE">Herpertz 2007</LINK>). KL has not received any payments from industry since the beginning of 2007 to avoid any kind of conflicts of interest. We are not aware of any secondary or personal interests.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-05-12 11:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>Jutta Stoffers: wrote protocol and final report, selected studies, obtained papers, extracted data, entered data.</P>
<P>Birgit Völlm: helped write the protocol and final report, selected studies, obtained papers, extracted data, entered data.</P>
<P>Gerta Rücker: helped write the protocol and final report, gave statistical support and helped extract data.</P>
<P>Antje Timmer: helped write the protocol, corrected final report.</P>
<P>Nick Huband: helped examine literature search retrievals.</P>
<P>Klaus Lieb: sought funds, helped write the protocol, revised final report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-06-18 19:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>Because of the deficiency in numbers of study effects per comparison, we did not perform sensitivity analyses as planned, nor was it possible to draw funnel plots. </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-05-12 15:01:18 +0100" MODIFIED_BY="Chris Champion">
<STUDIES MODIFIED="2010-05-12 14:55:24 +0100" MODIFIED_BY="Chris Champion">
<INCLUDED_STUDIES MODIFIED="2010-05-12 11:52:27 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bogenschutz-2004" MODIFIED="2010-05-12 11:49:54 +0100" MODIFIED_BY="[Empty name]" NAME="Bogenschutz 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-05-12 11:48:48 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author Affiliation: Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque, NM, US Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque, NM, US&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2010-05-12 11:48:48 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bogenschutz MP, Nurnberg H</AU>
<TI>Olanzapine versus placebo in the treatment of borderline personality disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>1</NO>
<PG>104-9</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:48:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-12 11:49:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nurnberg HG, Bogenschutz MP</AU>
<TI>Atypical antipsychotic treatment of BPD: a 12-week, double-blind, placebo-control trial with olanzapine</TI>
<SO>156th annual meeting of the American Psychiatric Association</SO>
<YR>2003 May 17-22</YR>
<CY>San Francisco</CY>
<IDENTIFIERS MODIFIED="2010-05-12 11:49:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-la-Fuente-1994" MODIFIED="2010-05-12 11:49:32 +0100" MODIFIED_BY="[Empty name]" NAME="De la Fuente 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-05-12 11:49:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De la Fuente JM, Lotstra F</AU>
<TI>A trial of carbamazepine in borderline personality disorder</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1994</YR>
<VL>4</VL>
<PG>479-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>De la Fuente JM, Lotstra F</AU>
<TI>Carbamazepine in borderline personality disorder</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1993</YR>
<VL>3</VL>
<PG>350</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frankenburg-2002" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Frankenburg 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-08 11:06:01 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 11:06:01 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frankenburg FR, Zanarini MC</AU>
<TI>Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>5</NO>
<PG>442-6</PG>
<IDENTIFIERS MODIFIED="2008-08-08 11:06:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-1986" MODIFIED="2010-05-12 11:50:16 +0100" MODIFIED_BY="[Empty name]" NAME="Goldberg 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-05-12 11:50:16 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19860721&lt;/p&gt;" NOTES_MODIFIED="2010-05-12 11:50:16 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO</AU>
<TI>Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1986</YR>
<VL>43</VL>
<NO>7</NO>
<PG>680-6</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:50:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hallahan-2007" MODIFIED="2010-05-08 20:47:32 +0100" MODIFIED_BY="[Empty name]" NAME="Hallahan 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-08 20:47:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hallahan B, Hibbeln JR, Davis JM, Garland MR</AU>
<TI>Omega-3 fatty acid supplementation in patients with recurrent self-harm</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>190</VL>
<PG>118-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollander-2001" MODIFIED="2010-05-12 11:50:35 +0100" MODIFIED_BY="[Empty name]" NAME="Hollander 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-12 11:50:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, et al 

</AU>
<TI>A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>3</NO>
<PG>199-203</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:50:35 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leone-1982" MODIFIED="2010-05-08 20:48:12 +0100" MODIFIED_BY="[Empty name]" NAME="Leone 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-05-08 20:48:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19820621&lt;/p&gt;" NOTES_MODIFIED="2010-05-08 20:48:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leone NF</AU>
<TI>Response of borderline patients to loxapine and chlorpromazine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1982</YR>
<VL>43</VL>
<NO>4</NO>
<PG>148-50</PG>
<IDENTIFIERS MODIFIED="2008-08-08 11:06:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linehan-2008" MODIFIED="2010-05-11 16:35:29 +0100" MODIFIED_BY="[Empty name]" NAME="Linehan 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-07-04 14:00:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Linehan M</AU>
<TI>Update on dialectical behavioral therapy for BPD</TI>
<SO>158th Annual Meeting of the American Psychiatric Association</SO>
<YR>2005 May 21-26</YR>
<CY>Atlanta, GA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-14 13:48:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM, McDavid JD, Brown MZ, Sayrs JHR, Gallop RJ</AU>
<TI>Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>9</NO>
<PG>999-1005</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-11 16:35:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM, McDavid JD, Brown MZ, Sayrs JHR, Gallop RJ</AU>
<TI>Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study</TI>
<SO>published ahead of print: Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>May 6th</VL>
<PG>e1-e7 (pii: ej07m03158)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loew-2006" MODIFIED="2010-05-12 11:50:55 +0100" MODIFIED_BY="[Empty name]" NAME="Loew 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-12 11:50:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20060117&lt;/p&gt;" NOTES_MODIFIED="2010-05-12 11:50:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Loew TH, Nickel MK, Muehlbacher M, Kaplan P, Nickel C, Kettler C, et al 

</AU>
<TI>Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>1</NO>
<PG>61-6</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:50:55 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 20:49:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loew TH, Nickel MK</AU>
<TI>Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2008</YR>
<VL>3</VL>
<PG>355-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montgomery-1979_x002f_82" MODIFIED="2010-05-08 20:49:58 +0100" MODIFIED_BY="[Empty name]" NAME="Montgomery 1979/82" YEAR="1979">
<REFERENCE MODIFIED="2010-05-08 20:49:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Montgomery D</AU>
<TI>Pharmacological prevention of suicidal behaviour</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1982</YR>
<VL>4</VL>
<PG>291-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 20:49:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Montgomery SA, Montgomery DB, Janyanthi Rani S, Roy DH, Shaw PJ, McAuley R</AU>
<TI>Maintenance therapy in repeat suicidal behaviour: a placebo controlled trial</TI>
<SO>Proceedings of the 10th international congress for suicide prevention and crisis intervention</SO>
<YR>1979</YR>
<PG>227-9</PG>
<CY>Ottawa</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montgomery-81_x002f_82_x002f_83" MODIFIED="2010-05-11 16:32:27 +0100" MODIFIED_BY="[Empty name]" NAME="Montgomery 81/82/83" YEAR="1981">
<REFERENCE MODIFIED="2010-05-11 16:32:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery D, Roy D, Montgomery S</AU>
<TI>Mianserin in the prophylaxis of suicidal behaviour: a double-blind placebo controlled trial</TI>
<SO>Dépression et Suicide</SO>
<YR>1981</YR>
<VL>1981</VL>
<PG>786-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 20:50:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Montgomery D</AU>
<TI>Pharmacological prevention of suicidal behaviour</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1982</YR>
<VL>4</VL>
<PG>291-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 20:51:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA, Roy D, Montgomery DB</AU>
<TI>The prevention of recurrent suicidal acts</TI>
<SO>British Journal of 
Clinical Pharamacology</SO>
<YR>1983</YR>
<VL>15</VL>
<PG>183-8S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nickel-2004" MODIFIED="2010-05-12 11:51:11 +0100" MODIFIED_BY="[Empty name]" NAME="Nickel 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-05-08 20:51:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nickel M</AU>
<TI>Topiramate reduced aggression in female patients with borderline personality disorder</TI>
<SO>European Archives of Psychiatry &amp; Clinical Neuroscience</SO>
<YR>2007</YR>
<VL>257</VL>
<NO>7</NO>
<PG>432-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-12 11:51:11 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2010-05-12 11:51:11 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, et al 

</AU>
<TI>Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study</TI>
<SO>The Journal of Clinical 
Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>11</NO>
<PG>1515-9</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:51:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-11-18 10:52:55 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nickel-2005" MODIFIED="2010-05-08 20:52:52 +0100" MODIFIED_BY="[Empty name]" NAME="Nickel 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-08 20:52:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nickel MK, Loew TH</AU>
<TI>Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up</TI>
<SO>European Psychiatry</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>2</NO>
<PG>115-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 20:52:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author Affiliation: Department of Psychosomatic Medicine, Inntalklinik, 84359 Simbach/Inn, Germany. m.nickel@inntalklinik.de&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2010-05-08 20:52:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nickel MK, Nickel C, Kaplan P, Lahmann C, Muhlbacher M, Tritt K, et al 

</AU>
<TI>Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study</TI>
<SO>Biological Psychiatry</SO>
<YR>2005</YR>
<VL>57</VL>
<NO>5</NO>
<PG>495-9</PG>
<IDENTIFIERS MODIFIED="2008-08-08 11:08:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nickel, MK</AU>
<TI>Topiramate treatment of aggression in male borderline patients</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>41</VL>
<NO>5</NO>
<PG>461-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nickel-2006" MODIFIED="2010-05-08 20:53:46 +0100" MODIFIED_BY="[Empty name]" NAME="Nickel 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-08 20:53:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nickel MK, Loew TH, Pedrosa Gil F</AU>
<TI>Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up</TI>
<SO>Psychopharmacology</SO>
<YR>2007</YR>
<VL>191</VL>
<PG>1023-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 20:53:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nickel MK, Mühlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, et al 

</AU>
<TI>Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>833-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 20:53:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nickel, MK</AU>
<TI>Aripiprazole treatment of patients with borderline personality disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>11</NO>
<PG>1815-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pascual-2008" MODIFIED="2010-05-08 20:59:34 +0100" MODIFIED_BY="[Empty name]" NAME="Pascual 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-09-14 14:24:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Fondo de Investigación Sanitaria (Ministry of Health, Spain), Pfizer</AU>
<TI>Ziprasidone in the treatment of borderline personality disorder</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>(accessed 9 September 2009)</YR>
<IDENTIFIERS MODIFIED="2009-09-09 15:03:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-09-09 15:03:51 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT00635921"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 20:59:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pascual JC, Soler J, Puigdemont D, Perez-Egea R, Tiana T, Alvarez E, et al 

</AU>
<TI>Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>4</NO>
<PG>603-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reich-2009" MODIFIED="2010-05-12 11:52:27 +0100" MODIFIED_BY="[Empty name]" NAME="Reich 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-12 11:52:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>McLean Hospital, GlaxoSmithKline</AU>
<TI>Study of lamotrigine treatment of affective instability in borderline personality disorder</TI>
<SO>www.clinicaltrials.gov/</SO>
<YR>(accessed 8 September 2009)</YR>
<IDENTIFIERS MODIFIED="2010-05-12 11:52:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-05-12 11:52:27 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT00634062"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:03:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reich DB, Zanarini MC, Bieri KA</AU>
<TI>A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2009</YR>
<VL>e-pub ahead of print</VL>
<PG>

</PG>
<IDENTIFIERS MODIFIED="2010-05-08 21:03:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-05-08 21:03:15 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1097/YIC.0b013e32832d6c2f"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rinne-2002" MODIFIED="2010-05-08 21:03:38 +0100" MODIFIED_BY="[Empty name]" NAME="Rinne 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-08 21:03:38 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2010-05-08 21:03:38 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rinne T, van den Brink W, Wouters L, van Dyck R</AU>
<TI>SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder
</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>12</NO>
<PG>2048-54</PG>
<IDENTIFIERS MODIFIED="2008-08-08 11:09:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salzman-1995" MODIFIED="2010-05-08 21:04:28 +0100" MODIFIED_BY="[Empty name]" NAME="Salzman 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-05-08 21:04:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salzmann C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, et al 

</AU>
<TI>Effect of 
fluoxetine on 
anger in 
symptomatic 
volunteers with 
borderline 
personality 
disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1</NO>
<PG>23-9</PG>
<IDENTIFIERS MODIFIED="2008-08-08 11:10:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulz-2007" MODIFIED="2010-05-08 21:08:13 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-08 21:04:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Efficacy and safety of olanzapine in patients with borderline personality disorder: a randomized, flexible-dose, double-blind comparison with placebo</TI>
<TO>Summary ID #6257. Clinical Study Summary: F1D-MC-HGKL</TO>
<SO>www.lillytrials.com/results_files/zyprexa/zyprexa_summary_6257</SO>
<YR>(accessed 14 February 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:05:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Olanzapine in patients with borderline personality disorder</TI>
<SO>www.clinicaltrials.gov/</SO>
<YR>(accessed 14 February 2008)</YR>
<IDENTIFIERS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="NCT 00091650"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-09 14:37:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Olanzapine in patients with borderline personality disorder</TI>
<SO>www.who.int/trialsearch</SO>
<YR>(accessed 14 February 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-07 10:53:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz SC, Zanarini M, Detke H, Trzaskoma Q, Lin D, DeBerdt W</AU>
<TI>Olanzapine for the treatment of borderline personality disorder: a flexible-dose 12-week randomized double-blind placebo-controlled study</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9 (Suppl.1)</VL>
<PG>S191</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:06:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, et al 

</AU>
<TI>Olanzapine for the treatment of borderline personality disorder: variable dose, 12-week, randomised double-blind placebo-controlled study</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>193</VL>
<PG>485-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:07:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schulz SC, Zanarini MC, Detke HC, Trzaskoma Q, Lin D, DeBerdt W, et al 

</AU>
<TI>Olanzapine for the treatment of borderline personality disorder: A flexible-dose, 12-week, randomized, double-blind, placebo-controlled study</TI>
<SO>Proceedings of the Association of European Psychiatrsts 15th European Congress of Psychiatry,

; Madrid (Spain)</SO>
<YR>
2007 March 17-21
</YR>
<IDENTIFIERS MODIFIED="2008-08-08 11:10:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:07:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schulz SC, Zanarini MC, Detke HC, Trzaskoma Q, Lin D, DeBerdt W, et al 

</AU>
<TI>Olanzapine for the treatment of borderline personality disorder: a flexible-dose 12-week randomized double-blind placebo-controlled study</TI>
<SO>European Psychiatry</SO>
<YR>2007</YR>
<VL>22</VL>
<PG>S172</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:08:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Trzaskoma Q, et al 

</AU>
<TI>Olanzapine for the treatment of borderline personality disorder: two 12-week randomized double-blind placebo-controlled trials</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>S229-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-2004" MODIFIED="2010-05-08 21:09:58 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-05-08 21:09:58 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author Affiliation: Detp of Psychiatry, Harvard Medical School, Massachusetts Mental Health Ctr, Boston, MA, US Dept of Psychiatry &amp;amp; Human Behavior, Brown U Medical School, Providence, RI, US Dept of Psychiatry &amp;amp; Human Behavior, Brown U Medical School, Providence, RI, US Dept of Psychiatry &amp;amp; Human Behavior, Brown U Medical School, Providence, RI, US U Nevada, Reno Counseling &amp;amp; Testing Ctr, Reno, NV, US Dept of Psychiatry &amp;amp; Human Behavior, Brown U Medical School, Providence, RI, US&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2010-05-08 21:09:58 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J, et al 

</AU>
<TI>Combined 
dialectical 
behavior 
therapy and 
fluoxetine in the 
treatment of 
borderline 
personality 
disorder
</TI>
<SO>Journal of Clinical Psychiatry 
</SO>
<YR>
2004
</YR>
<VL>
65
</VL>
<NO>
3
</NO>
<PG>
379-85
</PG>
<IDENTIFIERS MODIFIED="2008-08-08 11:11:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soler-2005" MODIFIED="2010-05-08 21:11:46 +0100" MODIFIED_BY="[Empty name]" NAME="Soler 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-08 21:11:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pascual JC, Soler J, Barrachina J, Campins J, Puigdemont D, Alvarez E, et al 

</AU>
<TI>Olanzapine plus dialectical behavior therapy of patients with BPD</TI>
<SO>Proceedings of the 157th annual meeting of the American Psychiatric Association
</SO>
<YR>
2004 May
 1-6
</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:11:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, et al 

</AU>
<TI>Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<PG>1221-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soloff-1989" MODIFIED="2010-05-08 21:12:50 +0100" MODIFIED_BY="[Empty name]" NAME="Soloff 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-05-08 21:12:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM</AU>
<TI>Progress in pharmacotherapy of borderline disorders</TI>
<SO>Archives of 
General 
Psychiatry</SO>
<YR>1986</YR>
<VL>43</VL>
<PG>691-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:12:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19890927&lt;/p&gt;" NOTES_MODIFIED="2010-05-08 21:12:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Soloff PH, George A, Nathan S, Schulz PM, Cornelius JR, Herring J, et al 

</AU>
<TI>Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response</TI>
<SO>Journal of Clinical Psychopharmacology
</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>4</NO>
<PG>238-46</PG>
<IDENTIFIERS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="24"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soloff-1993" MODIFIED="2010-05-08 21:13:24 +0100" MODIFIED_BY="[Empty name]" NAME="Soloff 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-08 21:13:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19930607&lt;/p&gt;" NOTES_MODIFIED="2010-05-08 21:13:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF</AU>
<TI>Efficacy of phenelzine and haloperidol in borderline personality disorder</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1993</YR>
<VL>50</VL>
<NO>5</NO>
<PG>377-85</PG>
<IDENTIFIERS MODIFIED="2008-08-08 13:14:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tritt-2005" MODIFIED="2010-05-11 17:16:32 +0100" MODIFIED_BY="[Empty name]" NAME="Tritt 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-11 17:16:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leiberich P, Nickel MK, Tritt K, Pedrosa Gil F</AU>
<TI>Lamotrigine treatment of aggression in female borderline patients, part II: an 18-month follow-up</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>
2008</YR>
<VL>22</VL>
<NO>7</NO>
<PG>805-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:21:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author Affiliation: Department of Psychosomatic Medicine, University Clinic, Regensburg, Germany&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2010-05-08 21:21:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, et al 

</AU>
<TI>Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>3</NO>
<PG>287-91</PG>
<IDENTIFIERS MODIFIED="2008-08-08 13:14:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zanarini-2001" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-08 13:14:32 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 13:14:32 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Frankenburg FR</AU>
<TI>Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>11</NO>
<PG>849-54</PG>
<IDENTIFIERS MODIFIED="2008-08-08 13:14:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zanarini-2003" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-08 13:14:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 13:14:44 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Frankenburg FR</AU>
<TI>Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>160</VL>
<NO>1</NO>
<PG>167-9</PG>
<IDENTIFIERS MODIFIED="2008-08-08 13:14:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zanarini-2004" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-08-08 13:15:00 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2008-08-08 13:15:00 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Frankenburg FR, Parachini EA</AU>
<TI>A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>7</NO>
<PG>903-7</PG>
<IDENTIFIERS MODIFIED="2008-08-08 13:14:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zanarini-2007" MODIFIED="2010-05-08 21:24:35 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-08 21:22:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Efficacy and 
safety of 
olanzapine in 
patients with 
borderline 
personality 
disorder: a randomized double-blind comparison with placebo</TI>
<SO>www.clinicaltrials.gov/</SO>
<YR>(accessed 28 July 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-09 15:09:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Efficacy and safety of olanzapine in patients with borderline personality disorder</TI>
<SO>www.who.int/trialsearch/</SO>
<YR>(accessed 14 February, 2008)</YR>
<IDENTIFIERS MODIFIED="2009-09-09 15:09:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-09-09 15:09:48 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT00088036"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-07 10:41:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Efficacy and safety of olanzapine in patients with borderline personality disorder: a randomized double-blind comparison with placebo</TI>
<TO>Summary ID # 6253. Clinical Study Summary: Study F1D-MC-HGKK</TO>
<SO>www.lillytrials.com/results_files/zyprexa/zyprexa_summary_6523/</SO>
<YR>(accessed 14 February 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:23:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, et al 

</AU>
<TI>A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized double-blind placebo controlled study</TI>
<SO>European Psychiatry</SO>
<YR>2007</YR>
<VL>22</VL>
<PG>S172-3</PG>
<IDENTIFIERS MODIFIED="2008-07-01 09:07:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:23:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, et al 

</AU>
<TI>A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized double-blind placebo-controlled study</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9 (Suppl.1)</VL>
<PG>S191</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:24:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, et al 

</AU>
<TI>A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study</TI>
<SO>Proceedings of the Association of European Psychiatrists 15th European Congress of Psychiatry; Madrid (Spain)</SO>
<YR>
2007 March 17-21
</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:24:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Trzaskoma Q, et al 

</AU>
<TI>Olanzapine for the treatment of borderline personality disorder: two 12-week randomized double-blind placebo-controlled trials</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>S229-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-05-12 11:57:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bellino-2005" MODIFIED="2010-05-12 11:53:33 +0100" MODIFIED_BY="[Empty name]" NAME="Bellino 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-12 11:53:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellino S, Paradiso E, Bogetto F</AU>
<TI>Oxcarbazepine in the treatment of borderline personality disorder: a pilot study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>9</NO>
<PG>1111-5</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:53:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellino-2006a" MODIFIED="2010-05-12 11:53:44 +0100" MODIFIED_BY="[Empty name]" NAME="Bellino 2006a" YEAR="2006">
<REFERENCE MODIFIED="2010-05-12 11:53:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellino S, Paradiso E, Bogetto F</AU>
<TI>Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>7</NO>
<PG>1042-6</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:53:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellino-2006b" MODIFIED="2010-05-12 11:53:54 +0100" MODIFIED_BY="[Empty name]" NAME="Bellino 2006b" YEAR="2006">
<REFERENCE MODIFIED="2010-05-12 11:53:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellino S, Zizza M, Rinaldi C, Bogetto F</AU>
<TI>Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>51</VL>
<NO>7</NO>
<PG>453-60</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:53:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benedetti-1998" MODIFIED="2010-05-12 11:53:59 +0100" MODIFIED_BY="[Empty name]" NAME="Benedetti 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-12 11:53:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E</AU>
<TI>Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>3</NO>
<PG>103-7</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:53:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bohus-1999" MODIFIED="2010-05-12 11:54:16 +0100" MODIFIED_BY="[Empty name]" NAME="Bohus 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-12 11:54:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, Limberger MF, Bohme R, Schmahl CG</AU>
<TI>Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>9</NO>
<PG>598-603</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:54:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chengappa-1999" MODIFIED="2010-05-12 11:54:28 +0100" MODIFIED_BY="[Empty name]" NAME="Chengappa 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-12 11:54:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chengappa KN, Ebeling T, Kang JS, Levine J, Parepally H</AU>
<TI>Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>7</NO>
<PG>477-84</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:54:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coccaro-1997" MODIFIED="2010-05-12 11:54:48 +0100" MODIFIED_BY="[Empty name]" NAME="Coccaro 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-12 11:54:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coccaro EF, Kavoussi RJ</AU>
<TI>Fluoxetine and impulsive aggressive behavior in personality-disordered subjects</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1997</YR>
<VL>54</VL>
<NO>12</NO>
<PG>1081-8</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:54:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornelius-1990" MODIFIED="2010-05-12 11:54:52 +0100" MODIFIED_BY="[Empty name]" NAME="Cornelius 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-05-12 11:54:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JR, Soloff PH, Perel JM, Ulrich RF</AU>
<TI>Fluoxetine trial in borderline personality disorder</TI>
<SO>Psychopharmacology Bulletin
</SO>
<YR>1990</YR>
<VL>26</VL>
<NO>1</NO>
<PG>151-4</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:54:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornelius-1993" MODIFIED="2010-05-08 21:28:30 +0100" MODIFIED_BY="[Empty name]" NAME="Cornelius 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-08 21:28:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JR, Soloff PH, George A, Ulrich RF, Perel JM</AU>
<TI>Haloperidol vs. phenelzine in continuation therapy of borderline disorder</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1993</YR>
<VL>29</VL>
<NO>2</NO>
<PG>333-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:28:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JR, Soloff PH, Perel JM, Ulrich RF</AU>
<TI>Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>150</VL>
<NO>12</NO>
<PG>1843-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cowdry-1988" MODIFIED="2010-05-12 11:55:02 +0100" MODIFIED_BY="[Empty name]" NAME="Cowdry 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-05-12 11:55:02 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19880224&lt;/p&gt;" NOTES_MODIFIED="2010-05-12 11:55:02 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cowdry RW, Gardner DL</AU>
<TI>Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<NO>2</NO>
<PG>111-9</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:55:02 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frankenburg-1993" MODIFIED="2010-05-12 11:55:07 +0100" MODIFIED_BY="[Empty name]" NAME="Frankenburg 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-12 11:55:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frankenburg FR, Zanarini MC</AU>
<TI>Clozapine treatment of borderline patients: a preliminary study</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1993</YR>
<VL>34</VL>
<NO>6</NO>
<PG>402-5</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:55:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hilger-2003" MODIFIED="2010-05-12 11:55:16 +0100" MODIFIED_BY="[Empty name]" NAME="Hilger 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-12 11:55:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hilger E, Barnas C, Kasper S</AU>
<TI>Quetiapine in the treatment of borderline personality disorder</TI>
<SO>World Journal of Biological Psychiatry</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>1</NO>
<PG>42-4</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:55:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollander-2005" MODIFIED="2010-05-12 11:55:38 +0100" MODIFIED_BY="[Empty name]" NAME="Hollander 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-12 11:55:38 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author Affiliation: Department of Psychiatry, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1230, New York, NY 10029-6574, USA. eric.hollander@mssm.edu&amp;#182;&lt;/p&gt;" NOTES_MODIFIED="2010-05-12 11:55:38 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB</AU>
<TI>Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>3</NO>
<PG>621-4</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:55:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:33:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, et al 

</AU>
<TI>Divalproex in the 
treatment of impulsive aggression: efficacy in cluster B personality disorders</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<PG>1186-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koenigsberg-2003" MODIFIED="2010-05-08 21:35:03 +0100" MODIFIED_BY="[Empty name]" NAME="Koenigsberg 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-08 21:35:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koenigsberg HW, Reynolds D, Goodman M, New AS, Mitropoulou V, Trestman RL, et al 

</AU>
<TI>Risperidone in the treatment of schizotypal personality disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<PG>628-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-La-Malfa-2003" MODIFIED="2010-05-12 11:55:48 +0100" MODIFIED_BY="[Empty name]" NAME="La Malfa 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-05-12 11:55:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Malfa G, Lampronti L, Bertelli M, Conte M, Cabras P</AU>
<TI>[Aggressiveness and 
personality 
disorders: Evaluation of 
efficacy and 
existence of 
predictors in the 
treatment with 
fluvoxamine and 
lithium] Aggressività e disturbi della personalità</TI>
<SO>Minerva Psychiatrica</SO>
<YR>2003</YR>
<VL>44</VL>
<PG>75-81</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:55:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Links-1990" MODIFIED="2010-05-12 11:55:51 +0100" MODIFIED_BY="[Empty name]" NAME="Links 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-05-12 11:55:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Links PS, Steiner M, Boiago I, Irwin D</AU>
<TI>Lithium 
therapy for 
borderline 
patients: Preliminary 
findings</TI>
<SO>Journal of Personality Disorders</SO>
<YR>1990</YR>
<VL>4</VL>
<NO>2</NO>
<PG>173-81</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:55:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Markovitz-1991" MODIFIED="2010-05-12 11:55:57 +0100" MODIFIED_BY="[Empty name]" NAME="Markovitz 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-12 11:55:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY</AU>
<TI>Fluoxetine in the treatment of borderline and schizotypal personality disorders</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1991</YR>
<VL>148</VL>
<NO>8</NO>
<PG>1064-7</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:55:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Markovitz-1995a" MODIFIED="2010-05-12 11:56:01 +0100" MODIFIED_BY="[Empty name]" NAME="Markovitz 1995a" YEAR="1995">
<REFERENCE MODIFIED="2010-05-12 11:56:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Markovitz PJ</AU>
<TI>Pharmacotherapy of 
impulsivity, 
aggression, and 
related 
disorders</TI>
<SO>Impulsivity and Aggression</SO>
<YR>1995</YR>
<PG>263-87</PG>
<ED>Hollander E, Stein DJ</ED>
<PB>

Wiley
</PB>
<CY>New York, NY</CY>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Markovitz-1995b" MODIFIED="2010-05-12 11:56:05 +0100" MODIFIED_BY="[Empty name]" NAME="Markovitz 1995b" YEAR="1995">
<REFERENCE MODIFIED="2010-05-12 11:56:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Markovitz PJ, Wagner SC</AU>
<TI>Venlafaxine in the treatment of borderline personality disorder</TI>
<SO>Psychopharmacology Bulletin
</SO>
<YR>1995</YR>
<VL>31</VL>
<NO>4</NO>
<PG>773-7</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norden-1989" MODIFIED="2010-05-12 11:56:08 +0100" MODIFIED_BY="[Empty name]" NAME="Norden 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-05-12 11:56:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norden MJ</AU>
<TI>Fluoxetine in borderline personality disorder</TI>
<SO>Progress in Neuropsychopharmacology Biology &amp; Psychiatry</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>6</NO>
<PG>885-93</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parsons-1989" MODIFIED="2010-05-12 11:56:15 +0100" MODIFIED_BY="[Empty name]" NAME="Parsons 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-05-12 11:56:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parsons B, Quitkin FM, McGrath PJ, Stewart JW, Tricamo E, Ocepek-Welikson K, et al 

</AU>
<TI>Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression</TI>
<SO>Psychopharmacology Bulletin
</SO>
<YR>1989</YR>
<VL>25</VL>
<NO>4</NO>
<PG>524-34</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Philipsen-2004a" MODIFIED="2010-05-12 11:56:22 +0100" MODIFIED_BY="[Empty name]" NAME="Philipsen 2004a" YEAR="2004">
<REFERENCE MODIFIED="2010-05-12 11:56:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Philipsen A, Schmahl C, Lieb K</AU>
<TI>Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder
</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2004</YR>
<VL>37</VL>
<NO>5</NO>
<PG>196-9</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Philipsen-2004b" MODIFIED="2010-05-12 11:56:26 +0100" MODIFIED_BY="[Empty name]" NAME="Philipsen 2004b" YEAR="2004">
<REFERENCE MODIFIED="2010-05-12 11:56:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Philipsen A, Richter H, Schmahl C, Peters J, Rusch N, Bohus M, et al 

</AU>
<TI>Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>10</NO>
<PG>1414-9</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rocca-2002" MODIFIED="2010-05-12 11:56:30 +0100" MODIFIED_BY="[Empty name]" NAME="Rocca 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-05-12 11:56:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rocca P, Marchiaro L, Cocuzza E, Bogetto F</AU>
<TI>Treatment of borderline personality disorder with risperidone.[see comment]</TI>
<SO>The Journal of 
Clinical 
Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<PG>241-4</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-2003" MODIFIED="2010-05-12 11:56:34 +0100" MODIFIED_BY="[Empty name]" NAME="Russell 2003" YEAR="">
<REFERENCE MODIFIED="2010-05-12 11:56:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell JM, Kornstein SG, Shea M, McCullough JP, Harrison WM, Hirschfeld RM, et al 

</AU>
<TI>Chronic depression and comorbid personality disorders: Response to sertraline versus imipramine
</TI>
<SO>Journal of Clinical Psychiatry
</SO>
<YR>
2003
</YR>
<VL>
64
</VL>
<NO>
5
</NO>
<PG>
554-61
</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulz-1999" MODIFIED="2010-05-12 11:56:39 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-12 11:56:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulz SC, Camlin KL, Berry SA, Jesberger JA</AU>
<TI>Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia</TI>
<SO>Biological Psychiatry</SO>
<YR>1999</YR>
<VL>46</VL>
<NO>10</NO>
<PG>1429-35</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serban-1984" MODIFIED="2010-05-12 11:56:43 +0100" MODIFIED_BY="[Empty name]" NAME="Serban 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-05-12 11:56:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 19841128&lt;/p&gt;" NOTES_MODIFIED="2010-05-12 11:56:43 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serban G, Siegel S</AU>
<TI>Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>141</VL>
<NO>11</NO>
<PG>1455-8</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soloff-1986" MODIFIED="2010-05-12 11:56:47 +0100" MODIFIED_BY="[Empty name]" NAME="Soloff 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-05-12 11:56:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM</AU>
<TI>Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1986</YR>
<VL>43</VL>
<NO>7</NO>
<PG>691-7</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:47:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soloff PH, George A, Nathan S, Schulz PM, Ulrich RF, Perel JM</AU>
<TI>Amitriptyline and haloperidol in unstable and schizotypal borderline disorders</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1986</YR>
<VL>22</VL>
<NO>1</NO>
<PG>177-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soloff-1987" MODIFIED="2010-05-12 11:56:51 +0100" MODIFIED_BY="[Empty name]" NAME="Soloff 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-05-12 11:56:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Soloff PH, George A, Nathan RS, Schulz PM, Perel JM</AU>
<TI>Behavioral dyscontrol in borderline patients treated with amitriptyline</TI>
<SO>Psychopharmacology Bulletin
</SO>
<YR>1987</YR>
<VL>23</VL>
<NO>1</NO>
<PG>177-81</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:56:51 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-08 21:47:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soloff PH, George A, RS Nathan, Schulz PM, Perel JM</AU>
<TI>Paradoxical effects of amitriptyline on borderline patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>143</VL>
<NO>12</NO>
<PG>1603-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verkes-1998" MODIFIED="2010-05-12 11:57:14 +0100" MODIFIED_BY="[Empty name]" NAME="Verkes 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-05-12 11:57:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verkes RJ, Van der Mast RC, Hengeveld MW, Tuyl JP, Zwinderman AH, Van Kempen GM</AU>
<TI>Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<NO>4</NO>
<PG>543-7</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:57:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziegenhorn-2009" MODIFIED="2010-05-08 21:48:32 +0100" MODIFIED_BY="[Empty name]" NAME="Ziegenhorn 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-08 21:48:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziegenhorn AA, Roepke S, Schommer NC, Merkl A, Danker-hopfe H, Perschel FH, et al 

</AU>
<TI>Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder
</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>2</NO>
<PG>170-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2010-05-12 14:55:24 +0100" MODIFIED_BY="Chris Champion">
<STUDY DATA_SOURCE="PUB" ID="STD-AstraZen-NCT00254748" MODIFIED="2010-05-12 14:54:41 +0100" MODIFIED_BY="Chris Champion" NAME="AstraZen NCT00254748" YEAR="">
<REFERENCE MODIFIED="2010-05-12 14:54:41 +0100" MODIFIED_BY="Chris Champion" PRIMARY="YES" TYPE="OTHER">
<AU>AstraZeneca Netherlands Medical Director</AU>
<TI>The effect of quetiapine on psychotic-like symptoms in borderline personality disordered patients: a randomised placebo-controlled trial</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>(accessed 28 July 2007)</YR>
<IDENTIFIERS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="NCT00254748"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bohus-NCT00124839" MODIFIED="2010-05-12 14:54:51 +0100" MODIFIED_BY="Chris Champion" NAME="Bohus NCT00124839" YEAR="">
<REFERENCE MODIFIED="2010-05-12 14:54:51 +0100" MODIFIED_BY="Chris Champion" PRIMARY="YES" TYPE="OTHER">
<AU>Bohus M</AU>
<TI>Evaluation of the efficacy of the opioid antagonist naltrexone on the incidence and intensity of flashbacks and dissociative states in patients with borderline personality disorder</TI>
<SO>www.clinicaltrials.gov/</SO>
<YR>(accessed 27 July 2007)</YR>
<IDENTIFIERS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="NCT00124839"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casas-NCT00437099" MODIFIED="2010-05-08 21:50:28 +0100" MODIFIED_BY="[Empty name]" NAME="Casas NCT00437099" YEAR="">
<REFERENCE MODIFIED="2010-05-08 21:50:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Casas M</AU>
<TI>Efficacy of omega-3 fatty acids on borderline personality disorder: a randomised, double blind clinical trial</TI>
<SO>www.clinical
trials.gov/</SO>
<YR>(accessed 28 July 2007)</YR>
<IDENTIFIERS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="NCT00437099"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodman-NCT00255554" MODIFIED="2010-05-12 14:54:59 +0100" MODIFIED_BY="Chris Champion" NAME="Goodman NCT00255554" YEAR="">
<REFERENCE MODIFIED="2010-05-08 21:51:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Goodman M, New AS, Koenigsberg HW, Hazlett E, Flory J, Siever L</AU>
<TI>Psychotherapy and combined treatment in BPD: possible effects
</TI>
<SO>158th Annual Meeting of the American Psychiatric Association, Atlanta, GA</SO>
<YR>2005 May 21-26</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-12 14:54:59 +0100" MODIFIED_BY="Chris Champion" PRIMARY="NO" TYPE="OTHER">
<AU>Goodman M</AU>
<TI>Effects of Dialectical Behavioral Therapy and escitalopram on impulsive aggression, affective instability and cognitive processing in Borderline Personality Disorder</TI>
<SO>www.clinicaltrials.gov/</SO>
<YR>(accessed 28 July 2007)</YR>
<IDENTIFIERS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="NCT00255554"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malev-ISRCTN11135486" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Malev ISRCTN11135486" YEAR="">
<REFERENCE MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Malevani J</AU>
<TI>Quetiapine versus sertraline as the pharmacological component in a standardised psychopharmacological and psychotherapeutic treatment of borderline personality disorder: a randomised, rater-blinded study</TI>
<SO>www.controlled-trials.com/</SO>
<YR>(accessed 28 July 2007)</YR>
<IDENTIFIERS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="ISRCTN11135486"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ralevski-NCT00463775" MODIFIED="2010-05-12 14:55:13 +0100" MODIFIED_BY="Chris Champion" NAME="Ralevski NCT00463775" YEAR="">
<REFERENCE MODIFIED="2010-05-12 14:55:13 +0100" MODIFIED_BY="Chris Champion" PRIMARY="YES" TYPE="OTHER">
<AU>Ralevski E</AU>
<TI>Topiramate for treatment of patients with borderline personality disorder and alcohol dependence</TI>
<SO>www.clinicaltrials.gov/</SO>
<YR>(accessed 28 July 2007)</YR>
<IDENTIFIERS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="NCT00463775"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulz-NCT00222482" MODIFIED="2010-05-12 14:55:24 +0100" MODIFIED_BY="Chris Champion" NAME="Schulz NCT00222482" YEAR="">
<REFERENCE MODIFIED="2010-05-12 14:55:24 +0100" MODIFIED_BY="Chris Champion" PRIMARY="YES" TYPE="OTHER">
<AU>Schulz SC</AU>
<TI>A double-blind and placebo controlled assessment of Depakote ER in borderline personality disorder</TI>
<SO>www.clinicaltrials.gov/</SO>
<YR>(accessed 28 July 2007)</YR>
<IDENTIFIERS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE="NCT00222482"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-05-12 15:01:18 +0100" MODIFIED_BY="Chris Champion">
<ADDITIONAL_REFERENCES MODIFIED="2010-05-12 15:01:18 +0100" MODIFIED_BY="Chris Champion">
<REFERENCE ID="REF-Akiskal-2004" MODIFIED="2010-05-12 09:37:03 +0100" MODIFIED_BY="[Empty name]" NAME="Akiskal 2004" TYPE="JOURNAL_ARTICLE">
<AU>Akiskal HS</AU>
<TI>Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2004</YR>
<VL>110</VL>
<NO>6</NO>
<PG>401-7</PG>
<IDENTIFIERS MODIFIED="2010-05-12 09:37:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-APA-1980" MODIFIED="2010-05-12 09:38:28 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1980" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and statistical manual of mental disorders</SO>
<YR>1980</YR>
<EN>3rd</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and statistical manual of mental disorders</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-2000a" MODIFIED="2010-05-12 09:38:02 +0100" MODIFIED_BY="[Empty name]" NAME="APA 2000a" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and statistical manual of mental disorders, 4th edition, text revision</SO>
<YR>2000</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS MODIFIED="2010-05-12 09:35:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-APA-2000b" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="APA 2000b" TYPE="BOOK">
<AU>Task force for the Handbook of Psychiatric Measures</AU>
<SO>Handbook of Psychiatric Measures</SO>
<YR>2000</YR>
<EN>1st</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington (DC)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-2001" MODIFIED="2010-05-08 21:59:24 +0100" MODIFIED_BY="[Empty name]" NAME="APA 2001" TYPE="JOURNAL_ARTICLE">
<AU>American Psychiatric Association</AU>
<TI>Practice guideline for the treatment of patients with borderline personality disorder
</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>10 Suppl</NO>
<PG>1-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-2005" MODIFIED="2010-05-12 14:54:28 +0100" MODIFIED_BY="Chris Champion" NAME="APA 2005" TYPE="OTHER">
<AU>Oldham JM</AU>
<TI>Guideline Watch: Practice guideline for the treatment of patients with borderline personality disorder.</TI>
<SO>Available online at http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm</SO>
<YR>2005</YR>
<PB>American Psychiatric Association</PB>
<CY>Arlington, VA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arntz-2003" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Arntz 2003" TYPE="JOURNAL_ARTICLE">
<AU>Arntz A, van den Hoorn M, Cornelis J, Verheul R, van den Bosch W, de Bie AJHT</AU>
<TI>Reliability and validity of the Borderline Personality Disorder Severity Index</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>1</NO>
<PG>45-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Binks-2006" MODIFIED="2010-05-12 14:52:45 +0100" MODIFIED_BY="Chris Champion" NAME="Binks 2006" TYPE="COCHRANE_REVIEW">
<AU>Binks CA, Fenton M, McCarthy L, Lee T, Adams CE, Duggan C</AU>
<TI>Pharmacological interventions for people with borderline personality disorder</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-05-12 14:52:16 +0100" MODIFIED_BY="Chris Champion">
<IDENTIFIER MODIFIED="2010-05-12 14:52:16 +0100" MODIFIED_BY="Chris Champion" TYPE="DOI" VALUE="10.1002/14651858. CD005653"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Black-2004" MODIFIED="2010-05-12 14:56:08 +0100" MODIFIED_BY="Chris Champion" NAME="Black 2004" TYPE="JOURNAL_ARTICLE">
<AU>Black DW, Blum N, Pfohl B, Hale N</AU>
<TI>Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>3</NO>
<PG>226-39</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:58:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2008" MODIFIED="2010-05-08 22:07:15 +0100" MODIFIED_BY="[Empty name]" NAME="Duggan 2008" TYPE="JOURNAL_ARTICLE">
<AU>Duggan C, Huband N, Smailagic N, Ferriter M, Adams C</AU>
<TI>The use of pharmacological treatments for people with personality disorder: a systematic review of randomized controlled trials</TI>
<SO>Personality and Mental Health</SO>
<YR>2008</YR>
<VL>2</VL>
<PG>119-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2010-05-08 22:07:25 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Endicott-1976" MODIFIED="2010-05-08 22:07:33 +0100" MODIFIED_BY="[Empty name]" NAME="Endicott 1976" TYPE="JOURNAL_ARTICLE">
<AU>Endicott J, Spitzer RL, Fleiss JL, Cohen J</AU>
<TI>The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1976</YR>
<VL>33</VL>
<PG>766-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franke-2002" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Franke 2002" TYPE="BOOK">
<AU>Franke GH</AU>
<SO>SCL-90-R. Symptom-Checkliste von L.R. Derogatis</SO>
<YR>2002</YR>
<PB>Beltz</PB>
<CY>Göttingen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gunderson-1981" MODIFIED="2008-06-12 16:08:59 +0100" MODIFIED_BY="[Empty name]" NAME="Gunderson 1981" TYPE="JOURNAL_ARTICLE">
<AU>Gunderson JG, Kolb JE, Austin V</AU>
<TI>The diagnostic interview for borderline patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<PG>896-903</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK_SECTION">
<AU>Guy W</AU>
<TI>ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338)</TI>
<SO>Psychopharmacology Research Branch, Division of Extramural Research Programs</SO>
<YR>1976</YR>
<PG>218-222</PG>
<PB>Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herpertz-2007" MODIFIED="2010-05-12 14:53:27 +0100" MODIFIED_BY="Chris Champion" NAME="Herpertz 2007" TYPE="JOURNAL_ARTICLE">
<AU>Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Möller H-J et al</AU>
<TI>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders</TI>
<SO>The World Journal of Biological Psychiatry</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>4</NO>
<PG>212-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-05-12 11:58:31 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:58:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-05-12 14:53:12 +0100" MODIFIED_BY="Chris Champion" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Review of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ingenhoven-2010" MODIFIED="2010-03-16 10:50:42 +0000" MODIFIED_BY="[Empty name]" NAME="Ingenhoven 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ingenhoven T, Lafay P, Rinne T, Passchier J, Duivenvoorden H</AU>
<TI>Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2010</YR>
<VL>71</VL>
<NO>1</NO>
<PG>14-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kernberg-1975" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Kernberg 1975" TYPE="BOOK">
<AU>Kernberg OF</AU>
<SO>Borderline conditions and primary narcissism</SO>
<YR>1975</YR>
<PB>Jason Aronson</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lenzenweger-2007" MODIFIED="2010-05-08 22:18:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lenzenweger 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lenzenweger MF, Lane M, Loranger AW, Kessler RC</AU>
<TI>DSM-IV personality disorders in the National Comorbidity Survey Replication (NCS-R)</TI>
<SO>Biological Psychiatry</SO>
<YR>2007</YR>
<VL>62</VL>
<PG>553-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lieb-2004" MODIFIED="2010-05-12 11:58:46 +0100" MODIFIED_BY="[Empty name]" NAME="Lieb 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M</AU>
<TI>Borderline personality disorder</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>364</VL>
<NO>9432</NO>
<PG>453-61</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:58:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Linehan-1997" MODIFIED="2010-05-12 14:56:44 +0100" MODIFIED_BY="Chris Champion" NAME="Linehan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Linehan MM</AU>
<TI>Behavioral treatments of suicidal behaviors. Definitional obfuscation and treatment outcomes</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1997</YR>
<VL>836</VL>
<PG>302-28</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:58:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Links-2009" MODIFIED="2010-03-15 13:07:55 +0000" MODIFIED_BY="[Empty name]" NAME="Links 2009" TYPE="BOOK_SECTION">
<AU>Links PS, Kolla N</AU>
<TI>Assessing and managing suicide risk</TI>
<SO>Essentials of personality disorders</SO>
<YR>2009</YR>
<EN>1st</EN>
<ED>Oldham JM, Skodol AE, Bender DS</ED>
<PB>American Psychiatric Publishing</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGlashan-2000" MODIFIED="2010-05-12 14:56:27 +0100" MODIFIED_BY="Chris Champion" NAME="McGlashan 2000" TYPE="JOURNAL_ARTICLE">
<AU>McGlashan TH, Grilo CM, Skodol AE, Gunderson JG, Shea MT, Morey LC, et al</AU>
<TI>The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2000</YR>
<VL>102</VL>
<NO>4</NO>
<PG>256-64</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:59:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" MODIFIED="2010-05-12 11:59:20 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1896-900</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:59:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2009" MODIFIED="2010-03-12 10:03:41 +0000" MODIFIED_BY="[Empty name]" NAME="NICE 2009" TYPE="BOOK">
<AU>National Collaborating Centre for Mental Health (Commissioned by the National Institute for Health and Clinical Excellence)</AU>
<TI>Borderline Personality Disorder: treatment and management. National Clinical Practice Guideline Number 78</TI>
<SO>http://www.nice.org.uk/nicemedia/pdf/Borderline%20personality%20disorder%20full%20guideline-published.pdf</SO>
<YR>(accessed 12 March 2010)</YR>
<PB>The British Psychological Society and The Royal College of Psychiatrists</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2010" MODIFIED="2010-05-12 14:56:35 +0100" MODIFIED_BY="Chris Champion" NAME="NICE 2010" TYPE="OTHER">
<TI>National Institute for Health and Clinical Excellence</TI>
<SO>http://www.nice.org.uk/aboutnice/whatwedo/niceandthenhs/UsingNICEGuidanceToCutCostsInTheDownturn.jsp</SO>
<YR>(accessed 12 March 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nos_x00e8_-2006" MODIFIED="2010-05-12 14:57:03 +0100" MODIFIED_BY="Chris Champion" NAME="Nosè 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nosè M, Cipriani A, Biancosino B, Grassi L, Barbui C</AU>
<TI>Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>345-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oldham-2004" MODIFIED="2010-05-12 14:57:13 +0100" MODIFIED_BY="Chris Champion" NAME="Oldham 2004" TYPE="JOURNAL_ARTICLE">
<AU>Oldham JM, Bender DS, Skodol AE, Dyk IR, Sanislow CA, Yen S, et al</AU>
<TI>Testing an APA practice guideline: symptom-targeted medication utilization for patients with borderline personality disorder</TI>
<SO>Journal of Psychiatric Practice</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>3</NO>
<PG>156-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paris-2007" MODIFIED="2010-05-12 11:59:32 +0100" MODIFIED_BY="[Empty name]" NAME="Paris 2007" TYPE="JOURNAL_ARTICLE">
<AU>Paris J, Gunderson J, Weinberg I</AU>
<TI>The interface between borderline personality disorder and bipolar spectrum disorders</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>2007</YR>
<VL>48</VL>
<NO>2</NO>
<PG>145-54</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:59:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Perez-2007" MODIFIED="2010-05-12 15:00:33 +0100" MODIFIED_BY="Chris Champion" NAME="Perez 2007" TYPE="JOURNAL_ARTICLE">
<AU>Perez V, Barrachina J, Soler J, Pascual JC, Campins MJ, Puigdemont D, et al</AU>
<TI>The clinical global impression scale for borderline personality disorder patients (CGI-BPD): a scale sensible to detect changes</TI>
<TO>Impresión clínica global para pacientes con trastorno límite de la personalidad (ICG-TLP): una escala sensible al cambio</TO>
<SO>Actas Españolas de Psiquiatría</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>4</NO>
<PG>229-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2010-05-12 15:00:45 +0100" MODIFIED_BY="Chris Champion" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skodol-2002" MODIFIED="2010-05-12 15:00:59 +0100" MODIFIED_BY="Chris Champion" NAME="Skodol 2002" TYPE="JOURNAL_ARTICLE">
<AU>Skodol AE, Gunderson JG, McGlashan TH, Dyck IR, Stout RL, Bender DS, et al</AU>
<TI>Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>2</NO>
<PG>276-83</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:59:45 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Soloff-1998" MODIFIED="2010-03-30 15:57:50 +0100" MODIFIED_BY="[Empty name]" NAME="Soloff 1998" TYPE="JOURNAL_ARTICLE">
<AU>Soloff, PH</AU>
<TI>Algorithms for pharmacological treatment of personality dimensions: Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation</TI>
<SO>Bulletin of the Menninger Clinic</SO>
<YR>1998</YR>
<VL>62</VL>
<PG>195-214</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soloff-2002" MODIFIED="2010-05-12 11:59:55 +0100" MODIFIED_BY="[Empty name]" NAME="Soloff 2002" TYPE="JOURNAL_ARTICLE">
<AU>Soloff PH, Lynch KG, Kelly TM</AU>
<TI>Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder</TI>
<SO>Journal of Personality Disorder
</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>3</NO>
<PG>201-14</PG>
<IDENTIFIERS MODIFIED="2010-05-12 11:59:55 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Stern-1938" MODIFIED="2010-05-12 12:00:03 +0100" MODIFIED_BY="[Empty name]" NAME="Stern 1938" TYPE="JOURNAL_ARTICLE">
<AU>Stern A</AU>
<TI>Psychoanalytic investigation of and therapy in the borderline group of neuroses</TI>
<SO>Psychoanalytic Quarterly</SO>
<YR>1938</YR>
<VL>7</VL>
<PG>467-89</PG>
<IDENTIFIERS MODIFIED="2010-05-12 12:00:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Stone-1993" MODIFIED="2010-03-15 12:57:39 +0000" MODIFIED_BY="[Empty name]" NAME="Stone 1993" TYPE="JOURNAL_ARTICLE">
<AU>Stone MH</AU>
<TI>Long-term outcome in personality disorders</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>162</VL>
<PG>299-313</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Torgersen-2005" MODIFIED="2010-05-12 15:01:18 +0100" MODIFIED_BY="Chris Champion" NAME="Torgersen 2005" TYPE="BOOK_SECTION">
<AU>Torgersen S</AU>
<TI>Prevalence, sociodemographics, and functional impairment</TI>
<SO>Essentials of Personality Disorders</SO>
<YR>2009</YR>
<PG>83-102</PG>
<EN>1st</EN>
<ED>Oldham JM, Skodol AE, Bender DS</ED>
<PB>American Psychiatric Publishing</PB>
<CY>Arlington, VA</CY>
<IDENTIFIERS MODIFIED="2010-05-12 12:00:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1993" MODIFIED="2010-05-11 16:52:03 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1993" TYPE="BOOK">
<AU>World Health Organisation</AU>
<SO>The ICD-10 Classification of Mental and Behavioral Disorders: Diagnostic Criteria for Research</SO>
<YR>1993</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS MODIFIED="2010-05-11 16:52:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Zanarini-2003a" MODIFIED="2010-05-08 23:00:42 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC</AU>
<TI>Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD): a continuous measure of DSM-IV borderline psychopathology</TI>
<SO>Journal of Personality Disorders</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>3</NO>
<PG>233-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zanarini-2004a" MODIFIED="2010-05-12 12:00:23 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Frankenburg FR, Hennen J, Silk KR</AU>
<TI>Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>1</NO>
<PG>28-36</PG>
<IDENTIFIERS MODIFIED="2010-05-12 12:00:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Zanarini-2004b" MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2004b" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR</AU>
<TI>Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<PG>2108-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zanarini-2005" MODIFIED="2010-05-12 12:00:35 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2005" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR</AU>
<TI>The McLean Study of Adult Development (MSAD): overview and implications of the first six years of prospective follow-up</TI>
<SO>Journal of Personality Disorders
</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>5</NO>
<PG>505-23</PG>
<IDENTIFIERS MODIFIED="2010-05-12 12:00:35 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Zanarini-2007" MODIFIED="2010-05-08 23:03:28 +0100" MODIFIED_BY="[Empty name]" NAME="Zanarini 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zanarini MC, Frankenburg FR, Reich DB, Silk KR, Hudson JI, McSweeney LB</AU>
<TI>The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<NO>6</NO>
<PG>929-35</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-05-08 23:03:46 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Lieb-2010" MODIFIED="2010-05-08 23:03:46 +0100" MODIFIED_BY="[Empty name]" NAME="Lieb 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM</AU>
<TI>Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2010</YR>
<VL>196</VL>
<PG>4-12</PG>
<IDENTIFIERS MODIFIED="2010-03-12 13:42:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2008-08-07 10:44:53 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-05-12 12:28:35 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-05-12 12:28:35 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-05-12 11:07:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bogenschutz-2004">
<CHAR_METHODS MODIFIED="2010-05-12 11:06:32 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double, no further details<BR/>Duration: 12 weeks (patients had to be free of mood stabilisers, antipsychotics, benzodiazepines, and antidepressants for at least 2 weeks prior to participation)<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:06:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV, SCID-II)<BR/>Age: Mean 32.6 years (SD = 10.3)<BR/>Sex: 25 F, 15 M<BR/>Exclusions: Schizophrenia, schizoaffective disorder, bipolar affective disorder, current major depressive episode, psychotic disorder due to substance or general medical condition, substance dependence not in full or partial remission, suicide attempts in past 6 months, having current suicidal intent or definite plan, pregnancy, neurologic impairment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:06:49 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose (2.5-20 mg/day), mean dose at endpoint: 6.9 mg/day (SD = 3.2)<BR/>N = 20*<BR/>2. Placebo: no further details, mean pseudo-dose at endpoint: 10.2 mg/day (SD = 5.3)<BR/>N = 20*</P>
<P>Concomitant psychotherapy:<BR/>Allowed to continue if initiated more than 3 months prior to randomization<BR/>Concomitant pharmacotherapy:<BR/>Medication for stable, chronic medical conditions such as hypertension</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:07:14 +0100" MODIFIED_BY="[Empty name]">
<P>Avoidance of abandonment: CGI-BPD-abandonment<BR/>Interpersonal problems: CGI-BPD-unstable interpersonal relationships<BR/>Identity disturbance: CGI-BPD-identity disturbance<BR/>Impulsivity: CGI-BPD-impulsivity, OAS-M-aggression<BR/>Suicidal ideation: CGI-BPD-recurrent suicidal ideation<BR/>Affective instability: CGI-BPD-affective instability<BR/>Feelings of emptiness: CGI-BPD-chronic feelings of emptiness<BR/>Anger: CGI-BPD-inappropriate anger, AIAQ<BR/>Dissociative symptoms: CGI-BPD-transient paranoia or dissociation<BR/>Anxiety: HARS<BR/>General psychiatric pathology: SCL-90<BR/>Mental health status: CGI<BR/>Attrition<BR/>Adverse effects: weight</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 13:17:50 +0100" MODIFIED_BY="[Empty name]">
<P>*as randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:28:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-la-Fuente-1994">
<CHAR_METHODS MODIFIED="2010-05-12 11:28:46 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double. (One clinician was blind to drug treatment and performed all clinical and psychometric assessments, the other one was not blind to drug treatment and correctly adjusted the plasma levels of carbamazepine and asked for adverse side effects. Patients were instructed not to communicate side effects to the blind clinician)<BR/>Duration: 32 days (after at least 10 days psychotropic drug washout; 15 days for TCAs and MAOIs, no patient had taken neuroleptics in the 2-month period before the study)<BR/>Setting: Inpatients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:28:47 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-III-R; DIB)<BR/>Age: Mean 32.7 years (range 22-45)<BR/>Sex: 14 F, 6 M<BR/>Exclusions: DSM-III-R axis I disturbances (not excluded: patients who were depressed for less than 2 weeks), inability to stop alcohol or psychoactive substances, suspected poor treatment compliance, standard physical or neurological examinations abnormal, perturbed standard biological blood tests, perturbed electrocardiogram, positive history for epilepsy or standard traits for epilepsy, antecedents of encephalitis or cranial trauma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:28:57 +0100" MODIFIED_BY="[Empty name]">
<P>1. Carbamazepine: therapeutic range of blood drug levels required for the management of epileptic and affectively ill patients; averages were continuously between 6.44-7.07 micrograms/mL for carbamazepine and 1.07-1.24 micrograms/mL for 10.11-epoxycarbamazepine)<BR/>N = 10*<BR/>2. Placebo: no further details<BR/>N = 10*</P>
<P>Concomitant psychotherapy: Supportive atheoretical psychotherapy was administered to all patients<BR/>Concomitant pharmacotherapy: No further details</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Interpersonal problems: SCL-90-INT<BR/>Impulsivity: Acting-out scale<BR/>Anger: SCL-90-HOS<BR/>Psychotic symptoms: BPRS, SCL-90-PSY, SCL-90-PAR<BR/>Depression: HDRS-24<BR/>Anxiety: SCL-90-ANX<BR/>General psychiatric pathology: GAS, SCL-90-PST<BR/>Attrition<BR/>Adverse effects: asked for by the non-blind clinician</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 13:33:44 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:29:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frankenburg-2002">
<CHAR_METHODS MODIFIED="2010-05-12 11:29:15 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised in a 2:1 manner; tablets were supplied in numbered bottles containing drug or placebo as determined by a prearranged random number sequence<BR/>Blinding: Double-blind; one investigator was given either real drug blood levels or sham levels (in case of placebo) and adjusted the dose according to perceived response, reported or sham level, and side effects<BR/>Duration: 6 months<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:29:18 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV; DIPD-IV borderline module) + bipolar II disorder (DSM-IV)<BR/>Age: Valproate semisodium group: mean age 27.3 (SD 7.4), placebo group: mean age 26.4 (SD 7.3)<BR/>Sex: 30 F<BR/>Exclusions: Acutely suicidal patients (i.e. having clear-cut and pressing intent to commit suicide in near future); actively abusing alcohol or drugs; current criteria for major depressive episode or hypomanic episode met; current or lifetime schizophrenia, schizoaffective disorder, psychotic disorder not otherwise specified, bipolar I disorder; patients formerly been treated with valproate semisodium; subjects who were pregnant, breastfeeding or not using reliable forms of contraception; medically ill, seizure disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:29:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Valproate semisodium: Adjusted to achieve a serum valproate semisodium level of between 50 and 100 mg/L; actual average dose: 850 mg/day (SD 249) or 3.4 tablets/day (SD .9)<BR/>N = 20*<BR/>2. Placebo: tablets; actual average dose: 2.6 tablets/day (SD .5)<BR/>N = 10*</P>
<P>Concomitant pharmacotherapy: No other psychotropic medication allowed<BR/>Concomitant psychotherapy: No patient was in psychotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Interpersonal problems: SCL-90-INT<BR/>Impulsivity: MOAS<BR/>Anger: SCL-90-HOS<BR/>Depression: SCL-90-DEP<BR/>Attrition<BR/>Adverse effects: weight, menstrual changes, tremors, diarrhea, hair loss, increase in hepatic transaminases, thrombocytopenia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 13:37:43 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:30:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldberg-1986">
<CHAR_METHODS MODIFIED="2010-05-12 11:30:13 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double<BR/>Duration: 12 weeks (after 1 week placebo washout)<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:30:17 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD and/or schizotypal personality disorder (DSM-III; SIB) and having at least one psychotic symptom<BR/>Age: Mean 32 years (no SD given)<BR/>Sex: 29 F, 21 M<BR/>Exclusions: Current alcoholism or drug addiction, schizophrenia, mania, melancholia, severe hepatic, renal, or cardiovascular disease, organic brain syndrome, mental retardation, history of epilepsy or seizures, glaucoma, severe hypertensive or hypotensive cardiovascular disease, severe metabolic disorders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:30:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Thiothixene: mean final dose 8.67 mg/day (range 2 mg/day - 35 mg/day)<BR/>N = 24*<BR/>2. Placebo: no further details, mean pseudo-dose at endpoint 26.38 mg/day (not further specified)<BR/>N = 26*</P>
<P>Concomitant psychotherapy: Not specified<BR/>Concomitant pharmacotherapy: Patients had to pass one week placebo washout; no further details</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-04 14:46:39 +0100" MODIFIED_BY="[Empty name]">
<P>BPD severity: SIB-borderline score<BR/>Interpersonal problems: HSCL-INT<BR/>Anger: HSCL-HOS<BR/>Psychotic symptoms: SIB-psychotic<BR/>Depression: HSCL-DEP<BR/>Mental health status: GAS<BR/>Attrition<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 13:38:43 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:31:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hallahan-2007">
<CHAR_METHODS MODIFIED="2010-05-12 11:31:00 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, according to computer-generated list<BR/>Blinding: Double-blind; an independent colleague dispensed identically looking capsules according to computer-generated list, code was only revealed after completion of data collection</P>
<P>Duration: 12 weeks<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:31:06 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: Patients with recurrent self-harm, recruited at an accident and emergency department where they had presented acutely with self-harm; additionally, participants had to have a lifetime history of at least one other self-harm episode. Actually, 71% of all participants satisfied DSM-IV BPD criteria as assessed by SCID-II<BR/>Age: Mean 30.6 years<BR/>Sex: 17 M, 32 F<BR/>Exclusions: Current addiction, substance misuse, psychosis, eating disorder, dyslipidaemia, treatment, diet or illness known to interfere with study drug, weight loss &gt; 10% during previous 3 months, taking supplements containing omega-3 fatty acids of consuming fish more than once per week, changes to, or introduction of psychotropic medication during previous 6 weeks pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:31:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Omega-3 fatty acid: 1.2 g/day of eicosapentaenoic acid (E-EPA)+ 0.9 g/day of decosahexaenoic acid (DHA)<BR/>N = 22*<BR/>2.Placebo: capsules contained 99% corn oil and a 1% E-EPA + DHA mixture, ensuring blindness by also causing 'fishy breath', the most frequent side-effect of the active drug<BR/>N = 27*</P>
<P>Concomitant psychotherapy: Patients actually receiving psychotherapy were not eligible for study participation</P>
<P>Concomitant pharmacotherapy: Patients could continue to receive standard psychiatric care and had changes to their psychotropic medication as prescribed (53.1% of participants actually did) . Patients with changes to or introduction of psychotropic medication during the 6 weeks prior to screening were not eligible.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:31:26 +0100" MODIFIED_BY="[Empty name]">
<P>Suicidal ideation: Number of patients with OAS-M-suicidality subscale score of 1 or higher, indication at least slight suicidal tendencies</P>
<P>Self-mutilating behaviour: Number of patients with episodes of self-harm during treatment</P>
<P>Depression: Number of patients with at least 50% and 70% reduction of depressive pathology as assessed by both BDI and Ham-D</P>
<P>Attrition: Number of non-completers</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 13:41:19 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:32:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hollander-2001">
<CHAR_METHODS MODIFIED="2010-05-12 11:32:15 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double-blind; treating psychiatrist was kept blind to patient medication, blood valproate levels were read and dose adjustments to both valproate semisodium and placebo were determined by a psychiatrist not seeing patients for this study<BR/>Duration: 10 weeks (no washout reported)<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:32:19 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV; SCID-II)<BR/>Age: Mean 38.6 years (SD = 10.37, range 18 - 62)<BR/>Sex: 11 F, 10 M<BR/>Exclusions: Current suicidal ideation, current substance abuse, current major depression, bipolar disorder type I or II, psychotic disorders, medical or neurologic illness, pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:32:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Valproate semisodium: dose sufficient to maintain blood valproate level at 80 micrograms/mL or the highest tolerated dose; mean endpoint blood valproate level 64.57 micrograms/mL (SD 15.21, range 47-85 micrograms/mL)<BR/>N = 12**<BR/>2.Placebo: no further details<BR/>N = 4**</P>
<P>Concomitant psychotherapy: Not specified<BR/>Concomitant pharmacotherapy: Not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:32:33 +0100" MODIFIED_BY="[Empty name]">
<P>Impulsivity: AQ, OAS-M-aggression<BR/>Anger: OAS-M-irritability<BR/>Suicidal behaviour: OAS-M-suicidality<BR/>Depression: BDI<BR/>Mental health status: non-responders (CGI-I score of 3 or more)<BR/>Attrition<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 11:32:40 +0100" MODIFIED_BY="[Empty name]">
<P>**Initially 21 subjects entered the study, only 16 were randomised to a treatment group without giving reasons</P>
<P>Continuous outcomes based on ITT (LOCF)</P>
<P>Of the 16 patients randomised, 6 completed treatment (6 in valproate semisodium group, 0 in placebo group)<BR/>Reasons for early termination:<BR/>All patients dropped out owing to either lack of efficacy or impulsive decisions, none dropped out owing to side effects</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 12:28:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leone-1982">
<CHAR_METHODS MODIFIED="2010-05-12 11:33:06 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Drugs were supplied in identical opaque capsules<BR/>Duration: 6 weeks<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:28:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-III, no further details)<BR/>Age: Loxapine group: mean 29.5 years (range 16-54 years), chlorpromazine group: mean 32 years (range 16-59 years)<BR/>Sex: 48 F, 32 M<BR/>Exclusions: Using sedatives or tranquilisers, having been treated with psychotropic drugs within 48 hours of beginning treatment with study drugs, allergy/hypersensitivity to study drugs, organic brain syndrome, mental retardation, severe medical disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:33:20 +0100" MODIFIED_BY="[Empty name]">
<P>1. Loxapine: capsules of 5 mg, starting dose one or two capsules daily, increased based on symptom severity and tolerance; maximum dose 12 capsules/d; mean final dose 13.5 mg/day, overall mean daily dose 14.4 mg<BR/>N = 40*<BR/>2. Chlorpromazine: capsules of 50 mg, starting dose one or two capsules daily, increased based on symptom severity and tolerance; maximum dose 12 capsules daily; mean final dose105 mg/day, overall mean daily dose 110 mg<BR/>N = 40*</P>
<P>Concomitant psychotherapy: Not specified<BR/>Concomitant pharmacotherapy: Patients did not receive any other psychotropic medication during the study; nighttime sedatives were limited to flurazepam and chloral hydrate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:33:23 +0100" MODIFIED_BY="[Empty name]">
<P>BPD severity<BR/>Affective instability: POMS<BR/>Psychotic symptoms: BPRS<BR/>Mental health status: CGI, Systematic Nurses' Observation of Psychopathology (SNOOP)<BR/>Attrition<BR/>Adverse effects: Recorded upon appearance in terms of data of onset, intensity, duration, and any remedial action</P>
<P>Unable to use outcome data (except for attrition)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 11:33:24 +0100" MODIFIED_BY="[Empty name]">
<P>*As randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:34:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linehan-2008">
<CHAR_METHODS MODIFIED="2010-05-12 11:34:00 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT</P>
<P>Allocation: Content of tablets was determined by a random number sequence</P>
<P>Blinding: Patients, psychotherapists, pharmacotherapist, and assessment interviewers were kept naive to medication assignment</P>
<P>Duration: 24 weeks, last assessment after week 21, however</P>
<P>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:34:02 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD according to DSM-IV (SCID-II, PDE) + BPD criterion for inappropriate anger met + score of 6 or higher on the irritability scale of the OAS-M</P>
<P>Age: Overall mean age 36.8 years (SD=9.0)</P>
<P>Sex: 24 F</P>
<P>Exclusions: Episode of self-inflicted self-injury including suicide attempts during 8 weeks prior to screening, current diagnosis of schizophrenia, bipolar I disorder, schizoaffective disorder, major depressive disorder with psychotic features or other psychotic disorder, substance dependence during last 6 months, mental retardation, seizure disorder, pregnant women or planning to be, breastfeeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:34:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. DBT + olanzapine (allowed dosage range: 2.5 to 15 mg/day; mean daily dose 4.46 mg/day, SD 1.16)</P>
<P>N = 12*</P>
<P>2. DBT + placebo (dose was adjusted in response to perceived response and side effects, no further details)</P>
<P>N = 12*</P>
<P>Data refer to the intention to treat sample</P>
<P>Concomitant psychotherapy: All participants received DBT</P>
<P>Concomitant pharmacotherapy: n.s.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:34:21 +0100" MODIFIED_BY="[Empty name]">
<P>Suicidal ideation: Number of patients with high suicidality score on the OAS-M suicidality subscale</P>
<P>Self-mutilating behaviour: number of patients with self-injury</P>
<P>Depression: Ham-D</P>
<P>Attrition</P>
<P>Adverse effects: Weight gain (lb), remaining data on adverse effects not usable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 14:40:56 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:34:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loew-2006">
<CHAR_METHODS MODIFIED="2010-05-12 11:34:40 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomisation was carried out confidentially by the clinic administration, tablets were supplied in numbered boxes<BR/>Blinding: Double-blind, blind medication which constituted either the active drug or placebo<BR/>Duration: 10 weeks<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:34:44 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (SCID-II)<BR/>Age: Mean age active drug group: 24.9 (SD = 5.3), placebo group 25.6 (SD = 5.7)<BR/>Sex: 56 F<BR/>Exclusions: Currently suicidal patients, abusing alcohol or drugs, schizophrenia, severe somatic illness, current use of topiramate or other psychotropic medication, or psychotherapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:34:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. Topiramate: 200 mg/day<BR/>N = 28*<BR/>2. Placebo: analogous pseudo-dose<BR/>N = 28*</P>
<P>Concomitant psychotherapy: Not allowed<BR/>Concomitant pharmacotherapy: Any other psychotropic medication not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:34:55 +0100" MODIFIED_BY="[Empty name]">
<P>Interpersonal problems: SCL-90-R-INT<BR/>Anger: SCL-90-R-HOS<BR/>Psychotic symptoms: SCL-90-R-PAR, SCL-90-R-PSY<BR/>Depression: SCL-90-R-DEP<BR/>Anxiety: SCL-90-R-ANX<BR/>General psychiatric pathology: SCL-90-R-GSI<BR/>Attrition<BR/>Adverse effects: non-structured questionnaire<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 15:01:00 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:35:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montgomery-1979_x002f_82">
<CHAR_METHODS MODIFIED="2010-05-12 11:35:14 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double-blind, flupenthixol decanoate and placebo drawn from identical matching ampoules<BR/>Duration: 24 weeks<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:35:22 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: Patients admitted following a suicidal act, having a history of 2 or more previous documented suicidal acts; more than 75% BPD (23 out of 30*; DSM-III, clinical interview)*<BR/>Age: Flupenthixol group: 38.2 years (SD = 15.53), placebo group: 31.9 (SD = 11.0)*<BR/>Sex: 21 F, 9 M*<BR/>Exclusions: Overt schizophrenia or depression, organic illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:35:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Flupenthixol decanoate intra-muscular: 20 mg every four weeks<BR/>N = 14<BR/>2. Placebo: drawn from identical ampoules<BR/>N = 16</P>
<P>Concomitant psychotherapy: All patients attended the special crisis intervention clinic within two weeks of the index suicidal act<BR/>Concomitant pharmacotherapy: Not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:35:33 +0100" MODIFIED_BY="[Empty name]">
<P>Suicidal behaviour: Number of participants in each group with/without suicidal act within the 6 months of treatment<BR/>Adverse effects: Assessed by standard reporting form<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 11:35:34 +0100" MODIFIED_BY="[Empty name]">
<P>*Only reported for the completers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:36:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montgomery-81_x002f_82_x002f_83">
<CHAR_METHODS MODIFIED="2010-05-12 11:35:58 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised<BR/>Blinding: No further details<BR/>Duration: 6 months<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:36:03 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: Patients admitted following a suicidal act, having a history of 2 or more previous documented suicidal acts; more than 75% BPD (30 out of 38*; DSM-III, clinical interview)<BR/>Age: Mianserin group: mean age 35.1 (SD = 12.24), placebo group: mean age 36.2 (SD = 13.38)*<BR/>Sex: 26 F, 12 M*<BR/>Exclusions: Overt schizophrenia or depression, organic illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:36:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. Mianserin (30 mg nightly)<BR/>N = 17 completers of N = 29 allocated to mianserin<BR/>2. Placebo<BR/>N = 21 completers of N = 29 allocated to placebo</P>
<P>Concomitant psychotherapy: Patients were followed up in a clinic with back up from social workers, community nurses and a crisis intervention team<BR/>Concomitant pharmacotherapy: Not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:36:16 +0100" MODIFIED_BY="[Empty name]">
<P>Suicidal behaviour: Number of participants in each group with/without act of self-harm within the 6 months of treatment</P>
<P>Attrition<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 11:36:17 +0100" MODIFIED_BY="[Empty name]">
<P>*Only reported for the completers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:36:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nickel-2004">
<CHAR_METHODS MODIFIED="2010-05-12 11:36:41 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomisation was carried out confidentially by the clinic administration and arranged so that twice as many subjects would be treated with the active drug as with placebo<BR/>Blinding: Tablets were supplied in numbered boxes<BR/>Duration: 8 weeks<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:36:43 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV, SCID-II)<BR/>Age: Topiramate: mean age 25.5 years, placebo 26.6 years (no further details)<BR/>Sex: 31 F<BR/>Exclusions: Actively suicidal patients, abusing alcohol or drugs, major depression, schizophrenia, bipolar disorder, current use of topiramate or other psychotropic medication, psychotherapy, pregnant or planning to become, somatically ill</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:36:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Topiramate: 250 mg/day<BR/>N = 21*<BR/>2. Placebo: Matching<BR/>N = 10*</P>
<P>Concomitant psychotherapy: Not allowed<BR/>Concomitant pharmacotherapy: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:36:53 +0100" MODIFIED_BY="[Empty name]">
<P>Impulsivity: STAXI-anger-out<BR/>Anger: STAXI-trait anger<BR/>Attrition<BR/>Adverse effects: Non-structured questionnaire<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 15:10:23 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:37:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nickel-2005">
<CHAR_METHODS MODIFIED="2010-05-12 11:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomisation was carried out confidentially by the clinic administration, tablets were supplied in numbered boxes<BR/>Blinding: Double-blind (both clinician and subjects were blinded)<BR/>Duration: 8 weeks<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:37:09 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV, SCID-II)<BR/>Age: Mean age 29.1 years<BR/>Sex: 44 M<BR/>Exclusions: Actively suicidal, currently fulfilling criteria for an addictive illness, severe major depression, acute psychosis, bipolar disorder, current use of topiramate or other psychotropic medication, current psychotherapy, somatically ill</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:37:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. Topiramate: 250 mg/day<BR/>N = 22*<BR/>2. Placebo: matching<BR/>N = 22*</P>
<P>Concomitant psychotherapy: Not allowed<BR/>Concomitant pharmacotherapy: Psychotropic medication not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:37:17 +0100" MODIFIED_BY="[Empty name]">
<P>Impulsivity: STAXI-anger out<BR/>Anger: STAXI-trait anger<BR/>Attrition<BR/>Adverse effects: Weight<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 15:11:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:38:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nickel-2006">
<CHAR_METHODS MODIFIED="2010-05-12 11:37:40 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomisation was carried out confidentially by the clinic administration and arranged so that twice as many subjects would be treated with the active drug as with placebo<BR/>Blinding: Tablets were supplied in numbered boxes, both patients and clinicians were blinded<BR/>Duration: 8 weeks<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:37:45 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV, SCID-II)<BR/>Age: Aripiprazole group: mean age 22.1 years (SD = 3.4), Placebo group: mean age 21.2 years (SD = 4.6)<BR/>Sex: 43 F, 9 M<BR/>Exclusions: Current suicidal ideation, schizophrenia, current use of aripiprazole or another psychotropic medication, current psychotherapy, pregnancy, planned pregnancy or sexual activity without contraception, severe somatic illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:38:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Aripiprazole: 15 mg/day<BR/>N = 26*<BR/>2. Placebo: matching dose<BR/>N = 26*</P>
<P>Concomitant psychotherapy: Not allowed<BR/>Concomitant pharmacotherapy: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:38:07 +0100" MODIFIED_BY="[Empty name]">
<P>Interpersonal problems: SCL-90-R-INT (t-value transformed)<BR/>Impulsivity: STAXI-anger out<BR/>Self-mutilating behaviour: Number of patients with/without self-injury during the 8 week treatment<BR/>Anger: SCL-90-R-HOS (t-value transformed), STAXI-trait anger<BR/>Psychotic symptoms: SCL-90-R-PAR, SCL-90-R-PSY (both t-value transformed)<BR/>Depression: SCL-90-R-DEP (t-value transformed), Ham-D<BR/>Anxiety: SCL-90-R-ANX (t-value transformed), HARS<BR/>General psychiatric pathology: SCL-90-R-GSI (t-value transformed)<BR/>Adverse effects: Serious side effects, suicidal acts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 11:38:08 +0100" MODIFIED_BY="[Empty name]">
<P>*As randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:39:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pascual-2008">
<CHAR_METHODS MODIFIED="2010-05-12 11:38:39 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, randomisation was performed by blocks of 4 generated using the SPSS software package (SPSS Inc., Chicago, Ill)<BR/>Blinding: Double, no further details<BR/>Duration: 12 weeks, following a 2-week baseline period<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:38:42 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV, SCID-II, DIB-R)<BR/>Age: Mean 29.2 years<BR/>Sex: 49 F, 11 M<BR/>Exclusions: Schizophrenia, alcohol or other substance dependence, current major depressive episode, bipolar disorder, drug-induced psychosis, organic brain syndrome, mental retardation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:38:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ziprasidone: flexible dose 40 to 200 mg/day, mean dose 84.1 mg/day (SD 54.4, range 40 - 200 mg/day)<BR/>N = 30*<BR/>2. Placebo: No further details<BR/>N = 30*</P>
<P>Concomitant psychotherapy: Patients participated in weekly, 2-hour, non-specific group psychotherapy sessions</P>
<P>Concomitant pharmacotherapy: Allowed to continue with benzodiazepine (max. 40 mg/day), antidepressants, mood stabilisers if initiated prior to inclusion; doses could not be modified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:39:11 +0100" MODIFIED_BY="[Empty name]">
<P>BPD severity: CGI-BPD-global<BR/>Avoidance of abandonment: CGI-BPD-abandonment<BR/>Interpersonal problems: CGI-BPD-unstable relations<BR/>Identity disturbance: CGI-BPD-identity<BR/>Impulsivity: CGI-BPD-impulsivity, BIS<BR/>Suicidal ideation: CGI-BPD-suicide<BR/>Affective instability: CGI-BPD-affect instability<BR/>Feelings of emptiness: CGI-BPD-emptiness<BR/>Anger: CGI-BPD-anger<BR/>Psychotic paranoid symptoms: CGI-BPD-paranoid ideation, BPRS<BR/>Depression: Ham-D-17, BDI<BR/>Anxiety: HARS<BR/>General psychiatric pathology: SCL-90-R-GSI<BR/>Attrition<BR/>Adverse effects: treatment-emergent adverse events, EKG, laboratory assessment, UKU Side Effect Rating Scale for extrapyramidal side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 11:39:11 +0100" MODIFIED_BY="[Empty name]">
<P>*As randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:39:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reich-2009">
<CHAR_METHODS MODIFIED="2010-05-12 11:39:36 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised (prearranged random number sequence)<BR/>Blinding: Double<BR/>Duration: 12 weeks<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:39:39 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV, DIB-R &#8807; 8)<BR/>Age: Mean 31.2 years<BR/>Sex: 24 F, 3 M<BR/>Exclusions: Diagnosis of dementia, psychiatric disorder secondary to a general medical condition, bipolar disorder, or psychotic disorder (schizophrenia, schizoaffective disorder, or mood disorder with psychotic features); diagnosis of substance dependence (active within last 60 days); currently being hospitalized; unstable general medical condition; previous treatment with lamotrigine for 1 week or more; enrollment in a drug study within last 60 days; enrollment in psychotherapy in the last 30 days; active suicidal or homicidal ideation; pregnancy or nursing</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:39:50 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lamotrigine: flexible dose 25 to 275 mg/day, mean final dose 106.7 mg (range 25 - 225 mg/day)</P>
<P>N = 15*</P>
<P>2. Placebo: No further details</P>
<P>N = 12 (one patient of the 13 assigned to placebo was disqualified because of failure to adhere to the study protocol and not included in analyses)<BR/>
</P>
<P>Concomitant psychotherapy: Patients enrolled in psychotherapy in the last 30 days were not eligible</P>
<P>Concomitant pharmacotherapy: Patients could be taking one antidepressant, but had to have been on a stable dose of this medication for 1 month.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:39:53 +0100" MODIFIED_BY="[Empty name]">
<P>BPD severity: ZAN-BPD total score</P>
<P>Impulsivity: ZAN-BPD-impulsivity score</P>
<P>Affective instability: ZAN-BPD-affective instability score, ALS</P>
<P>Attrition</P>
<P>Adverse effects: rash</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:40:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rinne-2002">
<CHAR_METHODS MODIFIED="2010-05-12 11:40:09 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT, followed by single-blind half crossover and an open treatment phase; only the first RCT phase will be regarded in the following<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double-blind, no further details<BR/>Duration: 6 weeks, patients had to be medication free for at least 2 weeks before entering the trial<BR/>Setting: Outpatients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:40:10 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV, SCID-II) + score of 110 or more on the borderline trait and distress scale of a self-report screener for personality disorders (ADP-IV) + score of 20 or more on the BPDSI<BR/>Age: 29.2 (SD = 7.6)<BR/>Sex: 38 F<BR/>Exclusions: n.s.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:40:19 +0100" MODIFIED_BY="[Empty name]">
<P>1. Fluvoxamine: 150 mg/day<BR/>N = 20*<BR/>2. Placebo: No further details<BR/>N = 18*</P>
<P>Concomitant psychotherapy: Two patients who began psychotherapy dropped-out the study; thus, psychotherapeutic treatment is likely to not have been allowed</P>
<P>Concomitant pharmacotherapy: Patients had to stop taking all psychoactive drugs and be medication free for at least 2 weeks before entering the trial (6 weeks for fluoxetine)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:40:22 +0100" MODIFIED_BY="[Empty name]">
<P>Impulsivity: BPDSI-impulsivity<BR/>Affective instability: BPDSI-rapid mood shifts<BR/>Anger: BPDSI-anger<BR/>Attrition<BR/>Adverse effects: Any, number of subjects experiencing specific adverse events (not used here as data refer to intermediate assessment, whereas post-treatment data are not available)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 11:40:23 +0100" MODIFIED_BY="[Empty name]">
<P>*As randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:41:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salzman-1995">
<CHAR_METHODS MODIFIED="2010-05-12 11:40:52 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double-blind, active drug and placebo administered in identical capsules<BR/>Duration: 12 weeks (after 1 week placebo run-in)<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:41:03 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-III-R; DIB-R, SCID-II, clinical interview)<BR/>Age: Mean age of fluoxetine group: 37.0 (no further details), placebo group: 35.6 (no further details)*<BR/>Sex: 14 F, 8 M*<BR/>Exclusions: Self-mutilating behaviours during the past 4 years, recent suicidal behaviour, current suicidal or aggressive behaviour, current substance abuse or excessive daily alcohol use (&gt; 2 drinks/day), history of psychiatric hospitalization, concurrent secondary axis II disorder, major depression or other axis I disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:41:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Fluoxetine: maximum of 60 mg/day, according to needs of the patient and in accordance with package insert guidelines; mean daily dose 40 mg/day<BR/>Completers: N =13<BR/>2. Placebo: No further details<BR/>Completers: N = 9<BR/>Data are only reported for treatment completers</P>
<P>Concomitant psychotherapy: Not specified<BR/>Concomitant pharmacotherapy: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-06 16:52:50 +0000" MODIFIED_BY="[Empty name]">
<P>Anger: PDRS-anger, POMS-anger, OAS-M-anger against objects<BR/>Depression: Ham-D, PDRS-depression, POMS-depression<BR/>Mental health status: GAS<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 11:41:18 +0100" MODIFIED_BY="[Empty name]">
<P>* Completers only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:41:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schulz-2007">
<CHAR_METHODS MODIFIED="2010-05-12 11:41:38 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double-blind; olanzapine started at 2.5 or 5.0 mg/d at investigator's discretion, flexible dose thereafter<BR/>Duration:12 weeks (after screening period of 2 - 14 days)<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:41:42 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV; DIPD-IV) + ZAN-BPD total score of 9 or higher<BR/>Age: Olanzapine group mean age 31.79 (SD = 9.54), placebo group mean age 31.83 (SD = 9.62)<BR/>Sex: 223 F, 91 M<BR/>Exclusions: Bipolar disorder, schizophrenia, major depressive disorder or substance dependence within last 3 months, current PTSD, panic disorder, or obsessive-compulsive disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:41:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose, 2.5 to 20 mg/day, mean modal dose 7.09 mg/day<BR/>N = 150<BR/>2. Placebo: No further details<BR/>N = 155</P>
<P>Concomitant psychotherapy: Not specified<BR/>Concomitant pharmacotherapy: No medications with primarily CNS activity (except for protocol-specified benzodiazepines and hypnotics)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:41:54 +0100" MODIFIED_BY="[Empty name]">
<P>BPD severity: number of patients in each group with response/no response, i.e. 50% reduction at least in ZAN-BPD total score<BR/>Avoidance of abandonment: ZAN-BPD-frantic efforts to avoid abandonment<BR/>Interpersonal problems: ZAN-BPD unstable interpersonal relationships<BR/>Identity disturbance: ZAN-BPD-identity disturbance<BR/>Impulsivity: ZAN-BPD-impulsivity, OAS-M-aggression<BR/>Suicidal ideation: OAS-M-suicidal ideation<BR/>Suicidal behaviour: ZAN-BPD-suicidal or self-mutilating behaviour<BR/>Affective instability: ZAN-BPD-affective instability<BR/>Feelings of emptiness: ZAN-BPD-chronic feelings of emptiness<BR/>Anger: ZAN-BPD-intense anger, OAS-M-irritability, SCL-90-R-HOS<BR/>Dissociative symptoms: ZAN-BPD-paranoid ideation of disassociation<BR/>Depression: MADRS<BR/>General psychiatric pathology: SCL-90-R GSI<BR/>Mental health status: Sheehan Disability Scale-total, GAF<BR/>Attrition<BR/>Adverse effects: weight, Simpson-Angus Scale, BARS, AIMS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 15:18:32 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:42:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simpson-2004">
<CHAR_METHODS MODIFIED="2010-05-12 11:42:07 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised block assignment, equal number of patients with major depressive disorder, PTSD, or both were assigned to each treatment condition in order to minimize the possible confound to treatment response<BR/>Blinding: Double-blind, a non-treating study psychiatrist was available to break the blind in the event of a clinical emergency, but didn't occur<BR/>Duration: 12 weeks (after a 1-week placebo run-in)<BR/>Setting: Partial hospitalization</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:42:13 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV, SCID-II), patients had to meet at least one BPD criterion pertaining to affective instability or anger and one pertaining to impulsivity<BR/>Age: Fluoxetine completers mean age 39.78 (SD = 9.81), placebo completers mean age 32.73 (SD = 10.76)<BR/>Sex: 25 F<BR/>Exclusions: Primary diagnosis of substance dependence, seizure disorder, unstable medical conditions, lifetime history of schizophrenia or bipolar disorder, MAOI treatment in the prior 2 weeks, previous adequate trial of fluoxetine, pregnancy, lactating women, unwillingness to use effective contraception</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:42:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. DBT (weekly 1-hour sessions of individual DBT, weekly 2-hour skills group, round-the-clock emergency consultation availability) + fluoxetine 40 mg/day<BR/>N = 12<BR/>2. DBT (weekly 1-hour sessions of individual DBT, weekly 2-hour skills group, round-the-clock emergency consultation availability) + placebo (no further details)<BR/>N = 13<BR/>Data are only available for the 20 completers (fluoxetine N = 9, placebo N = 11)</P>
<P>Concomitant psychotherapy: Patients were recruited from a partial hospital program, all received DBT as depicted above<BR/>Concomitant pharmacotherapy: Only other psychotropic allowed was 50 to 100 mg/day trazodone for insomnia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:42:34 +0100" MODIFIED_BY="[Empty name]">
<P>Impulsivity: OAS-M-aggression, STAXI-anger out</P>
<P>Suicidal ideation: OAS-M-suicidality</P>
<P>Self-mutilating behaviour: OAS-M-assault against self</P>
<P>Psychotic symptoms/dissociation: DES</P>
<P>Depression: BDI</P>
<P>Anxiety: STAI-trait</P>
<P>Mental health status: GAF</P>
<P>Attrition: number of patients lost after randomisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 15:20:51 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:43:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soler-2005">
<CHAR_METHODS MODIFIED="2010-05-12 11:42:45 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double-blind, no further details<BR/>Duration: 12 weeks (after a 4 weeks selection phase during which the pre-intervention baseline was established but no therapeutic intervention was given)<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:42:51 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV, SCID-II and DIB-R), CGI-S score of at least 4<BR/>Age: DBT + olanzapine group mean age: 27.57 (SD = 6.3), DBT + placebo group mean age: 26.33 (SD = 5.4)<BR/>Sex: 52 F, 8 M)<BR/>Exclusions: Comorbid unstable axis I disorder, women not using medically accepted contraception</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:43:02 +0100" MODIFIED_BY="[Empty name]">
<P>1. DBT + olanzapine: weekly 150-minute skills training group sessions, phone calls + olanzapine flexible dose between 5 to 20 mg/day (mean dose 8.83 mg/day, SD = 3.8)<BR/>N = 30*<BR/>2. DBT + placebo: weekly 150-minute skills training group sessions, phone calls + placebo (no further details)<BR/>N = 30*</P>
<P>Concomitant psychotherapy: All patients received DBT as depicted above<BR/>Concomitant pharmacotherapy: Subjects could continue treatment with benzodiazepines, antidepressants, and mood stabilisers, but doses could not be modified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>Impulsivity: Behavioural biweekly reports of episodes of impulsivity/aggressive behaviour<BR/>Suicidal behaviour/self-mutilating behaviour: behavioural biweekly reports of episodes of self-injuring behaviour/suicide attempts<BR/>Depression: Ham-D<BR/>Anxiety: HARS<BR/>Mental health status: CGI-S<BR/>Attrition<BR/>Adverse effects: As reported by patients, scales assessing extrapyramidal side effects, weight, cholesterol levels<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-29 15:37:00 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:44:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soloff-1989">
<CHAR_METHODS MODIFIED="2010-05-12 11:43:48 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised<BR/>Blinding: Double-blind, no further details<BR/>Duration: 5 weeks (after 1-week washout)<BR/>Setting: Inpatient (after 3 weeks some allowed to complete as outpatients)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:43:50 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-III, DIB), GAS score of 50 or less and either score of 17 or higher on the Ham-D or 66 or greater on the IMPS<BR/>Age: Mean 25.1 years, no further details<BR/>Sex: 68 F, 22 M<BR/>Exclusions: Schizophrenia, mania, related disorders, chronicity of illness, organicity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:44:08 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amitriptyline: Mean dose after 3 weeks of treatment: 149.1 mg/day, plasma levels of 240.4 ng/mL amitriptyline + nortriptyline (SD = 99.4)<BR/>N = 29<BR/>2. Haloperidol: Mean dose after 3 weeks of treatment 4.8 mg/day, plasma level of 8.66 ng /mL (SD = 3.7)<BR/>N = 28<BR/>3. Placebo: No further details<BR/>N = 28</P>
<P>Concomitant psychotherapy: Patients were treated as psychiatric inpatients for at least 3 weeks, no further details<BR/>Concomitant pharmacotherapy: Biperiden hydrochloride (2 mg) was allowed as needed for extrapyramidal reactions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-04 14:46:04 +0100" MODIFIED_BY="[Empty name]">
<P>Interpersonal problems: SCL-90-INT<BR/>Impulsivity: Ward Scale of Impulsive Action Patterns, BIS, STIC<BR/>Anger: SCL-90-HOS, BDHI, BDHI<BR/>Psychotic symptoms: SCL-90-PAR, SCL-90-PSY, IMPS, SSI<BR/>Depression: SCL-90-DEP, Ham-D, BDI<BR/>Anxiety: SCL-90-ANX<BR/>General psychiatric pathology: SCL-90-GSI<BR/>Mental health status: GAS<BR/>Attrition<BR/>Adverse effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-30 09:09:24 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:45:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soloff-1993">
<CHAR_METHODS MODIFIED="2010-05-12 11:44:42 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double-blind, no further details<BR/>Duration: 5 weeks (after 1-week washout)<BR/>Setting: Patient in the hospital for a minimum of 2 weeks and after discharge were seen weekly as outpatients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:44:44 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-III-R, DIB), GAS score of 50 or less and either score of 17 or higher on the Ham-D or 66 or greater on the IMPS<BR/>Age: Mean 26.7 years (SD=7.2)<BR/>Sex: 82 F, 26 M<BR/>Exclusions: Drug- and/or alcohol-related deficits or physical dependence, evidence of central nervous system disease, physical disorders of known psychiatric consequence, borderline mental retardation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:45:00 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol up to 6 mg/day (six tablets); average dose after 3 weeks of medication 3.93 mg/day (SD = 0.65); mean plasma level by 4 weeks 5.29 ng/mL (SD = 4.04)<BR/>N = 30<BR/>2. Phenelzine sulfate up to 90 mg/day (six tablets); average dose after 3 weeks of medication 60.45 mg/day (SD = 9.55); mean plasma level by 3 weeks 77.54% platelet MAO inhibition (SD = 16.97)<BR/>N = 34<BR/>3. Placebo up to six tablets; average dose after 3 weeks of medication 4.31 tablets/day (SD = 0.6)<BR/>N = 28</P>
<P>Concomitant psychotherapy: Not specified, patients were inpatients, some were allowed after 2 weeks to complete as outpatients<BR/>Concomitant pharmacotherapy: Patients were at the start kept free of medication for at least 7 days in order to washout street drugs or prescribed medications</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:45:01 +0100" MODIFIED_BY="[Empty name]">
<P>BPD severity: Borderline Syndrome Index<BR/>Interpersonal problems: ADDS - rejection sensitivity<BR/>Impulsivity: Ward Scale of Impulsive Action Patterns, BIS, STIC<BR/>Anger: SCL-90-HOS, BDHI, BDHI, ADDS-reactivity<BR/>Psychotic symptoms: SCL-90-PAR, SCL-90-PSY, IMPS, SSI<BR/>Depression: SCL-90-DEP, Ham-D, BDI<BR/>Anxiety: SCL-90-ANX<BR/>General psychiatric pathology: SCL-90-GSI<BR/>Mental health status: GAS<BR/>Attrition<BR/>Adverse effects: Weight gain<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 11:45:02 +0100" MODIFIED_BY="[Empty name]">
<P>*Completers only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 11:45:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tritt-2005">
<CHAR_METHODS MODIFIED="2010-05-12 11:45:28 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomization in secrecy by the clinic administration so that twice as many subjects would be treated with the active drug compared to placebo<BR/>Blinding: Double-blind, tablets were supplied in numbered bottles<BR/>Duration: 8 weeks<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:45:29 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV, SCID-II)<BR/>Age: Lamotrigine group mean age 29.4, no further details; placebo group mean age 28.9, no further details<BR/>Sex: 27 F<BR/>Exclusions: Actively suicidal, abusing alcohol or drugs, major depression, bipolar disorder, schizophrenia, current use of lamotrigine or other psychotropic medication, psychotherapy, pregnant or planning to be or not using contraception, somatically ill</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:45:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lamotrigine: final dose 200 mg/day (one blinded capsule medication daily)<BR/>N = 18<BR/>2. Placebo, one blinded capsule medication daily<BR/>N = 9</P>
<P>Concomitant psychotherapy: Other psychotropic medication not allowed<BR/>Concomitant pharmacotherapy: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:45:40 +0100" MODIFIED_BY="[Empty name]">
<P>Impulsivity: STAXI-anger out<BR/>Anger: STAXI-trait<BR/>Attrition<BR/>Adverse effects: Non-structured questionnaire, patients were asked to note down any new symptoms, weight<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 11:45:40 +0100" MODIFIED_BY="[Empty name]">
<P>Continuous outcomes based on ITT data (LOCF)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 12:02:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zanarini-2001">
<CHAR_METHODS MODIFIED="2010-05-12 12:02:27 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Numbered bottles containing drug or placebo as determined by a random number sequence<BR/>Blinding: Tablets were supplied in numbered bottles containing drug or placebo<BR/>Duration: 6 months<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:02:27 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV; DIB-R)<BR/>Age: Olanzapine group mean age 27.6 years (SD = 7.7), placebo group mean age 25.8 years (SD = 4.5)<BR/>Sex: 28 F<BR/>Exclusions: Actively abusing alcohol or drugs, acutely suicidal, current or lifetime schizophrenia, schizoaffective disorder, bipolar disorder, medically ill, seizure disorder, pregnant or planning to be, breastfeeding, not using reliable forms of contraception, having been treated with olanzapine, being prescribed any psychotropic medication that patients thought was helpful</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 12:02:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine 2.5 mg/day at beginning, adjusted according to perceived response and side effects, mean dose at endpoint 5.33 mg/day (SD = 3.43); endpoint mean number of tablets/day 1.1 (SD = 0.68)<BR/>N = 19<BR/>2. Placebo: Endpoint mean number of tablets/day 1.2 (SD = 0.75)<BR/>N = 9</P>
<P>Concomitant psychotherapy: Not specified<BR/>Concomitant pharmacotherapy: No other psychotropic medication allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 12:02:27 +0100" MODIFIED_BY="[Empty name]">
<P>BPD severity<BR/>Avoidance of abandonment<BR/>Interpersonal problems: SCL-90-INT<BR/>Identity disturbance<BR/>Impulsivity<BR/>Suicidal ideation<BR/>Suicidal behaviour<BR/>Self-mutilating behaviour<BR/>Affective instability<BR/>Feelings of emptiness<BR/>Anger: SCL-90-HOS<BR/>Psychotic symptoms: SCL-90-PAR, SCL-90-PSY, PANSS<BR/>Dissociative symptoms: DES<BR/>Depression: SCL-90-DEP, Ham-D,<BR/>Anxiety: SCL-90-ANX<BR/>General psychiatric pathology: SCL-90-GSI<BR/>Mental health status: GAF<BR/>Attrition<BR/>Adverse effects: Weight, Simpson-Angus Scale, BARS, AIMS, structured questionnaire<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-30 09:12:40 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 12:02:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zanarini-2003">
<CHAR_METHODS MODIFIED="2010-05-12 12:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double-blind<BR/>Duration: 8 weeks<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV; DIB-R)<BR/>Age: Mean age 26.3 years (SD = 6.2)<BR/>Sex: 30 F<BR/>Exclusions: Major depressive episode, current or lifetime schizophrenia, schizoaffective disorder, bipolar I or bipolar II disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 12:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Ethyl-eicosapentaenoic acid (E-EPA): 1 g/day<BR/>N = 20<BR/>2. Placebo: Mineral oil<BR/>N = 10</P>
<P>Concomitant psychotherapy: Not specified<BR/>Concomitant pharmacotherapy: Not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 12:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Impulsivity: MOAS<BR/>Depression: MADRS<BR/>Attrition<BR/>Adverse effects: Structured questionnaire<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-30 09:15:24 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 12:02:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zanarini-2004">
<CHAR_METHODS MODIFIED="2010-05-12 12:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double-blind, dose was adjusted by an unblinded psychiatrist according to perceived response and side effects<BR/>Duration: 8 weeks<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV, DIB-R)<BR/>Age: Mean age 23 years (SD = 5.7)<BR/>Sex: 45 F<BR/>Exclusions: Current major depression, current or lifetime schizophrenia, schizoaffective disorder, bipolar disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 12:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Fluoxetine: Mean dose at endpoint 15.0 mg/day (SD = 6.5, range 10.0 - 30.0 mg/day)<BR/>N = 14<BR/>2. Olanzapine: Mean dose at endpoint 3.3 mg/day (SD = 1.8, range 2.5 - 7.5 mg/day)<BR/>N = 16<BR/>3. Fluoxetine + olanzapine: Mean dose at endpoint 12.7 mg/day fluoxetine (SD = 5.9, range 10.0 - 30.0 mg/day) and 3.2 mg/day olanzapine (SD = 1.5, range 2.5 - 7.5 mg/day)<BR/>N = 15</P>
<P>Concomitant psychotherapy: Not specified<BR/>Concomitant pharmacotherapy: Not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 12:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Impulsivity: OAS-M total<BR/>Depression: MADRS<BR/>Attrition<BR/>Adverse effects: Weight, Simpson-Angus Rating Scale, BARS, AIMS, structured questionnaire<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-30 11:08:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-12 12:02:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zanarini-2007">
<CHAR_METHODS MODIFIED="2010-05-12 12:02:29 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT<BR/>Allocation: Randomised, no further details<BR/>Blinding: Double-blind, no further details<BR/>Duration: 12 weeks (after a 2 weeks screening period)<BR/>Setting: Outpatient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 12:02:29 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: BPD (DSM-IV-TR, DIPD-IV), Zan-BPD total score of 9 or more<BR/>Age: Mean 32.98 (SD = 10.83)<BR/>Sex: 332 F, 119 M<BR/>Exclusions: Bipolar disorder, schizophrenia, major depressive disorder within last 3 months, substance dependence within last 3 months, current PTSD, current panic disorder, current obsessive-compulsive disorder, comorbid Cluster A Axis II PD, active suicidality, pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 12:02:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: 2.5 mg/day<BR/>N = 150<BR/>2. Olanzapine: 5 to 10 mg/day, mean dose 6.66 mg/day (SD = 2.91)<BR/>N = 148 (106 F, 42 M)<BR/>3. Placebo: Daily capsules<BR/>N = 153 (117 F, 36 M)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 12:02:29 +0100" MODIFIED_BY="[Empty name]">
<P>BPD severity: Number of patients in each group with response/no response, i.e. 50% reduction at least in ZAN-BPD total score<BR/>Avoidance of abandonment: ZAN-BPD-frantic efforts to avoid abandonment<BR/>Interpersonal problems: ZAN-BPD unstable interpersonal relationships, SCL-90-R-INT<BR/>Identity disturbance: ZAN-BPD-identity disturbance<BR/>Impulsivity: ZAN-BPD-impulsivity, OAS-M-aggression<BR/>Suicidal ideation: OAS-M-suicidal ideation<BR/>Suicidal behaviour: ZAN-BPD-suicidal or self-mutilating behaviour<BR/>Affective instability: ZAN-BPD-affective instability<BR/>Feelings of emptiness: ZAN-BPD-chronic feelings of emptiness<BR/>Anger: ZAN-BPD-intense anger, OAS-M-irritability, SCL-90-R-HOS<BR/>Dissociative symptoms: ZAN-BPD-paranoid ideation of disassociation, SCL-90-R-PAR<BR/>Depression: MADRS, SCL-90-R-DEP<BR/>Anxiety: SCL-90-R-ANX<BR/>General psychiatric pathology: SCL-90-R GSI<BR/>Mental health status: Sheehan Disability Scale-total, GAF<BR/>Attrition<BR/>Adverse effects: Weight, Simpson-Angus Scale, BARS, AIMS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-12 12:02:29 +0100" MODIFIED_BY="[Empty name]">
<P>* As randomised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>*as randomised<BR/>ADDS - Atypical Depression Inventory<BR/>ADP-IV - Assessment of DSM-IV Personality Disorders<BR/>AIAQ - Anger, Irritability, and Assault Questionnaire<BR/>AIMS - Abnormal Involuntary Movement Scale</P>
<P>ALS - Affective Lability Scale<BR/>AQ - Assault Questionnaire<BR/>BARS - Barnes Akathisia Rating Scale<BR/>BDHI - Buss-Durkee Hostility Inventory<BR/>BID - Beck Depression Inventory<BR/>BIS - Barratt Impulsiveness Scale<BR/>BPDSI - Borderline Personality Disorder Severity Index<BR/>BPRS - Brief Psychiatric Rating Scale<BR/>CGI - Clinical Global Impressions Scale<BR/>CGI-BPD - Clinical Global Impressions Scale modified for borderline personality disorder<BR/>CGI-I Clinical Global Impressions Scale-global improvement<BR/>CGI-S Clinical Global Impressions Scale-Severity of Illness<BR/>DBT - Dialectical Behaviour Therapy<BR/>DES - Dissociative Experiences Scale<BR/>DIB - Diagnostic Interview for Borderline Patients<BR/>DIB-R - Diagnostic Interview for Borderline Patients-Revised<BR/>GAF - Global Assesment of Functioning<BR/>GAS - Global Assessment Scale<BR/>Ham-D - Hamilton Rating Scale for Depression<BR/>HARS - Hamilton Anxiety Rating Scale<BR/>HDRS-24 - Hamilton's 24-item Depression Rating Scale<BR/>HSCL - Hopkins Symptom Checklist<BR/>HSCL-DEP - depression<BR/>HSCL-HOS - anger-hostility<BR/>HSCL-INT - interpersonal sensitivity<BR/>HSCL-PSY - psychotic<BR/>IMPS - Inpatient Multidimensional Rating Scale<BR/>ITT - intention to treat<BR/>LOCF - Last observation carried forward<BR/>MADRS - Montgomery-Asberg Depression Rating Scale<BR/>MAOI - monoamine oxidase inhibitor agents<BR/>MOAS - Modified Overt Aggression Scale<BR/>OAS-M - Overt Aggression Scale-Modified<BR/>PANSS - Positive and Negative Syndrome Scale<BR/>PDRS - Personality Disorder Rating Scale<BR/>POMS - Profile of Mood States<BR/>SCID-II - Structured Clinical Interview for DSM Axis II Personality Disorders<BR/>SCL-90 - Symptom Checklist-90<BR/>SCL-90-R - Symptom Checklist-90 - Revised<BR/>SCL-90-ANX - anxiety<BR/>SCL-90-DEP - depression<BR/>SCL-90-GSI - global severity index<BR/>SCL-90-HOS - hostiliy<BR/>SCL-90-INT - interpersonal sensitivity<BR/>SCL-90-PAR - paranoid ideation<BR/>SCL-90-PST - positive symptom total<BR/>SCL-90-PSY - psychoticism<BR/>SIB - Schedule for Interviewing Borderlines<BR/>SSI - Schizotypal Symptom Inventory<BR/>SSRI - Selective Serotonine Reuptake Inhibitor<BR/>STAXI - State-Trait Anger Expression Inventory<BR/>STIC - Self Report Test of Impulse Control<BR/>TCA - tricyclic antidepressant<BR/>ZAN-BPD - Zanarini Rating Scale for Borderline Personality Disorder</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-05-12 11:46:31 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellino-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellino-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-10 12:05:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bellino-2006b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-10 12:05:29 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison: fluoxetine vs. fluoxetine + Interpersonal Therapy; testing the effects of additional psychotherapy as compared to pharmacotherapy alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benedetti-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bohus-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chengappa-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; retrospective chart review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coccaro-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Patients: less than 70% BPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cornelius-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 11:46:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cornelius-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 11:46:23 +0100" MODIFIED_BY="[Empty name]">
<P>Investigates the effects of continuation therapy in patients of the <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK> trial, but only responders were allowed to enter this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 11:46:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cowdry-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 11:46:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised cross-over trial, no separate data first period available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frankenburg-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hilger-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hollander-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Data not sufficient for effect size calculation concerning any outcome of interest</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 14:19:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koenigsberg-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 14:19:03 +0000" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% BPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 11:46:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-La-Malfa-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 11:46:26 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% BPD; separate data on BPD patients available but not sufficient for effect size calculation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 11:46:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Links-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 11:46:27 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: BPD characteristics, mean DIB score 9.47 (SD = 0.75); exact number of BPD patients unclear<BR/>Data: no separate data for first arm of cross-over trial (randomised cross-over trial)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Markovitz-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Markovitz-1995a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Data: not sufficient for effect size calculation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Markovitz-1995b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Norden-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parsons-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 75% BPD; no separate data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Philipsen-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: administration in acute dissociative states only, not for continuous treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Philipsen-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial<BR/>Intervention: administered in acute states of aversive inner tension only, not for continuous treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rocca-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Russell-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: PD but not BPD patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schulz-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised; open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serban-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: less than 70% BPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 11:46:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soloff-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 11:46:28 +0100" MODIFIED_BY="[Empty name]">
<P>Midpoint analysis of the <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK> trial which has been included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 11:46:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soloff-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 11:46:29 +0100" MODIFIED_BY="[Empty name]">
<P>Compares haloperidol responders to patients receiving placebo of the <LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK> trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verkes-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Participants: suicide attempt repeaters, not clear how many patients actually had a BPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 11:46:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ziegenhorn-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 11:46:31 +0100" MODIFIED_BY="[Empty name]">
<P>Within-subject crossover-design, no separate data for first study periods available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-05-12 11:46:56 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-05-12 11:46:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AstraZen-NCT00254748">
<CHAR_STUDY_NAME MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>The effect of quetiapine on psychotic-like symptoms in borderline personality disordered patients: a randomised placebo-controlled trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-12-07 16:38:11 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>BPD according to DSM-IV, including criterion 9; 18-55 years, in- or outpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:46:33 +0100" MODIFIED_BY="[Empty name]">
<P>8 weeks of quetiapine (flexible dose between 200 mg/day and 600 mg/day) vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:46:35 +0100" MODIFIED_BY="[Empty name]">
<P>Psychotic-like symptoms, severity of psychiatric symptoms; mood, anger, impulsiveness, hostility, anxiety</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>June 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>AstraZeneca Netherlands</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-05-12 11:46:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bohus-NCT00124839">
<CHAR_STUDY_NAME MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Evaluation of the efficacy of the opioid antagonist naltrexone on the incidence and intensity of flashbacks and dissociative states in patients with borderline personality disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-05-11 15:19:28 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:46:37 +0100" MODIFIED_BY="[Empty name]">
<P>BPD according to DSM-IV, Dissociation Experience Scale (DES) score 25 at least, not actively abusing opiates, no other psychopharmacological treatment for at least two weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:46:37 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:46:38 +0100" MODIFIED_BY="[Empty name]">
<P>Reduction of dissociative symptoms, flashbacks, self-injurious behaviour, psychopathology (depression, anxiety, anger, borderline symptoms), safety</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>October 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2010-05-11 15:21:19 +0100" MODIFIED_BY="[Empty name]">
<P>Bohus M, Central Institute of Mental Health, Mannheim, Germany</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2010-05-11 15:22:31 +0100" MODIFIED_BY="[Empty name]">
<P>This study has been terminated in April 2008. (Difficulties in recruiting enough subjects)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-05-12 11:46:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casas-NCT00437099">
<CHAR_STUDY_NAME MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy of omega-3 fatty acids on borderline personality disorder: a randomised, double-blind, clinical trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-12-07 16:38:15 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-12 11:46:40 +0100" MODIFIED_BY="[Empty name]">
<P>BPD according to DSM-IV, CGI-S (BPD) &gt; 3, 18-65 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:46:42 +0100" MODIFIED_BY="[Empty name]">
<P>12 weeks of cognitive behaviour therapy (CBT) + placebo vs. CBT + Omacor (R) 1680 mg/day vs. CBT + Omacor (R) 3360 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:46:43 +0100" MODIFIED_BY="[Empty name]">
<P>Depression, manic symptoms, impulsivity, aggression, anger, psychotic symptoms, anxiety, suicidal and parasuicidal behaviour, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2010-05-12 11:46:44 +0100" MODIFIED_BY="[Empty name]">
<P>Unknown</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Casa M, Hospital Univesitari Vall d'Hebron, Barcelona, Spain</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-05-12 11:46:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goodman-NCT00255554">
<CHAR_STUDY_NAME MODIFIED="2010-05-12 11:46:45 +0100" MODIFIED_BY="[Empty name]">
<P>Effects of Dialectical Behavioural Therapy and escitalopram on impulsive aggression, affective instability and cognitive processing in borderline personality disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-05-11 15:19:36 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>BPD, 18-60 years, off psychotropic medication for at least 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:46:46 +0100" MODIFIED_BY="[Empty name]">
<P>Six months of DBT + escitalopram vs. DBT + placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:46:47 +0100" MODIFIED_BY="[Empty name]">
<P>Impulsivity, aggression, affective impulsivity, immediate and delayed memory, cognitive processing</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>November 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Goodman M, Bronx VA Medical Center, New York, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-05-12 11:46:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malev-ISRCTN11135486">
<CHAR_STUDY_NAME MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Quetiapine versus sertraline as the pharmacological component in a standardised psychopharmacological and psychotherapeutic treatment of borderline personality disorder: a randomised, rater-blinded study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-12-07 16:38:21 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>BPD according to DSM-IV, females, at least 18 years of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:46:49 +0100" MODIFIED_BY="[Empty name]">
<P>24 weeks of quetiapine (50-800 mg/day) vs. sertraline (25-200 mg/day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:46:49 +0100" MODIFIED_BY="[Empty name]">
<P>Anger, hostility, severity of affective symptoms, anxiety, depression, psychotic symptoms, interpersonal problems, duration of hospitalisation, co-medication</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>October 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Malevani J, University of Düsseldorf, Germany</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-05-12 11:46:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ralevski-NCT00463775">
<CHAR_STUDY_NAME MODIFIED="2010-05-12 11:46:51 +0100" MODIFIED_BY="[Empty name]">
<P>Topiramate for treatment of patients with borderline personality disorder and alcohol dependence</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-12-07 16:38:25 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>BPD and alcohol dependence, 21-60 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:46:52 +0100" MODIFIED_BY="[Empty name]">
<P>8 weeks of topiramate (250 mg/day) vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-12 11:46:52 +0100" MODIFIED_BY="[Empty name]">
<P>Hostility, aggression, drinking, craving, side effects</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>March 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Ralevski E, Yale University, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-05-12 11:46:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schulz-NCT00222482">
<CHAR_STUDY_NAME MODIFIED="2010-05-12 11:46:53 +0100" MODIFIED_BY="[Empty name]">
<P>A double-blind and placebo controlled assessment of Depakote ER in borderline personality disorder</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-12-07 16:38:37 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>BPD, 21-55 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-12 11:46:56 +0100" MODIFIED_BY="[Empty name]">
<P>12 weeks of DBT + Depakote ER vs. DBT + placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>SCL-90, impulsivity</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>March 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Schulz SC, University of Minnesota Medical School, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-05-12 12:02:30 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-05-12 11:43:10 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:07:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bogenschutz-2004">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned in equal numbers" (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>, p. 105)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 11:58:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-la-Fuente-1994">
<DESCRIPTION>
<P>Quote: "Of the 20 patients enrolled in the trial, we randomized 10 into the CBZ [carbamazepine] group and 10 received PLC [placebo]" (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>, p. 481)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:29:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frankenburg-2002">
<DESCRIPTION>
<P>Quote: "Prearranged random number sequence" (p. 443)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:30:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1986">
<DESCRIPTION>
<P>Quote: "Randomly allocated to thiothixene or placebo" (p. 681)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-08 17:31:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hallahan-2007">
<DESCRIPTION>
<P>Quote: "computer-generated list" (p. 119)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:32:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hollander-2001">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned [...] at an approximate ratio of 2:1" (p. 201)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 12:20:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leone-1982">
<DESCRIPTION>
<P>Quote: "Matched groups [...] Subjects [...] were selected randomly to receive loxapine or chlorpromazine. [...] There were 24 women and 16 men in each treatment group." (p. 148)</P>
<P>Comment: probably matching procedure used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-09 10:46:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-2008">
<DESCRIPTION>
<P>Quote: "random number sequence" (p. e2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loew-2006">
<DESCRIPTION>
<P>Quote: "Randomization was carried out confidentially by the clinic administration" (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>, p. 63)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-09 12:58:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-1979_x002f_82">
<DESCRIPTION>
<P>Quote: "Patients were randomly allocated" (Montgomery 1979, p. 227)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-09 13:19:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-81_x002f_82_x002f_83">
<DESCRIPTION>
<P>Quote: "randomly allocated" (Montgomery 1981, p. 787)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nickel-2004">
<DESCRIPTION>
<P>Quote: "Randomization was carried out confidentially by the clinic administration." (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>, p. 1516)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nickel-2005">
<DESCRIPTION>
<P>Quote: "Randomization was carried out confidentially by the clinic administration." (<LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>, p. 496)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nickel-2006">
<DESCRIPTION>
<P>Quote: "The random assignment was carried out confidentially by the clinic administration." (<LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>, p. 835)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 09:49:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pascual-2008">
<DESCRIPTION>
<P>Quote: "Randomization was performed by blocks of 4 generated using the SPSS software package" (p. 604)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:39:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reich-2009">
<DESCRIPTION>
<P>Quote: "patients were randomized [...] in a 1:1 manner. This was determined by a prearranged random number sequence." (p. e-3).</P>
<P>Twenty-eight patients completed all aspects of assessment before randomization. Fifteen patients were randomized to receive lamotrigine, and 13 patients were assigned to receive placebo." (p. e-3)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 10:07:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rinne-2002">
<DESCRIPTION>
<P>Quote: "randomized trial" (p. 2049)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 10:19:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salzman-1995">
<DESCRIPTION>
<P>Quote: "random-assignment comparison" (p. 24)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:41:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schulz-2007">
<DESCRIPTION>
<P>Quote: "patients [...] were randomly assigned to treatment" (Eli Lilly, 2008, p. 15), "All participants, study site personnel and investigators were masked to randomisation codes." (Schulz 2008, p. e1)</P>
<P>Comment: Randomisation conducted centrally</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 13:42:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Quote: "randomized block assignment minimized the possible confound of comorbid axis-I presentations expected to response to fluoxetine by assignment of an equal number of patients with major depressive disorder, posttraumatic stress disorder, or both to each treatment condition." (p. 380)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:43:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soler-2005">
<DESCRIPTION>
<P>Quote: "randomly assigned to receive dialectical behaviour therapy plus either olanzapine or placebo on a 1:1 ratio" (p. 1222)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soloff-1989">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned" (<LINK REF="STD-Soloff-1986" TYPE="STUDY">Soloff 1986</LINK>, p. 692)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 14:34:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soloff-1993">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned." (p. 378)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tritt-2005">
<DESCRIPTION>
<P>Quote: "Randomization was carried out confidentially in secrecy by the clinic administration section" (<LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>, p. 288)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-12 11:41:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2001">
<DESCRIPTION>
<P>Quote: "random number sequence" (p. 850)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-12 11:53:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2003">
<DESCRIPTION>
<P>Quote: "randomly assigned [...] 2:1 randomization ratio." (p. 168)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-12 12:16:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2004">
<DESCRIPTION>
<P>Quote: "The randomization procedure was designed to assign equal numbers of subjects to the 3 treatment groups." (p. 904) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 13:26:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2007">
<DESCRIPTION>
<P>Quote: "patients were randomised to 1 of 3 treatment groups" (Eli Lilly, 2008, p. 3)</P>
<P>Comment: randomisation conducted centrally</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-05-12 11:39:55 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:07:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bogenschutz-2004">
<DESCRIPTION>
<P>Comment: No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-30 14:05:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-la-Fuente-1994">
<DESCRIPTION>
<P>Quote: "The study was carried out by two clinicians. One of them [...] was blind and performed all the clinical and psychometric assessments. The other one [...] who was not blind to the drug treatment, correctly adjusted the plasma levels of CBZ and asked for adverse side effects." (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK> p. 480)</P>
<P>Comment: Unclear, who exactly enrolled patients.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-15 13:46:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frankenburg-2002">
<DESCRIPTION>
<P>Quote: "Tablets were supplied in numbered bottles containing drug or placebo as determined by a prearranged random number sequence" (p.443)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:30:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1986">
<DESCRIPTION>
<P>Comment: No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-08 17:32:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hallahan-2007">
<DESCRIPTION>
<P>Quote: "An independent colleague dispensed either active or placebo capsules according to a computer-generated list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:45:33 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hollander-2001">
<DESCRIPTION>
<P>Quote: "Although the planned patient assignment ratio was 2:1 [...], the ratio was actually 3:1" (p.202) </P>
<P>Comment: First, the authors say that there was an approximate ratio of 2:1 randomisation was planned. However, it remains unclear why the actual ratio turned out to be 3:1, even if taking the small number (16) of participants into account. A 2:1 ratio assignment would have been feasible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 12:09:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leone-1982">
<DESCRIPTION>
<P>Comment: No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-09 10:47:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-2008">
<DESCRIPTION>
<P>Quote: "each tablet contained either 5 mg of olanzapine or matching inert placebo as determined by a random number sequence" (p. e2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:46:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loew-2006">
<DESCRIPTION>
<P>Quote: "Tablets were supplied in numbered boxes." (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>, p. 63)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-09 13:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-1979_x002f_82">
<DESCRIPTION>
<P>Comment: No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-09 13:18:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-81_x002f_82_x002f_83">
<DESCRIPTION>
<P>Comment: No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2004">
<DESCRIPTION>
<P>Quote: "Tablets were supplied in numbered boxes." (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>, p. 1516)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2005">
<DESCRIPTION>
<P>Quote: "Tablets were supplied in numbered boxes." (<LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>, p. 496)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2006">
<DESCRIPTION>
<P>Quote: "Tablets were supplied in numbered boxes." (<LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>, p. 835)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 09:27:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pascual-2008">
<DESCRIPTION>
<P>Comment: No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:39:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-2009">
<DESCRIPTION>
<P>Insufficient information to permit judgement of 'Yes' or 'No' (unclear, if the number sequence was kept confidentially or if enrolling investigators could possibly foresee assignment)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 10:06:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rinne-2002">
<DESCRIPTION>
<P>Comment: No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 10:20:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salzman-1995">
<DESCRIPTION>
<P>Comment: No information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 11:07:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schulz-2007">
<DESCRIPTION>
<P>Quote: "All participants, study site personnel and investigators were masked to randomisation codes." (Schulz 2008, p. e1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 13:48:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Comment: No information given. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 14:02:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soler-2005">
<DESCRIPTION>
<P>Comment: No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soloff-1989">
<DESCRIPTION>
<P>Quote: "Numbered tablets [...] were given" (<LINK REF="STD-Soloff-1986" TYPE="STUDY">Soloff 1986</LINK>, p. 692)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-10 14:40:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soloff-1993">
<DESCRIPTION>
<P>Quote: "double-blind [...] trial" (p. 377)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tritt-2005">
<DESCRIPTION>
<P>Quote: "Tablets were supplied in numbered boxes." (<LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>, p. 288)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-12 11:40:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2001">
<DESCRIPTION>
<P>Quote: "Tablets were supplied in numbered bottles containing drug or placebo as determined by a random number sequence." (p. 850)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-12 11:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2003">
<DESCRIPTION>
<P>Comment: No information given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:51:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zanarini-2004">
<DESCRIPTION>
<P>Quote: "Forty-five subjects entered the trial and were randomized to fluoxetine (N = 14), olanzapine (N = 16), or OFC (N = 15)." (p. 905)</P>
<P>Comment: Allocation probably not adequately concealed, since equal numbers were intended (cf. to item above), but group sizes differed, actually.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-10 12:12:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2007">
<DESCRIPTION>
<P>Comment: Probably done, since this RCT was conducted in parallel with the olanzapine flexible-dose trial (Schulz 2008), where a randomisation code was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-05-12 11:42:35 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>observer-rated outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>self-rated outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 11:10:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bogenschutz-2004">
<DESCRIPTION>
<P>Quote: "double-blind trial", "pseudo-dose [...] for patients receiving placebo" (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>, p. 105)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-12 11:10:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bogenschutz-2004">
<DESCRIPTION>
<P>Quote: "double-blind trial", "pseudo-dose [...] for patients receiving placebo" (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>, p. 105)</P>
<P>Comment: No information provided on who actually adjusted the dose and if this person was blind to the patients' allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-06 12:47:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-la-Fuente-1994">
<DESCRIPTION>
<P>Quote (Eur Neuropsychopharmacol, 1994, 4): "[...] active or placebo treatment. We administered it in a single daily dose at 10 p.m. [...] The study was carried out by two clinicians. One of them [...] was blind [...]. The other one who was not blind to the drug treatment, correctly adjusted the plasma levels of CBZ and asked for adverse side effects." (p. 480)</P>
<P>Comment: Unclear, if opaque capsules were used, and if a pseudo-adjustment of the placebo dose was done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-13 17:44:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-la-Fuente-1994">
<DESCRIPTION>
<P>Quote: "The study was carried out by two clinicians. One of them [...] was blind to the drug treatment and performed all the clinical and psychometric assessments. [...] We instructed the patients to not communicate side effects to the blind clinician." (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>, p. 480)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 11:29:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frankenburg-2002">
<DESCRIPTION>
<P>Quote: "Tablets were supplied in numbered bottles [...] Each tablet contained either 250 mg of valproate semisodium or matching inert placebo. [...] One of the investigators [...] was given either the real or a sham level (if the subject was receiving placebo). This same investigator met with the subjects for [...] medication checks and adjusted the dose according to perceived response, reported or sham level, and side effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-12 11:29:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Frankenburg-2002">
<DESCRIPTION>
<P>Comment: No information given on who exactly assessed outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-08 17:15:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goldberg-1986">
<DESCRIPTION>
<P>Quote: "Both agents were provided in identical-appearing capsules containing 5 mg of thiothixene hydrochloride or an equivalent amount of lactose for placebo. The initial dose for all patients was one capsule [...] and on each succeeding visit the dose was increased by one capsule unless side-effects or marked improvement intervened. A maximum dose of 40 mg, or eight capsules, was to be allowed [...]. (p. 682)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-12 11:30:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goldberg-1986">
<DESCRIPTION>
<P>Quote: "Both agents were provided in identical-appearing capsules containing 5 mg of thiothixene hydrochloride or an equivalent amount of lactose for placebo. The initial dose for all patients was one capsule [...] and on each succeeding visit the dose was increased by one capsule unless side-effects or marked improvement intervened. A maximum dose of 40 mg, or eight capsules, was to be allowed [...]. (p. 682)</P>
<P>Comment: Trial described as "double-blind" (p. 681)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-08 17:35:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hallahan-2007">
<DESCRIPTION>
<P>Quote: "Participants were prescribed four identical capsules of either active agent or placebo [...] Placebo ensured a degree of equality in the incidence of 'fishy breath', the most frequent side-effect of taking active treatment." (p. 119)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-12 11:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hallahan-2007">
<DESCRIPTION>
<P>Quote: "identical capsules [...] Placebo ensured a degree of equality in the incidence of 'fishy breath' [...] An independent colleague dispensed [...] capsules according to a computer-generated list. The code was only revealed to the researchers once data collection was complete." (p. 119)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-15 15:24:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hollander-2001">
<DESCRIPTION>
<P>Quote: "The treating psychiatrist was kept blind to patient medication, blood valproate levels were read and dose adjustments to both valproate semisodium and placebo were determined by a psychiatrist not seeing patients for this study." (p. 201)</P>
<P>Comment: No information given if opaque capsules were used, and if the placebo pseudo-dose was also "adjusted".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-07 16:05:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hollander-2001">
<DESCRIPTION>
<P>Quote: "clinician-rated outcome measures [...] based on the average of the ratings of the treating psychiatrist and independent evaulator (a psychologist blind to side effects as well as to medication group)" (p.201)</P>
<P>Comment: No information given on who exactly assessed observer-rated outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-09 10:39:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leone-1982">
<DESCRIPTION>
<P>Quote: "drugs were supplied in identical opaque capsules" (p. 148)</P>
<P>Comment: No self-rated outcomes used. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-09 10:37:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leone-1982">
<DESCRIPTION>
<P>Comment: No information given. Within this review, only the outcomes of attrition and adverse effects, that were "recorded upon appearance" (p. 148), were used. For these, the review authors assume the risk of bias as moderately. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-09 12:28:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-2008">
<DESCRIPTION>
<P>Quote: "Patients, psychotherapists, pharmacotherapist, and assessment interviewers were kept naive to medication assignment. (p. e2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-09 12:28:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Linehan-2008">
<DESCRIPTION>
<P>Quote: "Patients, psychotherapists, pharmacotherapist, and assessment interviewers were kept naive to medication assignment. At the end of the study, the pharmacotherapist and interviewers were unable to guess group assignment above chance." (p. e2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-13 17:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loew-2006">
<DESCRIPTION>
<P>Quote: "blinded medication" (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>, p. 63), "subjects [...] were blinded regarding [...] assignment" (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>, p. 63)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-13 17:25:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loew-2006">
<DESCRIPTION>
<P>Quote: "blinded medication" (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>, p. 63), "clinicians were blinded regarding [...] assignment (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>, p. 63)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-09 13:01:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montgomery-1979_x002f_82">
<DESCRIPTION>
<P>Quote: "intramuscular flupenthixol decanoate or placebo drawn from identical matching ampoules" (Montgomery 1979, p. 227</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-10-07 16:10:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montgomery-1979_x002f_82">
<DESCRIPTION>
<P>Quote: "intramuscular flupenthixol decanoate or placebo drawn from identical matching ampoules" (Montgomery 1979, p. 227)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-09 13:19:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-81_x002f_82_x002f_83">
<DESCRIPTION>
<P>Quote: "double-blind conditions" (Montgomery 1981, p. 787)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-09 13:20:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-81_x002f_82_x002f_83">
<DESCRIPTION>
<P>Quote: "double-blind conditions" (Montgomery 1981, p. 787)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-13 17:25:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2004">
<DESCRIPTION>
<P>Quote: "blinded medication" (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>, p. 1516), "subjects [...] were blinded regarding [...] assignment" (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>, p. 1516)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-13 17:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2004">
<DESCRIPTION>
<P>Quote: "blinded medication" (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>, p. 1516), "clinicians [...] were blinded regarding [...] assignment" (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>, p. 1516)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 19:51:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2005">
<DESCRIPTION>
<P>Quote: "blinded medication" (<LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>, p. 496) "subjects [...] were blinded regarding [...] assignment" (<LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>, p. 496)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-13 17:25:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2005">
<DESCRIPTION>
<P>Quote: "blinded medication" (<LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>, p. 496), "clinicians [...] were blinded regarding [...] assignment" (<LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>, p. 496)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-13 17:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2006">
<DESCRIPTION>
<P>Quote: "subjects received medication in a blinded manner" (<LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>, p. 835), "the subjects [...] were blinded regarding the assignment (<LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>, p. 835)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-13 17:25:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2006">
<DESCRIPTION>
<P>Quote: "subjects received medication in a blinded manner" (<LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>, p. 835), "the clinicians [...] were blinded regarding the assignment (<LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>, p. 835)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-10 09:49:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pascual-2008">
<DESCRIPTION>
<P>Quote: "double-blind" (p. 604)</P>
<P>Comment: No further information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-10 09:50:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pascual-2008">
<DESCRIPTION>
<P>Quote: "double-blind" (p. 604)</P>
<P>Comment: No further information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 11:40:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reich-2009">
<DESCRIPTION>
<P>No self-rated outcomes used for this review</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-05-12 11:40:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reich-2009">
<DESCRIPTION>
<P>Quote: "double-blind placebo-controlled study" (e.g. p. e-1); "double-distinction between "prescribing psychiatrist (D.B.R.)" who fixed the dose and "study staff" who made assessments (p. 3)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-10 10:07:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rinne-2002">
<DESCRIPTION>
<P>Quote: "double-blind" (p. 2049)</P>
<P>Comment: No further information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-10 10:09:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rinne-2002">
<DESCRIPTION>
<P>Quote: "double-blind" (p. 2049)</P>
<P>Comment: No further information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-10 10:31:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salzman-1995">
<DESCRIPTION>
<P>Comment: No self-rated outcomes used within this review</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-10 10:29:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salzman-1995">
<DESCRIPTION>
<P>Quote: "Subjects were evaluated by independent observers" (p. 24)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-10 11:04:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schulz-2007">
<DESCRIPTION>
<P>Quote: "All participants, study site personnel and investigators were masked to randomisation codes." (Schulz 2008, p. e1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-10 11:07:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schulz-2007">
<DESCRIPTION>
<P>Quote: "All participants, study site personnel and investigators were masked to randomisation codes." (Schulz 2008, p. e1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 11:42:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Quote: "This study was double-blind" (p. 380)</P>
<P>Comment: No information given how blinding of participants was attempted, especially in light of the day-clinic setting with possibly shared group therapy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-09-29 15:21:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Quote: "This study was double-blind" (p. 380), "A non-treating study psychiatrist was available to break the blind in event of a clinical emergency." (p. 381)</P>
<P>Comment: In contrast, the treating clinician was probably blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-10 14:03:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soler-2005">
<DESCRIPTION>
<P>Quote: "double blind [...] study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-10 14:03:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soler-2005">
<DESCRIPTION>
<P>Quote: "double blind [...] study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-13 17:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soloff-1989">
<DESCRIPTION>
<P>Quote: "Double-blind [...] trial" (<LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>, p. 239)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-13 17:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soloff-1989">
<DESCRIPTION>
<P>Quote: "Weekly ratings by two 'blind investigators', an onward psychiatrist serving as the nonblind psychiatrist (for safety)." (<LINK REF="STD-Soloff-1986" TYPE="STUDY">Soloff 1986</LINK>, p. 693)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-13 17:49:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soloff-1993">
<DESCRIPTION>
<P>Average daily doses of medication, including placebo pseudo-dose, are given (p. 380) </P>
<P>Comment: The measures undertaken to ensure blinding seem elaborated and are described in detail, so the blinding of participants seems to have been thoroughly ensured. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-13 17:49:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soloff-1993">
<DESCRIPTION>
<P>Quote: "Medication could be increased up to six tablets (haloperidol, 6 mg; phenelzine sulfate, 90 mg; placebo, six tablets)" (p. 378)</P>
<P>Average daily doses of medication, including placebo pseudo-dose, are given (p. 380)</P>
<P>Comment: The measures undertaken to ensure blinding seem elaborated and are described in detail, so the blinding of the rating study personnel seems to have been thoroughly ensured. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-13 17:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tritt-2005">
<DESCRIPTION>
<P>Quote: "Each individual received one blinded capsule medication daily [...] Both subjects and clinicians were blinded regarding assignment." (<LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>, p. 288)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-13 17:25:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tritt-2005">
<DESCRIPTION>
<P>Quote: "Each individual received one blinded capsule medication daily [...] Both subjects and clinicians were blinded regarding assignment." (<LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>, p. 288)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-12 11:42:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2001">
<DESCRIPTION>
<P>Quote: "Each tablet contained either 2.5 mg of olanzapine or matching inert placebo. [...] Both subjects and clinicians were blinded to olanzapine/placebo assignment. The blind was broken after the acquisition of all endpoint data for all subjects." (p. 850)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-12 11:45:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2001">
<DESCRIPTION>
<P>Quote: "Each tablet contained either 2.5 mg of olanzapine or matching inert placebo. [...] Both subjects and clinicians were blinded to olanzapine/placebo assignment. The blind was broken after the acquisition of all endpoint data for all subjects." (p. 850)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-12 11:55:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2003">
<DESCRIPTION>
<P>Quote: "double- blind study" (p. 167), "subjects received two capsules per day [...] each contained either [...] E-EPA or placebo" (p. 167)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-12 11:55:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2003">
<DESCRIPTION>
<P>Quote: "double- blind study" (p. 167), "subjects received two capsules per day [...] each contained either [...] E-EPA or placebo" (p. 167)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-12 12:07:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2004">
<DESCRIPTION>
<P>Quote: "Dose was adjusted by an unblinded psychiatrist according to perceived response and side effects. Both subjects and raters were blinded to study assignment. The blind was broken after acquisition of all endpoint data for all subjects." (p. 904)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-12 12:07:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2004">
<DESCRIPTION>
<P>Quote: "Dose was adjusted by an unblinded psychiatrist according to perceived response and side effects. Both subjects and raters were blinded to study assignment. The blind was broken after acquisition of all endpoint data for all subjects." (p. 904)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-10 13:31:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2007">
<DESCRIPTION>
<P>Quote: "Double-blind treatment" (Eli Lilly, 2008, p. 1)</P>
<P>Comment: Probably equally managed as in Schulz 2008 </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-10-10 13:32:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2007">
<DESCRIPTION>
<P>Quote: "Double-blind treatment" (Eli Lilly, 2008, p. 1)</P>
<P>Comment: Probably equally managed as in Schulz 2008</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-05-12 12:02:30 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:11:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bogenschutz-2004">
<DESCRIPTION>
<P>Comment: "evaluable patients" refers to all patients remaining at least 2 weeks in the study, i.e. who attended both baseline and preliminary assessment after two weeks; reasons for early termination specified (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>, p.106). However, 2 patients dropped out of the olanzapine group due to "violation of protocol" (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>, p. 106)</P>
<P>Of the 40 patients enrolled, 23 completed the full 12 weeks of the trial (10 in olanzapine group, 13 in placebo group)<BR/>Reasons for early termination:<BR/>Lost to follow-up: 2 in the olanzapine group, 5 in the placebo group<BR/>Lack of efficacy: 2/2<BR/>Weight gain: 2/0<BR/>Sedation: 2/0<BR/>Violation of protocol: 2/0</P>
<P>Continuous data based on LOCF of patients remaining at least 2 weeks in the study<BR/>dichotomous data based on ITT sample</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:28:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-la-Fuente-1994">
<DESCRIPTION>
<P>Quote: "Of the 20 patients enrolled in the trial, we randomized 10 into the CBZ group and 10 received PLC. [...] Two patients receiving CBZ dropped out. [...] No patient on PLC dropped out." (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>, p. 481).</P>
<P>Reasons for early termination:</P>
<P>Dramatic increase in frequency and intensity of aggression (against self and others): 2 in carbamazepine group, 0 in placebo group</P>
<P>Comment: Reasons for early termination specified (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>, p.481). However, it remains unclear if the reported continuous outcomes confer to LOCF analyses. We decided to use the same numbers of patients for which dichotomous outcomes were reported. For dichotomous outcomes, lacking numbers of patients were imputed as having the unfavourable results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:30:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Frankenburg-2002">
<DESCRIPTION>
<P>Quote: "Endpoint values [...] are based on last observation carried forward." (p. 444)</P>
<P>Comment: reasons for early termination specified (p.444). For dichotomous outcomes, lacking numbers of patients were imputed as having the unfavourable result.</P>
<P>Of the 30 patients enrolled, 11 completed the full 24 weeks of the trial (7 in valproate semisodium group, 4 in placebo group)<BR/>Reasons for early termination:<BR/>Lost to follow-up: 9 in the valproate semisodium group, 3 in the placebo group<BR/>Moved out of the area: 1/0<BR/>Inability to use reliable forms of contraception: 1/0<BR/>Withdrawal of consent: 1/0<BR/>Diarrhea and tremors: 1/0<BR/>Development of a major depressive episode: 0/2<BR/>Hair loss: 0/1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goldberg-1986">
<DESCRIPTION>
<P>Quote: "Patients who terminated their participation early were assessed at that point and those assessments were taken as their endpoints." (p. 682)</P>
<P>Of the 50 patients enrolled, 40 completed treatment (17 in thiothixene group, 23 in placebo group)<BR/>reasons for early termination:<BR/>Adverse effects: 7 in thiothixene group, 0 in placebo group<BR/>Lack of efficacy: 0/3</P>
<P>Continuous data based on LOCF</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:32:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hallahan-2007">
<DESCRIPTION>
<P>Comment: LOCF used, reasons for early termination specified (p. 120)</P>
<P>Of the 49 patients enrolled, 39 completed treatment (19 of the 22 allocated to active treatment, 20 of the 27 allocated to placebo)<BR/>Reasons for early termination:<BR/>Left district: 1 in active group, 2 in placebo group</P>
<P>Lost to follow-up: 2 in active group, 2 in placebo group</P>
<P>Admitted to psychiatric hospital: 0 in active group, 2 in placebo group</P>
<P>Refused to continue treatment: 0 in active group, 1 in placebo group</P>
<P>Dichotomous outcomes calculated on basis of the ITT sample</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:32:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hollander-2001">
<DESCRIPTION>
<P>Quote: "Patients taking valproate semisodium had a 50% dropout rate [...] versus 100% dropout in the placebo group. [...] No patients dropped out owing to side effects; all dropped out owing to either lack of efficacy or impulsive decisions. [...]" (p.201)</P>
<P>Comment: LOCF used (p. 202)</P>
<P>Initially 21 subjects entered the study, only 16 were randomised to a treatment group without giving reasons</P>
<P>Of the 16 patients randomised, 6 completed treatment (6 in divalproex group, 0 in placebo group)<BR/>reasons for early termination:<BR/>"No patients dropped out owing to side effects; all dropped out owing to either lack of efficacy or impulsive decisions. [...]" (p.201)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:33:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Leone-1982">
<DESCRIPTION>
<P>Continuous outcomes based on available cases</P>
<P>Of the 80 patients enrolled, 69 completed at least 3 weeks of treatment and were included (34 in loxapine group, 35 in placebo group)<BR/>Reasons for early termination:<BR/>Did not follow study procedures: 4 in loxapine group, 4 in chlorpromazine group<BR/>Had to be admitted to hospital within 3 days: 2 in loxapine group, 1 in chlorpromazine group</P>
<P>Comment: Only dichotomous outcomes used here, for which dropped-out patients were imputed as having the negative outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:34:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Linehan-2008">
<DESCRIPTION>
<P>Quote: "Outcomes were intent-to-treat analyses" (p. e3)</P>
<P>Comment: Reasons for early termination specified (p. e4); dropped-out patients were imputed as having the negative outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:35:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loew-2006">
<DESCRIPTION>
<P>Quote: "Fifty-nine subjects were eligible to take part in the study [...] 56 patients were required [...] randomization was carried out [...] with a 1:1 assignment to the active drug (N = 28) and placebo (N = 28)" (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>, p. 63)</P>
<P>Of the 56 patients enrolled, 52 completed treatment (27 in topiramate group, 25 in placebo group)<BR/>reasons for early termination:<BR/>Absent more than twice for weekly evaluation: 1 in the topiramate group, 3 in the placebo group</P>
<P>LOCF used, reasons for early termination specified (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>, p. 63)</P>
<P>Comment: Not clear, why or how the 56 participants were finally chosen out of the 59 potential participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:35:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montgomery-1979_x002f_82">
<DESCRIPTION>
<P>Quote: "To preserve blindness patients with significant Parkinsonian side effects were removed from the trial and counted as drop outs." (Montgomery 1979, p. 227)</P>
<P>Reported dichotomous outcomes based on the completer sample (no further details on drop-out patients concerning diagnosis, sex, and age)</P>
<P>Of the 37 patients enrolled, 30 completed treatment (4 drop-outs in the active group leaving 14 completers, 3 drop-outs in the placebo group leaving 16 completers)<BR/>Reasons for early termination:<BR/>Parkinsonian side effects: 2 in flupenthixol group/0 in placebo group<BR/>No reason given: 2/3</P>
<P>Comment: Only dichotomous data used in this review, drop-outs were imputed as having the negative outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:36:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Montgomery-81_x002f_82_x002f_83">
<DESCRIPTION>
<P>Dichotomous outcomes used here are based on the ITT sample, dropped-out patients were imputed as having the negative outcome.</P>
<P>Comment: High drop-out rate (20 out of 58; Montgomery 1981, p. 787), but reasons not specified, nor to which treatment group the lost patients belonged. Therefore, drop-outs could not be imputed in categorial outcomes as having the negative outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:37:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nickel-2004">
<DESCRIPTION>
<P>Quote: "Two subjects, who failed to appear 2 to 3 times for the weekly evaluations, dropped out of the study, and their data were not further analyzed. Finally, data from 29 women [...] were evaluated." (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>, p. 1516).</P>
<P>Continuous outcomes based on available case analysis</P>
<P>Of the 31 patients enrolled, 29 completed treatment<BR/>Reasons for early termination:<BR/>Failed to appear at least 2 times for weekly evalutaion, no further details: 2 in topiramate group/0 in placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:37:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nickel-2005">
<DESCRIPTION>
<P>Quote: "Forty-eight subjects were eligible to take part in the study [...] 44 patients were required [...] randomization was carried out confidentially by the clinical administration [...] 1:1 randomisation ratio for topiramate (TG, N = 22) versus placebo treatment (N = 22)" (<LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>, p. 496)</P>
<P>Comment: Unclear, why or how the 44 participants were finally chosen out of the 47 potential participants</P>
<P>Quote: "Two subjects from the placebo group failed to appear appear more than twice for the weekly evaluations and dropped out of the study; their data were not further analyzed. Thus, data from 42 men (42 out of 44) were evaluated." (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>, p. 1516).</P>
<P>Comment: Reasons for early termination not further specified. Continuous outcomes based on available case analysis. For dichotomous data, drop-outs were imputed as having the negative outcome.</P>
<P>Of the 44 patients enrolled, 42 completed treatment (22 in the active group, 20 in the placebo group)<BR/>Reasons for early termination:<BR/>Failed to appear more than twice for weekly evaluation, no further reasons given: 0 in the active group, 2 in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:38:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2006">
<DESCRIPTION>
<P>Of the 52 patients enrolled, 47 completed treatment</P>
<P>Quote: "Five subjects who missed more than two weekly evaluations dropped out." (<LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>, p. 835)</P>
<P>Comment: Reasons for drop-out not further specified.</P>
<P>Quote: "according to the intent-to-treat principle performed with the last observation carried forward" (Nickel 2007, p. 1025)</P>
<P>Continuous outcomes based on ITT sample (LOCF)<BR/>Dichotomous outcomes based on ITT sample</P>
<P>Reasons for early termination:<BR/>Failed to appear more than twice for weekly evaluation, no further reasons given: 5 subjects, no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:40:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pascual-2008">
<DESCRIPTION>
<P>Quote: "All analyses were conducted on an intent-to-treat basis. [...] Patients were included in the analyses only if they had a baseline measure and at least 1 postbaseline measure. [...] The end point was based on a last-observation-carried-forward (LOCF) strategy." (p. 604 et seq.)</P>
<P>Comment: intent-to-treat data refer to all participants that were randomly assigned and initiated the experimental phase (p. 605) However, it remains unclear for which reason 5 out of the 65 eligible subjects "dropped out during the selection phase" (p. 605)</P>
<P>Reasons for drop-out specified and balanced across the two groups, including withdrawal due to "clinician decision/insufficient treatment effect (p. 605 et seq.)</P>
<P>Continuous data based on LOCF data of the ITT sample<BR/>Dichotomous data based on ITT sample</P>
<P>Of the 60 patients enrolled, 29 completed the full 12 weeks of the trial (13 in ziprasidone group, 16 in placebo group)<BR/>Reasons for early termination:</P>
<P>Need of psychiatric hospitalization: 4 in ziprasidone group/3 in placebo group,</P>
<P>Adverse events/patient decision: 9/4,</P>
<P>Clinician decision/insufficient treatment effect 3/7,</P>
<P>Other reasons: 1/0</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-13 17:00:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-2009">
<DESCRIPTION>
<P>Quote: "One patient in the placebo group was disqualified because of failure to adhere to the study protocol." (p. e-3)</P>
<P>Not clear if the reported mean changes are based on the ITT sample or completers only. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:40:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rinne-2002">
<DESCRIPTION>
<P>Quote: "The final study group comprised the 38 subjects eligible for participation" (p. 2049), "an intent-to-treat analysis was performed" (p. 2050)</P>
<P>Continuous outcomes based on ITT, BMDP imputation technique used for drop-outs</P>
<P>Of the 38 patients enrolled, 35 completed the RCT phase (19 in active drug group, 16 in placebo group)<BR/>Reasons for early termination:<BR/>Serious aggravation of self-damaging behaviours: 0 in the fluvoxamine group, 2 in the placebo group<BR/>Severe side effects: 1/0</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:41:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salzman-1995">
<DESCRIPTION>
<P>Quote: "Thirty-one subjects met criteria for this study; four decided not to enroll and were lost to follow-up. Of 27 subjects who enrolled in the study, 22 completed the trial. One subject dropped out because she wanted assurance that she would be in the medication group; four others dropped out without explanation and were lost to follow-up." (p. 24)</P>
<P>Of the 27 patients enrolled, 22 completed treatment<BR/>Reasons for early termination:<BR/>Wanted assurance to be in the active drug group: 1 (not specified, which group)<BR/>Dropped out without explanation: 4 (not specified, which group)</P>
<P>Comment: Continuous outcomes based on completer analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:45:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schulz-2007">
<DESCRIPTION>
<P>Quote: "Analyses were done on an intent-to-treat basis [...] In general, LOCF mean change analyses" (Eli Lilly, 2008, p. 5)</P>
<P>Quote: "Of the 314 randomized patients, 305 had both a baseline and a non-missing post-baseline observation and were thus qualified for the primary efficacy analysis." (Eli Lilly, p. 16)</P>
<P>Comment: Unclear, what "non-missing post-baseline observation" exactly means. However, discontinuing participants were enclosed in the 305 participants whose results were analysed using LOCF.</P>
<P>Continuous outcomes based on LOCF / ITT</P>
<P>314 patients were enrolled and randomly allocated. Outcomes refer partly to all of them, partly to 310 or 305 patients. No further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:44:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Of the 25 patients enrolled, 12 were randomised to fluoxetine and 13 to placebo. 20 completed treatment (9 in fluoxetine group, 11 in placebo group)<BR/>Reasons for early termination:<BR/>Negative experience of the placebo washout period, which led to a reversal of their willingness to tolerate a potential assignment to the placebo condition: 3 in fluoxetine group, 0 in placebo group<BR/>Sought hospitalization at another facility: 0/1<BR/>Intolerable lack of improvement: 0/1</P>
<P>Comment: Reasons for early termination specified (p. 381) Continuous outcomes are only reported for study completers, while drop-outs could be imputed as having the negative outcome for dichotomous data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:43:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soler-2005">
<DESCRIPTION>
<P>Quote: "All analyses were conducted on an intent-to-treat basis. The endpoint was based on a last-observation-carried-forward strategy. Patients were included in the analyses only if they had a baseline measure and at least one post-baseline measure." (p. 1222)</P>
<P>"Quote: Sixty subjects were randomly assigned to dialectical behaviour therapy plus olanzapine or placebo and started the experimental phase; 42 subjects (70%) completed the study.There were no between-group differences regarding demographic variables or concomitant treatments at baseline. Neither dialectical behaviour therapy intervention time nor dropout rates differed significantly between the two groups (eight of the 30 patients who received olanzapine versus 10 of the 30 who received placebo dropped out before the end of the study." (p. 1222 et seq.)</P>
<P>Comment: reasons for drop-out given; numbers balanced across groups</P>
<P>Continuous outcomes based on ITT (LOCF)</P>
<P>Of the 60 patients enrolled, 42 completed treatment (22 in active drug group, 20 in placebo group)<BR/>Reasons for early termination:<BR/>No reasons given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:44:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soloff-1989">
<DESCRIPTION>
<P>Quote: "Five patients failed to complete the minimum two weeks on medication needed for inclusion in outcome analysis, one taking amitriptyline, three taking haloperidol, and one taking placebo." (<LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>, p. 242)</P>
<P>Continuous outcomes based on LOCF / ITT<BR/>A minimum of 2 weeks receiving medication was required to include data for end-point analysis</P>
<P>Of the 90 patients enrolled, 85 completed treatment (29 in amitriptyline group, 28 in haloperidol group, 28 in placebo group)<BR/>Reasons for early termination:<BR/>Failed to complete the minimum 2 weeks on medication needed for inclusion in outcome analysis (1 in amitriptyline group, 3 in haloperidol group, 1 in placebo group)</P>
<P>Comment: Reasons for drop-out not further specified. Total number of drop-outs small, though, and balanced across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 11:45:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soloff-1993">
<DESCRIPTION>
<P>Quote: "Sixteen patients failed to complete the minimum 3 weeks of medication required for end-point analysis (p. 380)</P>
<P>Comment: Reasons for these drop-outs not further specified. Total number of drop-outs small, though, and balanced across groups</P>
<P>Continuous outcomes based on all cases with a minimum of 3 weeks of medication exposure</P>
<P>Of the 108 patients enrolled, 92 completed treatment (30 in haloperidol group, 34 in phenelzine group, 28 in placebo group)<BR/>Reasons for early termination: Relating to medication assignment (e.g. side effects), clinical worsening, factors unrelated to the protocol; not specified by group<BR/>Patients failing to complete the minimum 3 weeks of medication required for end-point analysis: 6 in the haloperidol group, 4 in the phenelzine group, 6 in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-13 17:50:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tritt-2005">
<DESCRIPTION>
<P>Quote: "Thirty-eight subjects were eligible to take part in the study [...] The necessary sample size was calculated [...] This resulted in a group size of n = 27 patients [...] active drug (n=18) compared to placebo (n = 9)" (<LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>, p. 288)</P>
<P>Comment: Not clear, why or how the 27 participants were finally chosen out of the 38 potential participants </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 12:02:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2001">
<DESCRIPTION>
<P>Quote: "Thirty subjects completed all aspects of pre-randomization assessment. However, 2 of these subjects were excluded [...] because it was determined that they were responding well to a selective serotonin reuptake inhibitor. Twenty-eight subjects entered the trial and were randomly assigned [...] All [...] completed at least 2 post-baseline visits and were included in all subsequent analyses." (p. 851)</P>
<P>Of the 28 patients enrolled, 9 completed treatment (8 in olanzapine group, 1 in placebo group)<BR/>Reasons for early termination:<BR/>Sedation: 1 in olanzapine group, 0 in placebo group<BR/>Increased anxiety or depression: 3/2<BR/>Perceived weight gain: 2/0<BR/>Lost to follow-up: 5/6</P>
<P>Continuous outcomes based on ITT sample (LOCF)</P>
<P>Comment: Overall high drop-out rate but adequately addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 12:02:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2003">
<DESCRIPTION>
<P>Quote: "The three subjects who discontinued their participation (two taking E-EPA and one taking placebo) did so because of life events unrelated to the study." (p. 168)</P>
<P>of the 30 patients enrolled, 27 completed treatment (18 in E-EPA group, 9 in placebo group)<BR/>reasons for early termination:<BR/>life events unrelated to the study: 2 in E-EPA group, 1 in placebo group</P>
<P>Comment: Continuous outcomes are based on completers only.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 12:02:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2004">
<DESCRIPTION>
<P>Comment: Reasons for drop-out specified (p. 905), but outcome data were only reported for completers.</P>
<P>Of the 45 patients enrolled, 42 completed treatment (13 in fluoxetine group, 16 in olanzapine group, 13 in fluoxetine + olanzapine group)<BR/>Reasons for early termination:<BR/>Onset of a number of psychosocial stressors culminating in a suicide gesture: 1/0/0<BR/>Dizziness and headaches: 0/0/1<BR/>Lost to follow-up: 0/0/1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 12:02:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2007">
<DESCRIPTION>
<P>Quote: "451 were randomly assigned (148 [...] to olanzapine 5-to-10 mg/day treatment group, 150 [...] to olanzapine 2.5-mg/day treatment group, and 153 to placebo)" (Eli Lilly 2008, p. 14), "last observation carried forward" (Eli Lilly 2008, p. 3)</P>
<P>Continuous data based on LOCF data<BR/>Dichotomous data based on ITT sample</P>
<P>Of the 451 patients enrolled, 294 completed the full 12 weeks of the double-blind treatment phase (97/103/94)</P>
<P>Comment: In this review, only the groups receiving olanzapine 5 to 10 mg/day or placebo group were included.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-05-12 11:45:44 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:28:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bogenschutz-2004">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:44:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-la-Fuente-1994">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:44:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Frankenburg-2002">
<DESCRIPTION>
<P>Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:44:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1986">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:45:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hallahan-2007">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:45:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hollander-2001">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:46:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leone-1982">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:46:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Linehan-2008">
<DESCRIPTION>
<P>Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:46:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loew-2006">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:47:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-1979_x002f_82">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:47:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-81_x002f_82_x002f_83">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:47:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nickel-2004">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:47:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nickel-2005">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:47:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nickel-2006">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:47:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pascual-2008">
<DESCRIPTION>
<P>Comment: The study protocol is available and all of the study's pre-specified primary and secondary outcomes that are of interest in the review are reported in the pre-specified way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:00:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reich-2009">
<DESCRIPTION>
<P>Comment: The study protocol is available and all of the study's pre-specified primary and secondary outcomes that are of interest in the review are reported in the pre-specified way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:48:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rinne-2002">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:48:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salzman-1995">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:48:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schulz-2007">
<DESCRIPTION>
<P>Comment: Several outcome measures (secondary and adverse events) are reported that were not pre-specified according to the study protocol. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:48:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-08 09:42:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soler-2005">
<DESCRIPTION>
<P>Comment: The study protocol is available and all of the study's pre-specified primary and secondary outcomes that are of interest in the review are reported in the pre-specified way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:48:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soloff-1989">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:49:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soloff-1993">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:45:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tritt-2005">
<DESCRIPTION>
<P>Comment: All outcomes (i.e. one assessment instrument) reported as planned to be assessed are also reported. However, it seems implausible to use only one assessment instrument in such a complex trial. There is no protocol available to check the pre-defined outcome measure(s).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-10-12 11:58:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zanarini-2001">
<DESCRIPTION>
<P>Quote: "Due to the small number of subjects, results pertaining to secondary outcome measures will not be reported." (p. 851)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:50:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2003">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:51:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2004">
<DESCRIPTION>
<P>Comment: Insufficient information to permit judgment of 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:51:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2007">
<DESCRIPTION>
<P>Comment: The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review are reported in the pre-specified way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-05-12 12:02:30 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:28:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bogenschutz-2004">
<DESCRIPTION>
<P>Quote: "No other psychotropic medications could be taken during the study or in the 2 weeks prior to the study." (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>, p. 105)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:29:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-la-Fuente-1994">
<DESCRIPTION>
<P>Quote: "Patients underwent a psychotropic washout period of at least 10 days before the beginning of the treatment period (15 days for tricyclic antidepressants and monoamine oxidase inhibitor agents). No patient had taken neuroleptics in the 2-month period before the study." (<LINK REF="STD-De-la-Fuente-1994" TYPE="STUDY">De la Fuente 1994</LINK>, p. 480)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-04 14:14:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frankenburg-2002">
<DESCRIPTION>
<P>Quote: "No other psychotropic medication was allowed during this study." (p. 443)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:30:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goldberg-1986">
<DESCRIPTION>
<P>Quote: "One-week placebo washout" (p. 681)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:31:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hallahan-2007">
<DESCRIPTION>
<P>Quote: "Patients had changes to their psychotropic medication as prescribed by their treating agency." (p. 118)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:32:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hollander-2001">
<DESCRIPTION>
<P>Comment: Not specified if there was a washout-period preceding the trial or if concomitant psychotropic medication was allowed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:33:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Leone-1982">
<DESCRIPTION>
<P>Quote: "Patients did not receive any other psychotropic medication during the study; nighttime sedatives were limited to flurazepam and chloral hydrate." (p. 148)</P>
<P>Comment: Actually, patient could thus receive concomitant sedatives, but it is not specified how many did.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:34:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Linehan-2008">
<DESCRIPTION>
<P>Quote: "To enhance compliance, tablets were given in [...] prescription bottles programmed to sound a sequence of alarms when medications were due, terminating only when the medication top was removed."</P>
<P>Comment: Compliance was thus controlled for</P>
<P>Comment: Not specified if concomitant medication was allowed or not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 15:29:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Loew-2006">
<DESCRIPTION>
<P>Quote: "exclusion criteria included [...] the current use of topiramate or other psychotropic medication." (p. 62)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 15:31:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-1979_x002f_82">
<DESCRIPTION>
<P>Comment: Not specified if there was a washout-period or if concomitant psychotropic medication was allowed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 15:32:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-81_x002f_82_x002f_83">
<DESCRIPTION>
<P>Quote: "Compliance was checked by tablet count." (Montgomery 1983, p. 184S)</P>
<P>Comment: Not specified if there was a washout-period or if concomitant psychotropic medication was allowed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 15:34:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2004">
<DESCRIPTION>
<P>Quote: "exclusion [...] current use of topiramate or other psychotropic medication"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2005">
<DESCRIPTION>
<P>Quote: "reasons for exclusion were [...] the current use of topiramate or other psychotropic medication." (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>, p. 495)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 15:38:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nickel-2006">
<DESCRIPTION>
<P>Quote: "Criteria for exclusion [...] current use of aripiprazole or another psychotropic medication" (p. 8349</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:39:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pascual-2008">
<DESCRIPTION>
<P>Quote: "Compliance was assessed by direct questioning of patients and by counting the capsules returned at follow-up visits."</P>
<P>Quote: "patients were allowed to continue with benzodiazepines [max. 40 mg/day], antidepressants, and mood stabilisers if they had been initiated prior to inclusion, but doses could not be modified during the study." (p. 604)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:00:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-2009">
<DESCRIPTION>
<P>Quote: "Patients could be taking one antidepressant, but had to have been on a stable dose of this medication for 1 month." (p. e-2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 15:48:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rinne-2002">
<DESCRIPTION>
<P>Quote: "The participants had to stop taking all psychoactive drugs [...] and they all had to be medication free for at least 2 weeks before entering the trial; the medication -free interval was 6 weeks for fluoxetine." (p. 2049)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 15:50:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Salzman-1995">
<DESCRIPTION>
<P>Quote: "Subjects were not included [...] if they were taking any other psychotropic medication"; "1-week placebo run-in" (p. 24), </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 15:53:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schulz-2007">
<DESCRIPTION>
<P>Quote: "No medication with primarily CNS acitivity (except for protocol-specified benzodiazepines and hypnotics)" (p.EliLilly, p. 4)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:43:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Quote: "Diary card records of pill ingestion were reviewed, and pill counts were made as a compliance measure." (p. 381)</P>
<P>Quote: "1-week placebo run-in" (p. 380), "the only other medication allowed was 50 to 100 mg/day of trazodone for insomnia." (p. 381)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soler-2005">
<DESCRIPTION>
<P>Quote: "Patients could continue treatment with benzodiazepines, antidepressants, and mood stabilisers, but doses could not be modified." (p. 1222)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:44:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soloff-1989">
<DESCRIPTION>
<P>Quote: "Patients were kept free of all medication for 7 days" (<LINK REF="STD-Soloff-1989" TYPE="STUDY">Soloff 1989</LINK>, p. 239), "Biperiden hydrochloride (2 mg) was allowed as needed for extrapyramidal reactions" (<LINK REF="STD-Soloff-1986" TYPE="STUDY">Soloff 1986</LINK>, p. 692)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 16:05:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soloff-1993">
<DESCRIPTION>
<P>Quote: "Patients were at the start kept free of medication for at least 7 days to [...] washout street drugs or prescribed medications." (p. 378)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 16:08:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tritt-2005">
<DESCRIPTION>
<P>Quote: "reasons for exclusion were [...] current use of lamotrigine or other psychotropic medication " (p. 288).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-06 16:09:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2001">
<DESCRIPTION>
<P>Quote: "excluded if [...] currently were being prescribed any psychotropic medication that they thought was helping" (p. 850)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:50:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2003">
<DESCRIPTION>
<P>Quote: "Potential subjects were excluded if they were [...] currently being prescribed any psychotropic medication" (p. 167) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:00:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zanarini-2004">
<DESCRIPTION>
<P>Quote: "Potential subjects were excluded if they [...] were currently being prescribed any psychotropic medication" (p. 904) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:02:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zanarini-2007">
<DESCRIPTION>
<P>Comment: Not specified if there was a washout period or if concomitant psychotropic medication was allowed. Probably, medication with primarily CNS activity was not allowed (except for protocol-specified benzodiazepines and hypnotics), as was the case for the <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK> trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2010-05-12 12:02:30 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Bias due to sponsoring improbable?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-15 13:22:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bogenschutz-2004">
<DESCRIPTION>
<P>Quote: "Supported by a grant from Eli Lilly and Co, Indianalpolis, Ind." (<LINK REF="STD-Bogenschutz-2004" TYPE="STUDY">Bogenschutz 2004</LINK>, p. 104)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-30 15:38:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-la-Fuente-1994">
<DESCRIPTION>
<P>No details about funding or sponsoring provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 13:26:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Frankenburg-2002">
<DESCRIPTION>
<P>Quote: "Supported by a grant from Abbott Laboratories, Chicago, Ill." (p. 442)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:30:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goldberg-1986">
<DESCRIPTION>
<P>No details about funding or sponsoring provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:32:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hallahan-2007">
<DESCRIPTION>
<P>Quote: "Pronova (now Epax) AS, Lysaker, Norway, provided the active preparation and placebo but were not otherwise involved in the study." (p. 118)</P>
<P>Quote: "B.H. [i.e. first author] received salary support from the Department of Psychiatry, University of Illinois at Chicago, USA." (p. 122)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 14:55:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hollander-2001">
<DESCRIPTION>
<P>"Supported in part by grants from the National Institute of Mental Health (1 RO3 MH58168-01A1), Richville, Md. (Dr. Hollander); Abbott Laboratories, Abbott Park, Ill. (Dr. Hollander); the National Center for Research Resources, National Institutes of Health (5 MO1 RR00071), Rockville, Md., for the Mount Sinai General Clinical Research Center; and the Seaver Foundation and the PBO Foundation, New York, N.Y." (p. 199)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 13:38:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leone-1982">
<DESCRIPTION>
<P>Quote: "This study was supported by a grant from Lederle Laboratories, Pear River, New York." (p. 148)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 14:00:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Linehan-2008">
<DESCRIPTION>
<P>Quote: This research was supported by a grant from Eli Lilly and Co., Protocol F1D-US-X173, to Dr. Linehan; by Remind Rx Medication Compliance Systems; and by a contribution of electronic pill bottles from IBV Technologies, Seattle, Wash. [...] Dr. Linehan is a consultant for, has received grant/research support and honoraria from, and is a member of the speakers/advisory board fro Eli Lilly. Drs. McDavid, Brown, Sayrs, and Gallop report no additional financial or other relationships relevant to the subject of this article." (p. 999)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Loew-2006">
<DESCRIPTION>
<P>Quote: "The study was planned and conducted independent[ly] of any institutional influence and approved by the clinic's ethics committee in accordance with the Declaration of Helsinki and ethical laws pertaining to the medical professions." (<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>, p.63)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 14:10:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-1979_x002f_82">
<DESCRIPTION>
<P>No details about funding/sponsoring provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 14:11:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Montgomery-81_x002f_82_x002f_83">
<DESCRIPTION>
<P>No details about funding/sponsoring provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:25:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nickel-2004">
<DESCRIPTION>
<P>Quote: "The authors report no financial affiliation or other relationship relevant to the subject matter of this article." (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>, p. 1515)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:37:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nickel-2005">
<DESCRIPTION>
<P>Quote: "The study was planned and conducted in accordance with the Declaration of Helsinki and ethical laws pertaining to the medical professions and its design approved by Ethikkommission der ROMED Kliniken KG. All subjects gave written informed consent. The study was conducted independent of any institutional influence and was not funded, and there were no conflicts of interest." (<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>, p. 496)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:38:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nickel-2006">
<DESCRIPTION>
<P>Quote: "The study was planned and conducted in accordance with the Declaration of Helsinki and ethical laws pertaining to the medical profession, and its design was approved by the clinic's ethics committee. The study was conducted independently of any institutional influence an was not funded." (<LINK REF="STD-Nickel-2006" TYPE="STUDY">Nickel 2006</LINK>, p. 835)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 15:06:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pascual-2008">
<DESCRIPTION>
<P>Quote: "This study was supported by grants from the Fondo de Investigación Sanitaria (Ministry of Health, Spain), the REM-TAP Network, and Pfizer, Madrid, Spain. The authors report no additional financial or other relationships relevant to the subject of this article." (p. 603)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:00:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reich-2009">
<DESCRIPTION>
<P>Quote: "The study was supported by a grant from GlaxoSmithKline." (p. e-5)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 15:11:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rinne-2002">
<DESCRIPTION>
<P>Quote: "Supported by the De Geestgronden Institute of Mental Health Care, by Stichting tot Steun of Vereiniging Bennekom, by national Fund for Menal Health grant 4820, and by Solvay Pharma." (p. 2053)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 14:31:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Salzman-1995">
<DESCRIPTION>
<P>No details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 14:37:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schulz-2007">
<DESCRIPTION>
<P>Quote: "This study was sponsored by Eli Lilly. S.C.S. has received honorarium from Eli Lilly, AstraZeneca and Bristol-Meyers Squibb; grant fees from Eli Lilly, AstraZeneca, Abbott, MIND Institute and the NIMH; and consultation fees from Eli Lilly, AstraZeneca and Vanda. H.C.D., Q.T., Y.T., D.L. and S.C. are employed by Lilly Research Laboratories." (p. e-1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 11:43:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simpson-2004">
<DESCRIPTION>
<P>Quote:"Support for this study was provided by the Department of Psychiatry and Human Behaviour at Brown Medical School and Eli Lilly."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 15:10:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Soler-2005">
<DESCRIPTION>
<P>Quote: "Supported by grants from the Fondo de Investigación Sanitaria (Ministry of Health, Spain) and from Eli Lilly and Co. Madrid." (p. 1223)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 15:38:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soloff-1989">
<DESCRIPTION>
<P>Quote: "This work was supported by NIMH grants 35392, MHCRC 30915, and MH00658." (p. 245)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-06 10:01:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Soloff-1993">
<DESCRIPTION>
<P>Quote: "This study was supported by National Institute of Mental Health grant MH35392 and by Clinical Research Center grant MH30915." (p. 697)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:00:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tritt-2005">
<DESCRIPTION>
<P>Quote: "The study was conducted independently of any institutional influence and was not funded." (p. 288)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:00:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zanarini-2001">
<DESCRIPTION>
<P>Quote: "Supported, in part, by a grant from Eli Lilly." (p. 849)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:00:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zanarini-2003">
<DESCRIPTION>
<P>Quote: "Capsules were supplied by Laxdale Pharmaceuticals (Stirling, U.K.)" (p. 167), "Supported by an Independent Investigator Award from the National Alliance for Research on Schizophrenia and Depression to Dr. Zanarini." (p. 169)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-13 17:00:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zanarini-2004">
<DESCRIPTION>
<P>Quote: "Supported by a grant from Eli Lilly, Indianapolis, Ind." (p. 903)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 12:02:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zanarini-2007">
<DESCRIPTION>
<P>Eli Lilly was the study sponsor. Most study results used here are from the company's study report (the remaining references were either clinical trial register entries or congress abstracts and did not provide detailed data).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-05-11 15:30:22 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-07 15:17:11 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-08-28 13:28:13 +0100" MODIFIED_BY="[Empty name]">First-generation antipsychotics vs. placebo: outcome scales</TITLE>
<TABLE COLS="5" ROWS="21">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Haloperidol</P>
</TH>
<TH>
<P/>
</TH>
<TH>
<P>Flupenthixol decanoate</P>
</TH>
<TH>
<P>Thiothixene</P>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH VALIGN="TOP">
<P>
<B>Soloff 1989</B>
</P>
<P/>
</TH>
<TH VALIGN="TOP">
<P>
<B>Soloff 1993</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Montgomery 1979/82</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Goldberg 1986</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>BPD severity</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BSI</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SIB-borderline score</P>
</TD>
</TR>
<TR>
<TH>
<P>avoidance of abandonment</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>interpersonal problems</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SCL-90-INT</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ADS-rejection sensitivity</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>HSCL-INT</P>
</TD>
</TR>
<TR>
<TH>
<P>identity disturbance</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>impulsivity</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BIS, Ward Scale of Impulse Action Patterns, STIC</P>
<P>BIS used because of width of use and self-reporting format</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BIS, Ward Scale of Impulse Action Patterns, STIC</P>
<P>BIS used because of width of use and self-reporting format</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal ideation</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal behaviour</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>number of patients with suicidal act during treatment (6 months period)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>self-mutilating behaviour</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>affective instability</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>feelings of emptiness</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>anger</P>
</TH>
<TD VALIGN="TOP">
<P>SCL-90-HOS, BDHI</P>
<P>SCL-90-HOS used because of greater sensitivity to change</P>
</TD>
<TD VALIGN="TOP">
<P>SCL-90-HOS, BDHI, ADS-reactivity</P>
<P>SCL-90-HOS used because of greater sensitivity to change than BDHI and greater width of than ADS scale</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HSCL-HOS</P>
</TD>
</TR>
<TR>
<TH>
<P>psychotic/paranoid symptoms</P>
</TH>
<TD VALIGN="TOP">
<P>SCL-90-PAR,SCL-90-PSY, SSI</P>
<P>SCL-90-PAR used because regarded as most adequately reflecting BPD relevant pathology</P>
</TD>
<TD VALIGN="TOP">
<P>SCL-90-PAR, SCL-90-PSY, SSI</P>
<P>SCL-90-PAR used because regarded as most adequately reflecting BPD relevant pathology</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>SIB-suspicious/paranoid subscale, HSCL-90-PSY</P>
<P>SIB-suspicious/paranoid subscale used because regarded as most adequately reflecting BPD-relevant pathology</P>
</TD>
</TR>
<TR>
<TH>
<P>dissociative symptoms</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH>
<P>depression</P>
</TH>
<TD VALIGN="TOP">
<P>BDI, SCL-90-DEP, Ham-D</P>
<P>BDI used because of width of use and self-report format</P>
</TD>
<TD VALIGN="TOP">
<P>BDI, SCL-90-DEP, Ham-D, ADS total</P>
<P>BDI used because of width of use and self-report format</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HSCL-DEP</P>
</TD>
</TR>
<TR>
<TH>
<P>anxiety</P>
</TH>
<TD VALIGN="TOP">
<P>SCL-90-ANX</P>
</TD>
<TD VALIGN="TOP">
<P>SCL-90-ANX</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>general psychiatric pathology</P>
</TH>
<TD VALIGN="TOP">
<P>SCL-90-GSI</P>
</TD>
<TD VALIGN="TOP">
<P>SCL-90-GSI</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>mental health status</P>
</TH>
<TD VALIGN="TOP">
<P>GAS</P>
</TD>
<TD VALIGN="TOP">
<P>GAS</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>GAS</P>
</TD>
</TR>
<TR>
<TH>
<P>attrition</P>
</TH>
<TD VALIGN="TOP">
<P>number of patients lost after randomisation</P>
</TD>
<TD VALIGN="TOP">
<P>number of patients lost after randomisation</P>
</TD>
<TD VALIGN="TOP">
<P>number of patients lost after randomisation</P>
</TD>
<TD VALIGN="TOP">
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TH>
<P>adverse events</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>ADS-weight gain</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-11-07 15:17:12 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-05-30 15:38:00 +0100" MODIFIED_BY="[Empty name]">Second-generation antipsychotics vs. placebo: outcome scales (part 1)</TITLE>
<TABLE COLS="3" ROWS="19">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Aripiprazole</P>
</TH>
<TH>
<P>Ziprasidone</P>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Nickel 2006</P>
</TH>
<TH>
<P>Pascual 2008</P>
</TH>
</TR>
<TR>
<TH>
<P>BPD severity</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>CGI-BPD-global</P>
</TD>
</TR>
<TR>
<TH>
<P>avoidance of abandonment</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>CGI-BPD-abandonment</P>
</TD>
</TR>
<TR>
<TH>
<P>interpersonal problems</P>
</TH>
<TD>
<P>SCL-90-R-INT (t-transformed)</P>
</TD>
<TD>
<P>CGI-BPD-unstable relations</P>
</TD>
</TR>
<TR>
<TH>
<P>identity disturbance</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>CGI-BPD-identity</P>
</TD>
</TR>
<TR>
<TH>
<P>impulsivity</P>
</TH>
<TD>
<P>STAXI-OUT</P>
</TD>
<TD>
<P>CGI-BPD-impulsivity</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal ideation</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>CGI-BPD-suicide</P>
</TD>
</TR>
<TR>
<TH>
<P>self-mutilating behaviour</P>
</TH>
<TD>
<P>number of patients with self-injury during treatment (8 weeks period)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>affective instability</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>CGI-BPD-affect instability</P>
</TD>
</TR>
<TR>
<TH>
<P>feelings of emptiness</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>CGI-BPD-emptiness</P>
</TD>
</TR>
<TR>
<TH>
<P>anger</P>
</TH>
<TD>
<P>SCL-90-R-HOS (t-transformed), STAXI-trait, STAXI-state, STAXI-anger in</P>
<P>SCL-90-R-HOS used because regarded as most comprehensive measure</P>
</TD>
<TD>
<P>CGI-BPD-anger</P>
</TD>
</TR>
<TR>
<TH>
<P>psychotic/paranoid symptoms</P>
</TH>
<TD>
<P>SCL-90-R-PAR, SCL-90-R-PSY</P>
<P>SCL-90-R-PAR used because considered as most adequately reflecting BPD relevant pathology</P>
</TD>
<TD>
<P>CGI-BPD-paranoid ideation; BPRS</P>
<P>CGI-BPD used because specific for assessment in BPD patients</P>
</TD>
</TR>
<TR>
<TH>
<P>dissociative symptoms</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>depression</P>
</TH>
<TD>
<P>Ham-D, SCL-90-R-DEP</P>
<P>Ham-D used because also reported by other trials within this comparison category</P>
</TD>
<TD>
<P>Ham-D-17; BDI</P>
<P>Ham-D used because also reported by other trials within this comparison category</P>
</TD>
</TR>
<TR>
<TH>
<P>anxiety</P>
</TH>
<TD>
<P>HARS; SCL-90-R-ANX</P>
<P>HARS used because also reported by other trials within this comparison category</P>
</TD>
<TD>
<P>HARS</P>
</TD>
</TR>
<TR>
<TH>
<P>general psychiatric pathology</P>
</TH>
<TD>
<P>SCL-90-R-GSI</P>
</TD>
<TD>
<P>SCL-90-R-GSI</P>
</TD>
</TR>
<TR>
<TH>
<P>adverse effects</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>attrition</P>
</TD>
</TR>
<TR>
<TH>
<P>patient reported adverse events</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>minor sedation, dizziness, uneasy feeling</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-11-07 15:17:12 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-05-30 15:38:14 +0100" MODIFIED_BY="[Empty name]">Second-generation antipsychotics vs. placebo: outcome scales (part 2)</TITLE>
<TABLE COLS="5" ROWS="21">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Olanzapine</P>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Bogenschutz 2004</P>
</TH>
<TH>
<P>Linehan 2007</P>
</TH>
<TH>
<P>Soler 2005</P>
</TH>
<TH>
<P>Zanarini 2001</P>
</TH>
</TR>
<TR>
<TH>
<P>BPD severity</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>avoidance of abandonment</P>
</TH>
<TD>
<P>CGI-abandonment</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>interpersonal problems</P>
</TH>
<TD>
<P>CGI-unstable relationships, SCL-90-R-INT</P>
<P>CGI-unstable relationships used because specific for assessment in BPD patients</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>identity disturbance</P>
</TH>
<TD>
<P>CGI-identity disturbance</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>impulsivitiy</P>
</TH>
<TD>
<P>CGI-impulsivity</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Behavioural reports of numbers of episodes of impulsivity/aggressive behaviour</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal ideation</P>
</TH>
<TD>
<P>CGI-recurrent suicidal ideation</P>
</TD>
<TD>
<P>number of patients with high suicidality scores on OAS-M-suicidality subscale (i.e., reporting frequent suicide ideation and/or planning or behaviour)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Behavioural reports of numbers of episodes of self-injuring behaviour/suicide attempts</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>self-mutilating behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>number of patients with self-injury during treatment</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>affective instability</P>
</TH>
<TD>
<P>CGI-affective instability</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>feelings of emptiness</P>
</TH>
<TD>
<P>CGI-chronic feelings of emptiness</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>anger</P>
</TH>
<TD>
<P>CGI-inappropriate anger, OAS-M, AIAQ, SCL-90-HOS</P>
<P>CGI-inappropriate anger used because specific for assessment in BPD patients</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>psychotic/paranoid symptoms</P>
</TH>
<TD>
<P>CGI-transient paranoia or dissociation, SCL-90-PSY, SCL-90-PAR</P>
<P>CGI-transient paranoia or dissociation used because specific for assessment in BPD patients</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>depression</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>Ham-D</P>
</TD>
<TD>
<P>Ham-D</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>anxiety</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>HARS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>general psychiatric pathology</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>mental health status</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>CGI-S</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>attrition</P>
</TH>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TH>
<P>adverse effects</P>
</TH>
<TD>
<P>baseline to endpoint weight change (kg)</P>
</TD>
<TD>
<P>baseline to endpoint weight change (kg)</P>
</TD>
<TD>
<P>baseline to endpoint weight change (kg), baseline to endpoint increase in cholesterol levels (mg/dl)</P>
</TD>
<TD>
<P>baseline to endpoint weight change (kg)</P>
</TD>
</TR>
<TR>
<TH>
<P>patient reported adverse events</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>constipation, sedation</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2008-11-25 17:08:12 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-05-30 15:39:10 +0100" MODIFIED_BY="[Empty name]">Second-generation antipsychotics vs. placebo: outcome scales (part 3)</TITLE>
<TABLE COLS="3" ROWS="22">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Olanzapine</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Schulz 2007</P>
</TH>
<TH VALIGN="TOP">
<P>Zanarini 2007</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>BPD severity</P>
</TH>
<TD VALIGN="TOP">
<P>Zan-BPD-total</P>
</TD>
<TD VALIGN="TOP">
<P>Zan-BPD-total</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT">
<P>avoidance of abandonment</P>
</TH>
<TD>
<P>Zan-BPD-frantic efforts to avoid abandonment</P>
</TD>
<TD>
<P>Zan-BPD-frantic efforts to avoid abandonment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT">
<P>interpersonal problems</P>
</TH>
<TD VALIGN="TOP">
<P>ZAN-BPD-unstable interpersonal relationships</P>
</TD>
<TD>
<P>ZAN-BPD-unstable interpersonal relationships, SCL-90-R-INT</P>
<P>ZAN-BPD-unstable relationships used because specific for assessment in BPD patients</P>
</TD>
</TR>
<TR>
<TH>
<P>identity disturbance</P>
</TH>
<TD>
<P>ZAN-BPD-identity disturbance</P>
</TD>
<TD>
<P>ZAN-BPD-identity disturbance</P>
</TD>
</TR>
<TR>
<TH>
<P>impulsivity</P>
</TH>
<TD>
<P>ZAN-BPD-impulsivity that are self-damaging, OAS-M-aggression</P>
<P>ZAN-BPD-impulsivity used because specific for assessment in BPD patients</P>
</TD>
<TD>
<P>ZAN-BPD-impulsivity that are self-damaging, OAS-M-aggression</P>
<P>ZAN-BPD-impulsivity used because specific for assessment in BPD patients</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal ideation</P>
</TH>
<TD>
<P>ZAN-BPD-suicidal or self-mutilating behaviour</P>
</TD>
<TD>
<P>ZAN-BPD-suicidal or self-mutilating behaviour, OAS-M-suicidality</P>
<P>ZAN-BPD subscale used because specific for assessment in BPD patients</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal behaviour</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>self-mutilating behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>affective instability</P>
</TH>
<TD>
<P>ZAN-BPD-affective instability</P>
</TD>
<TD>
<P>ZAN-BPD-affective instability</P>
</TD>
</TR>
<TR>
<TH>
<P>chronic feelings of emptiness</P>
</TH>
<TD>
<P>ZAN-BPD-chronic feelings of emptiness</P>
</TD>
<TD>
<P>ZAN-BPD-chronic feelings of emptiness</P>
</TD>
</TR>
<TR>
<TH>
<P>anger</P>
</TH>
<TD VALIGN="TOP">
<P>ZAN-BPD-intense anger</P>
</TD>
<TD>
<P>ZAN-BPD-intense anger, OAS-M-irritability, SCL-90-R-HOS</P>
<P>ZAN-BPD subscale used because specific for assessment in BPD patients</P>
</TD>
</TR>
<TR>
<TH>
<P>psychotic/paranoid symptoms</P>
</TH>
<TD VALIGN="TOP">
<P>ZAN-BPD-paranoid ideation of dissociation</P>
</TD>
<TD>
<P>ZAN-BPD-paranoid ideation of dissociation, SCL-90-R-PAR</P>
<P>ZAN-BPD subscale used because specific for assessment in BPD patients</P>
</TD>
</TR>
<TR>
<TH>
<P>depression</P>
</TH>
<TD VALIGN="TOP">
<P>MADRS</P>
</TD>
<TD>
<P>MADRS, SCL-90-R-DEP</P>
<P>MADRS used because also available for <LINK REF="STD-Schulz-2007" TYPE="STUDY">Schulz 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TH>
<P>anxiety</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>SCL-90-R-ANX</P>
</TD>
</TR>
<TR>
<TH>
<P>general psychiatric pathology</P>
</TH>
<TD>
<P>SCL-90-R-GSI</P>
</TD>
<TD>
<P>SCL-90-R-GSI</P>
</TD>
</TR>
<TR>
<TH>
<P>mental health status</P>
</TH>
<TD>
<P>GAF, Sheehan Scale</P>
<P>GAF used because of width of use</P>
</TD>
<TD VALIGN="TOP">
<P>GAF, Sheehan Scale</P>
<P>GAF used because of width of use</P>
</TD>
</TR>
<TR>
<TH>
<P>attrition</P>
</TH>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TH>
<P>adverse effects</P>
</TH>
<TD>
<P>baseline to endpoint weight change (kg)</P>
</TD>
<TD VALIGN="TOP">
<P>baseline to endpoint weight change (kg)</P>
</TD>
</TR>
<TR>
<TH>
<P>patient-reported adverse events</P>
</TH>
<TD>
<P>anxiety, dry mouth, fatigue, headache, increased appetite, insomnia, nausea, number of patients experiencing any AE, sedation, somnolence</P>
<P>all used</P>
</TD>
<TD VALIGN="TOP">
<P>disturbed attention, dry mouth, fatigue, headache, increased appetite, insomnia, nausea, number of patients experiencing any AE, somnolence</P>
</TD>
</TR>
<TR>
<TH>
<P>laboratory values</P>
</TH>
<TD VALIGN="TOP">
<P>lipids (baseline to endpoint mean changes): LDL cholesterol (mmol/L), total cholesterol (mmol/L)</P>
<P>liver function values (baseline to endpoint mean changes): ALT/SGPT (U/L), AST/SGOT (U/L), total bilirubin (umol/L), direct bilirubin (umol/L)</P>
<P>prolactin (micrograms/L)</P>
</TD>
<TD>
<P>lipids (baseline to endpoint mean changes): HDL cholesterol (mmol/L), total cholesterol (mmol/L), triglycerides fasting (mmol/L)</P>
<P>liver function values (baseline to endpoint mean changes): GGT (GGPT/SGGT/YGGT; U/L), ALT/SGPT (U/L), AST/SGOT (U/L)</P>
<P>prolactin baseline to endpoint mean change (micrograms/L)</P>
<P>blood values (baseline to endpoint mean changes): leukocyte count (GI/L), monocytes (GI/L), neutrophils segmented (GI/L), platelet count (GI/L)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]">Mood stabiliser vs. placebo: outcome scales (part 1)</TITLE>
<TABLE COLS="4" ROWS="21">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Carbamazepine</P>
</TH>
<TH>
<P>Valproate Semisodium</P>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>De la Fuente 1993</P>
</TD>
<TD>
<P>Frankenburg 2002</P>
</TD>
<TD>
<P>Hollander 2001</P>
</TD>
</TR>
<TR>
<TD>
<P>BPD severity</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>avoidance of abandonment</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>interpersonal problems</P>
</TD>
<TD>
<P>SCL-90-INT</P>
</TD>
<TD>
<P>SCL-90-INT</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>identity disturbance</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>impulsivity</P>
</TD>
<TD>
<P>Acting-out Scale: number of patients worsened or unimproved as compared to baseline</P>
</TD>
<TD>
<P>MOAS</P>
</TD>
<TD>
<P>OAS-M-aggression (not used: Assault Questionnaire, because of close affinity of OAS-M with the MOAS scale as used by the Frankenburg trial</P>
</TD>
</TR>
<TR>
<TD>
<P>suicidal ideation</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>OAS-M-suicidality</P>
</TD>
</TR>
<TR>
<TD>
<P>suicidal behaviour</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>self-mutilating behaviour</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>affective instability</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>feelings of emptiness</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>anger</P>
</TD>
<TD>
<P>SCL-90-HOS</P>
</TD>
<TD>
<P>SCL-90-HOS</P>
</TD>
<TD>
<P>OAS-M-irritability</P>
</TD>
</TR>
<TR>
<TD>
<P>psychotic/parnoid symptoms</P>
</TD>
<TD>
<P>SCL-90-PAR (not used: BPRS as the SCL-scale had also been used by another trial within this comparison category; SCL-90-PSY as the PAR subscale reflects BPD relevant pathology more adequately)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>dissociative symptoms</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>depression</P>
</TD>
<TD>
<P>SCL-90-DEP (not used: Ham-D as the SCL-90-DEP subscale was also available from other trials within this comparison category)</P>
</TD>
<TD>
<P>SCL-90-DEP</P>
</TD>
<TD>
<P>BDI</P>
</TD>
</TR>
<TR>
<TD>
<P>anxiety</P>
</TD>
<TD>
<P>SCL-90-ANX</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>general psychiatric pathology</P>
</TD>
<TD>
<P>SCL-90-total</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>mental health status</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>CGI-I: number of patients with an CGI-I of 3 or more (i.e., minimally improved to very much worse)</P>
</TD>
</TR>
<TR>
<TD>
<P>attrition</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TD>
<P>adverse effects: weith gain</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>weight gain (kg; derived out of lb data)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]">Mood stabilisers vs. placebo: outcome scales (part 2)</TITLE>
<TABLE COLS="3" ROWS="22">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Lamotrigine</P>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Tritt-2005" TYPE="STUDY">Tritt 2005</LINK>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Reich-2009" TYPE="STUDY">Reich 2009</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>BPD severity</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>ZAN-BPD-total</P>
</TD>
</TR>
<TR>
<TD>
<P>avoidance of abandonment</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>interpersonal problems</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>identity disturbance</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>impulsivity</P>
</TD>
<TD>
<P>STAXI-anger out (not used: STAXI-anger in, STAXI-control)</P>
</TD>
<TD>
<P>ZAN-BPD-impulsivity</P>
</TD>
</TR>
<TR>
<TD>
<P>suicidal ideation</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>suicidal behaivour</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>self-mutilating behaviour</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>affective instability</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>ZAN-BPD-affective instability (not used: Affective Lability Scale)</P>
</TD>
</TR>
<TR>
<TD>
<P>feelings of emptiness</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>anger</P>
</TD>
<TD>
<P>STAXI-anger trait (not used: STAXI-anger state, as this subscale refers only to the intensity of angry feelings at the time of testing)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>psychotic/paranoid sympotms</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>dissociative symptoms</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>depression</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>anxiety</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>general psychiatric pathology</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>mental health status</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>attrition</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TD>
<P>adverse effects: absolute weight</P>
</TD>
<TD>
<P>weight (kg)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>patient-reported adverse events</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>number of patients with rash</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]">Mood stabilisers vs. placebo: outcome scales (part 3)</TITLE>
<TABLE COLS="4" ROWS="22">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Topiramate</P>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<LINK REF="STD-Loew-2006" TYPE="STUDY">Loew 2006</LINK>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Nickel-2004" TYPE="STUDY">Nickel 2004</LINK>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Nickel-2005" TYPE="STUDY">Nickel 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>BPD severity</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>avoidance of abandonment</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>interpersonal problems</P>
</TD>
<TD>
<P>SCL-90-R-INT (t-transformed)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>identity disturbance</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>impulsivity</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>STAXI-anger out (not used: STAXI-anger in, STAXI-control)</P>
</TD>
<TD>
<P>STAXI-anger out (not used: STAXI-anger in, STAXI-control)</P>
</TD>
</TR>
<TR>
<TD>
<P>suicidal ideation</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>suicidal behaivour</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>self-mutilating behaviour</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>affective instability</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>feelings of emptiness</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>anger</P>
</TD>
<TD>
<P>SCL-90-R-HOS (t-transformed)</P>
</TD>
<TD>
<P>STAXI-anger trait (not used: STAXI-anger state, as this subscale refers only to the intensity of angry feelings at the time of testing)</P>
</TD>
<TD>
<P>STAXI-anger trait (not used: STAXI-anger state, as this subscale refers only to the intensity of angry feelings at the time of testing)</P>
</TD>
</TR>
<TR>
<TD>
<P>psychotic/paranoid sympotms</P>
</TD>
<TD>
<P>SCL-90-R-PAR (t-transformed) (not used: SCL-90-R-PSY, as the SCL-90-R-PAR subscale reflects BPD relevant pathology more adequately)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>dissociative symptoms</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>depression</P>
</TD>
<TD>
<P>SCL-90-R-DEP (t-tranformed)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>anxiety</P>
</TD>
<TD>
<P>SCL-90-R-ANX (t-tranformed)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>general psychiatric pathology</P>
</TD>
<TD>
<P>SCL-90-R-GSI (t-transformed)</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>mental health status</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>attrition</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TD>
<P>adverse effects: absolute weight</P>
</TD>
<TD>
<P>weight (kg)</P>
</TD>
<TD>
<P>weight (kg)</P>
</TD>
<TD>
<P>weight (kg)</P>
</TD>
</TR>
<TR>
<TD>
<P>patient-reported adverse events</P>
</TD>
<TD>
<P>memory problems, troubles in concentrating, headache, fatigue, dizziness, menstrual pain, paresthesia</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2009-10-23 17:01:52 +0100" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">Antidepressants vs. placebo: outcome scales (part 1)</TITLE>
<TABLE COLS="4" ROWS="21">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Amitriptyline</P>
</TH>
<TH>
<P>Fluoxetine</P>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Soloff 1989</P>
</TD>
<TD>
<P>Salzman 1995</P>
</TD>
<TD>
<P>Simpson 2004</P>
</TD>
</TR>
<TR>
<TD>
<P>BPD severity</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>avoidance of abandonment</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>interpersonal problems</P>
</TD>
<TD>
<P>SCL-90-INT</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>identity disturbance</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>impulsivity</P>
</TD>
<TD>
<P>BIS; not used: Ward Scale of Impulsive Action, Self-Report Test of Impulse Control total because BIS is a self-report measure and broadly used</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>OAS-M-aggression; not used: STAXI-anger-out because other OAS-M-subscales were also used for several outcomes (s. below)</P>
</TD>
</TR>
<TR>
<TD>
<P>suicidal ideation</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>OAS-M-suicidality</P>
</TD>
</TR>
<TR>
<TD>
<P>suicidal behaviour</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>self-mutilating behaviour</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>OAS-M-assault against self</P>
</TD>
</TR>
<TR>
<TD>
<P>affective instability</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>feelings of emptiness</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>anger</P>
</TD>
<TD>
<P>SCL-90-HOS not used: BDHI, ADDS-reactivity)</P>
</TD>
<TD>
<P>POMS-anger; not used: OAS-M-anger against objects (only one spectrum of anger entailed), PDRS-anger (only based on one interviewer-rated item)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>psychotic/paranoid symptoms</P>
</TD>
<TD>
<P>SCL-90-PAR (not used: SCL-90-PSY, IMPS, SSI because SCL-90-PAR is a self-rated measure most adequately reflecting BPD relevant pathology</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>dissociative symptoms</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>DES</P>
</TD>
</TR>
<TR>
<TD>
<P>depression</P>
</TD>
<TD>
<P>BDI; not used: SCL-90-DEP, Ham-D-17, Ham-D-24, ADS, as all but the SCL-90-DEP scale are observer rated, and the BDI is more commonly used in the assessment of depression than the SCL-90-DEP</P>
</TD>
<TD>
<P>Ham-D; not used: POMS-dep because the Ham-D was also used by other studies within this comparison category</P>
</TD>
<TD>
<P>BDI</P>
</TD>
</TR>
<TR>
<TD>
<P>anxiety</P>
</TD>
<TD>
<P>SCL-90-ANX</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>STAI</P>
</TD>
</TR>
<TR>
<TD>
<P>general psychiatric pathology</P>
</TD>
<TD>
<P>SCL-90-GSI</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>mental health status</P>
</TD>
<TD>
<P>GAS</P>
</TD>
<TD>
<P>GAS</P>
</TD>
<TD>
<P>GAF</P>
</TD>
</TR>
<TR>
<TD>
<P>attrition</P>
</TD>
<TD>
<P>number of non-completers</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>number of non-completers</P>
</TD>
</TR>
<TR>
<TD>
<P>adverse effects</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-09" MODIFIED="2009-10-23 17:03:12 +0100" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2008-08-29 17:42:36 +0100" MODIFIED_BY="[Empty name]">Antidepressants vs. placebo: outcome scales (part 2)</TITLE>
<TABLE COLS="4" ROWS="21">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>SSRI: Fluvoxamine</P>
</TH>
<TH>
<P>MAOI: Phenelzine</P>
</TH>
<TH>
<P>Mianserin</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Rinne 2002</P>
</TD>
<TD>
<P>Soloff 1993</P>
</TD>
<TD>
<P>Montgomery 81/82/83</P>
</TD>
</TR>
<TR>
<TD>
<P>BPD severity</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>BSI</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>avoidance of abandonment</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>dysfunctional interpersonal patterns</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>ADI-rejection sensitivity</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>identity disturbance</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>impulsivity</P>
</TD>
<TD>
<P>BPDSI-impulsivity</P>
</TD>
<TD>
<P>BIS; not used: Ward Scale of Impulsive Action, Self-Report Test of Impulse Control total because BIS is a self-report measure and broadly used</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>suicidal ideation</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>suicidal behaviour</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>self-mutilating behaviour</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>number of patients with self-harming behaviour during 6 months of treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>affective instability</P>
</TD>
<TD>
<P>BPDSI-rapid mood shifts</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>feelings of emptiness</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>anger</P>
</TD>
<TD>
<P>BPDSI-anger</P>
</TD>
<TD>
<P>SCL-90-HOS; not used: BDHI, ADDS-reactivity)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>psychotic/paranoid ideation</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>SCL-90-PAR; not used: SCL-90-PSY, IMPS, SSI because SCL-90-PAR is a self-rated measure most adequately reflecting BPD relevant pathology</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>dissociative symptoms</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>depression</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>BDI; not used: SCL-90-DEP, Ham-D-17, Ham-D-24, ADS, as all but the SCL-90-DEP scale are observer rated, and the BDI is more commonly used in the assessment of depression than the SCL-90-DEP</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>anxiety</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>SCL-90-ANX</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>general psychiatric pathology</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>SCL-90-GSI</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>mental health status</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>GAS</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>attrition</P>
</TD>
<TD>
<P>number of patients not completing the study protocol</P>
</TD>
<TD>
<P>number of patients not completing the study protocol</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>adverse effects</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>ADI-weight gain</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-10" MODIFIED="2009-10-23 17:01:43 +0100" MODIFIED_BY="[Empty name]" NO="10">
<TITLE MODIFIED="2008-06-11 18:10:20 +0100" MODIFIED_BY="[Empty name]">Miscellaneous active agents vs. placebo: outcome scales</TITLE>
<TABLE COLS="3" ROWS="21">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Omega-3 fatty acid</P>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Hallahan 2007</P>
</TH>
<TH>
<P>Zanarini 2003</P>
</TH>
</TR>
<TR>
<TH>
<P>BPD severity</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>avoidance of abandonment</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>interpersonal problems</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>identity disturbance</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>impulsivity</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>MOAS</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal ideation</P>
</TH>
<TD>
<P>OAS-M-suicidality: number of patients with suicidality subscale score &gt;1 (i.e., at least slight suicidal tendency)</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>self-mutilating behaviour</P>
</TH>
<TD>
<P>number of patients with self-harm episodes during treatment</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>affective instability</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>feelings of emptiness</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>anger</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>psychotic/paranoid symptoms</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>dissociative symptoms</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>depression</P>
</TH>
<TD>
<P>number of patients not experiencing at least a 50% or 70% reduction of depressive pathology as assessed both by BDI and HAM-D</P>
<P>BDI used as it shows high concurrent validity with MADRS, whereas HAM-D mainly focusses on somatic depressive symptoms</P>
<P>50% cut-off data used as this is more sensitive to change, as are the continuous data reported by the other relevant trial in this comparison category</P>
</TD>
<TD>
<P>MADRS</P>
</TD>
</TR>
<TR>
<TH>
<P>anxiety</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>general psychiatric pathology</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>mental health status</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>attrition</P>
</TH>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TH>
<P>adverse effects</P>
</TH>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-11" MODIFIED="2009-10-23 17:01:41 +0100" MODIFIED_BY="[Empty name]" NO="11">
<TITLE MODIFIED="2008-09-01 08:18:03 +0100" MODIFIED_BY="[Empty name]">First-generation antipsychotic vs. first generation antipsychotic: outcome scales</TITLE>
<TABLE COLS="2" ROWS="21">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Loxapine vs. Chlorpromazine</P>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Leone 1982</P>
</TH>
</TR>
<TR>
<TH>
<P>BPD severity</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>avoidance of abandonment</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>interpersonal problems</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>identity disturbance</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>impulsivity</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal ideation</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>self-mutilating behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>affective instability</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>feelings of emptiness</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>anger</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>psychotic/paranoid symptoms</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>dissociative symptoms</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>depression</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>anxiety</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>general psychiatric pathology</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>mental health status</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>attrition</P>
</TH>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TH>
<P>patient-reported adverse events</P>
</TH>
<TD>
<P>number of patients experiencing any AE, sleepiness/drowsiness, restlessness, muscle spasms, fainting spells</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-12" MODIFIED="2009-10-23 17:01:39 +0100" MODIFIED_BY="[Empty name]" NO="12">
<TITLE MODIFIED="2008-09-01 08:18:37 +0100" MODIFIED_BY="[Empty name]">First-generation antipsychotics vs. antidepressants: outcome scales</TITLE>
<TABLE COLS="3" ROWS="21">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Haloperidol vs. Amitriptyline</P>
</TH>
<TH>
<P>Haloperidol vs. Phenelzine Sulfate</P>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH VALIGN="TOP">
<P>
<B>Soloff 1989</B>
</P>
<P/>
</TH>
<TH VALIGN="TOP">
<P>
<B>Soloff 1993</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>BPD severity</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BSI</P>
</TD>
</TR>
<TR>
<TH>
<P>avoidance of abandonment</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>interpersonal problems</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>SCL-90-INT</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ADS-rejection sensitivity</P>
</TD>
</TR>
<TR>
<TH>
<P>identity disturbance</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>impulsivity</P>
</TH>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BIS, Ward Scale of Impulse Action Patterns, STIC</P>
<P>BIS used because of width of use and self-reporting format</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>BIS, Ward Scale of Impulse Action Patterns, STIC</P>
<P>BIS used because of width of use and self-reporting format</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal ideation</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal behaviour</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>self-mutilating behaviour</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>affective instability</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>feelings of emptiness</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>anger</P>
</TH>
<TD VALIGN="TOP">
<P>SCL-90-HOS, BDHI</P>
<P>SCL-90-HOS used because of greater sensitivity to change</P>
</TD>
<TD VALIGN="TOP">
<P>SCL-90-HOS, BDHI, ADS-reactivity</P>
<P>SCL-90-HOS used because of greater sensitivity to change than BDHI and greater width of than ADS scale</P>
</TD>
</TR>
<TR>
<TH>
<P>psychotic/paranoid symptoms</P>
</TH>
<TD VALIGN="TOP">
<P>SCL-90-PAR,SCL-90-PSY, SSI</P>
<P>SCL-90-PAR used because regarded as most adequately reflecting BPD relevant pathology</P>
</TD>
<TD VALIGN="TOP">
<P>SCL-90-PAR, SCL-90-PSY, SSI</P>
<P>SCL-90-PAR used because regarded as most adequately reflecting BPD relevant pathology</P>
</TD>
</TR>
<TR>
<TH>
<P>dissociative symptoms</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>depression</P>
</TH>
<TD VALIGN="TOP">
<P>BDI, SCL-90-DEP, Ham-D</P>
<P>BDI used because of width of use and self-report format</P>
</TD>
<TD VALIGN="TOP">
<P>BDI, SCL-90-DEP, Ham-D, ADS total</P>
<P>BDI used because of width of use and self-report format</P>
</TD>
</TR>
<TR>
<TH>
<P>anxiety</P>
</TH>
<TD VALIGN="TOP">
<P>SCL-90-ANX</P>
</TD>
<TD VALIGN="TOP">
<P>SCL-90-ANX</P>
</TD>
</TR>
<TR>
<TH>
<P>general psychiatric pathology</P>
</TH>
<TD VALIGN="TOP">
<P>SCL-90-GSI</P>
</TD>
<TD VALIGN="TOP">
<P>SCL-90-GSI</P>
</TD>
</TR>
<TR>
<TH>
<P>mental health status</P>
</TH>
<TD VALIGN="TOP">
<P>GAS</P>
</TD>
<TD VALIGN="TOP">
<P>GAS</P>
</TD>
</TR>
<TR>
<TH>
<P>attrition</P>
</TH>
<TD VALIGN="TOP">
<P>number of patients lost after randomisation</P>
</TD>
<TD VALIGN="TOP">
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TH>
<P>adverse events</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>ADS-weight gain</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-13" MODIFIED="2009-10-23 17:01:37 +0100" MODIFIED_BY="[Empty name]" NO="13">
<TITLE MODIFIED="2008-06-11 18:38:33 +0100" MODIFIED_BY="[Empty name]">Second-generation antipsychotics vs. antidepressants: outcome scales</TITLE>
<TABLE COLS="2" ROWS="22">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Olanzapine vs. Fluoxetine</P>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Zanarini 2004</P>
</TH>
</TR>
<TR>
<TH>
<P>BPD severity</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>avoidance of abandonment</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>interpersonal problems</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>identity disturbance</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>impulsivity</P>
</TH>
<TD>
<P>OAS-M</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal ideation</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>self-mutilating behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>affective instability</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>feelings of emptiness</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>anger</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>psychotic/paranoid symptoms</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>dissociative symptoms</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>depression</P>
</TH>
<TD>
<P>MADRS</P>
</TD>
</TR>
<TR>
<TH>
<P>anxiety</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>general psychiatric pathology</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>mental health status</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>attrition</P>
</TH>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TH>
<P>Adverse effects</P>
</TH>
<TD>
<P>baseline to endpoint weight change (kg)</P>
</TD>
</TR>
<TR>
<TH>
<P>patient-reported adverse events</P>
</TH>
<TD>
<P>number of patients experiencing mild sedation, akathisia</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-14" MODIFIED="2010-05-11 16:39:29 +0100" MODIFIED_BY="[Empty name]" NO="14">
<TITLE MODIFIED="2008-06-11 18:41:26 +0100" MODIFIED_BY="[Empty name]">Second-generation antipsychotics vs. second-generation antipsychotics plus antidepressants: outcome scales</TITLE>
<TABLE COLS="2" ROWS="22">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Olanzapine vs. Olanzapine + Fluoxetine</P>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH>
<P>
<LINK REF="STD-Zanarini-2004" TYPE="STUDY">Zanarini 2004</LINK>
</P>
</TH>
</TR>
<TR>
<TH>
<P>BPD severity</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>avoidance of abandonment</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>interpersonal problems</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>identity disturbance</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>impulsivity</P>
</TH>
<TD>
<P>OAS-M</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal ideation</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>self-mutilating behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>affective instability</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>feelings of emptiness</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>anger</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>psychotic/paranoid symptoms</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>dissociative symptoms</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>depression</P>
</TH>
<TD>
<P>MADRS</P>
</TD>
</TR>
<TR>
<TH>
<P>anxiety</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>general psychiatric pathology</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>mental health status</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>attrition</P>
</TH>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TH>
<P>Adverse effects</P>
</TH>
<TD>
<P>baseline to endpoint weight change (kg)</P>
</TD>
</TR>
<TR>
<TH>
<P>patient-reported adverse events</P>
</TH>
<TD>
<P>number of patients experiencing mild sedation, akathisia</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-15" MODIFIED="2010-03-29 15:26:32 +0100" MODIFIED_BY="[Empty name]" NO="15">
<TITLE MODIFIED="2010-03-29 15:26:32 +0100" MODIFIED_BY="[Empty name]">Antidepressants vs. antidepressants plus second-generation antipsychotics: outcome scales</TITLE>
<TABLE COLS="2" ROWS="22">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Fluoxetine vs. Fluoxetine + Olanzapine</P>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Zanarini 2004</P>
</TH>
</TR>
<TR>
<TH>
<P>BPD severity</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>avoidance of abandonment</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>interpersonal problems</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>identity disturbance</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>impulsivity</P>
</TH>
<TD>
<P>OAS-M</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal ideation</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>suicidal behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>self-mutilating behaviour</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>affective instability</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>feelings of emptiness</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>anger</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>psychotic/paranoid symptoms</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>dissociative symptoms</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>depression</P>
</TH>
<TD>
<P>MADRS</P>
</TD>
</TR>
<TR>
<TH>
<P>anxiety</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>general psychiatric pathology</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>mental health status</P>
</TH>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TH>
<P>attrition</P>
</TH>
<TD>
<P>number of patients lost after randomisation</P>
</TD>
</TR>
<TR>
<TH>
<P>Adverse effects</P>
</TH>
<TD>
<P>baseline to endpoint weight change (kg)</P>
</TD>
</TR>
<TR>
<TH>
<P>patient-reported adverse events</P>
</TH>
<TD>
<P>number of patients experiencing mild sedation, akathisia</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-05-12 15:04:51 +0100" MODIFIED_BY="Chris Champion">
<COMPARISON ID="CMP-001" MODIFIED="2010-05-12 12:05:36 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Active drug versus placebo: BPD severity</NAME>
<CONT_OUTCOME CHI2="4.330050547083965" CI_END="0.18701337636706084" CI_START="-0.402667034478143" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.10782682905554107" ESTIMABLE="YES" I2="53.81116275081632" I2_Q="53.81116275081632" ID="CMP-001.01" MODIFIED="2010-05-08 23:06:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11474711083982259" P_Q="0.11474711083982259" P_Z="0.4735074753013152" Q="4.330050547083965" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.07912504982202703" TOTALS="SUB" TOTAL_1="94" TOTAL_2="86" UNITS="" WEIGHT="300.0" Z="0.7167838633577919">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8211854643196537" CI_START="-0.2151653215334095" DF="0" EFFECT_SIZE="0.3030100713931221" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" MODIFIED="2010-05-08 23:04:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2517474024304369" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="28" WEIGHT="100.0" Z="1.146115456253696">
<NAME>

First-generation antipsychotics: Haloperidol</NAME>
<CONT_DATA CI_END="0.8211854643196537" CI_START="-0.21516532153340945" EFFECT_SIZE="0.30301007139312214" ESTIMABLE="YES" MEAN_1="24.03" MEAN_2="20.08" MODIFIED="2008-08-28 12:04:17 +0100" MODIFIED_BY="[Empty name]" ORDER="397" SD_1="13.24" SD_2="12.44" SE="0.2643800585183365" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0455346099246704" CI_START="-0.9813007462166475" DF="0" EFFECT_SIZE="-0.46788306814598857" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" MODIFIED="2010-05-08 23:05:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07407718856509597" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.7861363207988932">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.0455346099246704" CI_START="-0.9813007462166475" EFFECT_SIZE="-0.46788306814598857" ESTIMABLE="YES" MEAN_1="3.88" MEAN_2="4.3" MODIFIED="2008-09-03 08:44:43 +0100" MODIFIED_BY="[Empty name]" ORDER="444" SD_1="0.6" SD_2="1.1" SE="0.26195260837466" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3518971792331461" CI_START="-0.6499284423887607" DF="0" EFFECT_SIZE="-0.14901563157780728" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" MODIFIED="2010-05-08 23:06:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5598488172679325" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0" Z="0.5830660840020292">
<NAME>

Antidepressants: Phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.3518971792331461" CI_START="-0.6499284423887607" EFFECT_SIZE="-0.14901563157780728" ESTIMABLE="YES" MEAN_1="18.3" MEAN_2="20.08" MODIFIED="2008-09-01 16:38:44 +0100" MODIFIED_BY="[Empty name]" ORDER="625" SD_1="11.24" SD_2="12.44" SE="0.25557245682170165" STUDY_ID="STD-Soloff-1993" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8328352927967707" CI_START="-0.2824533503604213" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2751909712181747" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2010-05-08 23:06:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.33343439048065526" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="0.967219375481799">
<NAME>SMD on basis of post-
means and pre-
SDs</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8328352927967707" CI_START="-0.2824533503604213" DF="0" EFFECT_SIZE="0.2751909712181747" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2010-05-08 23:05:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.33343439048065526" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0" Z="0.967219375481799">
<NAME>

First-generation antipsychotics: Thiothixene</NAME>
<CONT_DATA CI_END="0.8328352927967707" CI_START="-0.2824533503604213" EFFECT_SIZE="0.2751909712181747" ESTIMABLE="YES" MEAN_1="15.2859" MEAN_2="14.0812" MODIFIED="2008-08-29 10:17:02 +0100" MODIFIED_BY="[Empty name]" ORDER="454" SD_1="4.4436" SD_2="4.1812" SE="0.2845176370470188" STUDY_ID="STD-Goldberg-1986" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.998218344272602" CI_END="0.05940516285253844" CI_START="-0.4245535039611704" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.182574170554316" ESTIMABLE="YES" I2="33.29371745655101" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2010-05-08 23:07:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.22332908708646393" P_Q="0.4827224739797398" P_Z="0.13919404041084776" Q="0.4927066089944079" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.011972391956336375" TOTALS="SUB" TOTAL_1="309" TOTAL_2="314" UNITS="" WEIGHT="200.0" Z="1.478799010459611">
<NAME>SMD on basis of change from baseline scores</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.505511735278194" CI_END="0.09996796695764176" CI_START="-0.4098638928120687" DF="1" EFFECT_SIZE="-0.15494796292721347" ESTIMABLE="YES" I2="60.08799376511532" ID="CMP-001.03.01" MODIFIED="2010-05-08 23:06:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.113448914704385" P_Z="0.2335187992448814" STUDIES="2" TAU2="0.020331611436520503" TOTAL_1="294" TOTAL_2="302" WEIGHT="100.0" Z="1.1913434635189841">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.19813515101115842" CI_START="-0.250853773564189" EFFECT_SIZE="-0.026359311276515293" ESTIMABLE="YES" MEAN_1="-6.37" MEAN_2="-6.19" MODIFIED="2008-08-29 13:46:55 +0100" MODIFIED_BY="[Empty name]" ORDER="491" SD_1="6.73" SD_2="6.89" SE="0.11454009566423534" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="50.56943256205927"/>
<CONT_DATA CI_END="-0.05550492245555261" CI_START="-0.5174935929477436" EFFECT_SIZE="-0.2864992577016481" ESTIMABLE="YES" MEAN_1="-8.52" MEAN_2="-6.69" MODIFIED="2008-08-29 17:07:18 +0100" MODIFIED_BY="[Empty name]" ORDER="538" SD_1="6.15" SD_2="6.58" SE="0.11785641831592279" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="49.43056743794074"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.33514382377722535" CI_START="-1.2035875296226743" DF="0" EFFECT_SIZE="-0.43422185292272447" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" MODIFIED="2010-05-08 23:07:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2686473591406566" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0" Z="1.1061829488927135">
<NAME>

Mood stabiliz
ers: 
Lamotrigine</NAME>
<CONT_DATA CI_END="0.33514382377722535" CI_START="-1.2035875296226743" EFFECT_SIZE="-0.43422185292272447" ESTIMABLE="YES" MEAN_1="-8.8" MEAN_2="-6.6" MODIFIED="2009-10-23 17:19:59 +0100" MODIFIED_BY="[Empty name]" ORDER="321" SD_1="5.0" SD_2="4.8" SE="0.39254072154825703" STUDY_ID="STD-Reich-2009" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-05-12 12:05:47 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Active drug versus placebo: Avoidance of abandonment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.42909049886003925" CI_START="-0.5834336749898776" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.07717158806491922" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-05-08 23:08:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7651191459509211" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.2987652781896397">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.42909049886003925" CI_START="-0.5834336749898776" DF="0" EFFECT_SIZE="-0.07717158806491922" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" MODIFIED="2010-05-08 23:08:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7651191459509211" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.2987652781896397">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.42909049886003925" CI_START="-0.5834336749898776" EFFECT_SIZE="-0.07717158806491922" ESTIMABLE="YES" MEAN_1="4.44" MEAN_2="4.53" MODIFIED="2008-08-28 14:56:22 +0100" MODIFIED_BY="[Empty name]" ORDER="445" SD_1="1.2" SD_2="1.1" SE="0.2583017294798727" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.0981482375601708" CI_END="0.20794812016438713" CI_START="-0.2189860997543513" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.005518989794982096" ESTIMABLE="YES" I2="35.445309693282326" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-05-08 23:08:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2124446772564036" P_Q="1.0" P_Z="0.9595860830434837" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.012686783556621308" TOTALS="SUB" TOTAL_1="310" TOTAL_2="321" UNITS="" WEIGHT="100.0" Z="0.05067301108478908">
<NAME>SMD on basis of change from baseline scores</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.0981482375601708" CI_END="0.20794812016438713" CI_START="-0.2189860997543513" DF="2" EFFECT_SIZE="-0.005518989794982096" ESTIMABLE="YES" I2="35.445309693282326" ID="CMP-002.02.01" MODIFIED="2010-05-08 23:08:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2124446772564036" P_Z="0.9595860830434837" STUDIES="3" TAU2="0.012686783556621308" TOTAL_1="310" TOTAL_2="321" WEIGHT="100.0" Z="0.05067301108478908">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.6835168115082051" CI_START="-0.6465873999255716" EFFECT_SIZE="0.01846470579131674" ESTIMABLE="YES" MEAN_1="-0.8125" MEAN_2="-0.8421" MODIFIED="2008-08-29 13:18:27 +0100" MODIFIED_BY="[Empty name]" ORDER="479" SD_1="1.16726" SD_2="1.83373" SE="0.33931853389283395" STUDY_ID="STD-Bogenschutz-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="9.280125750751077"/>
<CONT_DATA CI_END="0.3593282332409691" CI_START="-0.09015543888237795" EFFECT_SIZE="0.13458639717929555" ESTIMABLE="YES" MEAN_1="-0.54" MEAN_2="-0.71" MODIFIED="2008-08-29 13:48:23 +0100" MODIFIED_BY="[Empty name]" ORDER="492" SD_1="1.26" SD_2="1.26" SE="0.11466630909262028" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="45.91502642702846"/>
<CONT_DATA CI_END="0.07608424604325154" CI_START="-0.3842112497008687" EFFECT_SIZE="-0.15406350182880857" ESTIMABLE="YES" MEAN_1="-1.06" MEAN_2="-0.87" MODIFIED="2008-08-29 17:08:34 +0100" MODIFIED_BY="[Empty name]" ORDER="539" SD_1="1.26" SD_2="1.2" SE="0.11742447804522745" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="44.804847822220474"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-05-12 12:07:25 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Active drug versus placebo: Interpersonal problems</NAME>
<CONT_OUTCOME CHI2="15.371092009787422" CI_END="-0.21422346949324683" CI_START="-0.5930301253965333" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4036267974448901" ESTIMABLE="YES" I2="47.95425077863002" I2_Q="52.530943680996444" ID="CMP-003.01" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.052319013977803364" P_Q="0.03939048560101632" P_Z="2.9567876897147875E-5" Q="14.74644861898729" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.07839997283805161" TOTALS="SUB" TOTAL_1="234" TOTAL_2="216" UNITS="" WEIGHT="800.0" Z="4.176769198000592">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6246433908001309" CI_END="-8.561700707636066E-4" CI_START="-0.7432423019869778" DF="1" EFFECT_SIZE="-0.37204923602887074" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" MODIFIED="2010-05-08 23:09:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.42932720005921765" P_Z="0.049473907544452064" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="56" WEIGHT="100.0" Z="1.964484711507317">
<NAME>

First-generation antipsychotics: Haloperidol</NAME>
<CONT_DATA CI_END="0.0069289001406313" CI_START="-1.0600665788043697" EFFECT_SIZE="-0.5265688393318692" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="1.74" MODIFIED="2008-08-28 12:42:45 +0100" MODIFIED_BY="[Empty name]" ORDER="410" SD_1="0.92" SD_2="1.06" SE="0.2721977259177528" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="28" WEIGHT="48.40993978943934"/>
<CONT_DATA CI_END="0.2897387079399344" CI_START="-0.743847803685416" EFFECT_SIZE="-0.2270545478727408" ESTIMABLE="YES" MEAN_1="0.57" MEAN_2="0.73" MODIFIED="2008-08-28 12:10:59 +0100" MODIFIED_BY="[Empty name]" ORDER="398" SD_1="0.7" SD_2="0.69" SE="0.26367487356353203" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="28" WEIGHT="51.59006021056066"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.20357361162359777" CI_START="-1.3333480812800431" DF="0" EFFECT_SIZE="-0.7684608464518204" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" MODIFIED="2010-05-08 23:09:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.007669253604378233" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="2.666294243722363">
<NAME>

Second-generation antipsychotics: Aripiprazole</NAME>
<CONT_DATA CI_END="-0.20357361162359777" CI_START="-1.3333480812800431" EFFECT_SIZE="-0.7684608464518204" ESTIMABLE="YES" MEAN_1="59.7" MEAN_2="64.2" MODIFIED="2008-08-28 14:27:02 +0100" MODIFIED_BY="[Empty name]" ORDER="419" SD_1="5.3" SD_2="6.2" SE="0.28821306885431625" STUDY_ID="STD-Nickel-2006" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3845013529325326" CI_START="-0.6286279379842935" DF="0" EFFECT_SIZE="-0.12206329252588047" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.03" MODIFIED="2010-05-08 23:09:41 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6367279227028766" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.47227863083220945">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.3845013529325326" CI_START="-0.6286279379842935" EFFECT_SIZE="-0.12206329252588047" ESTIMABLE="YES" MEAN_1="4.37" MEAN_2="4.5" MODIFIED="2008-08-28 14:57:32 +0100" MODIFIED_BY="[Empty name]" ORDER="447" SD_1="1.1" SD_2="1.0" SE="0.2584560989151486" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.38335589865844366" CI_START="-1.4581748702643202" DF="0" EFFECT_SIZE="-0.5374094858029382" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.04" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2526472413992614" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.00000000000001" Z="1.1439431313331756">
<NAME>

Mood stabiliser: Carbamazepine</NAME>
<CONT_DATA CI_END="0.38335589865844366" CI_START="-1.4581748702643202" EFFECT_SIZE="-0.5374094858029382" ESTIMABLE="YES" MEAN_1="6.14" MEAN_2="11.0" MODIFIED="2008-08-29 22:04:23 +0100" MODIFIED_BY="[Empty name]" ORDER="554" SD_1="7.17" SD_2="9.76" SE="0.46978688982259964" STUDY_ID="STD-De-la-Fuente-1994" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.22886815591314147" CI_START="-1.848409666995853" DF="0" EFFECT_SIZE="-1.0386389114544972" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.05" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.01193992029800924" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0" Z="2.5139150129369376">
<NAME>

Mood stabiliser: Valproate 
semisodium</NAME>
<CONT_DATA CI_END="-0.22886815591314147" CI_START="-1.848409666995853" EFFECT_SIZE="-1.0386389114544972" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.2" MODIFIED="2008-08-29 22:24:48 +0100" MODIFIED_BY="[Empty name]" ORDER="563" SD_1="0.5" SD_2="0.9" SE="0.41315593650124394" STUDY_ID="STD-Frankenburg-2002" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.35404014380164006" CI_START="-1.4579880008861053" DF="0" EFFECT_SIZE="-0.9060140723438727" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.06" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.001294937613863548" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="3.2170993220100814">
<NAME>

Mood stabiliser: Topiramate</NAME>
<CONT_DATA CI_END="-0.35404014380164006" CI_START="-1.4579880008861053" EFFECT_SIZE="-0.9060140723438727" ESTIMABLE="YES" MEAN_1="60.1" MEAN_2="66.9" MODIFIED="2008-09-01 12:52:56 +0100" MODIFIED_BY="[Empty name]" ORDER="580" SD_1="7.5" SD_2="7.3" SE="0.2816245262138144" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.13226473668961447" CI_START="-0.9169860607158503" DF="0" EFFECT_SIZE="-0.3923606620131179" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.07" MODIFIED="2010-05-08 23:10:28 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.14269402505348033" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0" Z="1.4658321316458958">
<NAME>

Antidepressants: Amitriptyline</NAME>
<CONT_DATA CI_END="0.13226473668961447" CI_START="-0.9169860607158503" EFFECT_SIZE="-0.3923606620131179" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.74" MODIFIED="2008-09-01 14:10:40 +0100" MODIFIED_BY="[Empty name]" ORDER="601" SD_1="0.95" SD_2="1.06" SE="0.2676709382625959" STUDY_ID="STD-Soloff-1989" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7415139328940761" CI_START="-0.2626289064008091" DF="0" EFFECT_SIZE="0.23944251324663351" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.08" MODIFIED="2010-05-08 23:10:39 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.34993005630567997" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0" Z="0.9347249892469498">
<NAME>

Antidepressants: Phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.7415139328940761" CI_START="-0.2626289064008091" EFFECT_SIZE="0.23944251324663351" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.73" MODIFIED="2008-09-01 16:39:55 +0100" MODIFIED_BY="[Empty name]" ORDER="626" SD_1="0.71" SD_2="0.69" SE="0.25616359464139027" STUDY_ID="STD-Soloff-1993" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.571738875873897E-33" CI_END="0.37499117035080237" CI_START="-0.7370808243458415" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.18104482699751961" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2010-05-08 23:11:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.5233678875425309" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="0.6381625329917935">
<NAME>SMD on basis of post-
means and pre-
SDs</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.571738875873897E-33" CI_END="0.37499117035080237" CI_START="-0.7370808243458415" DF="0" EFFECT_SIZE="-0.18104482699751961" ESTIMABLE="YES" I2="100.0" ID="CMP-003.02.01" MODIFIED="2010-05-08 23:11:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.5233678875425309" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0" Z="0.6381625329917935">
<NAME>

First-generation antipsychotics: Thiothixene</NAME>
<CONT_DATA CI_END="0.3749911703508024" CI_START="-0.7370808243458415" EFFECT_SIZE="-0.1810448269975196" ESTIMABLE="YES" MEAN_1="0.4583" MEAN_2="0.6209" MODIFIED="2008-08-29 10:22:48 +0100" MODIFIED_BY="[Empty name]" ORDER="455" SD_1="0.9927" SD_2="0.7706" SE="0.28369704838163506" STUDY_ID="STD-Goldberg-1986" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3851799867849416" CI_END="0.11728910111272164" CI_START="-0.308492287798368" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.09560159334282317" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2010-05-08 23:11:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5348442931152609" P_Q="1.0" P_Z="0.3787782303000571" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="166" TOTAL_2="174" UNITS="" WEIGHT="100.0" Z="0.8801496951089369">
<NAME>SMD on basis of change from baseline scores</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.3851799867849416" CI_END="0.11728910111272164" CI_START="-0.308492287798368" DF="1" EFFECT_SIZE="-0.09560159334282317" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" MODIFIED="2010-05-08 23:11:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5348442931152609" P_Z="0.3787782303000571" STUDIES="2" TAU2="0.0" TOTAL_1="166" TOTAL_2="174" WEIGHT="100.0" Z="0.8801496951089369">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.37264316684027127" CI_START="-0.9655772101473905" EFFECT_SIZE="-0.2964670216535596" ESTIMABLE="YES" MEAN_1="-2.125" MEAN_2="-1.5263" MODIFIED="2008-08-29 13:20:12 +0100" MODIFIED_BY="[Empty name]" ORDER="480" SD_1="1.74642" SD_2="2.14394" SE="0.3413890223349442" STUDY_ID="STD-Bogenschutz-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="10.123205929685916"/>
<CONT_DATA CI_END="0.15158298971815992" CI_START="-0.2975375198183624" EFFECT_SIZE="-0.07297726505010124" ESTIMABLE="YES" MEAN_1="-0.87" MEAN_2="-0.78" MODIFIED="2008-08-29 13:50:10 +0100" MODIFIED_BY="[Empty name]" ORDER="493" SD_1="1.22" SD_2="1.24" SE="0.11457366387319552" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="89.87679407031408"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.22139225667611168" CI_START="-0.6213922566761116" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.6548375728956203" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-08 23:12:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3522506989453881" Q="0.0" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="144" TOTAL_2="147" WEIGHT="100.0" Z="0.930232558139535">
<NAME>Mean Change Difference</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MCD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.22139225667611168" CI_START="-0.6213922566761116" DF="0" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-0.6548375728956203" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-08 23:12:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3522506989453881" STUDIES="1" TAU2="0.0" TOTAL_1="144" TOTAL_2="147" WEIGHT="100.0" Z="0.930232558139535">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<IV_DATA CI_END="0.22139225667611168" CI_START="-0.6213922566761116" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="540" SE="0.215" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-05-12 12:07:36 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Active drug versus placebo: Identity disturbance</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1260839131238375" CI_START="-0.8960216044409305" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3849688456585465" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2010-05-08 23:12:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.13983298357231122" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.4764132659383629">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1260839131238375" CI_START="-0.8960216044409305" DF="0" EFFECT_SIZE="-0.3849688456585465" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" MODIFIED="2010-05-08 23:12:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.13983298357231122" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.4764132659383629">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.1260839131238375" CI_START="-0.8960216044409305" EFFECT_SIZE="-0.3849688456585465" ESTIMABLE="YES" MEAN_1="4.62" MEAN_2="5.03" MODIFIED="2008-08-28 15:01:01 +0100" MODIFIED_BY="[Empty name]" ORDER="448" SD_1="1.1" SD_2="1.0" SE="0.2607459947292414" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.7780431376807642" CI_END="0.10067462941241596" CI_START="-0.21180367550603157" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.0555645230468078" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2010-05-08 23:12:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.41105778574994434" P_Q="1.0" P_Z="0.48577966824302543" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="310" TOTAL_2="321" UNITS="" WEIGHT="100.0" Z="0.6970369608111618">
<NAME>SMD on basis of change from baseline scores</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7780431376807642" CI_END="0.10067462941241596" CI_START="-0.21180367550603157" DF="2" EFFECT_SIZE="-0.0555645230468078" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" MODIFIED="2010-05-08 23:12:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.41105778574994434" P_Z="0.48577966824302543" STUDIES="3" TAU2="0.0" TOTAL_1="310" TOTAL_2="321" WEIGHT="100.0" Z="0.6970369608111618">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.5128472065442093" CI_START="-0.8194082180007622" EFFECT_SIZE="-0.15328050572827645" ESTIMABLE="YES" MEAN_1="-1.375" MEAN_2="-1.1053" MODIFIED="2008-08-29 13:22:07 +0100" MODIFIED_BY="[Empty name]" ORDER="481" SD_1="1.78419" SD_2="1.66315" SE="0.33986732283185617" STUDY_ID="STD-Bogenschutz-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="5.501292613313778"/>
<CONT_DATA CI_END="0.27865703687851295" CI_START="-0.17039540890646154" EFFECT_SIZE="0.05413081398602569" ESTIMABLE="YES" MEAN_1="-0.78" MEAN_2="-0.85" MODIFIED="2008-08-29 13:51:03 +0100" MODIFIED_BY="[Empty name]" ORDER="494" SD_1="1.33" SD_2="1.25" SE="0.11455630035221129" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="48.422321607408456"/>
<CONT_DATA CI_END="0.07099294565378075" CI_START="-0.3893491253068071" EFFECT_SIZE="-0.15917808982651319" ESTIMABLE="YES" MEAN_1="-1.01" MEAN_2="-0.82" MODIFIED="2008-08-29 17:10:29 +0100" MODIFIED_BY="[Empty name]" ORDER="541" SD_1="1.24" SD_2="1.14" SE="0.11743635969632793" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="46.07638577927777"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-05-12 12:08:26 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Active drug versus placebo: Impulsivity</NAME>
<CONT_OUTCOME CHI2="102.7092626171351" CI_END="-0.1658891634724118" CI_START="-0.5097713882880774" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3378302758802446" ESTIMABLE="YES" I2="86.36929168483354" I2_Q="88.90568872058275" ID="CMP-005.01" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.9984014443252818E-15" P_Q="2.220446049250313E-16" P_Z="1.1766458230926005E-4" Q="99.1499131668297" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.7071491104819364" TOTALS="SUB" TOTAL_1="345" TOTAL_2="289" UNITS="" WEIGHT="1200.0" Z="3.850941548185228">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.006098871339788147" CI_END="0.4325442870913853" CI_START="-0.3021674857168974" DF="1" EFFECT_SIZE="0.06518840068724398" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.01" MODIFIED="2010-05-08 23:13:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9377522691020863" P_Z="0.727989285735509" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="56" WEIGHT="100.0" Z="0.3478014706866664">
<NAME>

First-generation antipsychotics: Haloperidol</NAME>
<CONT_DATA CI_END="0.5742160787412464" CI_START="-0.47360695818930976" EFFECT_SIZE="0.050304560275968295" ESTIMABLE="YES" MEAN_1="104.02" MEAN_2="103.06" MODIFIED="2008-08-28 12:43:41 +0100" MODIFIED_BY="[Empty name]" ORDER="411" SD_1="15.71" SD_2="21.48" SE="0.26730670695881414" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="28" WEIGHT="49.16523428262575"/>
<CONT_DATA CI_END="0.5948198841252513" CI_START="-0.43565304150560513" EFFECT_SIZE="0.07958342130982311" ESTIMABLE="YES" MEAN_1="240.95" MEAN_2="237.74" MODIFIED="2008-08-28 12:13:03 +0100" MODIFIED_BY="[Empty name]" ORDER="400" SD_1="37.6" SD_2="42.02" SE="0.2628805768266905" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="28" WEIGHT="50.83476571737426"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.1802626901282143" CI_START="-2.4921220251916916" DF="0" EFFECT_SIZE="-1.836192357659953" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.02" MODIFIED="2010-05-08 23:13:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.0957679352560526E-8" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="5.486671922073197">
<NAME>

Second-generation antipsychotics: Aripiprazole</NAME>
<CONT_DATA CI_END="-1.1802626901282143" CI_START="-2.4921220251916916" EFFECT_SIZE="-1.836192357659953" ESTIMABLE="YES" MEAN_1="14.3" MEAN_2="20.7" MODIFIED="2008-08-28 14:29:03 +0100" MODIFIED_BY="[Empty name]" ORDER="424" SD_1="2.6" SD_2="4.1" SE="0.33466414317080734" STUDY_ID="STD-Nickel-2006" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.46966562711047805" CI_START="-0.5425453192319839" DF="0" EFFECT_SIZE="-0.036439846060752935" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.03" MODIFIED="2010-05-08 23:13:41 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8877764216667946" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.14111838276266908">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.46966562711047805" CI_START="-0.5425453192319839" EFFECT_SIZE="-0.036439846060752935" ESTIMABLE="YES" MEAN_1="5.77" MEAN_2="6.12" MODIFIED="2008-08-29 10:56:14 +0100" MODIFIED_BY="[Empty name]" ORDER="463" SD_1="9.53" SD_2="9.43" SE="0.25822182303518143" STUDY_ID="STD-Soler-2005" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5332973617165861" CI_START="-0.47887381961116904" DF="0" EFFECT_SIZE="0.027211771052708545" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.04" MODIFIED="2010-05-08 23:13:49 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9160699084638976" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.10538551621059843">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.5332973617165861" CI_START="-0.47887381961116904" EFFECT_SIZE="0.027211771052708545" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="3.96" MODIFIED="2008-08-28 15:03:00 +0100" MODIFIED_BY="[Empty name]" ORDER="450" SD_1="1.4" SD_2="1.5" SE="0.25821167871237233" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5302213281474988" CI_END="0.23586176223010424" CI_START="-1.478219034072469" DF="1" EFFECT_SIZE="-0.6211786359211824" ESTIMABLE="YES" I2="34.64997633965735" ID="CMP-005.01.05" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.21607966580329452" P_Z="0.15544116836279448" STUDIES="2" TAU2="0.14469754164259135" TOTAL_1="32" TOTAL_2="14" WEIGHT="100.0" Z="1.4205721888926905">
<NAME>

Mood stabiliser: Valproate 
semisodium</NAME>
<CONT_DATA CI_END="0.46649362349968365" CI_START="-1.0602207817553058" EFFECT_SIZE="-0.2968635791278111" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="3.2" MODIFIED="2008-08-29 22:25:57 +0100" MODIFIED_BY="[Empty name]" ORDER="564" SD_1="1.9" SD_2="2.1" SE="0.3894751172209076" STUDY_ID="STD-Frankenburg-2002" TOTAL_1="20" TOTAL_2="10" WEIGHT="64.51269583451933"/>
<CONT_DATA CI_END="0.019675261075739803" CI_START="-2.4411831675170195" EFFECT_SIZE="-1.21075395322064" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="6.0" MODIFIED="2008-08-29 22:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="569" SD_1="2.9" SD_2="4.4" SE="0.6277815429272416" STUDY_ID="STD-Hollander-2001" TOTAL_1="12" TOTAL_2="4" WEIGHT="35.48730416548067"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6897752138760681" CI_START="-2.5420554739517596" DF="0" EFFECT_SIZE="-1.6159153439139138" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.06" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="6.268662912056963E-4" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="9" WEIGHT="100.0" Z="3.4197156277069056">
<NAME>

Mood stabiliser: Lamotrigine</NAME>
<CONT_DATA CI_END="-0.6897752138760681" CI_START="-2.5420554739517596" EFFECT_SIZE="-1.6159153439139138" ESTIMABLE="YES" MEAN_1="17.8" MEAN_2="23.2" MODIFIED="2008-09-01 09:05:23 +0100" MODIFIED_BY="[Empty name]" ORDER="575" SD_1="3.0" SD_2="3.7" SE="0.47252915734325773" STUDY_ID="STD-Tritt-2005" TOTAL_1="18" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.0230292508181096" CI_END="-2.27464707181805" CI_START="-4.442639130973203" DF="1" EFFECT_SIZE="-3.3586431013956264" ESTIMABLE="YES" I2="50.56917740583327" ID="CMP-005.01.07" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.15493019381585793" P_Z="1.2575068253759755E-9" STUDIES="2" TAU2="0.30940349115579874" TOTAL_1="41" TOTAL_2="30" WEIGHT="100.0" Z="6.072733973227376">
<NAME>

Mood stabiliser: Topiramate</NAME>
<CONT_DATA CI_END="-1.710079502231478" CI_START="-3.889120410490049" EFFECT_SIZE="-2.7995999563607636" ESTIMABLE="YES" MEAN_1="17.6" MEAN_2="22.6" MODIFIED="2008-09-01 13:48:43 +0100" MODIFIED_BY="[Empty name]" ORDER="598" SD_1="1.8" SD_2="1.6" SE="0.5558879972914216" STUDY_ID="STD-Nickel-2004" TOTAL_1="19" TOTAL_2="10" WEIGHT="49.46285909965298"/>
<CONT_DATA CI_END="-2.839708844799016" CI_START="-4.97189618255781" EFFECT_SIZE="-3.9058025136784127" ESTIMABLE="YES" MEAN_1="19.7" MEAN_2="24.8" MODIFIED="2008-09-01 13:54:18 +0100" MODIFIED_BY="[Empty name]" ORDER="600" SD_1="0.9" SD_2="1.6" SE="0.5439353362044443" STUDY_ID="STD-Nickel-2005" TOTAL_1="22" TOTAL_2="20" WEIGHT="50.53714090034702"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3952029791659006" CI_START="-0.6444532723789582" DF="0" EFFECT_SIZE="-0.12462514660652883" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.08" MODIFIED="2010-05-08 23:14:31 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.6384353138328136" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0" Z="0.46988761632292536">
<NAME>

Antidepressants: Amitriptyline</NAME>
<CONT_DATA CI_END="0.3952029791659006" CI_START="-0.6444532723789582" EFFECT_SIZE="-0.12462514660652883" ESTIMABLE="YES" MEAN_1="100.5" MEAN_2="103.06" MODIFIED="2008-09-01 14:11:37 +0100" MODIFIED_BY="[Empty name]" ORDER="602" SD_1="19.01" SD_2="21.48" SE="0.26522330505701497" STUDY_ID="STD-Soloff-1989" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.31232076645959006" CI_START="-1.4965255689675385" DF="0" EFFECT_SIZE="-0.5921024012539743" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.09" MODIFIED="2010-05-08 23:14:39 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.19944386939045206" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0" Z="1.2831376097444354">
<NAME>

Antidepressants: Fluoxetine</NAME>
<CONT_DATA CI_END="0.31232076645959006" CI_START="-1.4965255689675385" EFFECT_SIZE="-0.5921024012539743" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="7.45" MODIFIED="2008-09-01 15:59:24 +0100" MODIFIED_BY="[Empty name]" ORDER="613" SD_1="3.81" SD_2="10.05" SE="0.4614488709218837" STUDY_ID="STD-Simpson-2004" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5917274076745764" CI_START="-0.6820107679815322" DF="0" EFFECT_SIZE="-0.045141680153477894" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.10" MODIFIED="2010-05-08 23:14:49 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.889510619885097" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="0.13892347578711578">
<NAME>

Antidepressants: Fluvoxamine</NAME>
<CONT_DATA CI_END="0.5917274076745764" CI_START="-0.6820107679815322" EFFECT_SIZE="-0.045141680153477894" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.73" MODIFIED="2008-09-01 16:29:55 +0100" MODIFIED_BY="[Empty name]" ORDER="621" SD_1="0.66" SD_2="0.64" SE="0.3249391789092026" STUDY_ID="STD-Rinne-2002" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.887922551246992E-36" CI_END="0.4981102832901942" CI_START="-0.5022480174013395" DF="0" EFFECT_SIZE="-0.0020688670555726813" ESTIMABLE="YES" I2="100.0" ID="CMP-005.01.11" MODIFIED="2010-05-08 23:15:00 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Z="0.9935316964152241" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0" Z="0.008106905125735014">
<NAME>

Antidepressants: Phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.4981102832901942" CI_START="-0.5022480174013395" EFFECT_SIZE="-0.002068867055572681" ESTIMABLE="YES" MEAN_1="237.66" MEAN_2="237.74" MODIFIED="2008-09-01 16:41:25 +0100" MODIFIED_BY="[Empty name]" ORDER="627" SD_1="34.73" SD_2="42.02" SE="0.25519813337954994" STUDY_ID="STD-Soloff-1993" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3413814389813023" CI_START="-1.2817733113075152" DF="0" EFFECT_SIZE="-0.47019593616310645" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.12" MODIFIED="2010-05-08 23:15:09 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.25615507004482485" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="9" WEIGHT="100.0" Z="1.1355258645459445">
<NAME>

Miscellaneous: Omega-3 fatty acids</NAME>
<CONT_DATA CI_END="0.3413814389813023" CI_START="-1.2817733113075152" EFFECT_SIZE="-0.47019593616310645" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="12.9" MODIFIED="2008-10-13 09:42:11 +0100" MODIFIED_BY="[Empty name]" ORDER="640" SD_1="8.1" SD_2="17.1" SE="0.4140776981342655" STUDY_ID="STD-Zanarini-2003" TOTAL_1="18" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.397488641271164" CI_END="-0.048039364836648085" CI_START="-0.46189472778545715" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2549670463110526" ESTIMABLE="YES" I2="72.96379762123804" I2_Q="86.32079445228747" ID="CMP-005.02" MODIFIED="2010-05-08 23:15:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.024754671165003628" P_Q="0.006855825644261682" P_Z="0.015736070418936092" Q="7.310366062649174" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.2220231465554483" TOTALS="SUB" TOTAL_1="181" TOTAL_2="186" UNITS="" WEIGHT="200.0" Z="2.4149800763897886">
<NAME>SMD on basis of change from baseline scores</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.08712257862199028" CI_END="0.028885248707906458" CI_START="-0.3974663881183226" DF="1" EFFECT_SIZE="-0.18429056970520805" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.01" MODIFIED="2010-05-08 23:15:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7678675906956556" P_Z="0.09019128369483147" STUDIES="2" TAU2="0.0" TOTAL_1="166" TOTAL_2="174" WEIGHT="100.0" Z="1.694389551316741">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.38892942622463567" CI_START="-0.9483996334744866" EFFECT_SIZE="-0.2797351036249255" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.9474" MODIFIED="2008-08-29 13:22:59 +0100" MODIFIED_BY="[Empty name]" ORDER="483" SD_1="1.50555" SD_2="2.22295" SE="0.34116164129744303" STUDY_ID="STD-Bogenschutz-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="10.163874776973032"/>
<CONT_DATA CI_END="0.05141972822755014" CI_START="-0.39840407039190895" EFFECT_SIZE="-0.1734921710821794" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-0.48" MODIFIED="2008-08-29 13:51:43 +0100" MODIFIED_BY="[Empty name]" ORDER="495" SD_1="1.27" SD_2="1.26" SE="0.11475307765030679" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="89.83612522302697"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5469032193625949" CI_START="-2.268903059829163" DF="0" EFFECT_SIZE="-1.4079031395958788" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.02" MODIFIED="2010-05-08 23:15:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.001350980716723596" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0" Z="3.204924161411227">
<NAME>

Mood stabiliz
ers: 
Lamotrigine</NAME>
<CONT_DATA CI_END="-0.5469032193625949" CI_START="-2.268903059829163" EFFECT_SIZE="-1.4079031395958788" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.1" MODIFIED="2009-10-23 17:22:29 +0100" MODIFIED_BY="[Empty name]" ORDER="323" SD_1="0.8" SD_2="0.7" SE="0.43929374571407503" STUDY_ID="STD-Reich-2009" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="8.446690690703197E-33" CI_END="0.1959545616655482" CI_START="-0.39595456166554815" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="-0.09999999999999999" ESTIMABLE="YES" I2="100.00000000000001" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.7078446220398392" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-08 23:15:58 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.5078099583217437" Q="0.0" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="144" TOTAL_2="147" WEIGHT="100.00000000000001" Z="0.662251655629139">
<NAME>Mean Change Difference</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MCD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="8.446690690703197E-33" CI_END="0.1959545616655482" CI_START="-0.39595456166554815" DF="0" EFFECT_SIZE="-0.09999999999999999" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-005.03.01" LOG_CI_END="-0.7078446220398392" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-08 23:15:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.5078099583217437" STUDIES="1" TAU2="0.0" TOTAL_1="144" TOTAL_2="147" WEIGHT="100.00000000000001" Z="0.662251655629139">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<IV_DATA CI_END="0.19595456166554817" CI_START="-0.3959545616655482" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="542" SE="0.151" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="100.00000000000001"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.457944455315932" CI_START="0.525140033427468" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.16374097857091496" LOG_CI_START="-0.27972487252628847" LOG_EFFECT_SIZE="-0.057991946977686754" METHOD="MH" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.6082253813949476" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.5126082524208109">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.457944455315932" CI_START="0.525140033427468" DF="0" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.16374097857091496" LOG_CI_START="-0.27972487252628847" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6082253813949476" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.5126082524208109">
<NAME>

Mood stabiliser: Carbamazepine</NAME>
<DICH_DATA CI_END="1.457944455315932" CI_START="0.525140033427468" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.16374097857091496" LOG_CI_START="-0.27972487252628847" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2008-09-25 11:05:14 +0100" MODIFIED_BY="[Empty name]" ORDER="555" O_E="0.0" SE="0.2604940361258638" STUDY_ID="STD-De-la-Fuente-1994" TOTAL_1="10" TOTAL_2="10" VAR="0.06785714285714284" WEIGHT="100.0">
<FOOTNOTE>event: status quo or worsened after tratment according to Acting-out Scale</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-05-12 12:08:36 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Active drug versus placebo: Suicidal ideation</NAME>
<CONT_OUTCOME CHI2="2.790771926243143" CI_END="0.3918546811374015" CI_START="-0.433365655968017" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.02075548741530774" ESTIMABLE="YES" I2="28.335240110705048" I2_Q="28.335240110705048" ID="CMP-006.01" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.24773767431945326" P_Q="0.24773767431945326" P_Z="0.9214623259230665" Q="2.790771926243143" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.06942304618414227" TOTALS="SUB" TOTAL_1="51" TOTAL_2="45" UNITS="" WEIGHT="300.0" Z="0.09859186931400311">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.23491546226574767" CI_START="-0.782263767864765" DF="0" EFFECT_SIZE="-0.2736741527995087" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.01" MODIFIED="2010-05-08 23:16:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2915787448952243" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.0546646394219537">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.23491546226574767" CI_START="-0.782263767864765" EFFECT_SIZE="-0.2736741527995087" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="3.13" MODIFIED="2008-08-28 15:05:03 +0100" MODIFIED_BY="[Empty name]" ORDER="451" SD_1="1.6" SD_2="1.5" SE="0.25948926565842345" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6661778488042573" CI_START="-0.6341634927566063" DF="0" EFFECT_SIZE="0.5160071780238255" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.02" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3792337373932477" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="4" WEIGHT="100.00000000000001" Z="0.8793090541985437">
<NAME>

Mood stabiliser: Valproate 
semisodium</NAME>
<CONT_DATA CI_END="1.6661778488042573" CI_START="-0.6341634927566063" EFFECT_SIZE="0.5160071780238255" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.3" MODIFIED="2008-08-29 22:43:20 +0100" MODIFIED_BY="[Empty name]" ORDER="570" SD_1="1.2" SD_2="0.6" SE="0.5868325539922321" STUDY_ID="STD-Hollander-2001" TOTAL_1="12" TOTAL_2="4" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4818848278845517E-32" CI_END="1.3299559705958064" CI_START="-0.457564792307089" DF="0" EFFECT_SIZE="0.43619558914435874" ESTIMABLE="YES" I2="100.0" ID="CMP-006.01.03" MODIFIED="2010-05-08 23:17:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.33879379697767664" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0" Z="0.9565512890040948">
<NAME>

Antidepressants: Fluoxetine</NAME>
<CONT_DATA CI_END="1.3299559705958064" CI_START="-0.45756479230708885" EFFECT_SIZE="0.4361955891443588" ESTIMABLE="YES" MEAN_1="2.13" MEAN_2="1.0" MODIFIED="2008-09-01 16:00:10 +0100" MODIFIED_BY="[Empty name]" ORDER="614" SD_1="3.48" SD_2="1.18" SE="0.45600857388264043" STUDY_ID="STD-Simpson-2004" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.20866630664266753" CI_END="0.5026079825064196" CI_START="0.07486041908959548" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.28873420079800755" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2010-05-08 23:17:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6478147660501258" P_Q="1.0" P_Z="0.008145138330587828" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="166" TOTAL_2="174" UNITS="" WEIGHT="100.0" Z="2.645993492744196">
<NAME>SMD on basis of change from baseline scores</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.20866630664266753" CI_END="0.5026079825064196" CI_START="0.07486041908959548" DF="1" EFFECT_SIZE="0.28873420079800755" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.01" MODIFIED="2010-05-08 23:17:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6478147660501258" P_Z="0.008145138330587828" STUDIES="2" TAU2="0.0" TOTAL_1="166" TOTAL_2="174" WEIGHT="100.0" Z="2.645993492744196">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="1.1115568473460922" CI_START="-0.23621024203006685" EFFECT_SIZE="0.4376733026580127" ESTIMABLE="YES" MEAN_1="-0.125" MEAN_2="-0.5263" MODIFIED="2008-08-29 13:24:21 +0100" MODIFIED_BY="[Empty name]" ORDER="484" SD_1="0.34157" SD_2="1.17229" SE="0.34382445289994457" STUDY_ID="STD-Bogenschutz-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="10.0726882819271"/>
<CONT_DATA CI_END="0.49758550277077174" CI_START="0.046517792777610506" EFFECT_SIZE="0.2720516477741911" ESTIMABLE="YES" MEAN_1="-0.28" MEAN_2="-0.61" MODIFIED="2008-08-29 14:14:03 +0100" MODIFIED_BY="[Empty name]" ORDER="496" SD_1="1.21" SD_2="1.21" SE="0.11507040781134902" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="89.9273117180729"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="-0.003961764757537345" CI_START="-0.19603823524246267" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="-0.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-08 23:17:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.041269087139214705" Q="0.0" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="144" TOTAL_2="147" WEIGHT="100.0" Z="2.0408163265306123">
<NAME>Mean Change Difference</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MCD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.003961764757537345" CI_START="-0.19603823524246267" DF="0" EFFECT_SIZE="-0.1" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-08 23:17:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.041269087139214705" STUDIES="1" TAU2="0.0" TOTAL_1="144" TOTAL_2="147" WEIGHT="100.0" Z="2.0408163265306123">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<IV_DATA CI_END="-0.003961764757537345" CI_START="-0.19603823524246267" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="543" SE="0.049" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="2.406516221827249" CI_END="1.1152147321578958" CI_START="0.41219110830607897" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6779982274662892" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" I2="58.44615586091051" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.04735849788863702" LOG_CI_START="-0.3849013809586868" LOG_EFFECT_SIZE="-0.1687714415350249" METHOD="MH" MODIFIED="2010-05-08 23:18:25 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.12083119749400606" P_Q="0.0" P_Z="0.12589407232551317" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.20755959636254986" TOTALS="SUB" TOTAL_1="34" TOTAL_2="39" WEIGHT="200.0" Z="1.5304957189625794">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.883036552964966" CI_START="0.4994733759164719" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="0.45985014868385343" LOG_CI_START="-0.3014876565886039" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2010-05-08 23:18:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6835061309928883" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.407683394754871">
<NAME>

Second-generation 
antipsychotic
s

 versus placebo: Olanzapine</NAME>
<DICH_DATA CI_END="2.883036552964966" CI_START="0.4994733759164719" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.45985014868385343" LOG_CI_START="-0.3014876565886039" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2008-09-25 13:27:26 +0100" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.44721359549995804" STUDY_ID="STD-Linehan-2008" TOTAL_1="12" TOTAL_2="12" VAR="0.20000000000000007" WEIGHT="100.0">
<FOOTNOTE>event: severe suicidality acc. to OAS-M-suicidality score (i.e., frequent suicide ideation and/or planning or behaviour)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.945863888846669" CI_START="0.2823100204263183" DF="0" EFFECT_SIZE="0.5167464114832536" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" I2="0.0" ID="CMP-006.04.02" LOG_CI_END="-0.02417135469311909" LOG_CI_START="-0.5492737065550896" LOG_EFFECT_SIZE="-0.28672253062410424" MODIFIED="2010-05-08 23:18:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03232205577009331" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="27" WEIGHT="100.00000000000001" Z="2.1404049385295716">
<NAME>

Miscellaneous: Omega-3 fatty acids</NAME>
<DICH_DATA CI_END="0.945863888846669" CI_START="0.2823100204263183" EFFECT_SIZE="0.5167464114832536" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.02417135469311909" LOG_CI_START="-0.5492737065550896" LOG_EFFECT_SIZE="-0.28672253062410424" MODIFIED="2008-09-25 13:28:15 +0100" MODIFIED_BY="[Empty name]" ORDER="642" O_E="0.0" SE="0.3084477207822841" STUDY_ID="STD-Hallahan-2007" TOTAL_1="22" TOTAL_2="27" VAR="0.09513999645578591" WEIGHT="100.00000000000001">
<FOOTNOTE>event: mild suicidality acc. to OAS-M-suicidality score &gt;1 (i.e. at least slight suicidal tendency, thinking of being better off dead))</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-05-12 12:08:44 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Active drug versus placebo: Suicidal behaviour</NAME>
<DICH_OUTCOME CHI2="4.023523811484235" CI_END="1.145792267921372" CI_START="0.6261831501413062" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8470394393028912" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="35" I2="75.1461642367885" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.05910588720106793" LOG_CI_START="-0.2032986229201694" LOG_EFFECT_SIZE="-0.0720963678595507" METHOD="MH" MODIFIED="2010-05-08 23:19:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04486995510917968" P_Q="0.0" P_Z="0.2814753252996094" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.20011367375003694" TOTALS="SUB" TOTAL_1="47" TOTAL_2="48" WEIGHT="200.0" Z="1.0770110952405778">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.919294062930495" CI_START="0.2639497763137819" DF="0" EFFECT_SIZE="0.4925925925925926" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="-0.036545544674819484" LOG_CI_START="-0.5784787017089836" LOG_EFFECT_SIZE="-0.3075121231919015" MODIFIED="2010-05-08 23:19:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.026127838521190005" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="2.2243063685714866">
<NAME>

First-generation antipsychotics: Flupenthixol 
decanoate</NAME>
<DICH_DATA CI_END="0.919294062930495" CI_START="0.2639497763137819" EFFECT_SIZE="0.4925925925925926" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.036545544674819484" LOG_CI_START="-0.5784787017089836" LOG_EFFECT_SIZE="-0.3075121231919015" MODIFIED="2008-09-25 13:32:41 +0100" MODIFIED_BY="[Empty name]" ORDER="419" O_E="0.0" SE="0.3183342190542599" STUDY_ID="STD-Montgomery-1979_x002f_82" TOTAL_1="18" TOTAL_2="19" VAR="0.10133667502088553" WEIGHT="100.0">
<FOOTNOTE>event: suicidal act during treatment</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4123841237254866" CI_START="0.7080226853317149" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="0.14995282711736466" LOG_CI_START="-0.14995282711736466" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-08 23:19:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.0">
<NAME>

Antidepressants: Mianserin</NAME>
<DICH_DATA CI_END="1.4123841237254866" CI_START="0.7080226853317149" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.14995282711736466" LOG_CI_START="-0.14995282711736466" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-11-06 14:52:26 +0000" MODIFIED_BY="[Empty name]" ORDER="909" O_E="0.0" SE="0.17616606585441105" STUDY_ID="STD-Montgomery-81_x002f_82_x002f_83" TOTAL_1="29" TOTAL_2="29" VAR="0.031034482758620696" WEIGHT="100.0">
<FOOTNOTE>event: suicidal act during treatment</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6536974377620605" CI_START="-0.35988370859616337" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.14690686458294858" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2010-05-08 23:19:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5699343282535347" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.5681482231567081">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6536974377620605" CI_START="-0.35988370859616337" DF="0" EFFECT_SIZE="0.14690686458294858" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.01" MODIFIED="2010-05-08 23:19:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5699343282535347" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5681482231567081">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.6536974377620605" CI_START="-0.35988370859616337" EFFECT_SIZE="0.14690686458294858" ESTIMABLE="YES" MEAN_1="1.23" MEAN_2="0.88" ORDER="635" SD_1="2.87" SD_2="1.68" SE="0.2585713702785415" STUDY_ID="STD-Soler-2005" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2010-05-12 12:08:54 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Active drug versus placebo: Self-mutilating behaviour</NAME>
<DICH_OUTCOME CHI2="3.3249652604087845" CI_END="1.7300039160833822" CI_START="0.549646138953467" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9751358740450526" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" I2="39.84899560261535" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.23804708621057497" LOG_CI_START="-0.2599168184305885" LOG_EFFECT_SIZE="-0.010934866110006786" METHOD="MH" MODIFIED="2010-05-08 23:20:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1896677228796344" P_Q="0.0" P_Z="0.9314041718791531" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1837712576086467" TOTALS="SUB" TOTAL_1="60" TOTAL_2="65" WEIGHT="300.0" Z="0.08607830226901667">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2481847418628311" CI_START="0.06540109834974692" DF="0" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="0.09627886934782945" LOG_CI_START="-1.1844149580483807" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2010-05-08 23:19:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09585788348665068" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.6652751020650962">
<NAME>

Second-generation antipsychotics: Aripiprazole</NAME>
<DICH_DATA CI_END="1.2481847418628311" CI_START="0.06540109834974692" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.09627886934782945" LOG_CI_START="-1.1844149580483807" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2008-09-25 13:35:54 +0100" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.7522858937492222" STUDY_ID="STD-Nickel-2006" TOTAL_1="26" TOTAL_2="26" VAR="0.5659340659340659" WEIGHT="100.0">
<FOOTNOTE>event: self-injury during treatment</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.883036552964966" CI_START="0.4994733759164719" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="0.45985014868385343" LOG_CI_START="-0.3014876565886039" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2010-05-08 23:20:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6835061309928883" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="0.407683394754871">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="2.883036552964966" CI_START="0.4994733759164719" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.45985014868385343" LOG_CI_START="-0.3014876565886039" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2008-09-25 14:34:46 +0100" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.44721359549995804" STUDY_ID="STD-Linehan-2008" TOTAL_1="12" TOTAL_2="12" VAR="0.20000000000000007" WEIGHT="100.0">
<FOOTNOTE>event: intentional self-injury during last week (week 21)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.969372532719322" CI_START="0.5072446553979795" DF="0" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="0.4726646869038982" LOG_CI_START="-0.2947825202303361" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2010-05-08 23:20:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6496210063321841" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="27" WEIGHT="100.0" Z="0.4542887601011906">
<NAME>

Miscellaneous: Omega-3 fatty acids</NAME>
<DICH_DATA CI_END="2.969372532719322" CI_START="0.5072446553979795" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4726646869038982" LOG_CI_START="-0.2947825202303361" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2008-09-25 14:35:34 +0100" MODIFIED_BY="[Empty name]" ORDER="645" O_E="0.0" SE="0.4508022883955928" STUDY_ID="STD-Hallahan-2007" TOTAL_1="22" TOTAL_2="27" VAR="0.2032227032227032" WEIGHT="100.0">
<FOOTNOTE>event: self-harm during treatment</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9154405434139015" CI_START="-0.8465969057007567" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.034421818856572396" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2010-05-08 23:20:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9389602783571566" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="9" TOTAL_2="11" UNITS="" WEIGHT="100.0" Z="0.07657672119868042">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9154405434139015" CI_START="-0.8465969057007567" DF="0" EFFECT_SIZE="0.034421818856572396" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.01" MODIFIED="2010-05-08 23:20:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9389602783571566" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0" Z="0.07657672119868042">
<NAME>

Antidepressants: Fluoxetine</NAME>
<CONT_DATA CI_END="0.9154405434139015" CI_START="-0.8465969057007567" EFFECT_SIZE="0.034421818856572396" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="6.55" MODIFIED="2008-09-01 16:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="615" SD_1="12.37" SD_2="12.64" SE="0.44950760907174436" STUDY_ID="STD-Simpson-2004" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2010-05-12 12:09:06 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Active drug versus placebo: Affective instability</NAME>
<CONT_OUTCOME CHI2="1.655028054344396" CI_END="0.09700533859112292" CI_START="-0.7041909365576053" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3035927989832412" ESTIMABLE="YES" I2="39.57806350321182" I2_Q="39.57806350321182" ID="CMP-009.01" MODIFIED="2010-05-08 23:21:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1982760345411262" P_Q="0.1982760345411262" P_Z="0.13744947549769054" Q="1.655028054344396" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0584262486096949" TOTALS="SUB" TOTAL_1="50" TOTAL_2="48" UNITS="" WEIGHT="200.0" Z="1.4853562614539213">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4061400371220719" CI_START="-0.6066613520417811" DF="0" EFFECT_SIZE="-0.10026065745985455" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.01" MODIFIED="2010-05-08 23:21:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6979812426051388" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.38804701452839474">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.4061400371220719" CI_START="-0.6066613520417811" EFFECT_SIZE="-0.10026065745985455" ESTIMABLE="YES" MEAN_1="4.44" MEAN_2="4.53" MODIFIED="2008-08-28 15:06:14 +0100" MODIFIED_BY="[Empty name]" ORDER="452" SD_1="0.6" SD_2="1.1" SE="0.2583724489716906" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.011239247129312235" CI_START="-1.2984907319929322" DF="0" EFFECT_SIZE="-0.64362574243181" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.02" MODIFIED="2010-05-08 23:21:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.054063715455027604" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="1.926325723313782">
<NAME>

Antidepressants: Fluvoxamine</NAME>
<CONT_DATA CI_END="0.011239247129312235" CI_START="-1.2984907319929322" EFFECT_SIZE="-0.64362574243181" ESTIMABLE="YES" MEAN_1="4.17" MEAN_2="5.83" MODIFIED="2008-09-01 16:30:50 +0100" MODIFIED_BY="[Empty name]" ORDER="622" SD_1="2.64" SD_2="2.39" SE="0.33412093014290756" STUDY_ID="STD-Rinne-2002" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.9038832278184576" CI_END="-0.026011193768484514" CI_START="-0.33270797305169975" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.17935958341009214" ESTIMABLE="YES" I2="0.0" I2_Q="17.329860112183688" ID="CMP-009.02" MODIFIED="2010-05-08 23:21:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5925939449708492" P_Q="0.2714061540344953" P_Z="0.021881641437631306" Q="1.209626597169188" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="325" TOTAL_2="333" UNITS="" WEIGHT="200.0" Z="2.292416142011487">
<NAME>SMD on basis of change from baseline scores</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6942566306492697" CI_END="-0.005676627359455649" CI_START="-0.3184925484506438" DF="2" EFFECT_SIZE="-0.16208458790504973" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.01" MODIFIED="2010-05-08 23:21:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7067147291255522" P_Z="0.04224501612462021" STUDIES="3" TAU2="0.0" TOTAL_1="310" TOTAL_2="321" WEIGHT="99.99999999999999" Z="2.0310983765452773">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.2657838042769963" CI_START="-1.079596634784771" EFFECT_SIZE="-0.40690641525388727" ESTIMABLE="YES" MEAN_1="-1.875" MEAN_2="-1.0526" MODIFIED="2008-08-29 13:25:16 +0100" MODIFIED_BY="[Empty name]" ORDER="485" SD_1="2.06155" SD_2="1.89952" SE="0.3432156023462565" STUDY_ID="STD-Bogenschutz-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="5.406142381974918"/>
<CONT_DATA CI_END="0.10823893582938718" CI_START="-0.3411153939229128" EFFECT_SIZE="-0.11643822904676282" ESTIMABLE="YES" MEAN_1="-0.93" MEAN_2="-0.78" MODIFIED="2008-08-29 14:14:42 +0100" MODIFIED_BY="[Empty name]" ORDER="497" SD_1="1.33" SD_2="1.24" SE="0.11463331298349091" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="48.46183295246294"/>
<CONT_DATA CI_END="0.048934802062880756" CI_START="-0.4116266556638252" EFFECT_SIZE="-0.18134592680047223" ESTIMABLE="YES" MEAN_1="-1.29" MEAN_2="-1.07" MODIFIED="2008-08-29 17:15:22 +0100" MODIFIED_BY="[Empty name]" ORDER="544" SD_1="1.21" SD_2="1.21" SE="0.11749232673650026" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="46.13202466556213"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.17110557893045908" CI_START="-1.387110560094127" DF="0" EFFECT_SIZE="-0.608002490581834" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.02" MODIFIED="2010-05-08 23:21:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.12613507309387123" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0" Z="1.529522065914433">
<NAME>

Mood stabiliz
ers: 
Lamotrigine</NAME>
<CONT_DATA CI_END="0.17110557893045908" CI_START="-1.387110560094127" EFFECT_SIZE="-0.608002490581834" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.8" MODIFIED="2009-10-23 17:21:13 +0100" MODIFIED_BY="[Empty name]" ORDER="322" SD_1="1.2" SD_2="1.0" SE="0.39751142146376056" STUDY_ID="STD-Reich-2009" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2010-05-12 12:09:17 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Active drug versus placebo: Chronic feelings of emptiness</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6919186226749596" CI_START="-0.3225095514183063" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.18470453562832664" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.01" MODIFIED="2010-05-08 23:22:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4753937580921991" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.7137306452204908">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6919186226749596" CI_START="-0.3225095514183063" DF="0" EFFECT_SIZE="0.18470453562832664" ESTIMABLE="YES" I2="0.0" ID="CMP-010.01.01" MODIFIED="2010-05-08 23:22:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4753937580921991" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7137306452204908">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.6919186226749596" CI_START="-0.3225095514183063" EFFECT_SIZE="0.18470453562832667" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="4.4" MODIFIED="2008-08-28 15:07:25 +0100" MODIFIED_BY="[Empty name]" ORDER="453" SD_1="1.5" SD_2="1.7" SE="0.2587874527529449" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.5901022769784428" CI_END="0.1635633069578285" CI_START="-0.21569155486534003" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.026064123953755774" ESTIMABLE="YES" I2="22.782972017106726" I2_Q="0.0" ID="CMP-010.02" MODIFIED="2010-05-08 23:22:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.27388399000239716" P_Q="1.0" P_Z="0.7876254801539435" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.006816897470185853" TOTALS="SUB" TOTAL_1="310" TOTAL_2="321" UNITS="" WEIGHT="100.0" Z="0.26939532952786677">
<NAME>SMD on basis of change from baseline scores</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.5901022769784428" CI_END="0.1635633069578285" CI_START="-0.21569155486534003" DF="2" EFFECT_SIZE="-0.026064123953755774" ESTIMABLE="YES" I2="22.782972017106726" ID="CMP-010.02.01" MODIFIED="2010-05-08 23:22:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.27388399000239716" P_Z="0.7876254801539435" STUDIES="3" TAU2="0.006816897470185853" TOTAL_1="310" TOTAL_2="321" WEIGHT="100.0" Z="0.26939532952786677">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.5259413769815692" CI_START="-0.8059525633767163" EFFECT_SIZE="-0.14000559319757358" ESTIMABLE="YES" MEAN_1="-1.6875" MEAN_2="-1.4211" MODIFIED="2008-08-29 13:25:58 +0100" MODIFIED_BY="[Empty name]" ORDER="486" SD_1="2.12034" SD_2="1.60955" SE="0.3397751057835998" STUDY_ID="STD-Bogenschutz-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="7.656097743635584"/>
<CONT_DATA CI_END="0.3347523115371409" CI_START="-0.11456121637235857" EFFECT_SIZE="0.11009554758239117" ESTIMABLE="YES" MEAN_1="-0.69" MEAN_2="-0.85" MODIFIED="2008-08-29 14:15:19 +0100" MODIFIED_BY="[Empty name]" ORDER="498" SD_1="1.35" SD_2="1.54" SE="0.11462290415885884" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="46.90808605660402"/>
<CONT_DATA CI_END="0.08268242975410814" CI_START="-0.3775549717236897" EFFECT_SIZE="-0.14743627098479078" ESTIMABLE="YES" MEAN_1="-0.99" MEAN_2="-0.78" MODIFIED="2008-08-29 17:15:58 +0100" MODIFIED_BY="[Empty name]" ORDER="545" SD_1="1.48" SD_2="1.36" SE="0.11740965780700353" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="45.435816199760396"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2010-05-12 15:04:51 +0100" MODIFIED_BY="Chris Champion" NO="11">
<NAME>Active drug versus placebo: Anger</NAME>
<CONT_OUTCOME CHI2="78.20376165490534" CI_END="-0.48601964942520054" CI_START="-0.8243956799751282" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6552076647001643" ESTIMABLE="YES" I2="82.098047838442" I2_Q="84.46389000391565" ID="CMP-011.01" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="6.084921455595804E-11" P_Q="1.3834045020644226E-11" P_Z="3.1922925581751535E-14" Q="77.23941194433112" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.521961665954659" TOTALS="SUB" TOTAL_1="338" TOTAL_2="286" UNITS="" WEIGHT="1300.0" Z="7.590274187683255">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7924351592586937" CI_END="-0.08930580583990061" CI_START="-0.8356739251214218" DF="1" EFFECT_SIZE="-0.46248986548066123" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.01" MODIFIED="2010-05-08 23:22:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3733648496072036" P_Z="0.015140599623895917" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="56" WEIGHT="100.0" Z="2.428998388702514">
<NAME>

First-generation antipsychotics: Haloperidol</NAME>
<CONT_DATA CI_END="-0.10050404114065625" CI_START="-1.1764794561200325" EFFECT_SIZE="-0.6384917486303444" ESTIMABLE="YES" MEAN_1="0.78" MEAN_2="1.39" MODIFIED="2008-08-28 12:44:48 +0100" MODIFIED_BY="[Empty name]" ORDER="412" SD_1="0.82" SD_2="1.05" SE="0.2744885680212833" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="28" WEIGHT="48.11732378321528"/>
<CONT_DATA CI_END="0.2188367732916322" CI_START="-0.8173591888059472" EFFECT_SIZE="-0.2992612077571575" ESTIMABLE="YES" MEAN_1="0.79" MEAN_2="1.04" MODIFIED="2008-08-28 12:17:44 +0100" MODIFIED_BY="[Empty name]" ORDER="402" SD_1="0.66" SD_2="0.97" SE="0.2643405619365868" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="28" WEIGHT="51.88267621678473"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5543914479623239" CI_START="-1.7339073523115829" DF="0" EFFECT_SIZE="-1.1441494001369534" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.02" MODIFIED="2010-05-08 23:23:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.4330505877875087E-4" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="3.8023931833945426">
<NAME>

Second-generation antipsychotics: Aripiprazole</NAME>
<CONT_DATA CI_END="-0.5543914479623239" CI_START="-1.7339073523115829" EFFECT_SIZE="-1.1441494001369534" ESTIMABLE="YES" MEAN_1="64.6" MEAN_2="73.1" MODIFIED="2008-08-28 14:33:26 +0100" MODIFIED_BY="[Empty name]" ORDER="429" SD_1="6.8" SD_2="7.8" SE="0.30090244352782247" STUDY_ID="STD-Nickel-2006" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5819549171972664" CI_START="-0.4305540362819413" DF="0" EFFECT_SIZE="0.07570044045766261" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.03" MODIFIED="2010-05-08 23:23:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7694654203244217" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.2930742220125649">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.5819549171972664" CI_START="-0.4305540362819413" EFFECT_SIZE="0.07570044045766261" ESTIMABLE="YES" MEAN_1="3.66" MEAN_2="3.56" MODIFIED="2008-08-28 15:09:39 +0100" MODIFIED_BY="[Empty name]" ORDER="455" SD_1="1.4" SD_2="1.2" SE="0.2582978466608951" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5669172636046149" CI_START="-1.2506415685056542" DF="0" EFFECT_SIZE="-0.34186215245051965" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.04" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.46094365567149753" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.00000000000001" Z="0.7372938852300212">
<NAME>

Mood stabiliser: Carbamazepine</NAME>
<CONT_DATA CI_END="0.5669172636046149" CI_START="-1.2506415685056542" EFFECT_SIZE="-0.34186215245051965" ESTIMABLE="YES" MEAN_1="5.57" MEAN_2="8.33" MODIFIED="2008-08-29 22:07:33 +0100" MODIFIED_BY="[Empty name]" ORDER="556" SD_1="8.46" SD_2="6.98" SE="0.4636714874474585" STUDY_ID="STD-De-la-Fuente-1994" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6147845845785347" CI_START="-0.905446362103749" DF="0" EFFECT_SIZE="-0.1453308887626072" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.05" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.7078561553840451" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0" Z="0.37473688907273245">
<NAME>

Mood stabiliser: Valproate 
semisodium</NAME>
<CONT_DATA CI_END="0.6147845845785347" CI_START="-0.905446362103749" EFFECT_SIZE="-0.1453308887626072" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.6" MODIFIED="2008-09-11 14:55:18 +0100" MODIFIED_BY="[Empty name]" ORDER="565" SD_1="0.7" SD_2="0.6" SE="0.3878211433153036" STUDY_ID="STD-Frankenburg-2002" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0">
<FOOTNOTE>Frankenburg 2002 and Hollander 2001 were not pooled, as heterogeneity seemed considerable (I<SUP>2</SUP> 78%), and could not definitely be explained.</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.481527675675101" CI_START="-3.17418247691964" DF="0" EFFECT_SIZE="-1.8278550762973704" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.06" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.00779170513930269" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="4" WEIGHT="100.0" Z="2.6609650199837884">
<NAME>

Mood stabiliser: Valproate 
semisodium</NAME>
<CONT_DATA CI_END="-0.481527675675101" CI_START="-3.17418247691964" EFFECT_SIZE="-1.8278550762973704" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="5.7" MODIFIED="2008-09-11 14:49:12 +0100" MODIFIED_BY="[Empty name]" ORDER="639" SD_1="1.9" SD_2="0.6" SE="0.6869143572238715" STUDY_ID="STD-Hollander-2001" TOTAL_1="12" TOTAL_2="4" WEIGHT="100.0">
<FOOTNOTE>cf. to (1)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7506392744857608" CI_START="-2.6240141706978157" DF="0" EFFECT_SIZE="-1.6873267225917883" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.07" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="4.1456654562604896E-4" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="9" WEIGHT="100.0" Z="3.5306329908859504">
<NAME>

Mood stabiliser: Lamotrigine</NAME>
<CONT_DATA CI_END="-0.7506392744857608" CI_START="-2.6240141706978157" EFFECT_SIZE="-1.6873267225917883" ESTIMABLE="YES" MEAN_1="22.1" MEAN_2="27.9" MODIFIED="2008-09-01 09:06:00 +0100" MODIFIED_BY="[Empty name]" ORDER="576" SD_1="3.2" SD_2="3.6" SE="0.47791054095610863" STUDY_ID="STD-Tritt-2005" TOTAL_1="18" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.17191455131551092" CI_END="-2.3574490085468964" CI_START="-3.6404260448654933" DF="1" EFFECT_SIZE="-2.998937526706195" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.08" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6784161456476925" P_Z="5.058354793833825E-20" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="38" WEIGHT="100.0" Z="9.16276656220705">
<NAME>

Mood stabiliser: Topiramate (females)</NAME>
<CONT_DATA CI_END="-2.304756806458423" CI_START="-3.8901444026382714" EFFECT_SIZE="-3.097450604548347" ESTIMABLE="YES" MEAN_1="66.5" MEAN_2="75.8" MODIFIED="2008-09-11 14:58:18 +0100" MODIFIED_BY="[Empty name]" ORDER="581" SD_1="2.7" SD_2="3.2" SE="0.40444304300619394" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="65.48877309760097">
<FOOTNOTE>For Topiramate, data were analysed for male and female samples separately (I<SUP>2 </SUP>of all three estimates 93%).</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-1.7200334193275346" CI_START="-3.9039632657384367" EFFECT_SIZE="-2.8119983425329855" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="27.6" MODIFIED="2008-09-11 14:52:01 +0100" MODIFIED_BY="[Empty name]" ORDER="595" SD_1="2.0" SD_2="1.8" SE="0.5571351983091173" STUDY_ID="STD-Nickel-2004" TOTAL_1="19" TOTAL_2="10" WEIGHT="34.511226902399024">
<FOOTNOTE>cf. to (3)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.026291220279406335" CI_START="-1.272004933158337" DF="0" EFFECT_SIZE="-0.6491480767188716" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.09" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.041082598014721625" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="20" WEIGHT="100.00000000000001" Z="2.0426954248774276">
<NAME>

Mood stabiliser: Topiramate (males)</NAME>
<CONT_DATA CI_END="-0.026291220279406335" CI_START="-1.272004933158337" EFFECT_SIZE="-0.6491480767188716" ESTIMABLE="YES" MEAN_1="26.0" MEAN_2="27.6" MODIFIED="2008-09-11 14:52:10 +0100" MODIFIED_BY="[Empty name]" ORDER="637" SD_1="2.6" SD_2="2.2" SE="0.3177899498932025" STUDY_ID="STD-Nickel-2005" TOTAL_1="22" TOTAL_2="20" WEIGHT="100.00000000000001">
<FOOTNOTE>cf. to (3)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2630249385359086" CI_START="-0.7802000727746071" DF="0" EFFECT_SIZE="-0.25858756711934927" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.10" MODIFIED="2010-05-08 23:24:32 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.33122707061116485" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0" Z="0.9716452594768223">
<NAME>

Antidepressants: Amitriptyline</NAME>
<CONT_DATA CI_END="0.2630249385359086" CI_START="-0.7802000727746071" EFFECT_SIZE="-0.25858756711934927" ESTIMABLE="YES" MEAN_1="1.12" MEAN_2="1.39" MODIFIED="2008-09-01 14:12:29 +0100" MODIFIED_BY="[Empty name]" ORDER="603" SD_1="1.01" SD_2="1.05" SE="0.2661337196854997" STUDY_ID="STD-Soloff-1989" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2229237499622928" CI_START="-1.5294604684231388" DF="0" EFFECT_SIZE="-0.653268359230423" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.11" MODIFIED="2010-05-08 23:24:40 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.14393221346194007" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="9" WEIGHT="100.0" Z="1.4613033407832108">
<NAME>

Antidepressants: Fluoxetine</NAME>
<CONT_DATA CI_END="0.2229237499622927" CI_START="-1.5294604684231388" EFFECT_SIZE="-0.653268359230423" ESTIMABLE="YES" MEAN_1="40.31" MEAN_2="44.89" MODIFIED="2008-09-01 15:50:38 +0100" MODIFIED_BY="[Empty name]" ORDER="610" SD_1="5.07" SD_2="8.67" SE="0.4470450049613193" STUDY_ID="STD-Salzman-1995" TOTAL_1="13" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2772202939469626" CI_START="-1.0081100759201347" DF="0" EFFECT_SIZE="-0.365444890986586" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.12" MODIFIED="2010-05-08 23:24:47 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.2650591075031107" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="1.1145131889195707">
<NAME>

Antidepressants: Fluvoxamine</NAME>
<CONT_DATA CI_END="0.2772202939469626" CI_START="-1.0081100759201347" EFFECT_SIZE="-0.365444890986586" ESTIMABLE="YES" MEAN_1="1.59" MEAN_2="2.49" MODIFIED="2008-09-01 16:31:45 +0100" MODIFIED_BY="[Empty name]" ORDER="623" SD_1="2.0" SD_2="2.8" SE="0.3278964256500678" STUDY_ID="STD-Rinne-2002" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.16606028472332224" CI_START="-0.8418201721289523" DF="0" EFFECT_SIZE="-0.33787994370281504" ESTIMABLE="YES" I2="0.0" ID="CMP-011.01.13" MODIFIED="2010-05-08 23:24:57 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Z="0.1888094383276947" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0" Z="1.3141092601877928">
<NAME>

Antidepressants: Phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.16606028472332224" CI_START="-0.8418201721289523" EFFECT_SIZE="-0.33787994370281504" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="1.04" MODIFIED="2008-09-01 16:42:34 +0100" MODIFIED_BY="[Empty name]" ORDER="628" SD_1="0.85" SD_2="0.97" SE="0.25711708602869926" STUDY_ID="STD-Soloff-1993" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4829180446102202" CI_START="-0.6270835290901451" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.07208274223996243" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.02" MODIFIED="2010-05-08 23:25:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.7990649357412458" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="0.2545574385561143">
<NAME>SMD on basis of post-
means and pre-
SDs</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4829180446102202" CI_START="-0.6270835290901451" DF="0" EFFECT_SIZE="-0.07208274223996243" ESTIMABLE="YES" I2="0.0" ID="CMP-011.02.01" MODIFIED="2010-05-08 23:25:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7990649357412458" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0" Z="0.2545574385561143">
<NAME>

First-generation antipsychotics: Thiothixene</NAME>
<CONT_DATA CI_END="0.4829180446102202" CI_START="-0.6270835290901451" EFFECT_SIZE="-0.07208274223996243" ESTIMABLE="YES" MEAN_1="0.6167" MEAN_2="0.6769" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="456" SD_1="0.695" SD_2="0.9236" SE="0.2831688700547347" STUDY_ID="STD-Goldberg-1986" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2798451981161918" CI_END="-0.1153914422347046" CI_START="-0.4292528420878648" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2723221421612847" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.03" MODIFIED="2010-05-08 23:25:34 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.527333266478891" P_Q="1.0" P_Z="6.710809462665126E-4" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="310" TOTAL_2="321" UNITS="" WEIGHT="100.0" Z="3.4011292314290658">
<NAME>SMD on basis of change from baseline scores</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2798451981161918" CI_END="-0.1153914422347046" CI_START="-0.4292528420878648" DF="2" EFFECT_SIZE="-0.2723221421612847" ESTIMABLE="YES" I2="0.0" ID="CMP-011.03.01" MODIFIED="2010-05-08 23:25:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.527333266478891" P_Z="6.710809462665126E-4" STUDIES="3" TAU2="0.0" TOTAL_1="310" TOTAL_2="321" WEIGHT="100.0" Z="3.4011292314290658">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.030486330542012663" CI_START="-1.3387989310051023" EFFECT_SIZE="-0.6541563002315448" ESTIMABLE="YES" MEAN_1="-2.1875" MEAN_2="-1.1053" MODIFIED="2008-08-29 13:27:32 +0100" MODIFIED_BY="[Empty name]" ORDER="487" SD_1="1.68201" SD_2="1.55973" SE="0.34931388340496616" STUDY_ID="STD-Bogenschutz-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="5.253974342645559"/>
<CONT_DATA CI_END="-0.014857998990943921" CI_START="-0.46546339019333083" EFFECT_SIZE="-0.24016069459213737" ESTIMABLE="YES" MEAN_1="-0.91" MEAN_2="-0.61" MODIFIED="2008-08-29 14:15:57 +0100" MODIFIED_BY="[Empty name]" ORDER="499" SD_1="1.21" SD_2="1.28" SE="0.11495246717712793" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="48.51578333456512"/>
<CONT_DATA CI_END="-0.0318741132472615" CI_START="-0.49348370294289556" EFFECT_SIZE="-0.26267890809507854" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.81" MODIFIED="2008-08-29 17:16:38 +0100" MODIFIED_BY="[Empty name]" ORDER="546" SD_1="1.06" SD_2="1.14" SE="0.11775971225409028" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="46.23024232278933"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2010-05-12 12:09:30 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Active drug versus placebo: Psychotic symptoms</NAME>
<CONT_OUTCOME CHI2="8.30923850916407" CI_END="-0.2557612057644466" CI_START="-0.686861852110993" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4713115289377198" ESTIMABLE="YES" I2="15.756419889983183" I2_Q="0.0" ID="CMP-012.01" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.30611713737080304" P_Q="0.4962664653619243" P_Z="1.8228028221915475E-5" Q="5.378461099499312" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.014994560120159381" TOTALS="SUB" TOTAL_1="214" TOTAL_2="206" UNITS="" WEIGHT="700.0" Z="4.285558975821465">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.930777409664758" CI_END="0.19836023635822198" CI_START="-1.0853159801784087" DF="1" EFFECT_SIZE="-0.44347787191009336" ESTIMABLE="YES" I2="65.87936031230748" ID="CMP-012.01.01" MODIFIED="2010-05-08 23:26:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08690578986655362" P_Z="0.17566090604846696" STUDIES="2" TAU2="0.14134707169791588" TOTAL_1="58" TOTAL_2="56" WEIGHT="100.0" Z="1.3542365990535543">
<NAME>

First-generation antipsychotics: Haloperidol</NAME>
<CONT_DATA CI_END="-0.2324727356988926" CI_START="-1.3218262841470256" EFFECT_SIZE="-0.7771495099229592" ESTIMABLE="YES" MEAN_1="0.75" MEAN_2="1.44" MODIFIED="2008-08-28 12:45:21 +0100" MODIFIED_BY="[Empty name]" ORDER="413" SD_1="0.73" SD_2="1.0" SE="0.2779014198834302" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="28" WEIGHT="49.06274063032877"/>
<CONT_DATA CI_END="0.3934463782008668" CI_START="-0.6376174400768333" EFFECT_SIZE="-0.12208553093798327" ESTIMABLE="YES" MEAN_1="1.06" MEAN_2="1.18" MODIFIED="2008-08-28 12:25:38 +0100" MODIFIED_BY="[Empty name]" ORDER="403" SD_1="0.96" SD_2="0.98" SE="0.2630313175166993" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="28" WEIGHT="50.937259369671224"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.47191028171079585" CI_START="-1.6380629555139046" DF="0" EFFECT_SIZE="-1.0549866186123502" ESTIMABLE="YES" I2="0.0" ID="CMP-012.01.02" MODIFIED="2010-05-08 23:26:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.907519611775679E-4" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="3.546252258563211">
<NAME>

Second-generation antipsychotics: Aripiprazole</NAME>
<CONT_DATA CI_END="-0.47191028171079585" CI_START="-1.6380629555139046" EFFECT_SIZE="-1.0549866186123502" ESTIMABLE="YES" MEAN_1="60.2" MEAN_2="68.3" MODIFIED="2008-08-28 14:35:55 +0100" MODIFIED_BY="[Empty name]" ORDER="432" SD_1="5.1" SD_2="9.4" SE="0.29749339350150616" STUDY_ID="STD-Nickel-2006" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.27635694028876" CI_START="-0.7393864686782761" DF="0" EFFECT_SIZE="-0.23151476419475803" ESTIMABLE="YES" I2="0.0" ID="CMP-012.01.03" MODIFIED="2010-05-08 23:26:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.3716134794845143" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.8934551692980464">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.27635694028876" CI_START="-0.7393864686782761" EFFECT_SIZE="-0.23151476419475803" ESTIMABLE="YES" MEAN_1="1.96" MEAN_2="2.23" MODIFIED="2008-08-28 15:10:41 +0100" MODIFIED_BY="[Empty name]" ORDER="457" SD_1="1.2" SD_2="1.1" SE="0.259122978018752" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.346655457116112" CI_START="-1.5010042140951192" DF="0" EFFECT_SIZE="-0.5771743784895036" ESTIMABLE="YES" I2="0.0" ID="CMP-012.01.04" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.22075905305372423" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0" Z="1.2245122976539646">
<NAME>

Mood stabiliser: Carbamazepine</NAME>
<CONT_DATA CI_END="0.346655457116112" CI_START="-1.5010042140951192" EFFECT_SIZE="-0.5771743784895036" ESTIMABLE="YES" MEAN_1="4.85" MEAN_2="9.22" MODIFIED="2008-08-29 22:11:14 +0100" MODIFIED_BY="[Empty name]" ORDER="557" SD_1="7.4" SD_2="7.08" SE="0.47135041403447586" STUDY_ID="STD-De-la-Fuente-1994" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.04585907681505369" CI_START="-1.0183068651487452" DF="0" EFFECT_SIZE="-0.4862238941668458" ESTIMABLE="YES" I2="0.0" ID="CMP-012.01.05" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.0732870462190557" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="1.7910389412222918">
<NAME>

Mood stabiliser: Topiramate</NAME>
<CONT_DATA CI_END="0.04585907681505369" CI_START="-1.0183068651487452" EFFECT_SIZE="-0.4862238941668458" ESTIMABLE="YES" MEAN_1="67.5" MEAN_2="71.1" MODIFIED="2008-09-01 12:55:27 +0100" MODIFIED_BY="[Empty name]" ORDER="582" SD_1="7.2" SD_2="7.4" SE="0.2714758919954153" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.09163095082997019" CI_START="-0.9600025017409204" DF="0" EFFECT_SIZE="-0.4341857754554751" ESTIMABLE="YES" I2="0.0" ID="CMP-012.01.06" MODIFIED="2010-05-08 23:26:51 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.10557368079302568" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0" Z="1.6184127281458103">
<NAME>

Antidepressants: Amitriptyline</NAME>
<CONT_DATA CI_END="0.09163095082997019" CI_START="-0.9600025017409204" EFFECT_SIZE="-0.4341857754554751" ESTIMABLE="YES" MEAN_1="1.03" MEAN_2="1.44" MODIFIED="2008-09-01 14:13:30 +0100" MODIFIED_BY="[Empty name]" ORDER="604" SD_1="0.86" SD_2="1.0" SE="0.26827876962690156" STUDY_ID="STD-Soloff-1989" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.22402161097226286" CI_START="-0.7814613432317976" DF="0" EFFECT_SIZE="-0.27871986612976735" ESTIMABLE="YES" I2="0.0" ID="CMP-012.01.07" MODIFIED="2010-05-08 23:27:01 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.27721187382449985" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0" Z="1.0866039988168767">
<NAME>

Antidepressants: Phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.22402161097226286" CI_START="-0.7814613432317976" EFFECT_SIZE="-0.27871986612976735" ESTIMABLE="YES" MEAN_1="0.92" MEAN_2="1.18" MODIFIED="2008-09-01 16:43:30 +0100" MODIFIED_BY="[Empty name]" ORDER="629" SD_1="0.87" SD_2="0.98" SE="0.25650546697163357" STUDY_ID="STD-Soloff-1993" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7468222284505084" CI_START="-0.3655175518415681" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.19065233830447018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.02" MODIFIED="2010-05-08 23:27:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5016689231277112" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="0.6718661388644928">
<NAME>SMD on basis of post-
means and pre-
SDs</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7468222284505084" CI_START="-0.3655175518415681" DF="0" EFFECT_SIZE="0.19065233830447018" ESTIMABLE="YES" I2="0.0" ID="CMP-012.02.01" MODIFIED="2010-05-08 23:27:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5016689231277112" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0" Z="0.6718661388644928">
<NAME>

First-generation antipsychotics: Thiothixene</NAME>
<CONT_DATA CI_END="0.7468222284505084" CI_START="-0.3655175518415681" EFFECT_SIZE="0.19065233830447018" ESTIMABLE="YES" MEAN_1="2.0313" MEAN_2="1.8654" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="457" SD_1="0.9019" SD_2="0.8125" SE="0.28376536228881516" STUDY_ID="STD-Goldberg-1986" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2038546234664746" CI_END="-0.027060029425637705" CI_START="-0.34006864314751273" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.18356433628657523" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-012.03" MODIFIED="2010-05-08 23:27:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5477551743858926" P_Q="1.0" P_Z="0.021513617379307327" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="310" TOTAL_2="321" UNITS="" WEIGHT="100.0" Z="2.298847202252203">
<NAME>SMD on basis of change from baseline scores</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2038546234664746" CI_END="-0.027060029425637705" CI_START="-0.34006864314751273" DF="2" EFFECT_SIZE="-0.18356433628657523" ESTIMABLE="YES" I2="0.0" ID="CMP-012.03.01" MODIFIED="2010-05-08 23:27:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5477551743858926" P_Z="0.021513617379307327" STUDIES="3" TAU2="0.0" TOTAL_1="310" TOTAL_2="321" WEIGHT="100.0" Z="2.298847202252203">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.6182503865922586" CI_START="-0.7120265360364728" EFFECT_SIZE="-0.046888074722107105" ESTIMABLE="YES" MEAN_1="-0.8125" MEAN_2="-0.7368" MODIFIED="2009-09-11 13:03:53 +0100" MODIFIED_BY="[Empty name]" ORDER="488" SD_1="1.10868" SD_2="1.88096" SE="0.3393625936807477" STUDY_ID="STD-Bogenschutz-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="5.5364127998187485"/>
<CONT_DATA CI_END="0.11428666042887138" CI_START="-0.3350285918406504" EFFECT_SIZE="-0.11037096570588951" ESTIMABLE="YES" MEAN_1="-0.66" MEAN_2="-0.53" MODIFIED="2008-08-29 14:16:36 +0100" MODIFIED_BY="[Empty name]" ORDER="500" SD_1="1.18" SD_2="1.17" SE="0.11462334405470283" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="48.5299960289768"/>
<CONT_DATA CI_END="-0.04644891824578659" CI_START="-0.5082884336281083" EFFECT_SIZE="-0.2773686759369474" ESTIMABLE="YES" MEAN_1="-0.97" MEAN_2="-0.65" MODIFIED="2008-08-29 17:17:14 +0100" MODIFIED_BY="[Empty name]" ORDER="547" SD_1="1.12" SD_2="1.18" SE="0.1178183678438106" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="45.933591171204455"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2010-05-12 12:09:37 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Active drug versus placebo: Dissociation</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.3173702026991556" CI_START="-0.4687797642947912" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.42429521920218227" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.01" MODIFIED="2010-05-08 23:28:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3517663881779608" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="9" TOTAL_2="11" UNITS="" WEIGHT="100.00000000000001" Z="0.9311685623446009">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3173702026991556" CI_START="-0.4687797642947912" DF="0" EFFECT_SIZE="0.42429521920218227" ESTIMABLE="YES" I2="0.0" ID="CMP-013.01.01" MODIFIED="2010-05-08 23:28:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3517663881779608" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.00000000000001" Z="0.9311685623446009">
<NAME>

Antidepressants: Fluoxetine</NAME>
<CONT_DATA CI_END="1.3173702026991556" CI_START="-0.4687797642947912" EFFECT_SIZE="0.42429521920218227" ESTIMABLE="YES" MEAN_1="18.69" MEAN_2="12.66" MODIFIED="2008-09-01 16:02:46 +0100" MODIFIED_BY="[Empty name]" ORDER="616" SD_1="15.39" SD_2="12.0" SE="0.45565887462291904" STUDY_ID="STD-Simpson-2004" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2010-05-12 12:05:24 +0100" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Active drug versus placebo: Depression</NAME>
<CONT_OUTCOME CHI2="23.415165885328197" CI_END="-0.30370651182935904" CI_START="-0.6664591885981048" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.48508285021373193" ESTIMABLE="YES" I2="40.20969115246663" I2_Q="31.289566247841194" ID="CMP-014.01" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0538407564304606" P_Q="0.14919481611334795" P_Z="1.5898714386506052E-7" Q="14.55383040670415" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.07048916033388516" TOTALS="SUB" TOTAL_1="328" TOTAL_2="291" UNITS="" WEIGHT="1100.0" Z="5.241835425755111">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.350472093066514" CI_END="0.6800257418602265" CI_START="-0.8692354721559563" DF="1" EFFECT_SIZE="-0.09460486514786495" ESTIMABLE="YES" I2="77.01398885896242" ID="CMP-014.01.01" MODIFIED="2010-05-08 23:29:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.036998896671237125" P_Z="0.8108198917001599" STUDIES="2" TAU2="0.24060770892716773" TOTAL_1="58" TOTAL_2="56" WEIGHT="100.0" Z="0.239368450942382">
<NAME>

First-generation antipsychotics: Haloperidol</NAME>
<CONT_DATA CI_END="0.03999127430280747" CI_START="-1.024586699541748" EFFECT_SIZE="-0.4922977126194703" ESTIMABLE="YES" MEAN_1="16.22" MEAN_2="23.04" MODIFIED="2008-09-12 11:12:26 +0100" MODIFIED_BY="[Empty name]" ORDER="414" SD_1="12.32" SD_2="14.88" SE="0.27158100410053726" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="28" WEIGHT="49.68901473272084">
<FOOTNOTE>Despite of the high heterogeneity (I<SUP>2</SUP> 77%), we decided to pool estimates, as clinical heterogeneity was quite low, and the same pattern of more favourable results in the Soloff 1989 study and less favourable results in the Soloff 1993 study was found for several outcomes</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.8162471545291986" CI_START="-0.21990416101586907" EFFECT_SIZE="0.29817149675666477" ESTIMABLE="YES" MEAN_1="23.5" MEAN_2="19.54" MODIFIED="2008-09-12 11:22:41 +0100" MODIFIED_BY="[Empty name]" ORDER="404" SD_1="13.16" SD_2="13.04" SE="0.2643291723006384" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="28" WEIGHT="50.31098526727915">
<FOOTNOTE>cf. to (1)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6494786845831497" CI_START="-1.8456371368202749" DF="0" EFFECT_SIZE="-1.2475579107017123" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.02" MODIFIED="2010-05-08 23:29:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="4.34416734045528E-5" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="99.99999999999999" Z="4.088369010025882">
<NAME>

Second-generation antipsychotics: Aripiprazole</NAME>
<CONT_DATA CI_END="-0.6494786845831497" CI_START="-1.8456371368202749" EFFECT_SIZE="-1.2475579107017123" ESTIMABLE="YES" MEAN_1="13.9" MEAN_2="18.8" MODIFIED="2008-08-28 14:37:45 +0100" MODIFIED_BY="[Empty name]" ORDER="435" SD_1="2.8" SD_2="4.7" SE="0.30514806947277356" STUDY_ID="STD-Nickel-2006" TOTAL_1="26" TOTAL_2="26" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.018840721289229794" CI_END="0.06619341394835782" CI_START="-0.7971912493306181" DF="1" EFFECT_SIZE="-0.36549891769113013" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.03" MODIFIED="2010-05-08 23:29:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8908241023250367" P_Z="0.09702847130005117" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.00000000000001" Z="1.6594334959399524">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.39679465887783605" CI_START="-1.2238428222319437" EFFECT_SIZE="-0.4135240816770538" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="15.4" MODIFIED="2008-08-29 10:37:30 +0100" MODIFIED_BY="[Empty name]" ORDER="460" SD_1="7.2" SD_2="5.8" SE="0.41343552582934207" STUDY_ID="STD-Linehan-2008" TOTAL_1="12" TOTAL_2="12" WEIGHT="28.38160176931117"/>
<CONT_DATA CI_END="0.16364081868523445" CI_START="-0.856574941032084" EFFECT_SIZE="-0.3464670611734248" ESTIMABLE="YES" MEAN_1="13.71" MEAN_2="15.8" MODIFIED="2008-08-29 11:00:31 +0100" MODIFIED_BY="[Empty name]" ORDER="465" SD_1="5.46" SD_2="6.41" SE="0.2602639047871926" STUDY_ID="STD-Soler-2005" TOTAL_1="30" TOTAL_2="30" WEIGHT="71.61839823068884"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.20909894481518126" CI_START="-0.8090971441948258" DF="0" EFFECT_SIZE="-0.29999909968982225" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.04" MODIFIED="2010-05-08 23:29:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.24810718614535598" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.1549591225756795">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.20909894481518126" CI_START="-0.8090971441948258" EFFECT_SIZE="-0.29999909968982225" ESTIMABLE="YES" MEAN_1="14.24" MEAN_2="16.07" MODIFIED="2008-08-28 15:11:58 +0100" MODIFIED_BY="[Empty name]" ORDER="459" SD_1="6.5" SD_2="5.5" SE="0.2597486732004791" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2689204621792092" CI_START="-1.5932213328831748" DF="0" EFFECT_SIZE="-0.6621504353519828" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.05" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.1633571200924295" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0" Z="1.3938691554838618">
<NAME>

Mood stabiliser: Carbamazepine</NAME>
<CONT_DATA CI_END="0.2689204621792092" CI_START="-1.5932213328831748" EFFECT_SIZE="-0.6621504353519828" ESTIMABLE="YES" MEAN_1="12.28" MEAN_2="22.66" MODIFIED="2008-08-29 22:13:01 +0100" MODIFIED_BY="[Empty name]" ORDER="558" SD_1="13.65" SD_2="16.06" SE="0.47504490127132964" STUDY_ID="STD-De-la-Fuente-1994" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.621813900245562" CI_END="-0.005925541373872911" CI_START="-1.3055607767273751" DF="1" EFFECT_SIZE="-0.6557431590506241" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.06" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.4303742326837823" P_Z="0.047947159207572636" STUDIES="2" TAU2="0.0" TOTAL_1="32" TOTAL_2="14" WEIGHT="100.0" Z="1.97783645731667">
<NAME>

Mood stabiliser: Valproate 
semisodium</NAME>
<CONT_DATA CI_END="0.2815299359716744" CI_START="-1.2597023515305747" EFFECT_SIZE="-0.4890862077794501" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.2" MODIFIED="2008-08-29 22:28:07 +0100" MODIFIED_BY="[Empty name]" ORDER="566" SD_1="0.6" SD_2="1.1" SE="0.39317872666520726" STUDY_ID="STD-Frankenburg-2002" TOTAL_1="20" TOTAL_2="10" WEIGHT="71.10608334280614"/>
<CONT_DATA CI_END="0.1430188726400412" CI_START="-2.2747694150305664" EFFECT_SIZE="-1.0658752711952626" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="18.0" MODIFIED="2008-08-29 22:44:54 +0100" MODIFIED_BY="[Empty name]" ORDER="572" SD_1="9.1" SD_2="7.0" SE="0.6167940601821801" STUDY_ID="STD-Hollander-2001" TOTAL_1="12" TOTAL_2="4" WEIGHT="28.89391665719386"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.022770602211376834" CI_START="-1.043046212345959" DF="0" EFFECT_SIZE="-0.5101378050672911" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.07" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.06062551134574029" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="1.876216834690251">
<NAME>

Mood stabiliser: Topiramate</NAME>
<CONT_DATA CI_END="0.022770602211376834" CI_START="-1.043046212345959" EFFECT_SIZE="-0.5101378050672911" ESTIMABLE="YES" MEAN_1="70.3" MEAN_2="72.7" MODIFIED="2008-09-01 12:56:19 +0100" MODIFIED_BY="[Empty name]" ORDER="583" SD_1="5.2" SD_2="4.0" SE="0.27189704070186055" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.05634267050443997" CI_START="-1.1187069971975925" DF="0" EFFECT_SIZE="-0.5875248338510163" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.08" MODIFIED="2010-05-08 23:30:14 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.03016949054608166" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0" Z="2.1678580227844417">
<NAME>

Antidepressants: Amitriptyline</NAME>
<CONT_DATA CI_END="-0.05634267050443997" CI_START="-1.1187069971975925" EFFECT_SIZE="-0.5875248338510163" ESTIMABLE="YES" MEAN_1="15.34" MEAN_2="23.04" MODIFIED="2008-09-01 14:14:41 +0100" MODIFIED_BY="[Empty name]" ORDER="605" SD_1="10.71" SD_2="14.88" SE="0.27101628781777287" STUDY_ID="STD-Soloff-1989" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.87020876402274" CI_END="1.3586942256273145" CI_START="-1.1254609490196743" DF="1" EFFECT_SIZE="0.11661663830382002" ESTIMABLE="YES" I2="74.16160054992515" ID="CMP-014.01.09" MODIFIED="2010-05-08 23:30:22 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.04915046098180176" P_Z="0.8539994746449779" STUDIES="2" TAU2="0.5958188778847296" TOTAL_1="22" TOTAL_2="20" WEIGHT="99.99999999999999" Z="0.18401782095283284">
<NAME>

Antidepressant: Fluoxetine</NAME>
<CONT_DATA CI_END="0.3584736155842082" CI_START="-1.373236019774545" EFFECT_SIZE="-0.5073812020951683" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="6.0" MODIFIED="2008-09-01 15:52:03 +0100" MODIFIED_BY="[Empty name]" ORDER="611" SD_1="3.64" SD_2="4.36" SE="0.44177077972306067" STUDY_ID="STD-Salzman-1995" TOTAL_1="13" TOTAL_2="9" WEIGHT="50.77332457339704"/>
<CONT_DATA CI_END="1.679551934024897" CI_START="-0.15911229586171305" EFFECT_SIZE="0.760219819081592" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="13.91" MODIFIED="2008-09-01 16:03:34 +0100" MODIFIED_BY="[Empty name]" ORDER="617" SD_1="18.04" SD_2="9.54" SE="0.46905561642707694" STUDY_ID="STD-Simpson-2004" TOTAL_1="9" TOTAL_2="11" WEIGHT="49.226675426602945"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.16493461369300177" CI_START="-0.8429969995764351" DF="0" EFFECT_SIZE="-0.3390311929417167" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.10" MODIFIED="2010-05-08 23:30:32 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.18732967928630237" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0" Z="1.3185198659381387">
<NAME>

Antidepressants: Phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.16493461369300177" CI_START="-0.8429969995764351" EFFECT_SIZE="-0.3390311929417167" ESTIMABLE="YES" MEAN_1="15.69" MEAN_2="19.54" MODIFIED="2008-09-01 16:44:24 +0100" MODIFIED_BY="[Empty name]" ORDER="630" SD_1="9.46" SD_2="13.04" SE="0.2571301363749214" STUDY_ID="STD-Soloff-1993" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.46395910430157106" CI_START="-1.1484931931853786" DF="0" EFFECT_SIZE="-0.3422670444419037" ESTIMABLE="YES" I2="0.0" ID="CMP-014.01.11" MODIFIED="2010-05-08 23:30:40 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Z="0.40537330059398313" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="9" WEIGHT="100.00000000000001" Z="0.8320631639728007">
<NAME>

Miscellaneous: Omega-3 fatty acids</NAME>
<CONT_DATA CI_END="0.46395910430157106" CI_START="-1.1484931931853786" EFFECT_SIZE="-0.3422670444419037" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="8.0" MODIFIED="2008-10-13 09:42:57 +0100" MODIFIED_BY="[Empty name]" ORDER="641" SD_1="4.9" SD_2="5.5" SE="0.41134743041345845" STUDY_ID="STD-Zanarini-2003" TOTAL_1="18" TOTAL_2="9" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.679849394477433" CI_START="-0.4309254258202824" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.12446198432857529" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.02" MODIFIED="2010-05-08 23:31:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6604972459717657" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="0.4392267492398034">
<NAME>SMD on basis of post-
means and pre-
SDs</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.679849394477433" CI_START="-0.4309254258202824" DF="0" EFFECT_SIZE="0.12446198432857529" ESTIMABLE="YES" I2="0.0" ID="CMP-014.02.01" MODIFIED="2010-05-08 23:31:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6604972459717657" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0" Z="0.4392267492398034">
<NAME>

First-generation antipsychotics: Thiothixene</NAME>
<CONT_DATA CI_END="0.679849394477433" CI_START="-0.4309254258202824" EFFECT_SIZE="0.12446198432857529" ESTIMABLE="YES" MEAN_1="1.6905" MEAN_2="1.5065" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="458" SD_1="1.398" SD_2="1.5058" SE="0.28336613046447934" STUDY_ID="STD-Goldberg-1986" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.029387865456474368" CI_END="0.9699704512624654" CI_START="-0.1980302790789617" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.3859700860917518" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="-0.013241495681305254" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.41344635322645873" MODIFIED="2010-05-08 23:31:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8638865701655158" P_Q="1.0" P_Z="0.1951979860109304" Q="0.0" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="294" TOTAL_2="302" WEIGHT="100.00000000000001" Z="1.29535444319204">
<NAME>Mean Change Difference</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MCD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.029387865456474368" CI_END="0.9699704512624654" CI_START="-0.1980302790789617" DF="1" EFFECT_SIZE="0.3859700860917518" ESTIMABLE="YES" I2="0.0" ID="CMP-014.03.01" LOG_CI_END="-0.013241495681305254" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.41344635322645873" MODIFIED="2010-05-08 23:31:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8638865701655158" P_Z="0.1951979860109304" STUDIES="2" TAU2="0.0" TOTAL_1="294" TOTAL_2="302" WEIGHT="100.00000000000001" Z="1.29535444319204">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<IV_DATA CI_END="2.4049594826075613" CI_START="-2.004959482607561" EFFECT_SIZE="0.2" ESTIMABLE="YES" ESTIMATE="0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="503" SE="1.125" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="7.014956954124073"/>
<IV_DATA CI_END="1.0056288712228767" CI_START="-0.20562887122287676" EFFECT_SIZE="0.4" ESTIMABLE="YES" ESTIMATE="0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="504" SE="0.309" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="92.98504304587594"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8128532595866589" CI_START="0.28372614799325074" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4802371541501976" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-014.04" LOG_CI_END="-0.0899878483834738" LOG_CI_START="-0.5471006380995" LOG_EFFECT_SIZE="-0.318544243241487" METHOD="MH" MODIFIED="2010-05-08 23:31:20 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.006301874328962047" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="22" TOTAL_2="27" WEIGHT="100.0" Z="2.73164636073184">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8128532595866589" CI_START="0.28372614799325074" DF="0" EFFECT_SIZE="0.4802371541501976" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" I2="0.0" ID="CMP-014.04.01" LOG_CI_END="-0.0899878483834738" LOG_CI_START="-0.5471006380995" LOG_EFFECT_SIZE="-0.318544243241487" MODIFIED="2010-05-08 23:31:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.006301874328962047" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="27" WEIGHT="100.0" Z="2.73164636073184">
<NAME>

Miscellaneous: Omega-3 fatty acid</NAME>
<DICH_DATA CI_END="0.8128532595866589" CI_START="0.2837261479932508" EFFECT_SIZE="0.48023715415019763" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="-0.0899878483834738" LOG_CI_START="-0.5471006380995" LOG_EFFECT_SIZE="-0.31854424324148695" MODIFIED="2008-09-25 14:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="643" O_E="0.0" SE="0.268510315423996" STUDY_ID="STD-Hallahan-2007" TOTAL_1="22" TOTAL_2="27" VAR="0.07209778948909383" WEIGHT="100.0">
<FOOTNOTE>event: no response (at least 50% reduction of BDI score)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2010-05-12 12:09:50 +0100" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Active drug versus placebo: Anxiety</NAME>
<CONT_OUTCOME CHI2="25.609043979535677" CI_END="-0.15645415559689518" CI_START="-0.5499807649583257" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3532174602776104" ESTIMABLE="YES" I2="64.8561656296426" I2_Q="63.133682927718674" ID="CMP-015.01" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.002366406803985588" P_Q="0.005502970179832256" P_Z="4.3414502252291955E-4" Q="21.70002494232048" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.15552944032078517" TOTALS="SUB" TOTAL_1="253" TOTAL_2="247" UNITS="" WEIGHT="900.0" Z="3.51840757085371">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.9090190372151974" CI_END="0.7910680755760233" CI_START="-0.6751229457873176" DF="1" EFFECT_SIZE="0.05797256489435292" ESTIMABLE="YES" I2="74.41813430736309" ID="CMP-015.01.01" MODIFIED="2010-05-08 23:31:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.048027683490207695" P_Z="0.8768274092561882" STUDIES="2" TAU2="0.2082271687043591" TOTAL_1="58" TOTAL_2="56" WEIGHT="100.0" Z="0.15499227266947682">
<NAME>

First-generation antipsychotics: Haloperidol</NAME>
<CONT_DATA CI_END="0.21019944273045899" CI_START="-0.84450620174533" EFFECT_SIZE="-0.3171533795074355" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="1.54" MODIFIED="2008-08-28 12:47:01 +0100" MODIFIED_BY="[Empty name]" ORDER="415" SD_1="0.98" SD_2="1.07" SE="0.26906250645296864" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="28" WEIGHT="49.854404176653325"/>
<CONT_DATA CI_END="0.9523040634704336" CI_START="-0.09046370032013878" EFFECT_SIZE="0.4309201815751474" ESTIMABLE="YES" MEAN_1="1.57" MEAN_2="1.18" MODIFIED="2008-08-28 12:28:22 +0100" MODIFIED_BY="[Empty name]" ORDER="405" SD_1="0.78" SD_2="1.0" SE="0.2660170727665894" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="28" WEIGHT="50.145595823346675"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.4945649540510924E-31" CI_END="-0.16744524281195416" CI_START="-1.2931666356169194" DF="0" EFFECT_SIZE="-0.7303059392144368" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-015.01.02" MODIFIED="2010-05-08 23:32:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.010989484220719062" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.00000000000001" Z="2.543033023454293">
<NAME>

Second-generation antipsychotics: Aripiprazole</NAME>
<CONT_DATA CI_END="-0.16744524281195416" CI_START="-1.2931666356169194" EFFECT_SIZE="-0.7303059392144368" ESTIMABLE="YES" MEAN_1="16.3" MEAN_2="19.5" MODIFIED="2008-08-28 14:38:55 +0100" MODIFIED_BY="[Empty name]" ORDER="438" SD_1="3.5" SD_2="5.0" SE="0.2871791016785287" STUDY_ID="STD-Nickel-2006" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2773127532145798" CI_START="-0.7384003895681508" DF="0" EFFECT_SIZE="-0.2305438181767855" ESTIMABLE="YES" I2="0.0" ID="CMP-015.01.03" MODIFIED="2010-05-08 23:32:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.37360840236292103" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.8897346336326896">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.2773127532145798" CI_START="-0.7384003895681508" EFFECT_SIZE="-0.2305438181767855" ESTIMABLE="YES" MEAN_1="18.43" MEAN_2="19.93" MODIFIED="2008-08-29 11:01:21 +0100" MODIFIED_BY="[Empty name]" ORDER="466" SD_1="5.94" SD_2="6.87" SE="0.2591152569114908" STUDY_ID="STD-Soler-2005" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3878180291455944" CI_START="-0.6252568028352856" DF="0" EFFECT_SIZE="-0.11871938684484563" ESTIMABLE="YES" I2="0.0" ID="CMP-015.01.04" MODIFIED="2010-05-08 23:32:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6459718489971968" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.45936532058071555">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.3878180291455944" CI_START="-0.6252568028352856" EFFECT_SIZE="-0.11871938684484563" ESTIMABLE="YES" MEAN_1="15.79" MEAN_2="16.53" MODIFIED="2008-08-28 15:17:07 +0100" MODIFIED_BY="[Empty name]" ORDER="461" SD_1="6.9" SD_2="5.3" SE="0.25844220607416385" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.40600263361432387" CI_START="-1.431970968735201" DF="0" EFFECT_SIZE="-0.5129841675604385" ESTIMABLE="YES" I2="0.0" ID="CMP-015.01.05" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.2739268710201145" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0" Z="1.0940641277681622">
<NAME>

Mood stabiliser: Carbamazepine</NAME>
<CONT_DATA CI_END="0.40600263361432376" CI_START="-1.4319709687352007" EFFECT_SIZE="-0.5129841675604385" ESTIMABLE="YES" MEAN_1="10.42" MEAN_2="17.44" MODIFIED="2008-08-29 22:13:59 +0100" MODIFIED_BY="[Empty name]" ORDER="559" SD_1="12.5" SD_2="13.56" SE="0.468879432695505" STUDY_ID="STD-De-la-Fuente-1994" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8101749906643696" CI_START="-1.9876109975807994" DF="0" EFFECT_SIZE="-1.3988929941225845" ESTIMABLE="YES" I2="0.0" ID="CMP-015.01.06" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="3.2053267157796393E-6" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="4.657204078353396">
<NAME>

Mood stabiliser: Topiramate</NAME>
<CONT_DATA CI_END="-0.8101749906643696" CI_START="-1.9876109975807994" EFFECT_SIZE="-1.3988929941225845" ESTIMABLE="YES" MEAN_1="63.5" MEAN_2="69.8" MODIFIED="2008-09-01 12:57:02 +0100" MODIFIED_BY="[Empty name]" ORDER="584" SD_1="5.0" SD_2="3.8" SE="0.3003718476981962" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3743378474235072" CI_START="-0.6657148204762003" DF="0" EFFECT_SIZE="-0.1456884865263466" ESTIMABLE="YES" I2="0.0" ID="CMP-015.01.07" MODIFIED="2010-05-08 23:32:47 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.5829398276940367" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0" Z="0.5490956282635552">
<NAME>

Antidepressants: Amitriptyline</NAME>
<CONT_DATA CI_END="0.3743378474235072" CI_START="-0.6657148204762003" EFFECT_SIZE="-0.1456884865263466" ESTIMABLE="YES" MEAN_1="1.39" MEAN_2="1.54" MODIFIED="2008-09-01 14:15:39 +0100" MODIFIED_BY="[Empty name]" ORDER="606" SD_1="0.96" SD_2="1.07" SE="0.2653244335364094" STUDY_ID="STD-Soloff-1989" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0307731942086682" CI_START="-0.7340883614742012" DF="0" EFFECT_SIZE="0.14834241636723347" ESTIMABLE="YES" I2="0.0" ID="CMP-015.01.08" MODIFIED="2010-05-08 23:32:55 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.7417907673519251" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0" Z="0.3294828339630593">
<NAME>

Antidepressants: Fluoxetine</NAME>
<CONT_DATA CI_END="1.0307731942086682" CI_START="-0.7340883614742012" EFFECT_SIZE="0.14834241636723347" ESTIMABLE="YES" MEAN_1="101.33" MEAN_2="96.18" MODIFIED="2008-09-01 16:04:16 +0100" MODIFIED_BY="[Empty name]" ORDER="618" SD_1="38.06" SD_2="28.83" SE="0.45022805765918966" STUDY_ID="STD-Simpson-2004" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.179617812904464E-32" CI_END="0.3559532406604969" CI_START="-0.6457928681991314" DF="0" EFFECT_SIZE="-0.14491981376931723" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-015.01.09" MODIFIED="2010-05-08 23:33:05 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Z="0.5706564096189644" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0" Z="0.5670850390573665">
<NAME>

Antidepressants: Phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.35595324066049694" CI_START="-0.6457928681991313" EFFECT_SIZE="-0.1449198137693172" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="1.18" MODIFIED="2008-09-01 16:45:50 +0100" MODIFIED_BY="[Empty name]" ORDER="631" SD_1="0.78" SD_2="1.0" SE="0.2555521725810458" STUDY_ID="STD-Soloff-1993" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="-0.03380342146869483" CI_START="-0.4061965785313052" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="-0.22" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-015.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-08 23:33:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.020569766253906885" Q="0.0" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="138" TOTAL_2="136" WEIGHT="100.0" Z="2.3157894736842106">
<NAME>Mean Change Difference</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>MCD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.03380342146869483" CI_START="-0.4061965785313052" DF="0" EFFECT_SIZE="-0.22" ESTIMABLE="YES" I2="0.0" ID="CMP-015.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-08 23:33:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.020569766253906885" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="136" WEIGHT="100.0" Z="2.3157894736842106">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<IV_DATA CI_END="-0.03380342146869483" CI_START="-0.4061965785313052" EFFECT_SIZE="-0.22" ESTIMABLE="YES" ESTIMATE="-0.22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="548" SE="0.095" STUDY_ID="STD-Zanarini-2007" TOTAL_1="138" TOTAL_2="136" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2010-05-12 12:09:57 +0100" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Active drug versus placebo: General psychiatric pathology</NAME>
<CONT_OUTCOME CHI2="21.264153056427578" CI_END="-0.34095268385084493" CI_START="-0.7771843146274764" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5590684992391607" ESTIMABLE="YES" I2="67.08074861282054" I2_Q="67.41339583898939" ID="CMP-016.01" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.003398247965174739" P_Q="0.005279998299164257" P_Z="5.067848812407791E-7" Q="18.412473942832346" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1663856906529034" TOTALS="SUB" TOTAL_1="214" TOTAL_2="206" UNITS="" WEIGHT="700.0" Z="5.023726140393908">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.8516791135952326" CI_END="0.5433491254341793" CI_START="-0.706214348630491" DF="1" EFFECT_SIZE="-0.08143261159815586" ESTIMABLE="YES" I2="64.93294090374503" ID="CMP-016.01.01" MODIFIED="2010-05-08 23:33:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09127867500841436" P_Z="0.7983700058192879" STUDIES="2" TAU2="0.13197342144389598" TOTAL_1="58" TOTAL_2="56" WEIGHT="100.0" Z="0.25545718838955744">
<NAME>

First-generation antipsychotics: Haloperidol</NAME>
<CONT_DATA CI_END="0.12660187369979997" CI_START="-0.9324149167180211" EFFECT_SIZE="-0.4029065215091106" ESTIMABLE="YES" MEAN_1="1.02" MEAN_2="1.35" MODIFIED="2008-08-28 12:47:52 +0100" MODIFIED_BY="[Empty name]" ORDER="416" SD_1="0.74" SD_2="0.87" SE="0.2701623087901641" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="28" WEIGHT="49.578004065583215"/>
<CONT_DATA CI_END="0.7515742422597899" CI_START="-0.28225366966671495" EFFECT_SIZE="0.23466028629653748" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.16" MODIFIED="2008-08-28 12:29:20 +0100" MODIFIED_BY="[Empty name]" ORDER="406" SD_1="0.67" SD_2="0.84" SE="0.2637364564046093" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="28" WEIGHT="50.421995934416785"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6695256113421008" CI_START="-1.8693592311457206" DF="0" EFFECT_SIZE="-1.2694424212439106" ESTIMABLE="YES" I2="0.0" ID="CMP-016.01.02" MODIFIED="2010-05-08 23:33:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.3635439156067494E-5" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.00000000000001" Z="4.1473440734101406">
<NAME>

Second-generation antipsychotics: Aripiprazole</NAME>
<CONT_DATA CI_END="-0.6695256113421008" CI_START="-1.8693592311457206" EFFECT_SIZE="-1.2694424212439106" ESTIMABLE="YES" MEAN_1="60.1" MEAN_2="69.4" MODIFIED="2008-08-28 14:40:13 +0100" MODIFIED_BY="[Empty name]" ORDER="441" SD_1="4.2" SD_2="9.3" SE="0.30608562944721285" STUDY_ID="STD-Nickel-2006" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.10449833610641712" CI_START="-0.9187840503921316" DF="0" EFFECT_SIZE="-0.40714285714285725" ESTIMABLE="YES" I2="0.0" ID="CMP-016.01.03" MODIFIED="2010-05-08 23:34:07 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.11884069628106321" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.5596581101982416">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<CONT_DATA CI_END="0.10449833610641712" CI_START="-0.9187840503921316" EFFECT_SIZE="-0.40714285714285725" ESTIMABLE="YES" MEAN_1="2.06" MEAN_2="2.39" MODIFIED="2008-08-28 15:18:58 +0100" MODIFIED_BY="[Empty name]" ORDER="463" SD_1="0.8" SD_2="0.8" SE="0.26104622191276716" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.35661037491457437" CI_START="-1.4893421683692285" DF="0" EFFECT_SIZE="-0.5663658967273271" ESTIMABLE="YES" I2="0.0" ID="CMP-016.01.04" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2290953088862815" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0" Z="1.202692630096102">
<NAME>

Mood stabiliser: Carbamazepine</NAME>
<CONT_DATA CI_END="0.35661037491457437" CI_START="-1.4893421683692285" EFFECT_SIZE="-0.5663658967273271" ESTIMABLE="YES" MEAN_1="71.85" MEAN_2="125.11" MODIFIED="2008-08-29 22:15:08 +0100" MODIFIED_BY="[Empty name]" ORDER="560" SD_1="88.64" SD_2="90.87" SE="0.47091491421384296" STUDY_ID="STD-De-la-Fuente-1994" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.6142599303118768" CI_START="-1.7566010167298292" DF="0" EFFECT_SIZE="-1.185430473520853" ESTIMABLE="YES" I2="0.0" ID="CMP-016.01.05" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="4.746140509940217E-5" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.00000000000001" Z="4.067788617430614">
<NAME>

Mood stabiliser: Topiramate</NAME>
<CONT_DATA CI_END="-0.6142599303118768" CI_START="-1.7566010167298292" EFFECT_SIZE="-1.185430473520853" ESTIMABLE="YES" MEAN_1="64.2" MEAN_2="70.1" MODIFIED="2008-09-01 13:35:37 +0100" MODIFIED_BY="[Empty name]" ORDER="585" SD_1="4.1" SD_2="5.6" SE="0.29141889734418414" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.17896999128020818" CI_START="-0.8678415159514105" DF="0" EFFECT_SIZE="-0.34443576233560114" ESTIMABLE="YES" I2="0.0" ID="CMP-016.01.06" MODIFIED="2010-05-08 23:34:30 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.19712478708890108" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0" Z="1.2897865269950775">
<NAME>

Antidepressants: Amitriptyline</NAME>
<CONT_DATA CI_END="0.17896999128020818" CI_START="-0.8678415159514105" EFFECT_SIZE="-0.34443576233560114" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="1.35" MODIFIED="2008-09-01 14:16:31 +0100" MODIFIED_BY="[Empty name]" ORDER="607" SD_1="0.73" SD_2="0.87" SE="0.26704865892657575" STUDY_ID="STD-Soloff-1989" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2740459839124004" CI_START="-0.7297397627134855" DF="0" EFFECT_SIZE="-0.2278468894005425" ESTIMABLE="YES" I2="0.0" ID="CMP-016.01.07" MODIFIED="2010-05-08 23:34:42 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.37358675924931684" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0" Z="0.8897749319825379">
<NAME>

Antidepressants: Phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.2740459839124004" CI_START="-0.7297397627134855" EFFECT_SIZE="-0.2278468894005425" ESTIMABLE="YES" MEAN_1="0.99" MEAN_2="1.16" MODIFIED="2008-09-01 16:46:40 +0100" MODIFIED_BY="[Empty name]" ORDER="632" SD_1="0.64" SD_2="0.84" SE="0.256072497898844" STUDY_ID="STD-Soloff-1993" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.4980051419891907" CI_END="0.09862131058366955" CI_START="-0.5255901236985737" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.21348440655745207" ESTIMABLE="YES" I2="71.41227758655221" I2_Q="0.0" ID="CMP-016.02" MODIFIED="2010-05-08 23:34:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06144292479863722" P_Q="1.0" P_Z="0.18003701034718686" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.03621862139701072" TOTALS="SUB" TOTAL_1="280" TOTAL_2="277" UNITS="" WEIGHT="100.0" Z="1.3406410877257953">
<NAME>SMD on basis of change from baseline scores</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.4980051419891907" CI_END="0.09862131058366955" CI_START="-0.5255901236985737" DF="1" EFFECT_SIZE="-0.21348440655745207" ESTIMABLE="YES" I2="71.41227758655221" ID="CMP-016.02.01" MODIFIED="2010-05-08 23:34:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06144292479863722" P_Z="0.18003701034718686" STUDIES="2" TAU2="0.03621862139701072" TOTAL_1="280" TOTAL_2="277" WEIGHT="100.0" Z="1.3406410877257953">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.17769495054768955" CI_START="-0.28842956226739386" EFFECT_SIZE="-0.05536730585985216" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-0.56" MODIFIED="2008-08-29 14:23:09 +0100" MODIFIED_BY="[Empty name]" ORDER="505" SD_1="0.69" SD_2="0.75" SE="0.11891149952035193" STUDY_ID="STD-Schulz-2007" TOTAL_1="142" TOTAL_2="141" WEIGHT="50.35399245517035"/>
<CONT_DATA CI_END="-0.13494896240851653" CI_START="-0.6127637610146208" EFFECT_SIZE="-0.37385636171156866" ESTIMABLE="YES" MEAN_1="-0.74" MEAN_2="-0.53" MODIFIED="2008-08-29 17:19:42 +0100" MODIFIED_BY="[Empty name]" ORDER="549" SD_1="0.57" SD_2="0.55" SE="0.12189377008328887" STUDY_ID="STD-Zanarini-2007" TOTAL_1="138" TOTAL_2="136" WEIGHT="49.64600754482966"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2010-05-12 12:10:05 +0100" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Active drug versus placebo: Mental health status</NAME>
<CONT_OUTCOME CHI2="8.691395523421424" CI_END="0.4305510873224011" CI_START="-0.06702890657541949" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1817610903734908" ESTIMABLE="YES" I2="19.460574758834525" I2_Q="0.0" ID="CMP-017.01" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.27557845994945673" P_Q="0.922740821379892" P_Z="0.15216922748025286" Q="1.4143166345847504" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.022951574568810303" TOTALS="SUB" TOTAL_1="182" TOTAL_2="172" UNITS="" WEIGHT="600.0" Z="1.431911231527238">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.114670132093108" CI_END="1.0813120379304002" CI_START="-0.7654590654412865" DF="1" EFFECT_SIZE="0.15792648624455688" ESTIMABLE="YES" I2="83.64588802997798" ID="CMP-017.01.01" MODIFIED="2010-05-08 23:35:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01340651067220111" P_Z="0.7374649197289328" STUDIES="2" TAU2="0.3713301217713837" TOTAL_1="58" TOTAL_2="56" WEIGHT="100.0" Z="0.3352123332222129">
<NAME>

First-generation antipsychotics: Haloperidol</NAME>
<CONT_DATA CI_END="1.1695839906812162" CI_START="0.09418438581940514" EFFECT_SIZE="0.6318841882503107" ESTIMABLE="YES" MEAN_1="55.35" MEAN_2="48.16" MODIFIED="2008-09-12 11:23:43 +0100" MODIFIED_BY="[Empty name]" ORDER="417" SD_1="12.36" SD_2="9.95" SE="0.2743416749859757" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="28" WEIGHT="49.70013778557488">
<FOOTNOTE>Despite of the high heterogeneity (I<SUP>2</SUP> 84%), we decided to pool estimates, as clinical heterogeneity was quite low, and the same pattern of more favourable results in the Soloff 1989 study and less favourable results in the Soloff 1993 study was found for several outcomes</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.20795013143544433" CI_START="-0.8287105832059709" EFFECT_SIZE="-0.3103802258852633" ESTIMABLE="YES" MEAN_1="54.95" MEAN_2="58.43" MODIFIED="2008-09-12 11:23:13 +0100" MODIFIED_BY="[Empty name]" ORDER="407" SD_1="9.15" SD_2="12.8" SE="0.2644591234375893" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="28" WEIGHT="50.29986221442511">
<FOOTNOTE>cf. to (1)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4793221599673312" CI_START="-0.5328473800936633" DF="0" EFFECT_SIZE="-0.02676261006316603" ESTIMABLE="YES" I2="0.0" ID="CMP-017.01.02" MODIFIED="2010-05-08 23:35:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9174501407188712" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.10364617740410113">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.4793221599673312" CI_START="-0.5328473800936633" EFFECT_SIZE="-0.02676261006316603" ESTIMABLE="YES" MEAN_1="3.93" MEAN_2="3.97" MODIFIED="2008-08-29 11:02:20 +0100" MODIFIED_BY="[Empty name]" ORDER="467" SD_1="1.5" SD_2="1.45" SE="0.2582112600141785" STUDY_ID="STD-Soler-2005" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2495890908813467" CI_START="-0.5678735076602203" DF="0" EFFECT_SIZE="0.3408577916105633" ESTIMABLE="YES" I2="0.0" ID="CMP-017.01.03" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4622379790428214" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0" Z="0.7351667054305918">
<NAME>

Mood stabiliser: Carbamazepine</NAME>
<CONT_DATA CI_END="1.2495890908813467" CI_START="-0.5678735076602203" EFFECT_SIZE="0.3408577916105633" ESTIMABLE="YES" MEAN_1="67.12" MEAN_2="60.1" MODIFIED="2008-08-29 22:22:42 +0100" MODIFIED_BY="[Empty name]" ORDER="562" SD_1="16.17" SD_2="22.33" SE="0.4636469376165787" STUDY_ID="STD-De-la-Fuente-1994" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7932659303544138" CI_START="-0.2504308810386846" DF="0" EFFECT_SIZE="0.2714175246578646" ESTIMABLE="YES" I2="0.0" ID="CMP-017.01.04" MODIFIED="2010-05-08 23:35:45 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.30801647738742166" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0" Z="1.019392925791101">
<NAME>

Antidepressants: Amitriptyline</NAME>
<CONT_DATA CI_END="0.7932659303544138" CI_START="-0.2504308810386846" EFFECT_SIZE="0.2714175246578646" ESTIMABLE="YES" MEAN_1="51.48" MEAN_2="48.16" MODIFIED="2008-09-01 14:17:14 +0100" MODIFIED_BY="[Empty name]" ORDER="608" SD_1="13.8" SD_2="9.95" SE="0.26625407906105564" STUDY_ID="STD-Soloff-1989" TOTAL_1="29" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1624087567435653" CI_END="1.0730090427870345" CI_START="-0.2726069588580476" DF="1" EFFECT_SIZE="0.4002010419644934" ESTIMABLE="YES" I2="13.971742366991961" ID="CMP-017.01.05" MODIFIED="2010-05-08 23:35:52 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2809665946505223" P_Z="0.24368327928753686" STUDIES="2" TAU2="0.032928332252993874" TOTAL_1="22" TOTAL_2="20" WEIGHT="100.0" Z="1.1658298175212947">
<NAME>

Antidepressants: Fluoxetine</NAME>
<CONT_DATA CI_END="1.6282764048427023" CI_START="-0.13949867437416819" EFFECT_SIZE="0.7443888652342671" ESTIMABLE="YES" MEAN_1="91.5" MEAN_2="82.6" MODIFIED="2008-09-01 15:56:19 +0100" MODIFIED_BY="[Empty name]" ORDER="612" SD_1="10.3" SD_2="13.1" SE="0.4509713171162467" STUDY_ID="STD-Salzman-1995" TOTAL_1="13" TOTAL_2="9" WEIGHT="49.86732012792873"/>
<CONT_DATA CI_END="0.9390003792033299" CI_START="-0.8233302669513887" EFFECT_SIZE="0.05783505612597058" ESTIMABLE="YES" MEAN_1="59.92" MEAN_2="59.3" MODIFIED="2008-09-01 16:05:10 +0100" MODIFIED_BY="[Empty name]" ORDER="619" SD_1="13.15" SD_2="7.17" SE="0.44958240560942897" STUDY_ID="STD-Simpson-2004" TOTAL_1="9" TOTAL_2="11" WEIGHT="50.132679872071265"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6418790320761958" CI_START="-0.3597938438029329" DF="0" EFFECT_SIZE="0.14104259413663148" ESTIMABLE="YES" I2="0.0" ID="CMP-017.01.06" MODIFIED="2010-05-08 23:36:03 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.5809802422494801" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0" Z="0.5519534599582301">
<NAME>

Antidepressants: Phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.6418790320761958" CI_START="-0.3597938438029329" EFFECT_SIZE="0.14104259413663148" ESTIMABLE="YES" MEAN_1="60.1" MEAN_2="58.43" MODIFIED="2008-09-01 16:47:27 +0100" MODIFIED_BY="[Empty name]" ORDER="633" SD_1="10.7" SD_2="12.8" SE="0.255533490354975" STUDY_ID="STD-Soloff-1993" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.614225436960216" CI_START="-0.4956498349071336" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.05928780102654122" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.02" MODIFIED="2010-05-08 23:36:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8341387867544356" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="0.20939642080517656">
<NAME>SMD on basis of post-
means and pre-
SDs</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.614225436960216" CI_START="-0.4956498349071336" DF="0" EFFECT_SIZE="0.05928780102654122" ESTIMABLE="YES" I2="0.0" ID="CMP-017.02.01" MODIFIED="2010-05-08 23:36:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8341387867544356" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0" Z="0.20939642080517656">
<NAME>

First-generation antipsychotics: Thiothixene</NAME>
<CONT_DATA CI_END="0.614225436960216" CI_START="-0.4956498349071336" EFFECT_SIZE="0.05928780102654122" ESTIMABLE="YES" MEAN_1="72.42" MEAN_2="71.92" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="459" SD_1="9.25" SD_2="7.32" SE="0.28313664960731527" STUDY_ID="STD-Goldberg-1986" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.8273706519663642" CI_END="3.78814910555481" CI_START="-0.7456525453824847" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.5212482800861626" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="0.5784270649577489" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.18220010022776073" MODIFIED="2010-05-08 23:36:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.363034001966442" P_Q="1.0" P_Z="0.18841840735045562" Q="0.0" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="294" TOTAL_2="302" WEIGHT="100.0" Z="1.3152722902626235">
<NAME>Mean Change Difference</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>MCD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.8273706519663642" CI_END="3.78814910555481" CI_START="-0.7456525453824847" DF="1" EFFECT_SIZE="1.5212482800861626" ESTIMABLE="YES" I2="0.0" ID="CMP-017.03.01" LOG_CI_END="0.5784270649577489" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.18220010022776073" MODIFIED="2010-05-08 23:36:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.363034001966442" P_Z="0.18841840735045562" STUDIES="2" TAU2="0.0" TOTAL_1="294" TOTAL_2="302" WEIGHT="100.0" Z="1.3152722902626235">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<IV_DATA CI_END="3.9101699859458656" CI_START="-3.7101699859458654" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="508" SE="1.944" STUDY_ID="STD-Schulz-2007" TOTAL_1="150" TOTAL_2="155" WEIGHT="35.39780545062897"/>
<IV_DATA CI_END="5.120388173753138" CI_START="-0.5203881737531382" EFFECT_SIZE="2.3" ESTIMABLE="YES" ESTIMATE="2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-29 17:42:37 +0100" MODIFIED_BY="[Empty name]" ORDER="507" SE="1.439" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="64.60219454937103"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1106185944370914" CI_START="0.36998648726982875" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6410256410256411" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-017.04" LOG_CI_END="0.04556494033573843" LOG_CI_START="-0.4318141370446616" LOG_EFFECT_SIZE="-0.19312459835446158" METHOD="MH" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.1127814659394237" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="4" WEIGHT="100.0" Z="1.585814189346578">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1106185944370914" CI_START="0.36998648726982875" DF="0" EFFECT_SIZE="0.6410256410256411" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-017.04.01" LOG_CI_END="0.04556494033573843" LOG_CI_START="-0.4318141370446616" LOG_EFFECT_SIZE="-0.19312459835446158" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1127814659394237" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="4" WEIGHT="100.0" Z="1.585814189346578">
<NAME>

Mood stabiliser: Valproate 
semisodium</NAME>
<DICH_DATA CI_END="1.1106185944370914" CI_START="0.36998648726982875" EFFECT_SIZE="0.6410256410256411" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.04556494033573843" LOG_CI_START="-0.4318141370446616" LOG_EFFECT_SIZE="-0.19312459835446158" MODIFIED="2008-09-25 14:58:20 +0100" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.280414833117791" STUDY_ID="STD-Hollander-2001" TOTAL_1="12" TOTAL_2="4" VAR="0.07863247863247858" WEIGHT="100.0">
<FOOTNOTE>event: minimally improved to very much worse in terms of CGI-I score</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2010-05-12 12:10:12 +0100" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Active drug versus placebo: Attrition/leaving the study early for any reason</NAME>
<DICH_OUTCOME CHI2="26.92686093940866" CI_END="1.238988664517433" CI_START="0.836717232199225" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0181763924297405" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="226" I2="7.155906303911616" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="0.09306733304269107" LOG_CI_START="-0.07742128662326467" LOG_EFFECT_SIZE="0.007823023209713223" METHOD="MH" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.35954846952173003" P_Q="0.0" P_Z="0.8572550906206993" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.011096104849628205" TOTALS="SUB" TOTAL_1="841" TOTAL_2="788" WEIGHT="1500.0" Z="0.17986941030200101">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.434508666170877" CI_START="0.3644847643275353" DF="0" EFFECT_SIZE="1.4074074074074074" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-018.01.01" LOG_CI_END="0.7351602856409937" LOG_CI_START="-0.43832062072534794" LOG_EFFECT_SIZE="0.14841983245782284" MODIFIED="2010-05-08 23:37:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6200456169905693" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.49578569984501863">
<NAME>

First-generation antipsychotics: Flupenthixol 
decanoate</NAME>
<DICH_DATA CI_END="5.434508666170878" CI_START="0.3644847643275352" EFFECT_SIZE="1.4074074074074074" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7351602856409938" LOG_CI_START="-0.4383206207253481" LOG_EFFECT_SIZE="0.14841983245782284" MODIFIED="2008-09-22 14:01:20 +0100" MODIFIED_BY="[Empty name]" ORDER="638" O_E="0.0" SE="0.6893084932237592" STUDY_ID="STD-Montgomery-1979_x002f_82" TOTAL_1="18" TOTAL_2="19" VAR="0.47514619883040926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7817233629656225" CI_END="2.918330749547131" CI_START="0.4513795581023559" DF="1" EFFECT_SIZE="1.1477259446954664" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-018.01.02" LOG_CI_END="0.465134511191092" LOG_CI_START="-0.34545811296842655" LOG_EFFECT_SIZE="0.05983819911133268" MODIFIED="2010-05-08 23:37:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3766146358563073" P_Z="0.7722980212644632" STUDIES="2" TAU2="0.0" TOTAL_1="67" TOTAL_2="63" WEIGHT="100.0" Z="0.28937029936474923">
<NAME>

First-generation antipsychotics 
versus placebo: Haloperidol</NAME>
<DICH_DATA CI_END="25.475648348435783" CI_START="0.3091646794555758" EFFECT_SIZE="2.806451612903226" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4061252454975017" LOG_CI_START="-0.5098101279288101" LOG_EFFECT_SIZE="0.4481575587843459" MODIFIED="2008-08-28 12:50:31 +0100" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="1.1254299223836706" STUDY_ID="STD-Soloff-1989" TOTAL_1="31" TOTAL_2="29" VAR="1.2665925101965145" WEIGHT="17.899610624473517"/>
<DICH_DATA CI_END="2.645316226715529" CI_START="0.33719042722898485" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4224775959585648" LOG_CI_START="-0.4721247634086291" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2008-08-28 12:36:13 +0100" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.5254938542453881" STUDY_ID="STD-Soloff-1993" TOTAL_1="36" TOTAL_2="34" VAR="0.27614379084967317" WEIGHT="82.10038937552648"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.678199532496526" CI_START="0.7362887278519392" DF="0" EFFECT_SIZE="2.5277777777777777" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-018.01.03" LOG_CI_END="0.938429631373509" LOG_CI_START="-0.13295184826589634" LOG_EFFECT_SIZE="0.4027388915538063" MODIFIED="2010-05-08 23:38:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.14060951516295384" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="99.99999999999999" Z="1.4735250470910057">
<NAME>

First-generation antipsychotics 
versus placebo: Thiothixene</NAME>
<DICH_DATA CI_END="8.678199532496526" CI_START="0.7362887278519392" EFFECT_SIZE="2.5277777777777777" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.938429631373509" LOG_CI_START="-0.13295184826589634" LOG_EFFECT_SIZE="0.4027388915538063" MODIFIED="2008-08-28 13:38:24 +0100" MODIFIED_BY="[Empty name]" ORDER="431" O_E="0.0" SE="0.6293347845640435" STUDY_ID="STD-Goldberg-1986" TOTAL_1="24" TOTAL_2="26" VAR="0.396062271062271" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.818464456149844" CI_END="1.2947172484382437" CI_START="0.7232490848548634" DF="5" EFFECT_SIZE="0.9676792160002025" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="149" I2="53.78272008688156" ID="CMP-018.01.04" LOG_CI_END="0.11217493378342609" LOG_CI_START="-0.1407121072032901" LOG_EFFECT_SIZE="-0.014268586709932017" MODIFIED="2010-05-08 23:38:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.05510053115496649" P_Z="0.824957588221479" STUDIES="6" TAU2="0.062252390660641" TOTAL_1="384" TOTAL_2="383" WEIGHT="99.99999999999999" Z="0.2211731843010701">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="2.9965801800903877" CI_START="0.6810484632081674" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.47662590269158706" LOG_CI_START="-0.16682198272010076" LOG_EFFECT_SIZE="0.15490195998574316" MODIFIED="2008-08-29 13:30:56 +0100" MODIFIED_BY="[Empty name]" ORDER="489" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Bogenschutz-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.14285714285714285" WEIGHT="10.758271664344164"/>
<DICH_DATA CI_END="3.9966123923293475" CI_START="0.5629767861197648" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6016920306631093" LOG_CI_START="-0.24950951255174666" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2008-08-29 12:35:22 +0100" MODIFIED_BY="[Empty name]" ORDER="473" O_E="0.0" SE="0.5" STUDY_ID="STD-Linehan-2008" TOTAL_1="12" TOTAL_2="12" VAR="0.25" WEIGHT="7.06679643945274"/>
<DICH_DATA CI_END="1.6282975718299486" CI_START="0.9769220987970987" EFFECT_SIZE="1.2612374405076678" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="61" LOG_CI_END="0.21173377524251935" LOG_CI_START="-0.01014006618033337" LOG_EFFECT_SIZE="0.10079685453109298" MODIFIED="2008-08-29 14:28:12 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="0.13032979274501175" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" VAR="0.016985854876957716" WEIGHT="27.847967450063948"/>
<DICH_DATA CI_END="1.7449887261414208" CI_START="0.3667645471929152" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.2417926254554353" LOG_CI_START="-0.43561265147154815" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2008-08-29 12:18:04 +0100" MODIFIED_BY="[Empty name]" ORDER="468" O_E="0.0" SE="0.39791121287711073" STUDY_ID="STD-Soler-2005" TOTAL_1="30" TOTAL_2="30" VAR="0.15833333333333335" WEIGHT="10.00347639265858"/>
<DICH_DATA CI_END="1.0190740496129778" CI_START="0.41627225988026595" EFFECT_SIZE="0.6513157894736842" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.00820574256370607" LOG_CI_START="-0.3806225292581513" LOG_EFFECT_SIZE="-0.18620839334722264" MODIFIED="2008-08-29 12:38:03 +0100" MODIFIED_BY="[Empty name]" ORDER="474" O_E="0.0" SE="0.22839965159914624" STUDY_ID="STD-Zanarini-2001" TOTAL_1="19" TOTAL_2="9" VAR="0.05216640085061139" WEIGHT="19.285504184985346"/>
<DICH_DATA CI_END="1.0807412360460877" CI_START="0.5752527621618753" EFFECT_SIZE="0.7884791571232249" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="59" LOG_CI_END="0.0337217224363106" LOG_CI_START="-0.24014128732462878" LOG_EFFECT_SIZE="-0.1032097824441591" MODIFIED="2008-08-29 17:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="550" O_E="0.0" SE="0.16086848757733768" STUDY_ID="STD-Zanarini-2007" TOTAL_1="148" TOTAL_2="153" VAR="0.025878670295420046" WEIGHT="25.037983868495203"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9904953347940317" CI_START="0.7407652608595243" DF="0" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" I2="0.0" ID="CMP-018.01.05" LOG_CI_END="0.29896116404742984" LOG_CI_START="-0.13031939264735812" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2010-05-08 23:38:29 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.4413195633260423" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7699668505326244">
<NAME>

Second-generation antipsychotics: Ziprasidone</NAME>
<DICH_DATA CI_END="1.9904953347940317" CI_START="0.7407652608595243" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.29896116404742984" LOG_CI_START="-0.13031939264735812" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2008-08-28 15:35:51 +0100" MODIFIED_BY="[Empty name]" ORDER="472" O_E="0.0" SE="0.2521615239755452" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.06358543417366946" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="92.62160011346378" CI_START="0.2699154405600246" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-018.01.06" LOG_CI_END="1.9667122795130358" LOG_CI_START="-0.5687722708409984" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.27986325814353363" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="1.0806266081022762">
<NAME>

Mood stabiliser: Carbamazepine</NAME>
<DICH_DATA CI_END="92.62160011346378" CI_START="0.2699154405600246" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9667122795130358" LOG_CI_START="-0.5687722708409984" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2008-08-29 22:16:30 +0100" MODIFIED_BY="[Empty name]" ORDER="561" O_E="0.0" SE="1.4893561757289013" STUDY_ID="STD-De-la-Fuente-1994" TOTAL_1="10" TOTAL_2="10" VAR="2.2181818181818183" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4400502209503823" CI_END="1.5251151356320514" CI_START="0.39775276809978427" DF="1" EFFECT_SIZE="0.7788573469310835" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" I2="59.01723696447087" ID="CMP-018.01.07" LOG_CI_END="0.18330263114653672" LOG_CI_START="-0.4003867892645902" LOG_EFFECT_SIZE="-0.10854207905902677" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.11827266279001802" P_Z="0.46603568223798575" STUDIES="2" TAU2="0.13877407043773976" TOTAL_1="32" TOTAL_2="14" WEIGHT="100.00000000000001" Z="0.7289443951646317">
<NAME>

Mood stabiliser: Valproate 
semisodium</NAME>
<DICH_DATA CI_END="1.9731742292747863" CI_START="0.5947833159885004" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.2951654347057523" LOG_CI_START="-0.2256412221873285" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2008-08-29 22:37:58 +0100" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="0.3059244082935253" STUDY_ID="STD-Frankenburg-2002" TOTAL_1="20" TOTAL_2="10" VAR="0.09358974358974356" WEIGHT="50.59066066459189"/>
<DICH_DATA CI_END="1.0297890616548993" CI_START="0.2997137829495352" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.012748274471068424" LOG_CI_START="-0.5232932846776805" LOG_EFFECT_SIZE="-0.255272505103306" MODIFIED="2008-08-29 22:49:28 +0100" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.31487346529248716" STUDY_ID="STD-Hollander-2001" TOTAL_1="12" TOTAL_2="4" VAR="0.09914529914529913" WEIGHT="49.40933933540813"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3449107636759452" CI_END="2.475589760251628" CI_START="0.2236986956438066" DF="1" EFFECT_SIZE="0.7441681263783427" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="25.64562445267566" ID="CMP-018.01.08" LOG_CI_END="0.3936786776581124" LOG_CI_START="-0.6503365482071197" LOG_EFFECT_SIZE="-0.12832893527450373" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.24616995611072423" P_Z="0.6299251346703072" STUDIES="2" TAU2="0.26841132506576754" TOTAL_1="33" TOTAL_2="22" WEIGHT="100.00000000000001" Z="0.4818322282684156">
<NAME>

Mood stabiliser: Lamotrigine</NAME>
<DICH_DATA CI_END="2.624608365044303" CI_START="0.4120995781333429" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4190645086603422" LOG_CI_START="-0.38499783006278143" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2009-10-26 08:35:00 +0000" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.0" SE="0.47231019793873086" STUDY_ID="STD-Reich-2009" TOTAL_1="15" TOTAL_2="13" VAR="0.22307692307692312" WEIGHT="76.52013559472113"/>
<DICH_DATA CI_END="2.403382468552506" CI_START="0.02600501618772401" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.3808228888914814" LOG_CI_START="-1.584942871547406" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2008-09-01 08:59:04 +0100" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="1.1547005383792515" STUDY_ID="STD-Tritt-2005" TOTAL_1="18" TOTAL_2="9" VAR="1.3333333333333333" WEIGHT="23.479864405278885"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4931372291042204" CI_END="2.1589201273287664" CI_START="0.1406634937052355" DF="2" EFFECT_SIZE="0.5510728152799921" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-018.01.09" LOG_CI_END="0.33423657521888234" LOG_CI_START="-0.8518186000744523" LOG_EFFECT_SIZE="-0.2587910124277849" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4739903102013331" P_Z="0.3923808328747882" STUDIES="3" TAU2="0.0" TOTAL_1="72" TOTAL_2="61" WEIGHT="100.0" Z="0.8553077031271676">
<NAME>

Mood stabiliser: Topiramate</NAME>
<DICH_DATA CI_END="3.0135058276554862" CI_START="0.036871045707436295" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4790720356632876" LOG_CI_START="-1.4333145451026126" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2008-09-01 12:59:10 +0100" MODIFIED_BY="[Empty name]" ORDER="586" O_E="0.0" SE="1.1233453440081378" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" VAR="1.2619047619047616" WEIGHT="38.464351132961816"/>
<DICH_DATA CI_END="12.804356527890043" CI_START="0.1757214425495823" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.107357758250882" LOG_CI_START="-0.7551752401395198" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2008-09-01 13:45:19 +0100" MODIFIED_BY="[Empty name]" ORDER="596" O_E="0.0" SE="1.0940611029415575" STUDY_ID="STD-Nickel-2004" TOTAL_1="22" TOTAL_2="11" VAR="1.196969696969697" WEIGHT="40.55102479297782"/>
<DICH_DATA CI_END="3.9409080777837366" CI_START="0.010149944939211815" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5955963050059561" LOG_CI_START="-1.9935363136779936" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2008-09-23 14:38:49 +0100" MODIFIED_BY="[Empty name]" ORDER="643" O_E="0.0" SE="1.5208693166281149" STUDY_ID="STD-Nickel-2005" TOTAL_1="22" TOTAL_2="22" VAR="2.313043478260869" WEIGHT="20.984624074060356"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.73915478156275" CI_START="0.06339878088622447" DF="0" EFFECT_SIZE="0.9666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-018.01.10" LOG_CI_END="1.1684725795726907" LOG_CI_START="-1.1979190932141035" LOG_EFFECT_SIZE="-0.014723256820706345" MODIFIED="2010-05-08 23:39:15 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Z="0.980542261871929" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="29" WEIGHT="100.0" Z="0.02438907593833313">
<NAME>

Antidepressants: Amitriptyline</NAME>
<DICH_DATA CI_END="14.73915478156275" CI_START="0.06339878088622447" EFFECT_SIZE="0.9666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1684725795726907" LOG_CI_START="-1.1979190932141035" LOG_EFFECT_SIZE="-0.014723256820706345" MODIFIED="2008-09-01 14:20:55 +0100" MODIFIED_BY="[Empty name]" ORDER="609" O_E="0.0" SE="1.3900301824226613" STUDY_ID="STD-Soloff-1989" TOTAL_1="30" TOTAL_2="29" VAR="1.9321839080459768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.1203895495918927E-32" CI_END="8.113157044444973" CI_START="0.3254744097192127" DF="0" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="100.0" ID="CMP-018.01.11" LOG_CI_END="0.9091898825938717" LOG_CI_START="-0.4874831519640853" LOG_EFFECT_SIZE="0.21085336531489315" MODIFIED="2010-05-08 23:39:22 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Z="0.5539946428128573" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.5917848942606025">
<NAME>

Antidepressants: Fluoxetine</NAME>
<DICH_DATA CI_END="8.113157044444973" CI_START="0.3254744097192127" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9091898825938717" LOG_CI_START="-0.4874831519640853" LOG_EFFECT_SIZE="0.21085336531489315" MODIFIED="2008-09-01 16:06:38 +0100" MODIFIED_BY="[Empty name]" ORDER="620" O_E="0.0" SE="0.8204126541423669" STUDY_ID="STD-Simpson-2004" TOTAL_1="12" TOTAL_2="13" VAR="0.6730769230769229" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.5537318334993575" CI_START="0.04446902176151794" DF="0" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-018.01.12" LOG_CI_END="0.6583674516940081" LOG_CI_START="-1.3519424241433209" LOG_EFFECT_SIZE="-0.3467874862246563" MODIFIED="2010-05-08 23:39:30 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Z="0.4989103839008485" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="99.99999999999999" Z="0.6762051875275232">
<NAME>

Antidepressants: Fluvoxamine</NAME>
<DICH_DATA CI_END="4.5537318334993575" CI_START="0.04446902176151794" EFFECT_SIZE="0.45" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6583674516940081" LOG_CI_START="-1.3519424241433209" LOG_EFFECT_SIZE="-0.3467874862246563" MODIFIED="2008-09-01 16:36:00 +0100" MODIFIED_BY="[Empty name]" ORDER="624" O_E="0.0" SE="1.1808659722612234" STUDY_ID="STD-Rinne-2002" TOTAL_1="20" TOTAL_2="18" VAR="1.3944444444444444" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1178973434798696" CI_START="0.7216401799453687" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-018.01.13" LOG_CI_END="0.4938618119772089" LOG_CI_START="-0.14167929386584638" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-05-08 23:39:38 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Z="0.2774320848267027" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.0861060679422907">
<NAME>

Antidepressants: Mianserin</NAME>
<DICH_DATA CI_END="3.1178973434798696" CI_START="0.7216401799453687" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.4938618119772089" LOG_CI_START="-0.14167929386584638" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-11-06 14:54:51 +0000" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="0.37331999155142226" STUDY_ID="STD-Montgomery-81_x002f_82_x002f_83" TOTAL_1="29" TOTAL_2="29" VAR="0.13936781609195398" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9363804907653834" CI_START="0.18374580143803762" DF="0" EFFECT_SIZE="0.5964912280701754" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-018.01.14" LOG_CI_END="0.28699069842886965" LOG_CI_START="-0.7357825756893424" LOG_EFFECT_SIZE="-0.2243959386302363" MODIFIED="2010-05-08 23:39:49 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Z="0.3897723974863134" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="34" WEIGHT="100.00000000000001" Z="0.8600302122119992">
<NAME>

Antidepressants: Phenelzine 
sulfate</NAME>
<DICH_DATA CI_END="1.9363804907653834" CI_START="0.18374580143803762" EFFECT_SIZE="0.5964912280701754" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.28699069842886965" LOG_CI_START="-0.7357825756893424" LOG_EFFECT_SIZE="-0.2243959386302363" MODIFIED="2008-09-01 16:48:58 +0100" MODIFIED_BY="[Empty name]" ORDER="634" O_E="0.0" SE="0.6007820840263964" STUDY_ID="STD-Soloff-1993" TOTAL_1="38" TOTAL_2="34" VAR="0.3609391124871001" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.23675051497680188" CI_END="1.7943597470809647" CI_START="0.2060736854935003" DF="1" EFFECT_SIZE="0.6080874330079182" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-018.01.15" LOG_CI_END="0.2539095181447403" LOG_CI_START="-0.6859774617608095" LOG_EFFECT_SIZE="-0.21603397180803463" MODIFIED="2010-05-08 23:39:57 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.6265630035544859" P_Z="0.3675886468414683" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="37" WEIGHT="99.99999999999999" Z="0.9009994036164626">
<NAME>

Miscellaneous: Omega-3 fatty acids</NAME>
<DICH_DATA CI_END="1.7990961044245124" CI_START="0.15377092714444993" EFFECT_SIZE="0.525974025974026" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.25505436318238217" LOG_CI_START="-0.8131257670980088" LOG_EFFECT_SIZE="-0.2790357019578133" MODIFIED="2008-09-22 13:41:59 +0100" MODIFIED_BY="[Empty name]" ORDER="636" O_E="0.0" SE="0.6274542961036235" STUDY_ID="STD-Hallahan-2007" TOTAL_1="22" TOTAL_2="27" VAR="0.39369889369889366" WEIGHT="77.42162393280277"/>
<DICH_DATA CI_END="9.750049494803644" CI_START="0.10256358191134896" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.989006820341157" LOG_CI_START="-0.989006820341157" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-09-22 14:29:40 +0100" MODIFIED_BY="[Empty name]" ORDER="639" O_E="0.0" SE="1.161895003862225" STUDY_ID="STD-Zanarini-2003" TOTAL_1="20" TOTAL_2="10" VAR="1.3499999999999999" WEIGHT="22.578376067197215"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2010-05-12 12:10:39 +0100" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Active drug versus placebo: AE - body weight change</NAME>
<CONT_OUTCOME CHI2="90.44521440929528" CI_END="0.798792315060962" CI_START="0.5432846387701596" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.6710384769155608" ESTIMABLE="YES" I2="86.7322996817765" I2_Q="94.25924606034212" ID="CMP-019.01" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.118927421359331E-14" P_Q="3.3306690738754696E-16" P_Z="7.43072557989933E-25" Q="87.09657394404842" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.40434094982471175" TOTALS="SUB" TOTAL_1="547" TOTAL_2="509" UNITS="" WEIGHT="600.0" Z="10.294886369662123">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3355006095479489" CI_START="-0.6967841714100782" DF="0" EFFECT_SIZE="-0.18064178093106467" ESTIMABLE="YES" I2="0.0" ID="CMP-019.01.01" MODIFIED="2010-05-08 23:41:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49274035252242243" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="28" WEIGHT="100.0" Z="0.6859568042831717">
<NAME>

First-generation antipsychotics: Haloperidol</NAME>
<CONT_DATA CI_END="0.3355006095479489" CI_START="-0.6967841714100782" EFFECT_SIZE="-0.18064178093106467" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="0.41" MODIFIED="2008-08-28 12:39:56 +0100" MODIFIED_BY="[Empty name]" ORDER="409" SD_1="0.66" SD_2="0.76" SE="0.26334279331165206" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.629517116334796" CI_END="1.2027128334113688" CI_START="0.8962919294805394" DF="5" EFFECT_SIZE="1.049502381445954" ESTIMABLE="YES" I2="0.0" ID="CMP-019.01.02" MODIFIED="2010-05-08 23:41:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7568755999514637" P_Z="4.2642292928251405E-41" STUDIES="6" TAU2="0.0" TOTAL_1="376" TOTAL_2="376" WEIGHT="100.00000000000001" Z="13.425891268745984">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="1.5372574171223035" CI_START="0.14309080319232348" EFFECT_SIZE="0.8401741101573135" ESTIMABLE="YES" MEAN_1="3.71" MEAN_2="0.08" MODIFIED="2008-08-29 13:36:02 +0100" MODIFIED_BY="[Empty name]" ORDER="490" SD_1="3.4" SD_2="4.8" SE="0.3556612838110772" STUDY_ID="STD-Bogenschutz-2004" TOTAL_1="16" TOTAL_2="19" WEIGHT="4.830670572765426"/>
<CONT_DATA CI_END="1.4248123851003418" CI_START="-0.2184517347047772" EFFECT_SIZE="0.6031803251977823" ESTIMABLE="YES" MEAN_1="1.043" MEAN_2="-1.315" MODIFIED="2008-08-29 10:40:41 +0100" MODIFIED_BY="[Empty name]" ORDER="461" SD_1="2.223" SD_2="4.853" SE="0.41920773360300917" STUDY_ID="STD-Linehan-2008" TOTAL_1="12" TOTAL_2="12" WEIGHT="3.4771388506601855"/>
<CONT_DATA CI_END="1.360687953515852" CI_START="0.8842484704029335" EFFECT_SIZE="1.1224682119593927" ESTIMABLE="YES" MEAN_1="2.86" MEAN_2="-0.35" MODIFIED="2008-08-29 14:30:23 +0100" MODIFIED_BY="[Empty name]" ORDER="510" SD_1="3.02" SD_2="2.68" SE="0.1215429178472187" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" WEIGHT="41.36388187050375"/>
<CONT_DATA CI_END="1.5123459646251227" CI_START="0.4377820990576625" EFFECT_SIZE="0.9750640318413926" ESTIMABLE="YES" MEAN_1="2.74" MEAN_2="-0.05" MODIFIED="2008-08-29 12:19:08 +0100" MODIFIED_BY="[Empty name]" ORDER="469" SD_1="3.2" SD_2="2.39" SE="0.2741284722687464" STUDY_ID="STD-Soler-2005" TOTAL_1="30" TOTAL_2="30" WEIGHT="8.131530848785296"/>
<CONT_DATA CI_END="1.5334863368056246" CI_START="-0.10337489233839925" EFFECT_SIZE="0.7150557222336127" ESTIMABLE="YES" MEAN_1="1.29" MEAN_2="-0.35" MODIFIED="2008-08-29 12:40:22 +0100" MODIFIED_BY="[Empty name]" ORDER="475" SD_1="2.56" SD_2="1.17" SE="0.41757431311375526" STUDY_ID="STD-Zanarini-2001" TOTAL_1="19" TOTAL_2="9" WEIGHT="3.504395021043701"/>
<CONT_DATA CI_END="1.3299834596256939" CI_START="0.8373707061445459" EFFECT_SIZE="1.0836770828851199" ESTIMABLE="YES" MEAN_1="3.17" MEAN_2="0.02" MODIFIED="2008-08-29 17:22:23 +0100" MODIFIED_BY="[Empty name]" ORDER="551" SD_1="3.28" SD_2="2.47" SE="0.12566882793939443" STUDY_ID="STD-Zanarini-2007" TOTAL_1="144" TOTAL_2="147" WEIGHT="38.692382836241656"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4662331085657296" CI_START="-0.09680709154953226" DF="0" EFFECT_SIZE="0.6847130085080987" ESTIMABLE="YES" I2="0.0" ID="CMP-019.01.03" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.08594578590561977" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0" Z="1.717182752334813">
<NAME>

Mood stabiliser: Valproate 
semisodium</NAME>
<CONT_DATA CI_END="1.4662331085657296" CI_START="-0.09680709154953226" EFFECT_SIZE="0.6847130085080987" ESTIMABLE="YES" MEAN_1="1.78" MEAN_2="0.14" MODIFIED="2008-08-29 22:39:07 +0100" MODIFIED_BY="[Empty name]" ORDER="568" SD_1="2.54" SD_2="1.81" SE="0.3987420719065053" STUDY_ID="STD-Frankenburg-2002" TOTAL_1="20" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6739209015006712" CI_START="-0.9280629531388386" DF="0" EFFECT_SIZE="-0.1270710258190837" ESTIMABLE="YES" I2="0.0" ID="CMP-019.01.04" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7558517363778243" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="9" WEIGHT="100.0" Z="0.31093276422565136">
<NAME>

Mood stabiliser: Lamotrigine</NAME>
<CONT_DATA CI_END="0.6739209015006712" CI_START="-0.9280629531388386" EFFECT_SIZE="-0.1270710258190837" ESTIMABLE="YES" MEAN_1="75.3" MEAN_2="76.6" MODIFIED="2008-09-01 09:00:22 +0100" MODIFIED_BY="[Empty name]" ORDER="578" SD_1="9.2" SD_2="11.3" SE="0.40867686020655325" STUDY_ID="STD-Tritt-2005" TOTAL_1="18" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7191233489120612" CI_END="-0.19456605848483816" CI_START="-0.9139610777767933" DF="2" EFFECT_SIZE="-0.5542635681308157" ESTIMABLE="YES" I2="0.0" ID="CMP-019.01.05" MODIFIED="2010-05-08 23:41:43 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.697982315098453" P_Z="0.00252658344539605" STUDIES="3" TAU2="0.0" TOTAL_1="69" TOTAL_2="58" WEIGHT="100.00000000000001" Z="3.02013942923391">
<NAME>

Mood stabilizer: Topiramate</NAME>
<CONT_DATA CI_END="0.07946224889165882" CI_START="-0.9824428821064708" EFFECT_SIZE="-0.45149031660740596" ESTIMABLE="YES" MEAN_1="72.8" MEAN_2="78.5" MODIFIED="2008-09-01 13:00:25 +0100" MODIFIED_BY="[Empty name]" ORDER="587" SD_1="11.3" SD_2="13.5" SE="0.27089914390629155" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" WEIGHT="45.89479293829547"/>
<CONT_DATA CI_END="0.34023623030043315" CI_START="-1.2100204249721427" EFFECT_SIZE="-0.43489209733585477" ESTIMABLE="YES" MEAN_1="68.7" MEAN_2="73.1" MODIFIED="2008-09-01 13:46:25 +0100" MODIFIED_BY="[Empty name]" ORDER="597" SD_1="9.9" SD_2="9.7" SE="0.3954809036035362" STUDY_ID="STD-Nickel-2004" TOTAL_1="19" TOTAL_2="10" WEIGHT="21.534145564417486"/>
<CONT_DATA CI_END="-0.14773707990607277" CI_START="-1.4082621000411186" EFFECT_SIZE="-0.7779995899735958" ESTIMABLE="YES" MEAN_1="82.3" MEAN_2="86.5" MODIFIED="2008-09-23 14:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="644" SD_1="3.9" SD_2="6.5" SE="0.3215684140315604" STUDY_ID="STD-Nickel-2005" TOTAL_1="22" TOTAL_2="20" WEIGHT="32.57106149728706"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6117785513951726" CI_START="-0.38939684697853316" DF="0" EFFECT_SIZE="0.11119085220831967" ESTIMABLE="YES" I2="0.0" ID="CMP-019.01.06" MODIFIED="2010-05-08 23:41:54 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.6633095425134036" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0" Z="0.43534842364809373">
<NAME>

Antidepressants: Phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.6117785513951726" CI_START="-0.38939684697853316" EFFECT_SIZE="0.11119085220831967" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.41" MODIFIED="2008-09-01 16:51:43 +0100" MODIFIED_BY="[Empty name]" ORDER="635" SD_1="0.83" SD_2="0.76" SE="0.25540658049608295" STUDY_ID="STD-Soloff-1993" TOTAL_1="34" TOTAL_2="28" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2010-05-12 12:10:28 +0100" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Active drug versus placebo: AE - any AE</NAME>
<DICH_OUTCOME CHI2="3.1297294268009295" CI_END="1.2925914365620623" CI_START="1.0128004358971006" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1441753232730185" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="187" I2="36.09671229489281" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="0.11146127438863307" LOG_CI_START="0.005523879588430666" LOG_EFFECT_SIZE="0.05849257698853192" METHOD="MH" MODIFIED="2010-05-08 23:42:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.20911640877771642" P_Q="0.0" P_Z="0.030436710415212422" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.008526295946959995" TOTALS="SUB" TOTAL_1="333" TOTAL_2="342" WEIGHT="200.0" Z="2.1643602710199903">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1918012751157232" CI_END="1.2775700096048899" CI_START="0.9992896123647963" DF="1" EFFECT_SIZE="1.1298948799189061" ESTIMABLE="YES" EVENTS_1="201" EVENTS_2="183" I2="0.0" ID="CMP-020.01.01" LOG_CI_END="0.10638470837778144" LOG_CI_START="-3.0862706539052075E-4" LOG_EFFECT_SIZE="0.053038040656195426" MODIFIED="2010-05-08 23:42:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6614216494413028" P_Z="0.05134022633946947" STUDIES="2" TAU2="0.0" TOTAL_1="303" TOTAL_2="312" WEIGHT="100.0" Z="1.9486249832742844">
<NAME>

Second-generation 
antipsychotics 
versus placebo: Olanzapine</NAME>
<DICH_DATA CI_END="1.3879726087165862" CI_START="0.9737899350574486" EFFECT_SIZE="1.1625806451612903" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="90" LOG_CI_END="0.1423808955132027" LOG_CI_START="-0.011534718567697331" LOG_EFFECT_SIZE="0.06542308847275269" MODIFIED="2008-09-25 15:03:32 +0100" MODIFIED_BY="[Empty name]" ORDER="511" O_E="0.0" SE="0.09041079360569804" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" VAR="0.00817411160041213" WEIGHT="48.051751860629714">
<FOOTNOTE>event: reporting any adverse event</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3049603593329397" CI_START="0.928039803787014" EFFECT_SIZE="1.1004795117698343" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="93" LOG_CI_END="0.11559731934905774" LOG_CI_START="-0.03243339641654542" LOG_EFFECT_SIZE="0.04158196146625619" MODIFIED="2008-09-25 15:03:37 +0100" MODIFIED_BY="[Empty name]" ORDER="552" O_E="0.0" SE="0.0869539752045762" STUDY_ID="STD-Zanarini-2007" TOTAL_1="148" TOTAL_2="153" VAR="0.007560993803878054" WEIGHT="51.94824813937029">
<FOOTNOTE>cf. to (1)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.675227988639741" CI_START="0.9853127504737849" DF="0" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" I2="0.0" ID="CMP-020.01.02" LOG_CI_END="0.8850912848316448" LOG_CI_START="-0.006425897171119568" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2010-05-08 23:42:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.053395329395009586" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.9317098414276155">
<NAME>

Second-generation 
antipsychotics 
versus placebo: Ziprasidone</NAME>
<DICH_DATA CI_END="7.675227988639741" CI_START="0.9853127504737849" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8850912848316448" LOG_CI_START="-0.006425897171119568" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2008-09-25 15:03:44 +0100" MODIFIED_BY="[Empty name]" ORDER="467" O_E="0.0" SE="0.523681605789648" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.2742424242424243" WEIGHT="100.0">
<FOOTNOTE>cf. to (1)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2010-05-12 12:10:49 +0100" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Active drug versus placebo: AE - increased appetite</NAME>
<DICH_OUTCOME CHI2="0.5877506528067534" CI_END="4.340003964505547" CI_START="1.7534777269383466" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.7586410216961177" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="0.6374901262318877" LOG_CI_START="0.24390025374805707" LOG_EFFECT_SIZE="0.44069518998997237" METHOD="MH" MODIFIED="2010-05-08 23:43:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.44329039256672254" P_Q="0.0" P_Z="1.1383655979622438E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="303" TOTAL_2="312" WEIGHT="100.0" Z="4.389069744551757">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5877506528067534" CI_END="4.340003964505547" CI_START="1.7534777269383466" DF="1" EFFECT_SIZE="2.7586410216961177" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="23" I2="0.0" ID="CMP-021.01.01" LOG_CI_END="0.6374901262318877" LOG_CI_START="0.24390025374805707" LOG_EFFECT_SIZE="0.44069518998997237" MODIFIED="2010-05-08 23:43:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.44329039256672254" P_Z="1.1383655979622438E-5" STUDIES="2" TAU2="0.0" TOTAL_1="303" TOTAL_2="312" WEIGHT="100.0" Z="4.389069744551757">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="4.390368942933819" CI_START="1.2133745204233621" EFFECT_SIZE="2.3080645161290323" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="12" LOG_CI_END="0.642501017542276" LOG_CI_START="0.0839948709807692" LOG_EFFECT_SIZE="0.3632479442615225" MODIFIED="2008-08-29 14:36:42 +0100" MODIFIED_BY="[Empty name]" ORDER="514" O_E="0.0" SE="0.3280692751402422" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" VAR="0.10762944929104393" WEIGHT="49.66288169376709"/>
<DICH_DATA CI_END="6.2299078985966485" CI_START="1.7367148709213414" EFFECT_SIZE="3.289312039312039" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="11" LOG_CI_END="0.7944816262054106" LOG_CI_START="0.23972852302397324" LOG_EFFECT_SIZE="0.517105074614692" MODIFIED="2008-08-29 17:24:28 +0100" MODIFIED_BY="[Empty name]" ORDER="553" O_E="0.0" SE="0.3258647188809252" STUDY_ID="STD-Zanarini-2007" TOTAL_1="148" TOTAL_2="153" VAR="0.10618781501134442" WEIGHT="50.33711830623291"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2010-05-12 12:10:57 +0100" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Active drug versus placebo: AE - paraesthesia</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="27.121552448899372" CI_START="0.3318394113669267" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="1.4333145451026124" LOG_CI_START="-0.4790720356632877" LOG_EFFECT_SIZE="0.4771212547196624" METHOD="MH" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.32808290363237314" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="0.9779826787265795">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.121552448899372" CI_START="0.3318394113669267" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-022.01.01" LOG_CI_END="1.4333145451026124" LOG_CI_START="-0.4790720356632877" LOG_EFFECT_SIZE="0.4771212547196624" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.32808290363237314" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="0.9779826787265795">
<NAME>

Mood stabiliser: Topiramate</NAME>
<DICH_DATA CI_END="27.121552448899372" CI_START="0.3318394113669267" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4333145451026124" LOG_CI_START="-0.4790720356632877" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-09-01 13:18:43 +0100" MODIFIED_BY="[Empty name]" ORDER="595" O_E="0.0" SE="1.1233453440081378" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" VAR="1.2619047619047616" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2010-05-12 12:11:05 +0100" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Active drug versus placebo: AE - headache</NAME>
<DICH_OUTCOME CHI2="2.989762753869182" CI_END="1.8444077571566297" CI_START="0.45909051104332016" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9201902519616806" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="42" I2="33.105060011477065" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="0.26585694009434196" LOG_CI_START="-0.33810168358796167" LOG_EFFECT_SIZE="-0.036122371746809816" METHOD="MH" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22427527317226104" P_Q="0.0" P_Z="0.8146369363045959" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08402598243271094" TOTALS="SUB" TOTAL_1="331" TOTAL_2="340" WEIGHT="200.0" Z="0.23444833763034797">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.9853423430802124" CI_END="1.918694387854208" CI_START="0.4299538907540963" DF="1" EFFECT_SIZE="0.9082676462507986" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="40" I2="66.50300417578838" ID="CMP-023.01.01" LOG_CI_END="0.28300580525224184" LOG_CI_START="-0.36657811666410045" LOG_EFFECT_SIZE="-0.041786155705929307" MODIFIED="2010-05-08 23:44:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08402170476484072" P_Z="0.8009178247109098" STUDIES="2" TAU2="0.19394592277603215" TOTAL_1="303" TOTAL_2="312" WEIGHT="100.0" Z="0.25215944383103694">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="2.3311314497006554" CI_START="0.7370123249681426" EFFECT_SIZE="1.310752688172043" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.3675667635549198" LOG_CI_START="-0.13252524942602623" LOG_EFFECT_SIZE="0.11752075706444681" MODIFIED="2008-08-29 14:39:58 +0100" MODIFIED_BY="[Empty name]" ORDER="515" O_E="0.0" SE="0.29375652392039625" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" VAR="0.08629289534579433" WEIGHT="51.95381520524299"/>
<DICH_DATA CI_END="1.1670387689295254" CI_START="0.3197536350072009" EFFECT_SIZE="0.6108722358722358" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="22" LOG_CI_END="0.06708528351108999" LOG_CI_START="-0.49518450969654615" LOG_EFFECT_SIZE="-0.21404961309272807" MODIFIED="2008-08-29 17:24:50 +0100" MODIFIED_BY="[Empty name]" ORDER="554" O_E="0.0" SE="0.33028005981053005" STUDY_ID="STD-Zanarini-2007" TOTAL_1="148" TOTAL_2="153" VAR="0.10908491790844732" WEIGHT="48.04618479475701"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.610561210332914" CI_START="0.15127308683518553" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-023.01.02" LOG_CI_END="0.8202383309235528" LOG_CI_START="-0.8202383309235528" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="0.0">
<NAME>

Mood stabiliser: Topiramate</NAME>
<DICH_DATA CI_END="6.610561210332914" CI_START="0.15127308683518553" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8202383309235528" LOG_CI_START="-0.8202383309235528" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-09-01 13:04:17 +0100" MODIFIED_BY="[Empty name]" ORDER="590" O_E="0.0" SE="0.9636241116594315" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" VAR="0.9285714285714286" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2010-05-12 12:11:11 +0100" MODIFIED_BY="[Empty name]" NO="24">
<NAME>Active drug versus placebo: AE - dizziness</NAME>
<DICH_OUTCOME CHI2="1.1899612918419091" CI_END="10.420465062780899" CI_START="0.5500849667986517" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3941890439324838" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="15.96365303176149" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="1.0178871018514506" LOG_CI_START="-0.2595702236661274" LOG_EFFECT_SIZE="0.3791584390926616" METHOD="MH" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2753374240469665" P_Q="0.0" P_Z="0.24464190018525278" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2773065248547276" TOTALS="SUB" TOTAL_1="58" TOTAL_2="58" WEIGHT="200.0" Z="1.1634625599018726">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="160.170939238357" CI_START="0.5057097147907748" DF="0" EFFECT_SIZE="9.000000000000002" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-024.01.01" LOG_CI_END="2.204583722276951" LOG_CI_START="-0.29609870339830113" LOG_EFFECT_SIZE="0.954242509439325" MODIFIED="2010-05-08 23:45:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.13470149407860724" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.4958164473948932">
<NAME>

Second-generation 
antipsychotics versus placebo: Ziprasidone</NAME>
<DICH_DATA CI_END="160.170939238357" CI_START="0.5057097147907748" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.204583722276951" LOG_CI_START="-0.29609870339830113" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2008-08-28 15:36:46 +0100" MODIFIED_BY="[Empty name]" ORDER="468" O_E="0.0" SE="1.4689132354192893" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" VAR="2.1577060931899643" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.300053252016756" CI_START="0.27108259810902935" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-024.01.02" LOG_CI_END="0.9190808787595482" LOG_CI_START="-0.5668983606481857" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6422762113256646" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="0.4645186373922791">
<NAME>

Mood stabiliser: Topiramate</NAME>
<DICH_DATA CI_END="8.300053252016756" CI_START="0.27108259810902935" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9190808787595482" LOG_CI_START="-0.5668983606481857" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2008-09-01 13:05:03 +0100" MODIFIED_BY="[Empty name]" ORDER="591" O_E="0.0" SE="0.8728715609439694" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" VAR="0.7619047619047619" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2010-05-12 12:11:18 +0100" MODIFIED_BY="[Empty name]" NO="25">
<NAME>Active drug versus placebo: AE - disturbance in attention</NAME>
<DICH_OUTCOME CHI2="1.297851321697152" CI_END="8.605178930242136" CI_START="0.8248425158084" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.664191704401611" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="22.94957185909884" I2_Q="0.0" ID="CMP-025.01" LOG_CI_END="0.9347599051817536" LOG_CI_START="-0.08362896180661049" LOG_EFFECT_SIZE="0.4255654716875716" METHOD="MH" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.25460619674754426" P_Q="0.0" P_Z="0.10140837364397834" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.38678744697423867" TOTALS="SUB" TOTAL_1="176" TOTAL_2="181" WEIGHT="200.0" Z="1.6380638567624297">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="203.80958047466106" CI_START="0.634205027024432" DF="0" EFFECT_SIZE="11.369127516778523" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-025.01.01" LOG_CI_END="2.309224595026078" LOG_CI_START="-0.19777031986125018" LOG_EFFECT_SIZE="1.055727137582414" MODIFIED="2010-05-08 23:45:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09879350580445784" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="1.6507310444673076">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="203.80958047466106" CI_START="0.634205027024432" EFFECT_SIZE="11.369127516778523" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.309224595026078" LOG_CI_START="-0.19777031986125018" LOG_EFFECT_SIZE="1.055727137582414" MODIFIED="2008-08-29 17:29:47 +0100" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="1.4726212228297886" STUDY_ID="STD-Zanarini-2007" TOTAL_1="148" TOTAL_2="153" VAR="2.168613265928702" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.215596021630528" CI_START="0.5543547598852561" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-025.01.02" LOG_CI_END="0.8582722104418815" LOG_CI_START="-0.25621221911391906" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.28969097697665425" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="1.058799807553724">
<NAME>

Mood stabiliser: Topiramate</NAME>
<DICH_DATA CI_END="7.215596021630528" CI_START="0.5543547598852561" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8582722104418815" LOG_CI_START="-0.25621221911391906" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-09-01 13:02:45 +0100" MODIFIED_BY="[Empty name]" ORDER="588" O_E="0.0" SE="0.6546536707079772" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" VAR="0.4285714285714286" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2010-05-12 12:11:24 +0100" MODIFIED_BY="[Empty name]" NO="26">
<NAME>Active drug versus placebo: AE - memory problems</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.215596021630528" CI_START="0.5543547598852561" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="0.8582722104418815" LOG_CI_START="-0.25621221911391906" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.28969097697665425" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="1.058799807553724">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.215596021630528" CI_START="0.5543547598852561" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-026.01.01" LOG_CI_END="0.8582722104418815" LOG_CI_START="-0.25621221911391906" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.28969097697665425" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="1.058799807553724">
<NAME>

Mood stabiliser: Topiramate</NAME>
<DICH_DATA CI_END="7.215596021630528" CI_START="0.5543547598852561" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8582722104418815" LOG_CI_START="-0.25621221911391906" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-09-01 13:16:13 +0100" MODIFIED_BY="[Empty name]" ORDER="594" O_E="0.0" SE="0.6546536707079772" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" VAR="0.4285714285714286" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2010-05-12 12:11:32 +0100" MODIFIED_BY="[Empty name]" NO="27">
<NAME>Active drug versus placebo: AE - fatigue</NAME>
<DICH_OUTCOME CHI2="2.1782627798826883" CI_END="4.575383836976437" CI_START="0.8974719440719082" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0263954764671257" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" I2="8.183713256684705" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="0.6604275336567438" LOG_CI_START="-0.04697911904513484" LOG_EFFECT_SIZE="0.30672420730580446" METHOD="MH" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.33650890309425807" P_Q="0.0" P_Z="0.08919862011923105" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.02709565109573752" TOTALS="SUB" TOTAL_1="331" TOTAL_2="340" WEIGHT="200.0" Z="1.6996402202604777">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.172068878288482" CI_END="5.2276760293281965" CI_START="0.7925500698158554" DF="1" EFFECT_SIZE="2.0354839724298337" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="16" I2="53.960944333037595" ID="CMP-027.01.01" LOG_CI_END="0.7183086655506878" LOG_CI_START="-0.10097329143469863" LOG_EFFECT_SIZE="0.3086676870579946" MODIFIED="2010-05-08 23:47:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14053712742682545" P_Z="0.13971632758380945" STUDIES="2" TAU2="0.2585749671434054" TOTAL_1="303" TOTAL_2="312" WEIGHT="100.0" Z="1.4768482197533386">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="2.796005918156971" CI_START="0.669067969396244" EFFECT_SIZE="1.367741935483871" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4465380863226407" LOG_CI_START="-0.1745297608057208" LOG_EFFECT_SIZE="0.13600416275845992" MODIFIED="2008-08-29 14:43:58 +0100" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="0.3648183277386251" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" VAR="0.1330924122540069" WEIGHT="59.13227430672131"/>
<DICH_DATA CI_END="10.739884892895436" CI_START="1.2189780707925175" EFFECT_SIZE="3.6182432432432434" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="1.0309996267407966" LOG_CI_START="0.08599589280503753" LOG_EFFECT_SIZE="0.558497759772917" MODIFIED="2008-08-29 17:25:29 +0100" MODIFIED_BY="[Empty name]" ORDER="555" O_E="0.0" SE="0.5550998711577911" STUDY_ID="STD-Zanarini-2007" TOTAL_1="148" TOTAL_2="153" VAR="0.3081358669593964" WEIGHT="40.86772569327869"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.051041650174891" CI_START="0.3979687020728242" DF="0" EFFECT_SIZE="1.9999999999999998" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-027.01.02" LOG_CI_END="1.0022110726501028" LOG_CI_START="-0.4001510813221406" LOG_EFFECT_SIZE="0.30102999566398114" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.40009658579133633" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.0" Z="0.8414487628554893">
<NAME>

Mood stabiliser: Topiramate</NAME>
<DICH_DATA CI_END="10.051041650174895" CI_START="0.3979687020728242" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.002211072650103" LOG_CI_START="-0.4001510813221406" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-09-01 13:03:30 +0100" MODIFIED_BY="[Empty name]" ORDER="589" O_E="0.0" SE="0.823754471047914" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" VAR="0.6785714285714286" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" MODIFIED="2010-05-12 12:11:40 +0100" MODIFIED_BY="[Empty name]" NO="28">
<NAME>Active drug versus placebo: AE - somnolence</NAME>
<DICH_OUTCOME CHI2="0.001700859102329439" CI_END="5.034782652560858" CI_START="1.7529392930921854" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.970802643033163" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-028.01" LOG_CI_END="0.701980727157586" LOG_CI_START="0.24376687608717998" LOG_EFFECT_SIZE="0.47287380162238296" METHOD="MH" MODIFIED="2010-05-08 23:47:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9671033973824597" P_Q="0.0" P_Z="5.2247035153717424E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="303" TOTAL_2="312" WEIGHT="100.0" Z="4.045340917771605">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.001700859102329439" CI_END="5.034782652560858" CI_START="1.7529392930921854" DF="1" EFFECT_SIZE="2.970802643033163" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="17" I2="0.0" ID="CMP-028.01.01" LOG_CI_END="0.701980727157586" LOG_CI_START="0.24376687608717998" LOG_EFFECT_SIZE="0.47287380162238296" MODIFIED="2010-05-08 23:47:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9671033973824597" P_Z="5.2247035153717424E-5" STUDIES="2" TAU2="0.0" TOTAL_1="303" TOTAL_2="312" WEIGHT="100.0" Z="4.045340917771605">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="6.733613439281839" CI_START="1.2756942048526008" EFFECT_SIZE="2.9308755760368665" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" LOG_CI_END="0.8282481809553137" LOG_CI_START="0.10574658264445493" LOG_EFFECT_SIZE="0.46699738179988437" MODIFIED="2008-08-29 14:54:10 +0100" MODIFIED_BY="[Empty name]" ORDER="517" O_E="0.0" SE="0.4244010152883902" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" VAR="0.18011622177781642" WEIGHT="40.22154990888366"/>
<DICH_DATA CI_END="5.93131617402931" CI_START="1.5153199868235507" EFFECT_SIZE="2.997972972972973" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" LOG_CI_END="0.7731510751000014" LOG_CI_START="0.18050435154319366" LOG_EFFECT_SIZE="0.4768277133215975" MODIFIED="2008-08-29 17:25:56 +0100" MODIFIED_BY="[Empty name]" ORDER="556" O_E="0.0" SE="0.3481236190658637" STUDY_ID="STD-Zanarini-2007" TOTAL_1="148" TOTAL_2="153" VAR="0.1211900541515146" WEIGHT="59.77845009111633"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" MODIFIED="2010-05-12 12:11:52 +0100" MODIFIED_BY="[Empty name]" NO="29">
<NAME>Active drug versus placebo: AE - sedation</NAME>
<DICH_OUTCOME CHI2="6.124440469325071" CI_END="6.365727345161655" CI_START="1.3096126824147438" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8873235468194487" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="6" I2="67.34395558227371" I2_Q="0.0" ID="CMP-029.01" LOG_CI_END="0.8038480331182196" LOG_CI_START="0.11714287217363978" LOG_EFFECT_SIZE="0.46049545264592967" METHOD="MH" MODIFIED="2010-05-08 23:48:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04678387164502773" P_Q="0.0" P_Z="0.008572399532845205" Q="0.0" RANDOM="YES" SCALE="63.85" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.1506994895729787" TOTALS="SUB" TOTAL_1="204" TOTAL_2="198" WEIGHT="300.0" Z="2.6286521597973906">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="39.123599232296236" CI_START="2.1785978448389427" DF="0" EFFECT_SIZE="9.23225806451613" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" I2="0.0" ID="CMP-029.01.01" LOG_CI_END="1.5924388015046764" LOG_CI_START="0.33817706967429334" LOG_EFFECT_SIZE="0.9653079355894849" MODIFIED="2010-05-08 23:48:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.002554040286982551" STUDIES="1" TAU2="0.0" TOTAL_1="155" TOTAL_2="159" WEIGHT="100.0" Z="3.016864406737646">
<NAME>

Second-generation antipsychotics: Olanzapine (1)</NAME>
<DICH_DATA CI_END="39.123599232296236" CI_START="2.1785978448389427" EFFECT_SIZE="9.23225806451613" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" LOG_CI_END="1.5924388015046764" LOG_CI_START="0.33817706967429334" LOG_EFFECT_SIZE="0.9653079355894849" MODIFIED="2008-09-12 11:20:26 +0100" MODIFIED_BY="[Empty name]" ORDER="493" O_E="0.0" SE="0.7367595499728722" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" VAR="0.5428146344762291" WEIGHT="100.0">
<FOOTNOTE>Due to statistical heterogeneity (I2 82%) we decided not to pool the two estimates for Olanzapine treatment. Might be consequence of different duration of treatments (Schulz 2007: 12 weeks, Zanarini 2001: 10 weeks).</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6598015403571607" CI_START="0.43597114473051424" DF="0" EFFECT_SIZE="1.263157894736842" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-029.01.02" LOG_CI_END="0.5634575355953317" LOG_CI_START="-0.3605422540777777" LOG_EFFECT_SIZE="0.10145764075877703" MODIFIED="2010-05-08 23:48:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.666891209855895" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="9" WEIGHT="100.0" Z="0.43041854352359965">
<NAME>

Second-generation antipsychotics: Olanzapine (2)</NAME>
<DICH_DATA CI_END="3.6598015403571607" CI_START="0.43597114473051424" EFFECT_SIZE="1.263157894736842" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.5634575355953317" LOG_CI_START="-0.3605422540777777" LOG_EFFECT_SIZE="0.10145764075877703" ORDER="635" O_E="0.0" SE="0.5427620503267098" STUDY_ID="STD-Zanarini-2001" TOTAL_1="19" TOTAL_2="9" VAR="0.2945906432748538" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="46.87043244213845" CI_START="0.7680748421607162" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-029.01.03" LOG_CI_END="1.670898960483472" LOG_CI_START="-0.1145964597161847" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2010-05-08 23:48:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.08756666748743326" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.7083756228354896">
<NAME>

Second-generation 
antipsychotics versus placebo: Ziprasidone</NAME>
<DICH_DATA CI_END="46.87043244213845" CI_START="0.7680748421607162" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.670898960483472" LOG_CI_START="-0.1145964597161847" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2008-08-28 15:37:12 +0100" MODIFIED_BY="[Empty name]" ORDER="469" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" VAR="1.0999999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-030" MODIFIED="2010-05-12 12:11:57 +0100" MODIFIED_BY="[Empty name]" NO="30">
<NAME>Active drug versus placebo: AE - insomnia</NAME>
<DICH_OUTCOME CHI2="1.1711739930260001" CI_END="1.3676254144114168" CI_START="0.33367860501085866" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6755348551023841" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" I2="14.61559034313359" I2_Q="0.0" ID="CMP-030.01" LOG_CI_END="0.13596716263939013" LOG_CI_START="-0.47667163878603463" LOG_EFFECT_SIZE="-0.17035223807332223" METHOD="MH" MODIFIED="2010-05-08 23:49:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2791602004348508" P_Q="0.0" P_Z="0.275718762878848" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04209156012353066" TOTALS="SUB" TOTAL_1="303" TOTAL_2="312" WEIGHT="100.0" Z="1.0899872829884663">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1711739930260001" CI_END="1.3676254144114168" CI_START="0.33367860501085866" DF="1" EFFECT_SIZE="0.6755348551023841" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" I2="14.61559034313359" ID="CMP-030.01.01" LOG_CI_END="0.13596716263939013" LOG_CI_START="-0.47667163878603463" LOG_EFFECT_SIZE="-0.17035223807332223" MODIFIED="2010-05-08 23:49:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2791602004348508" P_Z="0.275718762878848" STUDIES="2" TAU2="0.04209156012353066" TOTAL_1="303" TOTAL_2="312" WEIGHT="100.0" Z="1.0899872829884663">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="1.280714415587255" CI_START="0.13146148597859228" EFFECT_SIZE="0.4103225806451613" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.10745229792429922" LOG_CI_START="-0.8812014629680545" LOG_EFFECT_SIZE="-0.3868745825218776" MODIFIED="2008-08-29 14:55:54 +0100" MODIFIED_BY="[Empty name]" ORDER="494" O_E="0.0" SE="0.580740113063213" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" VAR="0.3372590789206735" WEIGHT="34.13841729310844"/>
<DICH_DATA CI_END="1.8901627843784512" CI_START="0.4048171364679485" EFFECT_SIZE="0.8747401247401247" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.27649920804253636" LOG_CI_START="-0.392741111494477" LOG_EFFECT_SIZE="-0.05812095172597031" MODIFIED="2008-08-29 17:26:26 +0100" MODIFIED_BY="[Empty name]" ORDER="557" O_E="0.0" SE="0.3931150764890514" STUDY_ID="STD-Zanarini-2007" TOTAL_1="148" TOTAL_2="153" VAR="0.15453946336299276" WEIGHT="65.86158270689157"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-031" MODIFIED="2010-05-12 12:12:03 +0100" MODIFIED_BY="[Empty name]" NO="31">
<NAME>Active drug versus placebo: AE - anxiety</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4155004957015818" CI_START="0.33353378150897756" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8975806451612903" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-031.01" LOG_CI_END="0.3830071309471254" LOG_CI_START="-0.47686017260217883" LOG_EFFECT_SIZE="-0.046926520827526755" METHOD="MH" MODIFIED="2010-05-08 23:49:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8306042125743721" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="159" WEIGHT="100.0" Z="0.2139267079049888">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4155004957015818" CI_START="0.33353378150897756" DF="0" EFFECT_SIZE="0.8975806451612903" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-031.01.01" LOG_CI_END="0.3830071309471254" LOG_CI_START="-0.47686017260217883" LOG_EFFECT_SIZE="-0.046926520827526755" MODIFIED="2010-05-08 23:49:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8306042125743721" STUDIES="1" TAU2="0.0" TOTAL_1="155" TOTAL_2="159" WEIGHT="100.0" Z="0.2139267079049888">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="2.4155004957015818" CI_START="0.33353378150897756" EFFECT_SIZE="0.8975806451612903" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3830071309471254" LOG_CI_START="-0.47686017260217883" LOG_EFFECT_SIZE="-0.046926520827526755" MODIFIED="2008-08-29 14:57:29 +0100" MODIFIED_BY="[Empty name]" ORDER="495" O_E="0.0" SE="0.5050903105166604" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" VAR="0.2551162217778164" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-032" MODIFIED="2010-05-12 12:12:10 +0100" MODIFIED_BY="[Empty name]" NO="32">
<NAME>Active drug versus placebo: AE - nausea</NAME>
<DICH_OUTCOME CHI2="1.0124934877339824" CI_END="1.5886212580117358" CI_START="0.4319394590662825" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8283647788545735" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="1.2339326509589243" I2_Q="0.0" ID="CMP-032.01" LOG_CI_END="0.20102036973006776" LOG_CI_START="-0.3645771199349739" LOG_EFFECT_SIZE="-0.08177837510245303" METHOD="MH" MODIFIED="2010-05-08 23:50:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3143064935331997" P_Q="0.0" P_Z="0.5708684749473731" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0027252542144458407" TOTALS="SUB" TOTAL_1="303" TOTAL_2="312" WEIGHT="99.99999999999999" Z="0.5667729183520164">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0124934877339824" CI_END="1.5886212580117358" CI_START="0.4319394590662825" DF="1" EFFECT_SIZE="0.8283647788545735" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" I2="1.2339326509589243" ID="CMP-032.01.01" LOG_CI_END="0.20102036973006776" LOG_CI_START="-0.3645771199349739" LOG_EFFECT_SIZE="-0.08177837510245303" MODIFIED="2010-05-08 23:50:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3143064935331997" P_Z="0.5708684749473731" STUDIES="2" TAU2="0.0027252542144458407" TOTAL_1="303" TOTAL_2="312" WEIGHT="99.99999999999999" Z="0.5667729183520164">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="1.47993435002612" CI_START="0.24194797396217502" EFFECT_SIZE="0.5983870967741935" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.1702424504937628" LOG_CI_START="-0.6162780102601788" LOG_EFFECT_SIZE="-0.223017779883208" MODIFIED="2008-08-29 14:58:19 +0100" MODIFIED_BY="[Empty name]" ORDER="496" O_E="0.0" SE="0.462006011985937" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" VAR="0.21344955511114974" WEIGHT="51.06050031447932"/>
<DICH_DATA CI_END="2.933461477684932" CI_START="0.4610882830918648" EFFECT_SIZE="1.1630067567567568" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4673803894200125" LOG_CI_START="-0.3362159136799671" LOG_EFFECT_SIZE="0.06558223787002272" MODIFIED="2008-08-29 17:26:54 +0100" MODIFIED_BY="[Empty name]" ORDER="558" O_E="0.0" SE="0.4720364463067826" STUDY_ID="STD-Zanarini-2007" TOTAL_1="148" TOTAL_2="153" VAR="0.22281840664193606" WEIGHT="48.939499685520666"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-033" MODIFIED="2010-05-12 12:15:10 +0100" MODIFIED_BY="[Empty name]" NO="33">
<NAME>Active drug versus placebo: AE - uneasy feeling</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="129.92776744614594" CI_START="0.3771326250203609" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-033.01" LOG_CI_END="2.1137019760147355" LOG_CI_START="-0.423505895986222" LOG_EFFECT_SIZE="0.8450980400142568" METHOD="MH" MODIFIED="2010-05-08 23:50:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.19166919687502434" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.3056570887327816">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="129.92776744614594" CI_START="0.3771326250203609" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-033.01.01" LOG_CI_END="2.1137019760147355" LOG_CI_START="-0.423505895986222" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2010-05-08 23:50:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.19166919687502434" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.3056570887327816">
<NAME>

Second-generation 
antipsychotics versus placebo: Ziprasidone</NAME>
<DICH_DATA CI_END="129.92776744614594" CI_START="0.3771326250203609" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1137019760147355" LOG_CI_START="-0.423505895986222" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2008-08-28 15:37:44 +0100" MODIFIED_BY="[Empty name]" ORDER="470" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Pascual-2008" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-034" MODIFIED="2010-05-12 12:15:18 +0100" MODIFIED_BY="[Empty name]" NO="34">
<NAME>Active drug versus placebo: AE - constipation</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="104.19600044608839" CI_START="0.4054858134584579" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-034.01" LOG_CI_END="2.017851048929624" LOG_CI_START="-0.3920243356439131" LOG_EFFECT_SIZE="0.8129133566428556" METHOD="MH" MODIFIED="2010-05-08 23:51:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.18607054049478944" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="9" WEIGHT="100.0" Z="1.3222931872500252">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="104.19600044608839" CI_START="0.4054858134584579" DF="0" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-034.01.01" LOG_CI_END="2.017851048929624" LOG_CI_START="-0.3920243356439131" LOG_EFFECT_SIZE="0.8129133566428556" MODIFIED="2010-05-08 23:51:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18607054049478944" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="9" WEIGHT="100.0" Z="1.3222931872500252">
<NAME>

Second-generation 
antipsychotics versus placebo: Olanzapine</NAME>
<DICH_DATA CI_END="104.19600044608839" CI_START="0.4054858134584579" EFFECT_SIZE="6.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.017851048929624" LOG_CI_START="-0.3920243356439131" LOG_EFFECT_SIZE="0.8129133566428556" MODIFIED="2008-08-29 12:42:50 +0100" MODIFIED_BY="[Empty name]" ORDER="477" O_E="0.0" SE="1.415572729974039" STUDY_ID="STD-Zanarini-2001" TOTAL_1="19" TOTAL_2="9" VAR="2.003846153846154" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-035" MODIFIED="2010-05-12 12:15:26 +0100" MODIFIED_BY="[Empty name]" NO="35">
<NAME>Active drug versus placebo: AE - dry mouth</NAME>
<DICH_OUTCOME CHI2="0.2988554974673663" CI_END="4.673972980542224" CI_START="1.0775370222091256" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2441878101752937" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-035.01" LOG_CI_END="0.6696861974795428" LOG_CI_START="0.03243220065635461" LOG_EFFECT_SIZE="0.35105919906794875" METHOD="MH" MODIFIED="2010-05-08 23:51:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5846009003594617" P_Q="0.0" P_Z="0.03081422283020328" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="303" TOTAL_2="312" WEIGHT="100.0" Z="2.1594635421504185">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2988554974673663" CI_END="4.673972980542224" CI_START="1.0775370222091256" DF="1" EFFECT_SIZE="2.2441878101752937" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" I2="0.0" ID="CMP-035.01.01" LOG_CI_END="0.6696861974795428" LOG_CI_START="0.03243220065635461" LOG_EFFECT_SIZE="0.35105919906794875" MODIFIED="2010-05-08 23:51:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5846009003594617" P_Z="0.03081422283020328" STUDIES="2" TAU2="0.0" TOTAL_1="303" TOTAL_2="312" WEIGHT="100.0" Z="2.1594635421504185">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="4.960073254806604" CI_START="0.7130592717067858" EFFECT_SIZE="1.8806451612903226" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.695488090587647" LOG_CI_START="-0.14687436873816415" LOG_EFFECT_SIZE="0.2743068609247414" MODIFIED="2008-08-29 14:59:56 +0100" MODIFIED_BY="[Empty name]" ORDER="497" O_E="0.0" SE="0.4948078783694042" STUDY_ID="STD-Schulz-2007" TOTAL_1="155" TOTAL_2="159" VAR="0.24483483649643112" WEIGHT="57.23044572416693"/>
<DICH_DATA CI_END="8.729136928157184" CI_START="0.9258774619531022" EFFECT_SIZE="2.8429054054054053" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9409713060345188" LOG_CI_START="-0.03344648752871077" LOG_EFFECT_SIZE="0.453762409252904" MODIFIED="2008-08-29 17:27:18 +0100" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="0.5723778353849107" STUDY_ID="STD-Zanarini-2007" TOTAL_1="148" TOTAL_2="153" VAR="0.3276163864399159" WEIGHT="42.76955427583307"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-036" MODIFIED="2010-05-12 12:15:31 +0100" MODIFIED_BY="[Empty name]" NO="36">
<NAME>Active drug versus placebo: AE - nasopharyngitis</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6635813169605993" CI_START="0.2312692528214214" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6202702702702703" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-036.01" LOG_CI_END="0.2210440343266547" LOG_CI_START="-0.6358821027140847" LOG_EFFECT_SIZE="-0.20741903419371496" METHOD="MH" MODIFIED="2010-05-08 23:52:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.3427127637029863" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="0.9488188518363191">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6635813169605993" CI_START="0.2312692528214214" DF="0" EFFECT_SIZE="0.6202702702702703" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-036.01.01" LOG_CI_END="0.2210440343266547" LOG_CI_START="-0.6358821027140847" LOG_EFFECT_SIZE="-0.20741903419371496" MODIFIED="2010-05-08 23:52:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3427127637029863" STUDIES="1" TAU2="0.0" TOTAL_1="148" TOTAL_2="153" WEIGHT="100.0" Z="0.9488188518363191">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<DICH_DATA CI_END="1.6635813169605993" CI_START="0.2312692528214214" EFFECT_SIZE="0.6202702702702703" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.2210440343266547" LOG_CI_START="-0.6358821027140847" LOG_EFFECT_SIZE="-0.20741903419371496" MODIFIED="2008-08-29 15:00:34 +0100" MODIFIED_BY="[Empty name]" ORDER="498" O_E="0.0" SE="0.5033626547505204" STUDY_ID="STD-Schulz-2007" TOTAL_1="148" TOTAL_2="153" VAR="0.25337396219749164" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-037" MODIFIED="2010-05-12 12:15:41 +0100" MODIFIED_BY="[Empty name]" NO="37">
<NAME>Active drug versus placebo: AE - menstrual pain</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.314744082697417" CI_START="0.4398876251199111" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-037.01" LOG_CI_END="0.8003557546182762" LOG_CI_START="-0.35665825538556345" LOG_EFFECT_SIZE="0.22184874961635637" METHOD="MH" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.45228156896633354" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.00000000000001" Z="0.7516167574528501">
<NAME>Risk Ratio</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.314744082697417" CI_START="0.4398876251199111" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-037.01.01" LOG_CI_END="0.8003557546182762" LOG_CI_START="-0.35665825538556345" LOG_EFFECT_SIZE="0.22184874961635637" MODIFIED="2010-05-12 08:52:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.45228156896633354" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="28" WEIGHT="100.00000000000001" Z="0.7516167574528501">
<NAME>

Mood stabiliser: Topiramate</NAME>
<DICH_DATA CI_END="6.314744082697417" CI_START="0.4398876251199111" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8003557546182762" LOG_CI_START="-0.35665825538556345" LOG_EFFECT_SIZE="0.22184874961635637" MODIFIED="2008-09-01 13:10:54 +0100" MODIFIED_BY="[Empty name]" ORDER="593" O_E="0.0" SE="0.6796357567879738" STUDY_ID="STD-Loew-2006" TOTAL_1="28" TOTAL_2="28" VAR="0.46190476190476193" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-038" MODIFIED="2010-05-12 12:16:02 +0100" MODIFIED_BY="[Empty name]" NO="38">
<NAME>Active drug versus placebo: AE - liver function: AST/SGOT baseline to endpoint mean change (U/L)</NAME>
<CONT_OUTCOME CHI2="0.5801548397387647" CI_END="0.5224449662863988" CI_START="0.1778337537842491" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.350139360035324" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-038.01" MODIFIED="2010-05-08 23:53:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4462517685381451" P_Q="1.0" P_Z="6.810512971286087E-5" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="265" TOTAL_2="261" UNITS="" WEIGHT="100.0" Z="3.98281025307531">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5801548397387647" CI_END="0.5224449662863988" CI_START="0.1778337537842491" DF="1" EFFECT_SIZE="0.350139360035324" ESTIMABLE="YES" I2="0.0" ID="CMP-038.01.01" MODIFIED="2010-05-08 23:53:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4462517685381451" P_Z="6.810512971286087E-5" STUDIES="2" TAU2="0.0" TOTAL_1="265" TOTAL_2="261" WEIGHT="100.0" Z="3.98281025307531">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.6633123940165037" CI_START="0.17268298561584502" EFFECT_SIZE="0.41799768981617436" ESTIMABLE="YES" MEAN_1="2.32" MEAN_2="-1.07" MODIFIED="2008-08-29 16:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="499" SD_1="9.12" SD_2="6.91" SE="0.12516286326449894" STUDY_ID="STD-Schulz-2007" TOTAL_1="130" TOTAL_2="131" WEIGHT="49.33460496277534"/>
<CONT_DATA CI_END="0.5261349311738606" CI_START="0.041991897424813907" EFFECT_SIZE="0.28406341429933724" ESTIMABLE="YES" MEAN_1="2.83" MEAN_2="0.14" MODIFIED="2008-08-29 16:30:55 +0100" MODIFIED_BY="[Empty name]" ORDER="500" SD_1="11.59" SD_2="6.5" SE="0.12350814544754524" STUDY_ID="STD-Zanarini-2007" TOTAL_1="135" TOTAL_2="130" WEIGHT="50.665395037224656"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-039" MODIFIED="2010-05-12 12:16:10 +0100" MODIFIED_BY="[Empty name]" NO="39">
<NAME>Active drug versus placebo: AE - liver function: ALT/SGPT baseline to endpoint mean change (U/L)</NAME>
<CONT_OUTCOME CHI2="0.1870077674026494" CI_END="0.6333677408228251" CI_START="0.28817963467730895" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.46077368775006705" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-039.01" MODIFIED="2010-05-08 23:53:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6654187901722715" P_Q="1.0" P_Z="1.6722504853847002E-7" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="268" TOTAL_2="262" UNITS="" WEIGHT="100.0" Z="5.232508403016232">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.1870077674026494" CI_END="0.6333677408228251" CI_START="0.28817963467730895" DF="1" EFFECT_SIZE="0.46077368775006705" ESTIMABLE="YES" I2="0.0" ID="CMP-039.01.01" MODIFIED="2010-05-08 23:53:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6654187901722715" P_Z="1.6722504853847002E-7" STUDIES="2" TAU2="0.0" TOTAL_1="268" TOTAL_2="262" WEIGHT="100.0" Z="5.232508403016232">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.6670208413361713" CI_START="0.17814426451998758" EFFECT_SIZE="0.42258255292807945" ESTIMABLE="YES" MEAN_1="5.33" MEAN_2="-1.94" ORDER="641" SD_1="21.14" SD_2="11.95" SE="0.1247157041334381" STUDY_ID="STD-Schulz-2007" TOTAL_1="131" TOTAL_2="132" WEIGHT="49.85551271492408"/>
<CONT_DATA CI_END="0.7424776748177195" CI_START="0.2550117916600469" EFFECT_SIZE="0.49874473323888324" ESTIMABLE="YES" MEAN_1="6.78" MEAN_2="-0.45" ORDER="642" SD_1="18.07" SD_2="9.22" SE="0.1243558266893528" STUDY_ID="STD-Zanarini-2007" TOTAL_1="137" TOTAL_2="130" WEIGHT="50.14448728507592"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-040" MODIFIED="2010-05-12 12:16:17 +0100" MODIFIED_BY="[Empty name]" NO="40">
<NAME>Active drug versus placebo: AE - liver function: GGT (GGPT/SGGT/YGGT) baseline to endpoint mean change (U/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.49655243547003075" CI_START="0.015549951483591673" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2560511934768112" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-040.01" MODIFIED="2010-05-08 23:53:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.03691632347410835" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="137" TOTAL_2="131" UNITS="" WEIGHT="100.0" Z="2.086688256799921">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.49655243547003075" CI_START="0.015549951483591673" DF="0" EFFECT_SIZE="0.2560511934768112" ESTIMABLE="YES" I2="0.0" ID="CMP-040.01.01" MODIFIED="2010-05-08 23:53:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.03691632347410835" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="131" WEIGHT="100.0" Z="2.086688256799921">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.49655243547003075" CI_START="0.015549951483591673" EFFECT_SIZE="0.2560511934768112" ESTIMABLE="YES" MEAN_1="2.48" MEAN_2="-0.48" MODIFIED="2008-08-29 16:33:17 +0100" MODIFIED_BY="[Empty name]" ORDER="504" SD_1="12.9" SD_2="9.89" SE="0.12270697007203328" STUDY_ID="STD-Zanarini-2007" TOTAL_1="137" TOTAL_2="131" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-041" MODIFIED="2010-05-12 12:16:22 +0100" MODIFIED_BY="[Empty name]" NO="41">
<NAME>Active drug versus placebo: AE - liver function: total bilirubin baseline to endpoint mean change (&#956;mol/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.045761758956297444" CI_START="-0.5308091270073839" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.28828544298184067" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-041.01" MODIFIED="2010-05-08 23:55:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.019817289651849965" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="132" UNITS="" WEIGHT="100.0" Z="2.3297893060707127">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.045761758956297444" CI_START="-0.5308091270073839" DF="0" EFFECT_SIZE="-0.28828544298184067" ESTIMABLE="YES" I2="0.0" ID="CMP-041.01.01" MODIFIED="2010-05-08 23:55:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.019817289651849965" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="132" WEIGHT="100.0" Z="2.3297893060707127">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="-0.045761758956297416" CI_START="-0.5308091270073839" EFFECT_SIZE="-0.28828544298184067" ESTIMABLE="YES" MEAN_1="-0.87" MEAN_2="0.11" MODIFIED="2008-08-29 16:36:31 +0100" MODIFIED_BY="[Empty name]" ORDER="507" SD_1="3.69" SD_2="3.06" SE="0.12373884721277488" STUDY_ID="STD-Schulz-2007" TOTAL_1="132" TOTAL_2="132" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-042" MODIFIED="2010-05-12 12:16:29 +0100" MODIFIED_BY="[Empty name]" NO="42">
<NAME>Active drug versus placebo: AE - liver function: direct bilirubin baseline to endpoint mean change (&#956;mol/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.10793949653476681" CI_START="-0.5999072877202514" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.35392339212750906" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-042.01" MODIFIED="2010-05-08 23:55:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.004802211858837084" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="2.8200102294689886">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.10793949653476681" CI_START="-0.5999072877202514" DF="0" EFFECT_SIZE="-0.35392339212750906" ESTIMABLE="YES" I2="0.0" ID="CMP-042.01.01" MODIFIED="2010-05-08 23:55:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.004802211858837084" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="130" WEIGHT="100.0" Z="2.8200102294689886">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="-0.10793949653476681" CI_START="-0.5999072877202514" EFFECT_SIZE="-0.35392339212750906" ESTIMABLE="YES" MEAN_1="-0.27" MEAN_2="0.03" MODIFIED="2008-08-29 16:38:16 +0100" MODIFIED_BY="[Empty name]" ORDER="508" SD_1="0.94" SD_2="0.74" SE="0.12550429371816615" STUDY_ID="STD-Schulz-2007" TOTAL_1="128" TOTAL_2="130" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-043" MODIFIED="2010-05-12 12:16:35 +0100" MODIFIED_BY="[Empty name]" NO="43">
<NAME>Active drug versus placebo: AE - lipids: total cholesterol baseline to endpoint change (mmol/L)</NAME>
<CONT_OUTCOME CHI2="0.8062889319632811" CI_END="0.6360694138125533" CI_START="0.19739149677548792" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.41673045529402064" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-043.01" MODIFIED="2010-05-08 23:56:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3692197636022745" P_Q="1.0" P_Z="1.962383640427364E-4" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="164" TOTAL_2="163" UNITS="" WEIGHT="100.0" Z="3.7238103488498475">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8062889319632811" CI_END="0.6360694138125533" CI_START="0.19739149677548792" DF="1" EFFECT_SIZE="0.41673045529402064" ESTIMABLE="YES" I2="0.0" ID="CMP-043.01.01" MODIFIED="2010-05-08 23:56:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3692197636022745" P_Z="1.962383640427364E-4" STUDIES="2" TAU2="0.0" TOTAL_1="164" TOTAL_2="163" WEIGHT="100.0" Z="3.7238103488498475">
<NAME>

Second-generation antipsychotics: Olanzapine</NAME>
<CONT_DATA CI_END="0.6118896476323653" CI_START="0.1279479684096957" EFFECT_SIZE="0.3699188080210305" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="-0.08" MODIFIED="2008-08-29 16:39:55 +0100" MODIFIED_BY="[Empty name]" ORDER="510" SD_1="0.74" SD_2="0.6" SE="0.12345677855306011" STUDY_ID="STD-Schulz-2007" TOTAL_1="134" TOTAL_2="133" WEIGHT="82.16852500740846"/>
<CONT_DATA CI_END="1.151865538556795" CI_START="0.11301722705857975" EFFECT_SIZE="0.6324413828076874" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="-0.1" MODIFIED="2008-08-29 12:27:44 +0100" MODIFIED_BY="[Empty name]" ORDER="471" SD_1="0.53" SD_2="0.65" SE="0.26501719411492203" STUDY_ID="STD-Soler-2005" TOTAL_1="30" TOTAL_2="30" WEIGHT="17.831474992591538"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-044" MODIFIED="2010-05-12 12:16:41 +0100" MODIFIED_BY="[Empty name]" NO="44">
<NAME>Active drug versus placebo: AE - lipids: LDL cholesterol baseline to endpoint mean change (mmol/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5935633944482592" CI_START="0.10265381744141863" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.34810860594483894" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-044.01" MODIFIED="2010-05-08 23:56:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.005441619901960254" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="128" TOTAL_2="131" UNITS="" WEIGHT="100.0" Z="2.7796578527569564">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5935633944482592" CI_START="0.10265381744141863" DF="0" EFFECT_SIZE="0.34810860594483894" ESTIMABLE="YES" I2="0.0" ID="CMP-044.01.01" MODIFIED="2010-05-08 23:56:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.005441619901960254" STUDIES="1" TAU2="0.0" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0" Z="2.7796578527569564">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.5935633944482592" CI_START="0.10265381744141863" EFFECT_SIZE="0.34810860594483894" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="-0.08" MODIFIED="2008-08-29 16:40:53 +0100" MODIFIED_BY="[Empty name]" ORDER="509" SD_1="0.65" SD_2="0.55" SE="0.12523433616103988" STUDY_ID="STD-Schulz-2007" TOTAL_1="128" TOTAL_2="131" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-045" MODIFIED="2010-05-12 12:16:52 +0100" MODIFIED_BY="[Empty name]" NO="45">
<NAME>Active drug versus placebo: AE - lipids: HDL cholesterol (dextran precip.) baseline to endpoint mean change (mmol/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.0377601331036255" CI_START="-0.5181837944456201" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2779719637746228" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-045.01" MODIFIED="2010-05-08 23:57:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.023325500958506763" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="137" TOTAL_2="132" UNITS="" WEIGHT="100.0" Z="2.268060803617668">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.0377601331036255" CI_START="-0.5181837944456201" DF="0" EFFECT_SIZE="-0.2779719637746228" ESTIMABLE="YES" I2="0.0" ID="CMP-045.01.01" MODIFIED="2010-05-08 23:57:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.023325500958506763" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="132" WEIGHT="100.0" Z="2.268060803617668">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="-0.03776013310362547" CI_START="-0.5181837944456201" EFFECT_SIZE="-0.2779719637746228" ESTIMABLE="YES" MEAN_1="-0.04" MEAN_2="0.02" MODIFIED="2008-08-29 16:42:14 +0100" MODIFIED_BY="[Empty name]" ORDER="512" SD_1="0.2" SD_2="0.23" SE="0.12255930852084915" STUDY_ID="STD-Zanarini-2007" TOTAL_1="137" TOTAL_2="132" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-046" MODIFIED="2010-05-12 12:16:58 +0100" MODIFIED_BY="[Empty name]" NO="46">
<NAME>Active drug versus placebo: AE - lipids: triglycerides, fasting, baseline to endpoint mean change (mmol/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6444520043626084" CI_START="0.08949246030204816" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3669722323323283" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-046.01" MODIFIED="2010-05-08 23:58:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.009539499554463805" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="101" TOTAL_2="102" UNITS="" WEIGHT="100.0" Z="2.592089338386583">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6444520043626084" CI_START="0.08949246030204816" DF="0" EFFECT_SIZE="0.3669722323323283" ESTIMABLE="YES" I2="0.0" ID="CMP-046.01.01" MODIFIED="2010-05-08 23:58:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.009539499554463805" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="102" WEIGHT="100.0" Z="2.592089338386583">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.6444520043626085" CI_START="0.08949246030204822" EFFECT_SIZE="0.36697223233232834" ESTIMABLE="YES" MEAN_1="0.21" MEAN_2="-0.06" MODIFIED="2008-08-29 16:43:35 +0100" MODIFIED_BY="[Empty name]" ORDER="513" SD_1="0.8" SD_2="0.66" SE="0.1415739137142341" STUDY_ID="STD-Zanarini-2007" TOTAL_1="101" TOTAL_2="102" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-047" MODIFIED="2010-05-12 12:17:03 +0100" MODIFIED_BY="[Empty name]" NO="47">
<NAME>Active drug versus placebo: AE - prolactin: baseline to endpoint mean change (&#956;g/L)</NAME>
<CONT_OUTCOME CHI2="1.1121684867111545" CI_END="0.5922619972800954" CI_START="0.22839485390325864" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.41032842559167704" ESTIMABLE="YES" I2="10.08556599574703" I2_Q="0.0" ID="CMP-047.01" MODIFIED="2010-05-08 23:59:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2916110878056767" P_Q="1.0" P_Z="9.849387332452744E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0017381629027015011" TOTALS="SUB" TOTAL_1="266" TOTAL_2="262" UNITS="" WEIGHT="100.0" Z="4.420453732255873">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1121684867111545" CI_END="0.5922619972800954" CI_START="0.22839485390325864" DF="1" EFFECT_SIZE="0.41032842559167704" ESTIMABLE="YES" I2="10.08556599574703" ID="CMP-047.01.01" MODIFIED="2010-05-08 23:59:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2916110878056767" P_Z="9.849387332452744E-6" STUDIES="2" TAU2="0.0017381629027015011" TOTAL_1="266" TOTAL_2="262" WEIGHT="100.0" Z="4.420453732255873">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.561839808187364" CI_START="0.07159974882984663" EFFECT_SIZE="0.31671977850860533" ESTIMABLE="YES" MEAN_1="7.75" MEAN_2="0.65" MODIFIED="2008-08-29 16:44:46 +0100" MODIFIED_BY="[Empty name]" ORDER="515" SD_1="27.96" SD_2="14.82" SE="0.12506353770387324" STUDY_ID="STD-Schulz-2007" TOTAL_1="129" TOTAL_2="130" WEIGHT="49.57964836899904"/>
<CONT_DATA CI_END="0.7452150161358466" CI_START="0.2595374891453599" EFFECT_SIZE="0.5023762526406033" ESTIMABLE="YES" MEAN_1="9.26" MEAN_2="0.03" MODIFIED="2008-08-29 16:45:01 +0100" MODIFIED_BY="[Empty name]" ORDER="514" SD_1="19.21" SD_2="17.35" SE="0.12389960499821655" STUDY_ID="STD-Zanarini-2007" TOTAL_1="137" TOTAL_2="132" WEIGHT="50.42035163100097"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-048" MODIFIED="2010-05-12 12:17:09 +0100" MODIFIED_BY="[Empty name]" NO="48">
<NAME>Active drug versus placebo: AE - platelet count baseline to endpoint mean change (GI/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-048.01" MODIFIED="2010-05-08 23:59:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="260" TOTAL_2="257" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-048.01.01" MODIFIED="2010-05-08 23:59:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="260" TOTAL_2="257" WEIGHT="0.0" Z="0.0">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.563430469845859" CI_START="0.07127376294451401" EFFECT_SIZE="0.3173521163951865" ESTIMABLE="YES" MEAN_1="1.04" MEAN_2="-12.56" MODIFIED="2008-09-12 10:59:23 +0100" MODIFIED_BY="[Empty name]" ORDER="517" SD_1="41.99" SD_2="43.46" SE="0.12555248738839445" STUDY_ID="STD-Schulz-2007" TOTAL_1="129" TOTAL_2="128" WEIGHT="0.0">
<FOOTNOTE>Due to considerable heterogeneity (I<SUP>2</SUP> 90%), estimates were not pooled.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.011123703990536166" CI_START="-0.49935123708443774" EFFECT_SIZE="-0.25523747053748697" ESTIMABLE="YES" MEAN_1="-6.44" MEAN_2="4.01" MODIFIED="2008-09-12 10:59:31 +0100" MODIFIED_BY="[Empty name]" ORDER="516" SD_1="41.1" SD_2="40.54" SE="0.1245501287128177" STUDY_ID="STD-Zanarini-2007" TOTAL_1="131" TOTAL_2="129" WEIGHT="0.0">
<FOOTNOTE>cf. to (1)</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-049" MODIFIED="2010-05-12 12:17:14 +0100" MODIFIED_BY="[Empty name]" NO="49">
<NAME>Active drug versus placebo: AE - erythrocyte count baseline to endpoint mean change (TI/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.06158458398875946" CI_START="-0.42378435570846773" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.18109988585985412" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-049.01" MODIFIED="2010-05-08 23:59:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.14357804977948788" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="1.462595666344228">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.06158458398875946" CI_START="-0.42378435570846773" DF="0" EFFECT_SIZE="-0.18109988585985412" ESTIMABLE="YES" I2="0.0" ID="CMP-049.01.01" MODIFIED="2010-05-08 23:59:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.14357804977948788" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="1.462595666344228">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.06158458398875946" CI_START="-0.42378435570846773" EFFECT_SIZE="-0.18109988585985412" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="0.07" MODIFIED="2008-08-29 16:47:44 +0100" MODIFIED_BY="[Empty name]" ORDER="519" SD_1="0.26" SD_2="0.29" SE="0.12382088230338807" STUDY_ID="STD-Zanarini-2007" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-050" MODIFIED="2010-05-12 12:17:19 +0100" MODIFIED_BY="[Empty name]" NO="50">
<NAME>Active drug versus placebo: AE - leukocyte count baseline to endpoint mean change (GI/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.15875078968983208" CI_START="-0.6480889851453882" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.40341988741761015" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-050.01" MODIFIED="2010-05-09 00:00:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0012307144022205318" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="3.2316645515464697">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.15875078968983208" CI_START="-0.6480889851453882" DF="0" EFFECT_SIZE="-0.40341988741761015" ESTIMABLE="YES" I2="0.0" ID="CMP-050.01.01" MODIFIED="2010-05-09 00:00:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0012307144022205318" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="3.2316645515464697">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="-0.15875078968983208" CI_START="-0.6480889851453882" EFFECT_SIZE="-0.40341988741761015" ESTIMABLE="YES" MEAN_1="-0.58" MEAN_2="0.12" MODIFIED="2008-08-29 16:48:36 +0100" MODIFIED_BY="[Empty name]" ORDER="520" SD_1="1.69" SD_2="1.77" SE="0.12483346615432563" STUDY_ID="STD-Zanarini-2007" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-051" MODIFIED="2010-05-12 12:17:24 +0100" MODIFIED_BY="[Empty name]" NO="51">
<NAME>Active drug versus placebo: AE - neutrophils, segmented, baseline to endpoint mean change (GI/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.14265620780210378" CI_START="-0.631602476541893" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3871293421719984" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-051.01" MODIFIED="2010-05-09 00:00:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0019114792508583129" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="3.103652145547313">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.14265620780210378" CI_START="-0.631602476541893" DF="0" EFFECT_SIZE="-0.3871293421719984" ESTIMABLE="YES" I2="0.0" ID="CMP-051.01.01" MODIFIED="2010-05-09 00:00:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0019114792508583129" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="3.103652145547313">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="-0.14265620780210378" CI_START="-0.631602476541893" EFFECT_SIZE="-0.3871293421719984" ESTIMABLE="YES" MEAN_1="-0.51" MEAN_2="0.09" MODIFIED="2008-08-29 16:49:36 +0100" MODIFIED_BY="[Empty name]" ORDER="521" SD_1="1.57" SD_2="1.52" SE="0.12473348301206935" STUDY_ID="STD-Zanarini-2007" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-052" MODIFIED="2010-05-12 12:17:31 +0100" MODIFIED_BY="[Empty name]" NO="52">
<NAME>Active drug versus placebo: AE - basophils baseline to endpoint mean change (GI/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.03892744298197712" CI_START="-0.5257330502587071" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2823302466203421" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-052.01" MODIFIED="2010-05-09 00:01:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.02300080454902615" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="2.2734212870626203">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.03892744298197712" CI_START="-0.5257330502587071" DF="0" EFFECT_SIZE="-0.2823302466203421" ESTIMABLE="YES" I2="0.0" ID="CMP-052.01.01" MODIFIED="2010-05-09 00:01:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02300080454902615" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="2.2734212870626203">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="-0.03892744298197712" CI_START="-0.5257330502587071" EFFECT_SIZE="-0.2823302466203421" ESTIMABLE="YES" MEAN_1="-0.01" MEAN_2="0.0" MODIFIED="2008-08-29 16:50:59 +0100" MODIFIED_BY="[Empty name]" ORDER="522" SD_1="0.03" SD_2="0.04" SE="0.12418738586948293" STUDY_ID="STD-Zanarini-2007" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-053" MODIFIED="2010-05-12 12:17:36 +0100" MODIFIED_BY="[Empty name]" NO="53">
<NAME>Active drug versus placebo: AE - monocytes baseline to endpoint mean change (GI/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.03832523918414296" CI_START="-0.5251203691535532" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2817228041688481" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-053.01" MODIFIED="2010-05-09 00:01:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.02329395355699481" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="2.26857877493257">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.03832523918414296" CI_START="-0.5251203691535532" DF="0" EFFECT_SIZE="-0.2817228041688481" ESTIMABLE="YES" I2="0.0" ID="CMP-053.01.01" MODIFIED="2010-05-09 00:01:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02329395355699481" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="2.26857877493257">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="-0.03832523918414296" CI_START="-0.5251203691535532" EFFECT_SIZE="-0.2817228041688481" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.01" MODIFIED="2008-08-29 16:52:05 +0100" MODIFIED_BY="[Empty name]" ORDER="523" SD_1="0.16" SD_2="0.12" SE="0.1241847130378895" STUDY_ID="STD-Zanarini-2007" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-054" MODIFIED="2010-05-12 12:17:46 +0100" MODIFIED_BY="[Empty name]" NO="54">
<NAME>Active drug versus placebo: AE - haemoglobin baseline to endpoint mean change (mml/L-F)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.03424265243777924" CI_START="-0.4514549307698356" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2086061391660282" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-054.01" MODIFIED="2010-05-09 00:02:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.09225876447318015" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="1.683601211351284">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.03424265243777924" CI_START="-0.4514549307698356" DF="0" EFFECT_SIZE="-0.2086061391660282" ESTIMABLE="YES" I2="0.0" ID="CMP-054.01.01" MODIFIED="2010-05-09 00:02:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.09225876447318015" STUDIES="1" TAU2="0.0" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0" Z="1.683601211351284">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.03424265243777924" CI_START="-0.4514549307698356" EFFECT_SIZE="-0.2086061391660282" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="0.03" MODIFIED="2008-08-29 16:53:23 +0100" MODIFIED_BY="[Empty name]" ORDER="524" SD_1="0.55" SD_2="0.5" SE="0.12390472147415345" STUDY_ID="STD-Zanarini-2007" TOTAL_1="132" TOTAL_2="130" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-055" MODIFIED="2010-05-12 12:17:56 +0100" MODIFIED_BY="[Empty name]" NO="55">
<NAME>Active drug versus placebo: AE - mean cell haemoglobin concentration (MCHC) baseline to endpoint mean change (mml/L-F)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.26866120811513555" CI_START="-0.21756615538957708" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.02554752636277924" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-055.01" MODIFIED="2010-05-09 00:04:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.836820429325032" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="130" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="0.2059622116049401">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.26866120811513555" CI_START="-0.21756615538957708" DF="0" EFFECT_SIZE="0.02554752636277924" ESTIMABLE="YES" I2="0.0" ID="CMP-055.01.01" MODIFIED="2010-05-09 00:04:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.836820429325032" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="130" WEIGHT="100.0" Z="0.2059622116049401">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.26866120811513555" CI_START="-0.21756615538957708" EFFECT_SIZE="0.02554752636277924" ESTIMABLE="YES" MEAN_1="-0.23" MEAN_2="-0.25" MODIFIED="2008-08-29 16:54:12 +0100" MODIFIED_BY="[Empty name]" ORDER="525" SD_1="0.75" SD_2="0.81" SE="0.12403987199254987" STUDY_ID="STD-Zanarini-2007" TOTAL_1="130" TOTAL_2="130" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-056" MODIFIED="2010-05-12 12:19:28 +0100" MODIFIED_BY="[Empty name]" NO="56">
<NAME>Active drug versus placebo: AE - calcium baseline to endpoint mean change (mmol/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.09127259831059925" CI_START="-0.5735126008113824" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3323925995609909" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-056.01" MODIFIED="2010-05-09 00:04:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.006894845711199306" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="134" TOTAL_2="134" UNITS="" WEIGHT="100.0" Z="2.7018808912109207">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.09127259831059925" CI_START="-0.5735126008113824" DF="0" EFFECT_SIZE="-0.3323925995609909" ESTIMABLE="YES" I2="0.0" ID="CMP-056.01.01" MODIFIED="2010-05-09 00:04:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.006894845711199306" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="134" WEIGHT="100.0" Z="2.7018808912109207">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="-0.09127259831059925" CI_START="-0.5735126008113824" EFFECT_SIZE="-0.3323925995609909" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="0.0" MODIFIED="2008-08-29 16:55:06 +0100" MODIFIED_BY="[Empty name]" ORDER="527" SD_1="0.09" SD_2="0.09" SE="0.12302266937163918" STUDY_ID="STD-Schulz-2007" TOTAL_1="134" TOTAL_2="134" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-057" MODIFIED="2010-05-12 12:19:34 +0100" MODIFIED_BY="[Empty name]" NO="57">
<NAME>Active drug versus placebo: AE - albumin baseline to endpoint mean change (g/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.02520115551180216" CI_START="-0.45427912902885903" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.21453898675852845" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-057.01" MODIFIED="2010-05-09 00:05:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.07944160197782134" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="137" TOTAL_2="132" UNITS="" WEIGHT="100.0" Z="1.75393525399801">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.02520115551180216" CI_START="-0.45427912902885903" DF="0" EFFECT_SIZE="-0.21453898675852845" ESTIMABLE="YES" I2="0.0" ID="CMP-057.01.01" MODIFIED="2010-05-09 00:05:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07944160197782134" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="132" WEIGHT="100.0" Z="1.75393525399801">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.025201155511802187" CI_START="-0.4542791290288591" EFFECT_SIZE="-0.21453898675852845" ESTIMABLE="YES" MEAN_1="-1.15" MEAN_2="-0.48" MODIFIED="2008-08-29 16:56:58 +0100" MODIFIED_BY="[Empty name]" ORDER="529" SD_1="2.88" SD_2="3.34" SE="0.12231864675135373" STUDY_ID="STD-Zanarini-2007" TOTAL_1="137" TOTAL_2="132" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-058" MODIFIED="2010-05-12 12:19:42 +0100" MODIFIED_BY="[Empty name]" NO="58">
<NAME>Active drug versus placebo: AE - creatine phosphokinase baseline to endpoint mean change (U/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.030609596979874365" CI_START="-0.44973779587740065" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.20956409944876314" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-058.01" MODIFIED="2010-05-09 00:05:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.08723425912704193" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="137" TOTAL_2="131" UNITS="" WEIGHT="100.0" Z="1.7101709865809058">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.030609596979874365" CI_START="-0.44973779587740065" DF="0" EFFECT_SIZE="-0.20956409944876314" ESTIMABLE="YES" I2="0.0" ID="CMP-058.01.01" MODIFIED="2010-05-09 00:05:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.08723425912704193" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="131" WEIGHT="100.0" Z="1.7101709865809058">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.030609596979874365" CI_START="-0.44973779587740065" EFFECT_SIZE="-0.20956409944876314" ESTIMABLE="YES" MEAN_1="-29.73" MEAN_2="15.08" MODIFIED="2008-08-29 16:58:09 +0100" MODIFIED_BY="[Empty name]" ORDER="530" SD_1="253.29" SD_2="160.96" SE="0.12253985191722755" STUDY_ID="STD-Zanarini-2007" TOTAL_1="137" TOTAL_2="131" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-059" MODIFIED="2010-05-12 12:20:07 +0100" MODIFIED_BY="[Empty name]" NO="59">
<NAME>Active drug versus placebo: AE - urea nitrogen baseline to endpoint mean change (mmol/L)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.09864403087924734" CI_START="-0.38004274789709924" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.14069935850892595" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-059.01" MODIFIED="2010-05-09 00:06:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.24924883520594077" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="137" TOTAL_2="132" UNITS="" WEIGHT="100.0" Z="1.152175859255257">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.09864403087924734" CI_START="-0.38004274789709924" DF="0" EFFECT_SIZE="-0.14069935850892595" ESTIMABLE="YES" I2="0.0" ID="CMP-059.01.01" MODIFIED="2010-05-09 00:06:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.24924883520594077" STUDIES="1" TAU2="0.0" TOTAL_1="137" TOTAL_2="132" WEIGHT="100.0" Z="1.152175859255257">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.09864403087924734" CI_START="-0.38004274789709924" EFFECT_SIZE="-0.14069935850892595" ESTIMABLE="YES" MEAN_1="-0.21" MEAN_2="-0.04" MODIFIED="2008-08-29 16:59:04 +0100" MODIFIED_BY="[Empty name]" ORDER="531" SD_1="1.17" SD_2="1.24" SE="0.12211621809180341" STUDY_ID="STD-Zanarini-2007" TOTAL_1="137" TOTAL_2="132" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-060" MODIFIED="2010-05-12 12:20:20 +0100" MODIFIED_BY="[Empty name]" NO="60">
<NAME>Active drug versus placebo: AE - pulse, standing, baseline to endpoint mean change</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3085645807053739" CI_START="-0.15203004513693608" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.07826726778421891" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-060.01" MODIFIED="2010-05-09 00:06:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5053472279815853" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="143" TOTAL_2="147" UNITS="" WEIGHT="100.0" Z="0.6660999387254674">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3085645807053739" CI_START="-0.15203004513693608" DF="0" EFFECT_SIZE="0.07826726778421891" ESTIMABLE="YES" I2="0.0" ID="CMP-060.01.01" MODIFIED="2010-05-09 00:06:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5053472279815853" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0" Z="0.6660999387254674">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.3085645807053739" CI_START="-0.15203004513693608" EFFECT_SIZE="0.07826726778421891" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="0.65" MODIFIED="2008-08-29 16:59:59 +0100" MODIFIED_BY="[Empty name]" ORDER="532" SD_1="11.5" SD_2="10.14" SE="0.11750078814596125" STUDY_ID="STD-Zanarini-2007" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-061" MODIFIED="2010-05-12 12:20:28 +0100" MODIFIED_BY="[Empty name]" NO="61">
<NAME>Active drug versus placebo: AE - pulse, supine, baseline to endpoint mean change</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.25445201749143737" CI_START="-0.20598110510155962" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.02423545619493887" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-061.01" MODIFIED="2010-05-09 00:06:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8365330165813647" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="143" TOTAL_2="147" UNITS="" WEIGHT="100.0" Z="0.20633016592495163">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.25445201749143737" CI_START="-0.20598110510155962" DF="0" EFFECT_SIZE="0.02423545619493887" ESTIMABLE="YES" I2="0.0" ID="CMP-061.01.01" MODIFIED="2010-05-09 00:06:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8365330165813647" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0" Z="0.20633016592495163">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.25445201749143737" CI_START="-0.20598110510155965" EFFECT_SIZE="0.02423545619493887" ESTIMABLE="YES" MEAN_1="0.69" MEAN_2="0.46" MODIFIED="2008-08-29 17:00:38 +0100" MODIFIED_BY="[Empty name]" ORDER="533" SD_1="8.94" SD_2="9.95" SE="0.11745958758039299" STUDY_ID="STD-Zanarini-2007" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-062" MODIFIED="2010-05-12 12:20:34 +0100" MODIFIED_BY="[Empty name]" NO="62">
<NAME>Active drug versus placebo: AE - diastolic blood pressure, standing, baseline to endpoint mean change</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.19826172268766024" CI_START="-0.2621840622859575" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.031961169799148634" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-062.01" MODIFIED="2010-05-09 00:07:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7855481601286903" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="143" TOTAL_2="147" UNITS="" WEIGHT="100.0" Z="0.2720960588821108">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.19826172268766024" CI_START="-0.2621840622859575" DF="0" EFFECT_SIZE="-0.031961169799148634" ESTIMABLE="YES" I2="0.0" ID="CMP-062.01.01" MODIFIED="2010-05-09 00:07:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7855481601286903" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0" Z="0.2720960588821108">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.19826172268766024" CI_START="-0.2621840622859575" EFFECT_SIZE="-0.031961169799148634" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.39" MODIFIED="2008-08-29 17:01:25 +0100" MODIFIED_BY="[Empty name]" ORDER="534" SD_1="7.79" SD_2="9.57" SE="0.11746281783888768" STUDY_ID="STD-Zanarini-2007" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-063" MODIFIED="2010-05-12 12:20:41 +0100" MODIFIED_BY="[Empty name]" NO="63">
<NAME>Active drug versus placebo: AE - diastolic blood pressure, supine, baseline to endpoint mean change</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.21857259505388638" CI_START="-0.24184734652738699" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.011637375736750317" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-063.01" MODIFIED="2010-05-09 00:07:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.921076015971225" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="143" TOTAL_2="147" UNITS="" WEIGHT="100.0" Z="0.09907840759570873">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.21857259505388638" CI_START="-0.24184734652738699" DF="0" EFFECT_SIZE="-0.011637375736750317" ESTIMABLE="YES" I2="0.0" ID="CMP-063.01.01" MODIFIED="2010-05-09 00:07:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.921076015971225" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0" Z="0.09907840759570873">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.21857259505388638" CI_START="-0.24184734652738699" EFFECT_SIZE="-0.011637375736750317" ESTIMABLE="YES" MEAN_1="-0.21" MEAN_2="-0.1" MODIFIED="2008-08-29 17:02:22 +0100" MODIFIED_BY="[Empty name]" ORDER="535" SD_1="8.61" SD_2="10.16" SE="0.11745622501561434" STUDY_ID="STD-Zanarini-2007" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-064" MODIFIED="2010-05-12 12:20:50 +0100" MODIFIED_BY="[Empty name]" NO="64">
<NAME>Active drug versus placebo: AE - systolic blood pressure, standing, baseline to endpoint mean change</NAME>
<CONT_OUTCOME CHI2="8.724260787597812E-34" CI_END="0.25952148792952606" CI_START="-0.20091954403219178" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.029300971948667133" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-064.01" MODIFIED="2010-05-09 00:07:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.8030115639777149" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="143" TOTAL_2="147" UNITS="" WEIGHT="100.0" Z="0.24945148561903477">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.724260787597812E-34" CI_END="0.25952148792952606" CI_START="-0.20091954403219178" DF="0" EFFECT_SIZE="0.029300971948667133" ESTIMABLE="YES" I2="100.0" ID="CMP-064.01.01" MODIFIED="2010-05-09 00:07:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.8030115639777149" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0" Z="0.24945148561903477">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.25952148792952606" CI_START="-0.20091954403219178" EFFECT_SIZE="0.02930097194866713" ESTIMABLE="YES" MEAN_1="0.69" MEAN_2="0.34" MODIFIED="2008-08-29 17:03:32 +0100" MODIFIED_BY="[Empty name]" ORDER="536" SD_1="11.37" SD_2="12.42" SE="0.11746160531357155" STUDY_ID="STD-Zanarini-2007" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-065" MODIFIED="2010-05-12 12:20:55 +0100" MODIFIED_BY="[Empty name]" NO="65">
<NAME>Active drug versus placebo: AE - systolic blood pressure, supine, baseline to endpoint mean change</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.18663038907774632" CI_START="-0.2738410576362286" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.04360533427924117" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-065.01" MODIFIED="2010-05-09 00:08:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7104840962562551" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="143" TOTAL_2="147" UNITS="" WEIGHT="100.0" Z="0.3712060121470665">
<NAME>SMD</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.18663038907774632" CI_START="-0.2738410576362286" DF="0" EFFECT_SIZE="-0.04360533427924117" ESTIMABLE="YES" I2="0.0" ID="CMP-065.01.01" MODIFIED="2010-05-09 00:08:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7104840962562551" STUDIES="1" TAU2="0.0" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0" Z="0.3712060121470665">
<NAME>

Second-generation antipsychotic: Olanzapine</NAME>
<CONT_DATA CI_END="0.18663038907774632" CI_START="-0.2738410576362286" EFFECT_SIZE="-0.04360533427924117" ESTIMABLE="YES" MEAN_1="-0.91" MEAN_2="-0.4" MODIFIED="2008-08-29 17:04:13 +0100" MODIFIED_BY="[Empty name]" ORDER="537" SD_1="11.3" SD_2="12.01" SE="0.11746936432151686" STUDY_ID="STD-Zanarini-2007" TOTAL_1="143" TOTAL_2="147" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-066" MODIFIED="2010-05-12 12:21:02 +0100" MODIFIED_BY="[Empty name]" NO="66">
<NAME>Drug versus drug: BPD severity</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9612422923945527" CI_START="-0.03454600340363939" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.46334814449545664" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-066.01" MODIFIED="2010-05-09 00:08:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.06815609564880255" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="34" UNITS="" WEIGHT="100.0" Z="1.8239733874088477">
<NAME>

First-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9612422923945527" CI_START="-0.03454600340363939" DF="0" EFFECT_SIZE="0.46334814449545664" ESTIMABLE="YES" I2="0.0" ID="CMP-066.01.01" MODIFIED="2010-05-09 00:08:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06815609564880255" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="1.8239733874088477">
<NAME>Haloperidol 
versus 
phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.9612422923945527" CI_START="-0.03454600340363939" EFFECT_SIZE="0.46334814449545664" ESTIMABLE="YES" MEAN_1="24.03" MEAN_2="18.3" MODIFIED="2008-09-25 16:01:53 +0100" MODIFIED_BY="[Empty name]" ORDER="652" SD_1="13.24" SD_2="11.24" SE="0.2540322943821527" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-067" MODIFIED="2010-05-12 12:21:07 +0100" MODIFIED_BY="[Empty name]" NO="67">
<NAME>Drug versus drug: Interpersonal problems</NAME>
<CONT_OUTCOME CHI2="0.7834917108605534" CI_END="0.05291684408501607" CI_START="-0.6662690472757513" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3066761015953676" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-067.01" MODIFIED="2010-05-09 00:09:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3760754180355421" P_Q="0.3760754180355421" P_Z="0.09461499799361861" Q="0.7834917108605534" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="1.67154033822543">
<NAME>

First-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.38286635795401114" CI_START="-0.6570167584903922" DF="0" EFFECT_SIZE="-0.13707520026819056" ESTIMABLE="YES" I2="0.0" ID="CMP-067.01.01" MODIFIED="2008-09-29 13:00:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6053539794946695" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="0.5167166414200216">
<NAME>Haloperidol vs. Amitriptyline</NAME>
<CONT_DATA CI_END="0.38286635795401114" CI_START="-0.6570167584903922" EFFECT_SIZE="-0.13707520026819056" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="1.34" MODIFIED="2008-09-25 16:05:28 +0100" MODIFIED_BY="[Empty name]" ORDER="654" SD_1="0.92" SD_2="0.95" SE="0.26528117981934074" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.035682512366850994" CI_START="-0.9600361488388498" DF="0" EFFECT_SIZE="-0.4621768182359994" ESTIMABLE="YES" I2="0.0" ID="CMP-067.01.02" MODIFIED="2008-09-29 13:00:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.06883675460416479" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="1.8194896882518876">
<NAME>Haloperidol vs. Phenelzine Sulfate</NAME>
<CONT_DATA CI_END="0.035682512366850994" CI_START="-0.9600361488388498" EFFECT_SIZE="-0.4621768182359994" ESTIMABLE="YES" MEAN_1="0.57" MEAN_2="0.9" MODIFIED="2008-09-25 16:06:36 +0100" MODIFIED_BY="[Empty name]" ORDER="653" SD_1="0.7" SD_2="0.71" SE="0.25401453012907443" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-068" MODIFIED="2010-05-12 12:21:13 +0100" MODIFIED_BY="[Empty name]" NO="68">
<NAME>Drug versus drug: Impulsivity</NAME>
<CONT_OUTCOME CHI2="0.08862340149214187" CI_END="0.49852525104272016" CI_START="-0.21607118083214819" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.14122703510528598" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-068.01" MODIFIED="2010-05-09 00:15:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7659345794533285" P_Q="0.7659345794533285" P_Z="0.4385153454876012" Q="0.08862340149214187" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="58" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="0.7747027275898976">
<NAME>

First-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.719412094029996" CI_START="-0.32191202553288095" DF="0" EFFECT_SIZE="0.19875003424855747" ESTIMABLE="YES" I2="0.0" ID="CMP-068.01.01" MODIFIED="2010-05-09 00:15:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.45435858452668154" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="0.7481684169896993">
<NAME>Haloperidol 
versus 
amitriptyline</NAME>
<CONT_DATA CI_END="0.719412094029996" CI_START="-0.32191202553288095" EFFECT_SIZE="0.19875003424855747" ESTIMABLE="YES" MEAN_1="104.02" MEAN_2="100.5" MODIFIED="2008-09-25 18:00:26 +0100" MODIFIED_BY="[Empty name]" ORDER="655" SD_1="15.71" SD_2="19.01" SE="0.2656487894105985" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.581241469387013" CI_START="-0.4011879758918533" DF="0" EFFECT_SIZE="0.09002674674757985" ESTIMABLE="YES" I2="0.0" ID="CMP-068.01.02" MODIFIED="2010-05-09 00:15:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7194380872076243" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="0.35920987938320437">
<NAME>Haloperidol 
versus 
phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.581241469387013" CI_START="-0.4011879758918533" EFFECT_SIZE="0.09002674674757985" ESTIMABLE="YES" MEAN_1="240.95" MEAN_2="237.66" MODIFIED="2008-09-25 18:00:42 +0100" MODIFIED_BY="[Empty name]" ORDER="656" SD_1="37.6" SD_2="34.73" SE="0.25062436173015024" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5346003885239863" CI_START="-0.9332318571723441" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.19931573432417896" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-068.02" MODIFIED="2010-05-09 00:15:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5945294546544273" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.5322837973793415">
<NAME>

Second-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5346003885239863" CI_START="-0.9332318571723441" DF="0" EFFECT_SIZE="-0.19931573432417896" ESTIMABLE="YES" I2="0.0" ID="CMP-068.02.01" MODIFIED="2010-05-09 00:15:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5945294546544273" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0" Z="0.5322837973793415">
<NAME>Olanzapine 
versus 
fluoxetine</NAME>
<CONT_DATA CI_END="0.5346003885239863" CI_START="-0.9332318571723441" EFFECT_SIZE="-0.19931573432417896" ESTIMABLE="YES" MEAN_1="-19.69" MEAN_2="-15.38" MODIFIED="2008-09-26 12:48:16 +0100" MODIFIED_BY="[Empty name]" ORDER="672" SD_1="20.83" SD_2="21.25" SE="0.3744538821311013" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-069" MODIFIED="2010-05-12 12:22:25 +0100" MODIFIED_BY="[Empty name]" NO="69">
<NAME>Drug versus drug: Anger</NAME>
<CONT_OUTCOME CHI2="1.4496281787857659" CI_END="0.22922857959965812" CI_START="-0.48738438315663446" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.12907790177848819" ESTIMABLE="YES" I2="31.016793503723303" I2_Q="31.016793503723303" ID="CMP-069.01" MODIFIED="2010-05-09 00:17:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22858790865286072" P_Q="0.22858790865286072" P_Z="0.4801470740864948" Q="1.4496281787857659" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.03017891232221987" TOTALS="SUB" TOTAL_1="58" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="0.7060660407614541">
<NAME>

First-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.160025120438812" CI_START="-0.8877372801398072" DF="0" EFFECT_SIZE="-0.3638560798504976" ESTIMABLE="YES" I2="0.0" ID="CMP-069.01.01" MODIFIED="2010-05-09 00:16:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.17342774643086104" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="1.3612720053116554">
<NAME>Haloperidol 
versus 
amitriptyline</NAME>
<CONT_DATA CI_END="0.160025120438812" CI_START="-0.8877372801398072" EFFECT_SIZE="-0.3638560798504976" ESTIMABLE="YES" MEAN_1="0.78" MEAN_2="1.12" MODIFIED="2008-09-25 18:04:38 +0100" MODIFIED_BY="[Empty name]" ORDER="657" SD_1="0.82" SD_2="1.01" SE="0.26729123821744566" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5684209686908168" CI_START="-0.41386958098151755" DF="0" EFFECT_SIZE="0.07727569385464965" ESTIMABLE="YES" I2="0.0" ID="CMP-069.01.02" MODIFIED="2010-05-09 00:17:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7577959921037223" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="0.30837632895069317">
<NAME>Haloperidol 
versus 
phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.5684209686908168" CI_START="-0.41386958098151755" EFFECT_SIZE="0.07727569385464965" ESTIMABLE="YES" MEAN_1="0.79" MEAN_2="0.73" MODIFIED="2008-09-25 18:04:50 +0100" MODIFIED_BY="[Empty name]" ORDER="659" SD_1="0.66" SD_2="0.85" SE="0.2505889285263701" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-070" MODIFIED="2010-05-12 12:22:33 +0100" MODIFIED_BY="[Empty name]" NO="70">
<NAME>Drug versus drug: Psychotic symptoms</NAME>
<CONT_OUTCOME CHI2="1.8409449344664661" CI_END="0.2767734914596487" CI_START="-0.43998231471035476" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.08160441162535305" ESTIMABLE="YES" I2="45.68006998591648" I2_Q="45.68006998591648" ID="CMP-070.01" MODIFIED="2010-05-09 00:17:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.17484041072405676" P_Q="0.17484041072405676" P_Z="0.6553852944081353" Q="1.8409449344664661" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.05645234631669483" TOTALS="SUB" TOTAL_1="58" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="0.4462934416113763">
<NAME>

First-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.17772503355903385" CI_START="-0.8691473479813112" DF="0" EFFECT_SIZE="-0.3457111572111387" ESTIMABLE="YES" I2="0.0" ID="CMP-070.01.01" MODIFIED="2010-05-09 00:17:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1954972087324199" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="1.2944871392834303">
<NAME>Haloperidol 
versus 
amitriptyline</NAME>
<CONT_DATA CI_END="0.17772503355903385" CI_START="-0.8691473479813112" EFFECT_SIZE="-0.3457111572111387" ESTIMABLE="YES" MEAN_1="0.75" MEAN_2="1.03" MODIFIED="2008-09-25 18:07:49 +0100" MODIFIED_BY="[Empty name]" ORDER="660" SD_1="0.73" SD_2="0.86" SE="0.2670641883723224" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.643142020391643" CI_START="-0.34025249288683723" DF="0" EFFECT_SIZE="0.15144476375240293" ESTIMABLE="YES" I2="0.0" ID="CMP-070.01.02" MODIFIED="2010-05-09 00:17:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.546058468764658" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="0.6036769141863836">
<NAME>Haloperidol 
versus 
phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.643142020391643" CI_START="-0.34025249288683723" EFFECT_SIZE="0.15144476375240293" ESTIMABLE="YES" MEAN_1="1.06" MEAN_2="0.92" MODIFIED="2008-09-25 18:07:59 +0100" MODIFIED_BY="[Empty name]" ORDER="661" SD_1="0.96" SD_2="0.87" SE="0.25087055707027545" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-071" MODIFIED="2010-05-12 12:22:40 +0100" MODIFIED_BY="[Empty name]" NO="71">
<NAME>Drug versus drug: Depression</NAME>
<CONT_OUTCOME CHI2="2.67421524535803" CI_END="0.7482297089605778" CI_START="0.02344002028482045" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3858348646226991" ESTIMABLE="YES" I2="62.60585225008252" I2_Q="62.60585225008252" ID="CMP-071.01" MODIFIED="2010-05-09 00:18:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10198564768086926" P_Q="0.10198564768086926" P_Z="0.03691198751892175" Q="2.67421524535803" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.11455623709071207" TOTALS="SUB" TOTAL_1="58" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="2.0867361952183683">
<NAME>

First-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5947715421024189" CI_START="-0.4441976330735176" DF="0" EFFECT_SIZE="0.07528695451445061" ESTIMABLE="YES" I2="0.0" ID="CMP-071.01.01" MODIFIED="2010-05-09 00:18:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7763718835396914" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="0.2840502353287643">
<NAME>Haloperidol 
versus 
amitriptyline</NAME>
<CONT_DATA CI_END="0.5947715421024189" CI_START="-0.4441976330735176" EFFECT_SIZE="0.07528695451445061" ESTIMABLE="YES" MEAN_1="16.22" MEAN_2="15.34" MODIFIED="2008-09-25 18:11:59 +0100" MODIFIED_BY="[Empty name]" ORDER="662" SD_1="12.32" SD_2="10.71" SE="0.26504802725233545" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1860302529610494" CI_START="0.17443647015685437" DF="0" EFFECT_SIZE="0.6802333615589519" ESTIMABLE="YES" I2="0.0" ID="CMP-071.01.02" MODIFIED="2010-05-09 00:18:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.00839130572531293" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="2.635905661741736">
<NAME>Haloperidol 
versus 
phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="1.1860302529610491" CI_START="0.17443647015685426" EFFECT_SIZE="0.6802333615589518" ESTIMABLE="YES" MEAN_1="23.5" MEAN_2="15.69" MODIFIED="2008-09-25 18:12:11 +0100" MODIFIED_BY="[Empty name]" ORDER="663" SD_1="13.16" SD_2="9.46" SE="0.2580643804640079" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.217868233173732E-32" CI_END="0.03133074952432868" CI_START="-1.4867984369392055" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.7277338437074384" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-071.02" MODIFIED="2010-05-09 00:19:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.060235543953137446" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.8790655455615153">
<NAME>

Second-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.217868233173732E-32" CI_END="0.03133074952432868" CI_START="-1.4867984369392055" DF="0" EFFECT_SIZE="-0.7277338437074384" ESTIMABLE="YES" I2="100.0" ID="CMP-071.02.01" MODIFIED="2010-05-09 00:19:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.060235543953137446" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0" Z="1.8790655455615153">
<NAME>Olanzapine 
versus 
fluoxetine</NAME>
<CONT_DATA CI_END="0.031330749524328794" CI_START="-1.4867984369392055" EFFECT_SIZE="-0.7277338437074383" ESTIMABLE="YES" MEAN_1="-13.63" MEAN_2="-8.23" MODIFIED="2008-09-26 12:52:16 +0100" MODIFIED_BY="[Empty name]" ORDER="673" SD_1="7.23" SD_2="7.19" SE="0.3872849701418861" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-072" MODIFIED="2010-05-12 12:22:46 +0100" MODIFIED_BY="[Empty name]" NO="72">
<NAME>Drug versus drug: Anxiety</NAME>
<CONT_OUTCOME CHI2="5.17520367626764" CI_END="0.6129253821885259" CI_START="-0.11184349370507979" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2505409442417231" ESTIMABLE="YES" I2="80.67708900838467" I2_Q="80.67708900838467" ID="CMP-072.01" MODIFIED="2010-05-09 00:20:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.022911528449463203" P_Q="0.022911528449463203" P_Z="0.17539969789286117" Q="5.17520367626764" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.2857270595185789" TOTALS="SUB" TOTAL_1="58" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="1.3550560563489766">
<NAME>

First-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.33740405401310536" CI_START="-0.7035032176698783" DF="0" EFFECT_SIZE="-0.18304958182838646" ESTIMABLE="YES" I2="0.0" ID="CMP-072.01.01" MODIFIED="2010-05-09 00:19:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49060803268011877" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="0.6893420721111484">
<NAME>Haloperidol 
versus 
amitriptyline</NAME>
<CONT_DATA CI_END="0.33740405401310536" CI_START="-0.7035032176698783" EFFECT_SIZE="-0.18304958182838646" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="1.39" MODIFIED="2008-09-25 18:14:24 +0100" MODIFIED_BY="[Empty name]" ORDER="664" SD_1="0.98" SD_2="0.96" SE="0.2655424487116925" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8575553931659886E-31" CI_END="1.1634486484460589" CI_START="0.15369035290346889" DF="0" EFFECT_SIZE="0.6585695006747639" ESTIMABLE="YES" I2="100.0" ID="CMP-072.01.02" MODIFIED="2010-05-09 00:20:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.010570160347712108" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="2.5565969763991334">
<NAME>Haloperidol 
versus 
phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="1.1634486484460589" CI_START="0.15369035290346877" EFFECT_SIZE="0.6585695006747638" ESTIMABLE="YES" MEAN_1="1.57" MEAN_2="1.05" MODIFIED="2008-09-25 18:14:36 +0100" MODIFIED_BY="[Empty name]" ORDER="665" SD_1="0.78" SD_2="0.78" SE="0.2575961353135656" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-073" MODIFIED="2010-05-12 12:22:55 +0100" MODIFIED_BY="[Empty name]" NO="73">
<NAME>Drug versus drug: General psychiatric pathology</NAME>
<CONT_OUTCOME CHI2="2.6217319971332484" CI_END="0.6022956473028214" CI_START="-0.11814087148611033" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2420773879083555" ESTIMABLE="YES" I2="61.85727598803168" I2_Q="61.85727598803168" ID="CMP-073.01" MODIFIED="2010-05-09 00:21:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10540937811977658" P_Q="0.10540937811977658" P_Z="0.18778697169831124" Q="2.6217319971332484" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1097181825260027" TOTALS="SUB" TOTAL_1="58" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="1.3171541125358017">
<NAME>

First-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.45234190193811974" CI_START="-0.5865460590527601" DF="0" EFFECT_SIZE="-0.06710207855732017" ESTIMABLE="YES" I2="0.0" ID="CMP-073.01.01" MODIFIED="2010-05-09 00:20:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8001219356277725" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="0.25318929893977193">
<NAME>Haloperidol 
versus 
amitriptyline</NAME>
<CONT_DATA CI_END="0.45234190193811974" CI_START="-0.5865460590527601" EFFECT_SIZE="-0.06710207855732017" ESTIMABLE="YES" MEAN_1="1.02" MEAN_2="1.07" MODIFIED="2008-09-26 09:30:39 +0100" MODIFIED_BY="[Empty name]" ORDER="665" SD_1="0.74" SD_2="0.73" SE="0.2650273089672809" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0284689923472836" CI_START="0.02853841357908382" DF="0" EFFECT_SIZE="0.5285037029631837" ESTIMABLE="YES" I2="0.0" ID="CMP-073.01.02" MODIFIED="2010-05-09 00:21:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03828033916692018" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="2.0718402767118924">
<NAME>Haloperidol 
versus 
phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="1.0284689923472836" CI_START="0.02853841357908382" EFFECT_SIZE="0.5285037029631837" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="0.99" MODIFIED="2008-09-26 09:30:53 +0100" MODIFIED_BY="[Empty name]" ORDER="666" SD_1="0.67" SD_2="0.64" SE="0.2550890186389966" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-074" MODIFIED="2010-05-12 12:23:02 +0100" MODIFIED_BY="[Empty name]" NO="74">
<NAME>Drug versus drug: Mental health status</NAME>
<CONT_OUTCOME CHI2="4.704650680692106" CI_END="0.23425071797960456" CI_START="-0.48753655012786884" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.12664291607413214" ESTIMABLE="YES" I2="78.74443677393518" I2_Q="78.74443677393518" ID="CMP-074.01" MODIFIED="2010-05-09 00:22:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03008119589044056" P_Q="0.03008119589044056" P_Z="0.4915911090257228" Q="4.704650680692106" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.2517183418842078" TOTALS="SUB" TOTAL_1="58" TOTAL_2="63" UNITS="" WEIGHT="200.0" Z="0.6877803623587017">
<NAME>

First-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>active drug</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.813319122136686" CI_START="-0.23114490284686323" DF="0" EFFECT_SIZE="0.2910871096449114" ESTIMABLE="YES" I2="0.0" ID="CMP-074.01.01" MODIFIED="2010-05-09 00:21:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.27462873644077135" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0" Z="1.0924651067362021">
<NAME>Haloperidol 
versus 
amitriptyline</NAME>
<CONT_DATA CI_END="0.813319122136686" CI_START="-0.23114490284686323" EFFECT_SIZE="0.2910871096449114" ESTIMABLE="YES" MEAN_1="55.35" MEAN_2="51.48" MODIFIED="2008-09-26 10:58:06 +0100" MODIFIED_BY="[Empty name]" ORDER="667" SD_1="12.36" SD_2="13.8" SE="0.2664498004101474" STUDY_ID="STD-Soloff-1989" TOTAL_1="28" TOTAL_2="29" WEIGHT="100.0">
<FOOTNOTE>Despite of the high heterogeneity (I<SUP>2</SUP> 84%), we decided to pool estimates, as clinical heterogeneity was quite low, and the same pattern of more favourable results in the Soloff 1989 study and less favourable results in the Soloff 1993 study was found for several outcomes</FOOTNOTE>
</CONT_DATA>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.009192721439619744" CI_START="-1.007795143248789" DF="0" EFFECT_SIZE="-0.5084939323442044" ESTIMABLE="YES" I2="0.0" ID="CMP-074.01.02" MODIFIED="2010-05-09 00:22:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.04592856528725986" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="1.9960492223645765">
<NAME>Haloperidol 
versus 
phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="-0.009192721439619744" CI_START="-1.007795143248789" EFFECT_SIZE="-0.5084939323442044" ESTIMABLE="YES" MEAN_1="54.95" MEAN_2="60.1" MODIFIED="2008-09-26 10:58:20 +0100" MODIFIED_BY="[Empty name]" ORDER="675" SD_1="9.15" SD_2="10.7" SE="0.25475019686229383" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-075" MODIFIED="2010-05-12 12:23:08 +0100" MODIFIED_BY="[Empty name]" NO="75">
<NAME>Drug versus drug: AE - attrition</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.8529338918137075" CI_START="0.45781728512091296" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-075.01" LOG_CI_END="0.4552917083016078" LOG_CI_START="-0.33930781434623425" LOG_EFFECT_SIZE="0.05799194697768673" METHOD="MH" MODIFIED="2010-05-09 00:22:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.7748118149460548" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.28608657375193586">
<NAME>

First-generation antipsychotic 
versus first-generation antipsychotic</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8529338918137075" CI_START="0.45781728512091296" DF="0" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-075.01.01" LOG_CI_END="0.4552917083016078" LOG_CI_START="-0.33930781434623425" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2010-05-09 00:22:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7748118149460548" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.28608657375193586">
<NAME>Loxapine 
versus 
chlorpromazine</NAME>
<DICH_DATA CI_END="2.8529338918137075" CI_START="0.45781728512091296" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4552917083016078" LOG_CI_START="-0.33930781434623425" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2008-09-25 15:51:59 +0100" MODIFIED_BY="[Empty name]" ORDER="646" O_E="0.0" SE="0.4667516929344155" STUDY_ID="STD-Leone-1982" TOTAL_1="40" TOTAL_2="40" VAR="0.21785714285714286" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22758330990538927" CI_END="5.129806257721798" CI_START="0.6399712356707532" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.811885330120475" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-075.02" LOG_CI_END="0.7101009630082618" LOG_CI_START="-0.1938395455008036" LOG_EFFECT_SIZE="0.2581307087537291" METHOD="MH" MODIFIED="2010-05-09 00:23:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6333216068086593" P_Q="0.0" P_Z="0.2629776727237225" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="67" TOTAL_2="68" WEIGHT="200.0" Z="1.119380949738759">
<NAME>

First-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.38050340998278" CI_START="0.3195056573506123" DF="0" EFFECT_SIZE="2.903225806451613" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-075.02.01" LOG_CI_END="1.4212830787801585" LOG_CI_START="-0.4955214475700541" LOG_EFFECT_SIZE="0.46288081560505223" MODIFIED="2010-05-09 00:23:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.34383938684750115" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="30" WEIGHT="100.0" Z="0.946606412128924">
<NAME>Haloperidol 
versus 
amitriptyline</NAME>
<DICH_DATA CI_END="26.38050340998278" CI_START="0.3195056573506123" EFFECT_SIZE="2.903225806451613" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4212830787801585" LOG_CI_START="-0.4955214475700541" LOG_EFFECT_SIZE="0.46288081560505223" MODIFIED="2008-09-26 11:00:42 +0100" MODIFIED_BY="[Empty name]" ORDER="677" O_E="0.0" SE="1.1259404671135462" STUDY_ID="STD-Soloff-1989" TOTAL_1="31" TOTAL_2="30" VAR="1.2677419354838708" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.153653543258983" CI_START="0.4864402357282139" DF="0" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-075.02.02" LOG_CI_END="0.7121152195489482" LOG_CI_START="-0.31297050973853996" LOG_EFFECT_SIZE="0.1995723549052041" MODIFIED="2010-05-09 00:23:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.44536517698759637" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="38" WEIGHT="100.00000000000001" Z="0.7631647124693222">
<NAME>Haloperidol 
versus 
phenelzine 
sulfate</NAME>
<DICH_DATA CI_END="5.153653543258983" CI_START="0.4864402357282139" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7121152195489482" LOG_CI_START="-0.31297050973853996" LOG_EFFECT_SIZE="0.1995723549052041" MODIFIED="2008-09-26 11:00:52 +0100" MODIFIED_BY="[Empty name]" ORDER="678" O_E="0.0" SE="0.6021404316396671" STUDY_ID="STD-Soloff-1993" TOTAL_1="36" TOTAL_2="38" VAR="0.36257309941520466" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.690017380199802" CI_START="0.012930488128094391" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-075.03" LOG_CI_END="0.8254272460361436" LOG_CI_START="-1.8883850801206539" LOG_EFFECT_SIZE="-0.5314789170422551" METHOD="MH" MODIFIED="2010-05-09 00:23:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.44267303009866277" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0" Z="0.7676872316519839">
<NAME>

Second-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.690017380199802" CI_START="0.012930488128094391" DF="0" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-075.03.01" LOG_CI_END="0.8254272460361436" LOG_CI_START="-1.8883850801206539" LOG_EFFECT_SIZE="-0.5314789170422551" MODIFIED="2010-05-09 00:23:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.44267303009866277" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0" Z="0.7676872316519839">
<NAME>Olanzapine 
versus 
fluoxetine</NAME>
<DICH_DATA CI_END="6.690017380199802" CI_START="0.012930488128094391" EFFECT_SIZE="0.29411764705882354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8254272460361436" LOG_CI_START="-1.8883850801206539" LOG_EFFECT_SIZE="-0.5314789170422551" MODIFIED="2008-09-26 12:53:46 +0100" MODIFIED_BY="[Empty name]" ORDER="674" O_E="0.0" SE="1.5941067939721714" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="14" VAR="2.541176470588235" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-076" MODIFIED="2010-05-12 12:23:13 +0100" MODIFIED_BY="[Empty name]" NO="76">
<NAME>Drug versus drug: AE - body weight change</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.20588861096749506" CI_START="-0.7813918987142876" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2877516438733963" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-076.01" MODIFIED="2010-05-09 19:50:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2532472184317406" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="34" UNITS="" WEIGHT="100.0" Z="1.1424977054714343">
<NAME>

First-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.20588861096749506" CI_START="-0.7813918987142876" DF="0" EFFECT_SIZE="-0.2877516438733963" ESTIMABLE="YES" I2="0.0" ID="CMP-076.01.01" MODIFIED="2010-05-09 19:50:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2532472184317406" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0" Z="1.1424977054714343">
<NAME>Haloperidol 
versus 
phenelzine 
sulfate</NAME>
<CONT_DATA CI_END="0.20588861096749506" CI_START="-0.7813918987142876" EFFECT_SIZE="-0.2877516438733963" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="0.5" MODIFIED="2008-09-26 11:05:58 +0100" MODIFIED_BY="[Empty name]" ORDER="680" SD_1="0.66" SD_2="0.83" SE="0.2518619008995383" STUDY_ID="STD-Soloff-1993" TOTAL_1="30" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.7641330050454131" CI_START="0.2024734423859894" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.9833032237157012" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-076.02" MODIFIED="2010-05-09 00:25:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.013579693255612169" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="2.4681933891954277">
<NAME>

Second-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7641330050454131" CI_START="0.2024734423859894" DF="0" EFFECT_SIZE="0.9833032237157012" ESTIMABLE="YES" I2="0.0" ID="CMP-076.02.01" MODIFIED="2010-05-09 00:25:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.013579693255612169" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0" Z="2.4681933891954277">
<NAME>Olanzapine 
versus 
fluoxetine</NAME>
<CONT_DATA CI_END="1.7641330050454131" CI_START="0.2024734423859894" EFFECT_SIZE="0.9833032237157012" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="0.4" MODIFIED="2008-09-26 12:54:47 +0100" MODIFIED_BY="[Empty name]" ORDER="675" SD_1="2.6" SD_2="2.3" SE="0.39838986200195387" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-077" MODIFIED="2010-05-12 12:23:21 +0100" MODIFIED_BY="[Empty name]" NO="77">
<NAME>Drug versus drug: AE - any AE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.454883932892446" CI_START="0.6598416686996869" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-077.01" LOG_CI_END="0.3900309634667457" LOG_CI_START="-0.18056026242671971" LOG_EFFECT_SIZE="0.10473535052001297" METHOD="MH" MODIFIED="2010-05-09 00:26:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.4718171015263314" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.7195256625475381">
<NAME>

First-generation antipsychotic 
versus first-generation antipsychotic</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.454883932892446" CI_START="0.6598416686996869" DF="0" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" ID="CMP-077.01.01" LOG_CI_END="0.3900309634667457" LOG_CI_START="-0.18056026242671971" LOG_EFFECT_SIZE="0.10473535052001297" MODIFIED="2010-05-09 00:26:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4718171015263314" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.7195256625475381">
<NAME>Loxapine 
versus 
chlorpromazine</NAME>
<DICH_DATA CI_END="2.454883932892446" CI_START="0.6598416686996869" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3900309634667457" LOG_CI_START="-0.18056026242671971" LOG_EFFECT_SIZE="0.10473535052001297" MODIFIED="2008-09-25 15:52:29 +0100" MODIFIED_BY="[Empty name]" ORDER="647" O_E="0.0" SE="0.33516811056194223" STUDY_ID="STD-Leone-1982" TOTAL_1="40" TOTAL_2="40" VAR="0.11233766233766235" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-078" MODIFIED="2010-05-12 12:23:27 +0100" MODIFIED_BY="[Empty name]" NO="78">
<NAME>Drug versus drug: AE - sedation</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.923810973223993" CI_START="1.2344048101130132" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-078.01" LOG_CI_END="0.996678483324114" LOG_CI_START="0.0914576053764373" LOG_EFFECT_SIZE="0.5440680443502757" METHOD="MH" MODIFIED="2010-05-09 19:48:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.018472524593818283" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0" Z="2.3560079049067584">
<NAME>

Second-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.923810973223993" CI_START="1.2344048101130132" DF="0" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" ID="CMP-078.01.01" LOG_CI_END="0.996678483324114" LOG_CI_START="0.0914576053764373" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2010-05-09 00:26:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.018472524593818283" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0" Z="2.3560079049067584">
<NAME>Olanzapine 
versus 
fluoxetine</NAME>
<DICH_DATA CI_END="9.923810973223993" CI_START="1.2344048101130132" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.996678483324114" LOG_CI_START="0.0914576053764373" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2008-09-26 12:57:13 +0100" MODIFIED_BY="[Empty name]" ORDER="676" O_E="0.0" SE="0.5317312246220784" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="14" VAR="0.28273809523809523" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-079" MODIFIED="2010-05-12 12:23:33 +0100" MODIFIED_BY="[Empty name]" NO="79">
<NAME>Drug versus drug: AE - sleepiness/drowsiness</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7633577414555113" CI_START="0.23160229687195705" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-079.01" LOG_CI_END="0.4414371118737813" LOG_CI_START="-0.6352571378898941" LOG_EFFECT_SIZE="-0.09691001300805639" METHOD="MH" MODIFIED="2010-05-09 00:27:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.7242226896387851" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.3528209336657809">
<NAME>

First-generation antipsychotic 
versus first-generation antipsychotic</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7633577414555113" CI_START="0.23160229687195705" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-079.01.01" LOG_CI_END="0.4414371118737813" LOG_CI_START="-0.6352571378898941" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-05-09 00:27:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7242226896387851" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.3528209336657809">
<NAME>Loxapine 
versus 
chlorpromazine</NAME>
<DICH_DATA CI_END="2.7633577414555113" CI_START="0.23160229687195705" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4414371118737813" LOG_CI_START="-0.6352571378898941" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2008-09-25 15:55:25 +0100" MODIFIED_BY="[Empty name]" ORDER="651" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Leone-1982" TOTAL_1="40" TOTAL_2="40" VAR="0.39999999999999997" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-080" MODIFIED="2010-05-12 12:23:41 +0100" MODIFIED_BY="[Empty name]" NO="80">
<NAME>Drug versus drug: AE - restlessness</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.500739760948548" CI_START="0.26468284681954973" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-080.01" LOG_CI_END="0.9294567210223326" LOG_CI_START="-0.5772742029109699" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2010-05-09 00:27:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6468655263592189" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.45812098266422213">
<NAME>

First-generation antipsychotic 
versus first-generation antipsychotic</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.500739760948548" CI_START="0.26468284681954973" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-080.01.01" LOG_CI_END="0.9294567210223326" LOG_CI_START="-0.5772742029109699" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-05-09 00:27:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6468655263592189" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.45812098266422213">
<NAME>Loxapine 
versus 
chlorpromazine</NAME>
<DICH_DATA CI_END="8.500739760948548" CI_START="0.26468284681954973" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9294567210223326" LOG_CI_START="-0.5772742029109699" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2008-09-25 15:56:09 +0100" MODIFIED_BY="[Empty name]" ORDER="648" O_E="0.0" SE="0.8850612031567835" STUDY_ID="STD-Leone-1982" TOTAL_1="40" TOTAL_2="40" VAR="0.7833333333333332" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.10690768493134" CI_START="0.2325683291700405" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-080.02" LOG_CI_END="0.3236455072249843" LOG_CI_START="-0.6334494271964708" LOG_EFFECT_SIZE="-0.1549019599857432" METHOD="MH" MODIFIED="2010-05-09 19:49:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.5258037942327114" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0" Z="0.6344245524405432">
<NAME>

Second-generation antipsychotic 
versus antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.10690768493134" CI_START="0.2325683291700405" DF="0" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-080.02.01" LOG_CI_END="0.3236455072249843" LOG_CI_START="-0.6334494271964708" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2010-05-09 00:28:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5258037942327114" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="100.0" Z="0.6344245524405432">
<NAME>Olanzapine 
versus 
fluoxetine</NAME>
<DICH_DATA CI_END="2.10690768493134" CI_START="0.2325683291700405" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3236455072249843" LOG_CI_START="-0.6334494271964708" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2008-09-26 12:58:59 +0100" MODIFIED_BY="[Empty name]" ORDER="677" O_E="0.0" SE="0.5622023021754967" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="14" VAR="0.31607142857142856" WEIGHT="100.0">
<FOOTNOTE>event: akathisia</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-081" MODIFIED="2010-05-12 12:23:48 +0100" MODIFIED_BY="[Empty name]" NO="81">
<NAME>Drug versus drug: AE - muscle spasms</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="27.631151946828567" CI_START="0.32571931916986163" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-081.01" LOG_CI_END="1.4413989910953926" LOG_CI_START="-0.4871564816560678" LOG_EFFECT_SIZE="0.4771212547196624" METHOD="MH" MODIFIED="2010-05-09 00:28:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.3321545154462269" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.9697833313292663">
<NAME>

First-generation antipsychotic 
versus first-generation antipsychotic</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.631151946828567" CI_START="0.32571931916986163" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-081.01.01" LOG_CI_END="1.4413989910953926" LOG_CI_START="-0.4871564816560678" LOG_EFFECT_SIZE="0.4771212547196624" MODIFIED="2010-05-09 00:28:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3321545154462269" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.9697833313292663">
<NAME>Loxapine 
versus 
chlorpromazine</NAME>
<DICH_DATA CI_END="27.631151946828567" CI_START="0.32571931916986163" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4413989910953926" LOG_CI_START="-0.4871564816560678" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-09-25 15:56:47 +0100" MODIFIED_BY="[Empty name]" ORDER="649" O_E="0.0" SE="1.132843031197762" STUDY_ID="STD-Leone-1982" TOTAL_1="40" TOTAL_2="40" VAR="1.2833333333333334" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-082" MODIFIED="2010-05-12 12:23:55 +0100" MODIFIED_BY="[Empty name]" NO="82">
<NAME>Drug versus drug: AE - fainting spells</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6791162158885493" CI_START="0.0076174983168983594" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-082.01" LOG_CI_END="0.4279915530350077" LOG_CI_START="-2.1181876330635214" LOG_EFFECT_SIZE="-0.8450980400142569" METHOD="MH" MODIFIED="2010-05-09 00:29:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.1932390536594553" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.3010566820093685">
<NAME>

First-generation antipsychotic 
versus first-generation antipsychotic</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6791162158885493" CI_START="0.0076174983168983594" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-082.01.01" LOG_CI_END="0.4279915530350077" LOG_CI_START="-2.1181876330635214" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2010-05-09 00:29:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1932390536594553" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="1.3010566820093685">
<NAME>Loxapine 
versus 
chlorpromazine</NAME>
<DICH_DATA CI_END="2.6791162158885493" CI_START="0.0076174983168983594" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4279915530350077" LOG_CI_START="-2.1181876330635214" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2008-09-25 15:57:23 +0100" MODIFIED_BY="[Empty name]" ORDER="650" O_E="0.0" SE="1.4956382577045184" STUDY_ID="STD-Leone-1982" TOTAL_1="40" TOTAL_2="40" VAR="2.2369337979094075" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-083" MODIFIED="2010-05-12 12:24:06 +0100" MODIFIED_BY="[Empty name]" NO="83">
<NAME>Drug versus combination of drugs: Impulsivity</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7556276599017874" CI_START="-0.7081090312692887" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.023759314316249384" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-083.01" MODIFIED="2010-05-09 00:30:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9492663477177521" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.06362811103677263">
<NAME>

Second-generation 
antipsychotic versus second-generation 
antipsychotic + antidepressant</NAME>
<GROUP_LABEL_1>single drug</GROUP_LABEL_1>
<GROUP_LABEL_2>drug combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7556276599017874" CI_START="-0.7081090312692887" DF="0" EFFECT_SIZE="0.023759314316249384" ESTIMABLE="YES" I2="0.0" ID="CMP-083.01.01" MODIFIED="2010-05-09 00:30:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9492663477177521" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0" Z="0.06362811103677263">
<NAME>Olanzapine 
versus 
olanzapine + 
fluoxetine</NAME>
<CONT_DATA CI_END="0.7556276599017874" CI_START="-0.7081090312692887" EFFECT_SIZE="0.023759314316249384" ESTIMABLE="YES" MEAN_1="-19.69" MEAN_2="-20.15" MODIFIED="2008-09-26 16:50:18 +0100" MODIFIED_BY="[Empty name]" ORDER="678" SD_1="20.83" SD_2="15.95" SE="0.3734090786149246" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.018047152328293" CI_START="-0.5263066172912847" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.2458702675185041" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-083.02" MODIFIED="2010-05-09 00:31:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5325778417619921" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.6240757508873146">
<NAME>

Antidepressant 
versus antidepressant + second-generation antipsychotic</NAME>
<GROUP_LABEL_1>single drug</GROUP_LABEL_1>
<GROUP_LABEL_2>drug combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.018047152328293" CI_START="-0.5263066172912847" DF="0" EFFECT_SIZE="0.2458702675185041" ESTIMABLE="YES" I2="0.0" ID="CMP-083.02.01" MODIFIED="2010-05-09 00:31:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5325778417619921" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="0.6240757508873146">
<NAME>Fluoxetine 
versus 
fluoxetine + 
olanzapine</NAME>
<CONT_DATA CI_END="1.018047152328293" CI_START="-0.5263066172912847" EFFECT_SIZE="0.2458702675185041" ESTIMABLE="YES" MEAN_1="-15.38" MEAN_2="-20.15" MODIFIED="2008-09-26 16:53:18 +0100" MODIFIED_BY="[Empty name]" ORDER="679" SD_1="21.25" SD_2="15.95" SE="0.39397503775611264" STUDY_ID="STD-Zanarini-2004" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-084" MODIFIED="2010-05-12 12:24:16 +0100" MODIFIED_BY="[Empty name]" NO="84">
<NAME>Drug versus combination of drugs: Depression</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4726138197445011" CI_START="-0.9982808364001123" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2628335083278056" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-084.01" MODIFIED="2010-05-09 00:32:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.48364621534975716" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.7004501758175674">
<NAME>

Second-generation 
antipsychotic 
versus second-generation 
antipsychotic + antidepressant</NAME>
<GROUP_LABEL_1>single drug</GROUP_LABEL_1>
<GROUP_LABEL_2>drug combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4726138197445011" CI_START="-0.9982808364001123" DF="0" EFFECT_SIZE="-0.2628335083278056" ESTIMABLE="YES" I2="0.0" ID="CMP-084.01.01" MODIFIED="2010-05-09 00:32:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.48364621534975716" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0" Z="0.7004501758175674">
<NAME>Olanzapine 
versus 
olanzapine + 
fluoxetine</NAME>
<CONT_DATA CI_END="0.4726138197445011" CI_START="-0.9982808364001123" EFFECT_SIZE="-0.2628335083278056" ESTIMABLE="YES" MEAN_1="-13.63" MEAN_2="-11.85" MODIFIED="2008-09-26 16:54:26 +0100" MODIFIED_BY="[Empty name]" ORDER="680" SD_1="7.23" SD_2="5.67" SE="0.3752351236417717" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.3266253658355487" CI_START="-0.24374818622429517" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.5414385898056268" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-084.02" MODIFIED="2010-05-09 00:33:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.17652708131849518" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.00000000000001" Z="1.3515257366213513">
<NAME>

Antidepressant 
versus antidepressant + second-generation antipsychotic</NAME>
<GROUP_LABEL_1>single drug</GROUP_LABEL_1>
<GROUP_LABEL_2>drug combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3266253658355487" CI_START="-0.24374818622429517" DF="0" EFFECT_SIZE="0.5414385898056268" ESTIMABLE="YES" I2="0.0" ID="CMP-084.02.01" MODIFIED="2010-05-09 00:33:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.17652708131849518" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.00000000000001" Z="1.3515257366213513">
<NAME>Fluoxetine 
versus 
fluoxetine + 
olanzapine</NAME>
<CONT_DATA CI_END="1.3266253658355487" CI_START="-0.24374818622429517" EFFECT_SIZE="0.5414385898056268" ESTIMABLE="YES" MEAN_1="-8.23" MEAN_2="-11.85" MODIFIED="2008-09-26 16:54:55 +0100" MODIFIED_BY="[Empty name]" ORDER="681" SD_1="7.19" SD_2="5.67" SE="0.40061285932975044" STUDY_ID="STD-Zanarini-2004" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-085" MODIFIED="2010-05-12 12:24:24 +0100" MODIFIED_BY="[Empty name]" NO="85">
<NAME>Drug versus combination of drugs: AE - attrition</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.627555752732272" CI_START="0.00976760341308864" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.188235294117647" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-085.01" LOG_CI_END="0.5596140959320774" LOG_CI_START="-2.010211982048814" LOG_EFFECT_SIZE="-0.7252989430583681" METHOD="MH" MODIFIED="2010-05-09 00:34:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.2685763330867653" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="1.1063470937584123">
<NAME>

Second-generation antipsychotic 
versus second-generation antipsychotic + antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.627555752732272" CI_START="0.00976760341308864" DF="0" EFFECT_SIZE="0.188235294117647" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-085.01.01" LOG_CI_END="0.5596140959320774" LOG_CI_START="-2.010211982048814" LOG_EFFECT_SIZE="-0.7252989430583681" MODIFIED="2010-05-09 00:34:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2685763330867653" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="1.1063470937584123">
<NAME>Olanzapine 
versus 
olanzapine + 
fluoxetine</NAME>
<DICH_DATA CI_END="3.627555752732273" CI_START="0.00976760341308864" EFFECT_SIZE="0.18823529411764706" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5596140959320774" LOG_CI_START="-2.010211982048814" LOG_EFFECT_SIZE="-0.725298943058368" MODIFIED="2008-09-26 16:58:31 +0100" MODIFIED_BY="[Empty name]" ORDER="688" O_E="0.0" SE="1.5095285590502205" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="15" VAR="2.2786764705882354" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.2758346631279895" CI_START="0.05439704127274793" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-085.02" LOG_CI_END="0.7222911769394742" LOG_CI_START="-1.26442472151255" LOG_EFFECT_SIZE="-0.27106677228653797" METHOD="MH" MODIFIED="2010-05-09 00:34:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.5927649964441791" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="15" WEIGHT="99.99999999999999" Z="0.5348335023654758">
<NAME>

Antidepressant 
versus antidepressant + second-generation antipsychotic</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.2758346631279895" CI_START="0.05439704127274793" DF="0" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-085.02.01" LOG_CI_END="0.7222911769394742" LOG_CI_START="-1.26442472151255" LOG_EFFECT_SIZE="-0.27106677228653797" MODIFIED="2010-05-09 00:34:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5927649964441791" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="99.99999999999999" Z="0.5348335023654758">
<NAME>Fluoxetine 
versus 
fluoxetine + 
olanzapine</NAME>
<DICH_DATA CI_END="5.2758346631279895" CI_START="0.05439704127274793" EFFECT_SIZE="0.5357142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7222911769394742" LOG_CI_START="-1.26442472151255" LOG_EFFECT_SIZE="-0.27106677228653797" MODIFIED="2008-09-26 16:58:50 +0100" MODIFIED_BY="[Empty name]" ORDER="689" O_E="0.0" SE="1.1670067531530235" STUDY_ID="STD-Zanarini-2004" TOTAL_1="14" TOTAL_2="15" VAR="1.361904761904762" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-086" MODIFIED="2010-05-12 12:25:43 +0100" MODIFIED_BY="[Empty name]" NO="86">
<NAME>Drug versus combination of drugs: AE - body weight change</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.460949289434617" CI_START="-0.05369198299964406" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.7036286532174865" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-086.01" MODIFIED="2010-05-09 00:35:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.06860566454910709" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.8210078437652666">
<NAME>

Second-generation 
antips
ychotic 
versus second-generation 
antipsychotic + antidepressant</NAME>
<GROUP_LABEL_1>single drug</GROUP_LABEL_1>
<GROUP_LABEL_2>drug combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.460949289434617" CI_START="-0.05369198299964406" DF="0" EFFECT_SIZE="0.7036286532174865" ESTIMABLE="YES" I2="0.0" ID="CMP-086.01.01" MODIFIED="2010-05-09 00:35:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06860566454910709" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0" Z="1.8210078437652666">
<NAME>Olanzapine 
versus 
olanzapine + 
fluoxetine</NAME>
<CONT_DATA CI_END="1.460949289434617" CI_START="-0.05369198299964406" EFFECT_SIZE="0.7036286532174865" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="1.4" MODIFIED="2008-09-26 17:00:06 +0100" MODIFIED_BY="[Empty name]" ORDER="690" SD_1="2.6" SD_2="1.1" SE="0.38639517980472043" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.24774890829017804" CI_START="-1.3221156041369375" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5371833479233797" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-086.02" MODIFIED="2010-05-09 00:36:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.17981050909965943" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.3413387036779136">
<NAME>

Antidepressant 
versus antidepressant + second-generation antipsychotic</NAME>
<GROUP_LABEL_1>single drug</GROUP_LABEL_1>
<GROUP_LABEL_2>drug combination</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.24774890829017804" CI_START="-1.3221156041369375" DF="0" EFFECT_SIZE="-0.5371833479233797" ESTIMABLE="YES" I2="0.0" ID="CMP-086.02.01" MODIFIED="2010-05-09 00:36:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.17981050909965943" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0" Z="1.3413387036779136">
<NAME>Fluoxetine 
versus 
fluoxetine + 
olanzapine</NAME>
<CONT_DATA CI_END="0.24774890829017804" CI_START="-1.3221156041369375" EFFECT_SIZE="-0.5371833479233797" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.4" MODIFIED="2008-09-26 17:00:47 +0100" MODIFIED_BY="[Empty name]" ORDER="691" SD_1="2.3" SD_2="1.1" SE="0.40048299989438746" STUDY_ID="STD-Zanarini-2004" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-087" MODIFIED="2010-05-12 12:24:37 +0100" MODIFIED_BY="[Empty name]" NO="87">
<NAME>Drug versus combination of drugs: AE - sedation</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.959322054267041" CI_START="0.8728040125071943" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6071428571428572" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-087.01" LOG_CI_END="0.47119223071661487" LOG_CI_START="-0.059083265850365926" LOG_EFFECT_SIZE="0.20605448243312446" METHOD="MH" MODIFIED="2010-05-09 00:36:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.12770721752102523" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="15" WEIGHT="99.99999999999999" Z="1.5232058318235058">
<NAME>

Second-generation antipsychotic 
versus second-generation antipsychotic + antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.959322054267041" CI_START="0.8728040125071943" DF="0" EFFECT_SIZE="1.6071428571428572" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" ID="CMP-087.01.01" LOG_CI_END="0.47119223071661487" LOG_CI_START="-0.059083265850365926" LOG_EFFECT_SIZE="0.20605448243312446" MODIFIED="2010-05-09 00:36:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.12770721752102523" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="15" WEIGHT="99.99999999999999" Z="1.5232058318235058">
<NAME>Olanzapine 
versus 
olanzapine + 
fluoxetine</NAME>
<DICH_DATA CI_END="2.959322054267041" CI_START="0.8728040125071943" EFFECT_SIZE="1.6071428571428572" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.47119223071661487" LOG_CI_START="-0.059083265850365926" LOG_EFFECT_SIZE="0.20605448243312446" MODIFIED="2008-09-26 17:02:01 +0100" MODIFIED_BY="[Empty name]" ORDER="692" O_E="0.0" SE="0.31148645158948646" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.0970238095238095" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.435243954367492" CI_START="0.14690857630106668" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-087.02" LOG_CI_END="0.15692572617866216" LOG_CI_START="-0.8329528500129644" LOG_EFFECT_SIZE="-0.33801356191715115" METHOD="MH" MODIFIED="2010-05-09 00:37:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.1807215409925879" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.00000000000001" Z="1.3385367126391192">
<NAME>

Antidepressant 
versus antidepressant + second-generation antipsychotic</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.435243954367492" CI_START="0.14690857630106668" DF="0" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-087.02.01" LOG_CI_END="0.15692572617866216" LOG_CI_START="-0.8329528500129644" LOG_EFFECT_SIZE="-0.33801356191715115" MODIFIED="2010-05-09 00:37:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1807215409925879" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.00000000000001" Z="1.3385367126391192">
<NAME>Fluoxetine 
versus 
fluoxetine + 
olanzapine</NAME>
<DICH_DATA CI_END="1.435243954367492" CI_START="0.14690857630106668" EFFECT_SIZE="0.45918367346938777" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15692572617866216" LOG_CI_START="-0.8329528500129644" LOG_EFFECT_SIZE="-0.33801356191715115" MODIFIED="2008-09-26 17:02:20 +0100" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="0.5814595756329395" STUDY_ID="STD-Zanarini-2004" TOTAL_1="14" TOTAL_2="15" VAR="0.3380952380952381" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-088" MODIFIED="2010-05-12 12:24:46 +0100" MODIFIED_BY="[Empty name]" NO="88">
<NAME>Drug versus combination of drugs: AE - akathisia</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2761460827526774" CI_START="0.2471282508017832" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-088.01" LOG_CI_END="0.3572001315795652" LOG_CI_START="-0.6070776047961651" LOG_EFFECT_SIZE="-0.12493873660829993" METHOD="MH" MODIFIED="2010-05-09 00:38:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6115277054727243" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="0.5078939703545916">
<NAME>

Second-generation antipsychotic 
versus second-generation antipsychotic + antidepressant</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2761460827526774" CI_START="0.2471282508017832" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-088.01.01" LOG_CI_END="0.3572001315795652" LOG_CI_START="-0.6070776047961651" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2010-05-09 00:38:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6115277054727243" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="0.5078939703545916">
<NAME>Olanzapine 
versus 
olanzapine + 
fluoxetine</NAME>
<DICH_DATA CI_END="2.2761460827526774" CI_START="0.2471282508017832" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3572001315795652" LOG_CI_START="-0.6070776047961651" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2008-09-26 17:03:35 +0100" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="0.566421515598881" STUDY_ID="STD-Zanarini-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.32083333333333336" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.921322482738998" CI_START="0.3929587337434778" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-088.02" LOG_CI_END="0.46557950108297264" LOG_CI_START="-0.4056530543280862" LOG_EFFECT_SIZE="0.029963223377443202" METHOD="MH" MODIFIED="2010-05-09 00:38:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.8927595430817905" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="0.13481323285218422">
<NAME>

Antidepressant 
versus antidepressant + second-generation antipsychotic</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.921322482738998" CI_START="0.3929587337434778" DF="0" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-088.02.01" LOG_CI_END="0.46557950108297264" LOG_CI_START="-0.4056530543280862" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2010-05-09 00:38:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8927595430817905" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="0.13481323285218422">
<NAME>Fluoxetine 
versus 
fluoxetine + 
olanzapine</NAME>
<DICH_DATA CI_END="2.921322482738998" CI_START="0.3929587337434778" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.46557950108297264" LOG_CI_START="-0.4056530543280862" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2008-09-26 17:03:53 +0100" MODIFIED_BY="[Empty name]" ORDER="695" O_E="0.0" SE="0.5117663157191591" STUDY_ID="STD-Zanarini-2004" TOTAL_1="14" TOTAL_2="15" VAR="0.261904761904762" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-05-12 15:06:43 +0100" MODIFIED_BY="Chris Champion">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-05-12 12:02:30 +0100" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-003.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3.1.1 Active drug versus placebo: Interpersonal problems, SMDs</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwUAAANgCAMAAABKgjSiAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-05-12 12:02:30 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-005.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 5.1 Active drug versus placebo: Impulsivity, SMDs</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyEAAAUACAMAAABnEK1oAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAB7bUlEQVR42uy9W8wmR3oeVjOc2Rqu9kDyJ4fDw3JFEksEyAZKdhNg
ZQeJA9gyYNRaii3AiBH4InAuBPhCyYUVRICBBNaFnQQSkMAXVi4iwxBiRJsoUSWALN/ktFoDO4ZW
2TgA11wtKR6GnPmXs7vc5bz8V2S+r7u6661jV/Xh6/7+73nIf7q/rmNXv0/V+1Z31XtFCgAAkriK
JgAAMAQAwBAAWADXjqmySgsldDQkfnnu8hOlHKZ0p8AddNMgTvmqvSrS9elTCt3Ey8VFvY+NIUqI
Q4viVhtiLytKqzGJ9T6lFTaNeh81Q1TXc7TdRtu4bStZvrTNZeLorgXnbESWHa8RI61yfh0CTV8a
jqqd/DkVdJtDd0KqunHZ5Mb+1Sp2l6dY723bIUrr/W3v7lo3I7N2hLZtl44tYn+BS/T8Cp5fI1sJ
5fw6QMOYh69Tt9pVUPMKepLaNJi21dY6fkMz3tcR1nvbDNFtkzrib+7db7Uw6cw1Sdfo4Mqf7mQt
LFy7v/vq6pH369zlSdZ781pWejBQW6iRWqvn6M3dfPMUjaaDN6ROuN7Xtk6Qgu5izRqtNXOQVh8U
r1mZMaaHbkifcL2P5n2IHZ2tkddfi3Qmc9shyRo1B7VSW/R1U2owWq7f4VHdZPwuT7LeR2GHNAft
9j/mWnum2VXtXZqpJrYwt0btde38OkSzdA3i36pm9dTcbGKio8NG1uF5eJcnWe8rl/LLRaXnfY2n
8B7mZHHtUt6VxstFYCZcwdfvAHAZLHUAAEMAAAwBADAEAC4N+FyW9/V+fzU9KdSlGI5ZiOGFAvma
uBXqA1gds7Vdr3ilbenaj9G/IdXp0p1X0elvmoaepu7uRTlvlfpPZ2cQueOqLR9D9p9Ctp8Flt+r
PtjXrKU18SuktfvR7/EUH3x7l0ltPmzlH+5VPxj7KazW7nfUc3+1fFS1vRarvOLrLAT7x/kYv0/B
1rSofvGG9r7b768OEbtgoUCy4duDivW1dolJftnAWsXbcsNGE92XfEqP6q/tsgkdXAzuS4UjnhL6
IK+XNllbxw6xX+/b8lWUuF3/5n9pYz5N79dr+HRWxeQeXijgxVcF2bXrCkp6rFWKtwte/KUvKlgf
U9aI2ls2oXj2ql22p8J7Wemz6U3W9qrbB4al6fiKjHgK7R1T/exAT1y/UECL8o/UdC7mysWnWkwX
5Oo8I+V+3hR9MDqRcSuSakHpO6baXvUV33pVeSkKK1Vh/tfUpCzLNYuf/qi1rp486T7K1J1poPSh
vtzZcm2vxYb5aqNrdm1UiKqFAlU1GchyneJ124t2nwrPIXVKVa7V12K9WZft1vZqsuNSwzNnLIVy
pEulBK/unsq7UmedwFx9yZrFK1U5/dXNqqii3ic6XCpXB3TWFMy0QuQIa3vVHbe8r/fDj/idL+5Z
CjPYOb8E/1KfRRhqvIGFAqkxV3XmgE4Nyv29qc0W77ay2/6V47VujVvvgkgum2gtYTdYRZ/7QqbJ
Nmtb9m1vVYHpxRlYZlE9u1PdaKOWjim94g1uvLbXivhRpyBiccZ82nltU4IgcwPrQwAAAI4df3m1
kq9hDAGOAavJKb5+BwAwBABGa1nsnK9uiCxOML+DVxq1cwuq6NP9wVjhAoucb5HwfnKZFsYGTowh
zke9/pn99jj4/riSIKJkArN2mnOmGWbQAUgzROUJwr+/Z2s/FPcopBKeHPz4YTzhLgToYjnZKN9z
iPJ9i+hgWUecRck6sjUIeKsDBHaI/XxY+72qvzihX/uhmZ+b4Ht+18eD5vHdeMJbHWCLCz1zxErw
co2uMrMLM9J1jNwHgDGEscGsj9MptcN9va68haJa5RSWhMBpPzi6uXpTlFKaDyE6oykpvjRTpcpP
5QBmABGGVO9Hn1hXpVK/BnxCZIJTRYmy+EaTShYAQgCFlnqtWauMDaLSw45OTT4NzE2liqqtWkkB
MDeAEjsk8Lgw9PW+FTmttWPWxzw5jIRiRUU8h8TrZT9FL8g8UmPIBRBhSO1n9Z5Xj+j3/IGPB7ar
lFdasDqgV5g8TxApXxHur/BWbAFZtx8D6xKAE8N83/bO7bMjphnNmz8YcDxY7QP9Gf2HLL8sRMFi
AI54DAGAyziG4MtFAABDAAAMAQAwBABgqQOAh4v+7DrGEADYFpz3IST4inlip0JSG9JepDaee5gK
J2tbfLKQPr7oT9qY2coMZ+cGp+J3F8hrsIHGGGwyShQvh24sWjteYNdM0ovRZtw3X5h+d9qGkpCn
zRBKydfuGvXt2rWo9A6TCcKz7n6KdCFdBMmOxK6nBTCTXRCcit9dIC+HgcYYbDIvExufZA1B/AyY
8Evh15N48wWh0oZKOvUxJNED0f5g6LNYGw1kLRPxI2Jbl0+0eDmYVBbVurj4ueLnx+cRkUhWZTEn
7Fd6/1Pkml6NITLsgWQ/hizYSLKKMDY+0xbcvnJmUYxrGLKixhP7iWkSSsOdQ3JQk6sQJLFD+Kpj
iKRyCSMTXzoaz6KgVM9e+fD20eWQ7eQTwiqa+foMZlxWPGtRE1+SmGIGjNaE5Rrk2KyWJQv7ivaB
dWONXEBBLX4ocnz+2TJ8QsjCGpcZZalY5lrYojJO0lFDpMfOfJ54GXBt1DguF29FCqozWLvC6s/V
IwZDSlnWgzNtzZgRxp/PBJTxMgcqdrJUuTpSfJO/ZnqKUooigtBUwR6bq59PWOMRxZtMaHbJpJqm
XvrhHu8Y0tkhVktO6MvmsnuYiRrkvZIxF0hkq1IsSCafVJ3dW7LFB/EpeKFQZIcMFB/cVF+M0Wbr
WjFT/1S7mRkZP/26uL7m1+/46uTEQHJC8Hq6FtaHAAejyCpJL4eWBZwA5ITgk9Q3MIYAABgCALDU
gUsLuz5khQUiGEMAoNhSX3V9iLswJL3AIZqMrW4YuUDDuW6zY2fRVwfDC0nKinefwCLrQ7rmia8P
8R+4uz6k+8gb60PWWx/iLgzJLXCIJZMiWGCSLSa13iPIztYoJswFC0nKiu8hU7lOWx/CCkysDwne
5DvrQ7qPvE99DEn0QAPrQ+bpV+TwM88nYzFkfTEynR3VZCcXucv1sGaNKGIK0LxSN4Yha60PsY+E
BvSGoUc5iy7gEySo1jKLybLLOJZt8cQNrfjViYxY6oevy5T1IVazmafiKRkgxtxY6OBKjmx8r/jq
e0l82pSNn/zayb9L+1nVtPUh4z+vknxDgJO31CvXh/TLGOR8HVyQUVdW5hHWreSQdQtDxtGg2E4Y
UMK6iFPXh3hmR2R9SCJr6TyFU2dI9fqQeYe8vquqXLs0kw5CMqNkhdWi1MzGpE8D67XP6RYf9XtS
kBxrQF1iTFkfEs6BTJfQYLXCQCE0ruoZfsYFxK9Wd2FegqzRTZs7SSwTofUqthFc8dZn8pcCkp3Z
pW5soJ7zfYj34sGvQu4NghTOzMKoFxK9rRNkJ3OKFlMygxczWZNq4G78uzfnsqI1E83n6lokPUWL
ZC79KX79jq9OTgxYH3IILQs4ZoqskvSSaFkAsFE8cu3K/QuMIQAQx+2333j9xWfBEACI4cHNz+/+
/cYrv/5gZS3LeCTvf2nfRlKxQOMCt02sen/kXYb7CFptxodt53VdrONXt2vimFtf1TWjPbA25O1a
UIiX2FxRbgA7U+6jtz9YrdbyRXz7z94xZzcfeXXNMWTXFlqzvYPZMw1O7ZV9KvPgdydOE9qgSNLV
0N5k5E4PV/xO1hMNbSpm69ed6RoWeol1U6YQgtHCi+I0CP/h5LPOA7v1Z+6cmdM/efmpgxfvf7mo
215DmS5nPyh044TiQ4bT4GxQYSNNc6k911thiFrXI7spPjaCDbfQlIE4ed9Fea7ZZtc/8d65OD87
F+Jsf/zOrU8deBhx7BCl/EeitNGT+lPtdDZOYjWkXmyCI0ptoPhILfRqNcoU3fd2a3Utz/6ZOzty
CPt35/yrqzFE+xyJb0+fkrCWOWp9IRzSctpBcqVHbvqXUMvSw7bF+HbN3WyRvrmaUvonXwsu/eX1
xhCtCzp7v7ENZYymuxthdt2O3jI/fE17heJHWS9rtOv6MyxvPba3PM7s35P01opaVsETDHsjrbdL
CCB8aFUjkVJrK8ivfvezRsE62/995s6h3xtejVohFRNQSrm6l2LTJkqIjSlcK1ensngevbo7T2vD
mkVRKplGqW56ct1Wu/O5v9QcdzS5+cN3bhy6+Nj7kGYKy/zfTW0JfmpC2sem+qn29qj9WXdVMZV/
gO40nP7fSPHh+xDW9E67FhXiPTd3MIlEEf0UpvPDrdU6j/Gb/87rrdm+xocn077LKm0yJaCJbU7d
qjc81nuMz3zvXKh//sYaRU/76kTPHhFYfhAbT5DV8MZDT9/61VUIgm97geNgNtaHAMAmAYYAABgC
AGAIAIAhAACGAMCWEO65WLbpeRT+vplmb4zAUYe/79OAEw5nDyuz+eBQDn7lo/tN8VuNb3QV5uvd
ZK42tO4WU8DsDJkMGf6mmP8ACgU144TD2+RWluQQ27iGIttxsqDYDooRNyYNIXi8ZG1qnX4AR6Rl
Ee13cW22ct2f8dPdoZGIPoAE/yVsfD8/Yf6IqvaXb93rdEUX5uDtsRur09TenWzuYMGpjSGu25DA
4xTxvlo6nb7sNmCW8a5Y8I2URYX7br75eUEOfvHUdfwskUzxKVczo1WR3eQ2WxuQ53IxhMr0J74L
eSgBMlQtYnu5jxAdOT6Hvsr5LXWzboQoW6tYQ0x0+gFsjiH99uc0TBoSZdwqCd4E5BDFJFWOCVOd
fgDbtdQLXALKCvGKmc4FWtaAulKZQ3EiSs06MJ2qMBVJgohdSoaI7KQvxdV3adWs5ChChZxytbZC
h00lg1iJh61Mc8ghZ03ASTBE9m8gmIM0x6We5zmN/Yo5/fK9usWL21u/fRlMFgt88AU5OHI96GIs
OSebyzetPEn2TkbCDjlyjFofspAjsvnzKZ5XHuHdE+bFIbHe+pDqN4bD/nKPUHQqX+yBHLBDKrX0
ZTRyebgcZH22YMlpAF8uAgAYAgBgCACAIQCwoqUeXc1hHWxXvaCTwdeA/osB/iWjKFoxYt+4DKzl
cJyWY94JmIshuTn+qV+KZyS1cF2G84o/n4Z//yuxQgOYXcsitubDLAbxlorYUBFfROLmRWZRiV1h
0i4lKeCfHMfQjkYAMN8Y4nXGvAv2looI961yuIjEy0s6q0ia//kKi5y6FapQJWs5nDWAGESAeRkS
9uDJa+5akPJ+W8bkOckNGaiAg2s5xAjjCQAKGWI6ZioWeIqehr9pjI3TDDpymLmppAAwN0PksOWe
EthgJYgsF+wx6z2w9hVYR8sqXRonKTClKTtGULBVD8kcf2If0xdyDjwBlmGIu0ijF7TkihDhLiJx
lmI4idgKkyZfs7VC5O1GasWIKFrLkboAAPU4Pv8hYyZ+gWMH/IeUo3LpNwgCnBhDxqzlAIATYggA
gCEAAIYAABgCAGAIAIAhAACGAAAAhgAAGAIAYAgAgCEAAIYAABgCAGAIAIAhAACGAAAAhgAAGAIA
M4DvdaL2/+juXPfXnEX0PFIGStQtvVe6JMlgLC80F1/Z21CRs9nuDLg8DGGSr5g4KL7PRCMfavad
J1Qh7USVeJbG15EzAPAZokKCCB0VN21/OoddDi2DeE7NJT9csGtif3XX3YfxhJtxF8vJpiuwrx4P
cnK1eXUVU33xuq+n9mrc/WuzGUFV4JLYIUqpZF+6k5pWRto45qd7MGqNkdeeICIMN+K2O+jmHyvd
LF5zZBe01QGdbESiBC9XJz4bQHie/KyvndBa8yJSOQGXXsvqNSod07vVXk6ajtklkI6cays/WiXi
CtszJ/WePljHgpsaKTOumKs6o0i1d1ChalnSYMjAGNJ3pnHDVJvRQ3cqlqrqRN3Y7NeA7GWCdWUd
auOz4oNaKIwgp2mp5yS0UVQ018uH7eSUCaxnIAirUTFFbHzV/q9HzlthRDnFMcT0i7Z7VIrPg7an
vPMMEnhmvdbOtJiarxNWrEZ2QjeX5/5e3DvQ3pipImcZomAUOUEtq5MhTxKUYqG6Mec1/2kPNiPt
ngbhyk6LKXe+SHl2DZdEa5UEhUZLcHON3x+3l3RwZnsBxdIP5ARcJiy897vSC1i5/mvBOfKvemkI
HBzr7f1+bdns9eJvDhSMAuCIxxAAwBgCAGW4CK5cPypLHQAAMAQAwBAAAEMAAAwBgNXB57Jat7G7
f3v/sY4jWfOjc7MeO8yIruj+mC/BBpdFrIwV8fmeqO+A891k8abx/eD+QoVneFuVvvrdXcigiShX
Ha9idIp+U6/FmkUONL8hUXCYkyD+MV+CDS6LWBtLsqpk65uPlS6e4sH2AsliggSN0l+RQVtSvM0o
WrFKR92XkCHdQ2jaQ9hOnHcxycc0L0H8hzGQuyyNLGtjRXrVqoqXFU/zCd9wVrIijxkqRhmVnhaR
nuUY4sqDo3QNycfMA7Cc8IDKqlJb4QHlqaunHFdJObUCuawyjZgIknP2ezaLi2W71UMwxBnJZeq5
kEwTajkMiTQzXGjYYiiLtch9yPr22snx7v9aUsu0sRUUTqOzOikty6OI1UJHdFyzmuttEWUyVVYV
uVg9Fym+jFWeGDOrJhOjJ2BuomN+Q/NYGRI+mX27yMP0rvFnXlhcca1K7YmqVAvUs9q8SA8YwRwM
n+3yHjC+ZPVwNTKcxgZeWoUgUko+3boeQYrruRRBZmnEoBImiMCDijHEUER2Sq9sJ/ns9Hg7Dptr
7mGxkUQOlWBqVRyxKtaM7Bso3m1OfjftuZylzWxjucWGxomEHYL1IacEklMJPk1aJnz9vt76EHx1
clIUWTX5pbTUgcsEOSl4Lj3rCx+IT4ivgSEAENGpnqX3/+hciLNb//iLR1JpaFnA4Rjy8COvvH6+
I4g4f/Pzjzz84OgsdXcrxX6fNh0xl1gg21i92dqE7ZZlN27fzHYk3d4rK22RkiteBXvp8zbk7TpQ
hLc/fb+zamTjeuUWFmTixJjYZs/+6OKee+Wvfu2No7LU2z3OVeSZhqf2it0HXfv7RrMt0tVmCNJW
Sa2zeXuu+MiW+iyFruGg0/hsj3H/qSR3slfRWk0R0usPf+qVt+6dmV/m+Jvf++Stze/l4NshZgc4
s4Gn8cHB3HF4HY4OOx22NW7PGL0VhmgRdKMbKX64hYq6UVVah7JM5nluD1548NaOFufi/OzcO74q
fum3/sWNo7FDvL1oe58dzB2H0o7TDiexmvTkDtybr7vvbqR4PSsJi3ilajxFjMbth7/8R2/tbY/4
39955eavf/Y4GOJvXB1tHZ3c0tnoD+tLX5GevpqLnFTxg7vQl7VrdHPklKkiCgkycZ/iT7ySD//w
P33tSMaQ3jVIiSHoUcZspL4bYZTe9DahK2/LO7L4+nbtLBqdseX1QKcXMShH4It3//nzv9TaHrG/
p37y3t2PjsYO0dUEsfNYx4HjJEipja4Tg4/mUfg8VRPGn+Aic3w3xK997m5jd+wVK3584sbDr4pN
myER/yHWaigS/M65gQp021brUiDI6OIdZy2DKZlDFJvQnWDUdk5KqS7MeYLRTGbAa+/f+/RT7em5
uXR+9kvPv/POq1vvUz3/IcbPRj8DpU2fo5xTrqUa34eOqqpCVXg7L0RcVyAbKz5wdRJr10KLPXmL
Snnm5pD371ma68Yb3/3WI0/Y348/Qr/25g2xeUz7tre03eCT4wiGT6UP8BivPLp/bXh2/vTDdXO8
x/ptr549IrAkR6YSZDo++u6DX3nyyY9/6/z1G0fSalgfAhwFu7E+BAC2bqkDAACGAAAYAgBgCACA
IQCwKYb4W5BWb21BfpqKHCkMpZHVAICNjiEyJvdTkgPANhlCRGZrvuaMn+4Ojdz3AST4L2HjN0JP
QY5+2i4LYbK1EUQf0l8AgAMjuhtQ53HIug5x3E2REF5AvzW47DZglqkcg7S+W7iw1JPeehzYEkOo
TAHiu5CHYisdf2Ix32LSPcogVELtAjbJENnrOsOkoUJ7I0aRQY2JJtkzALCwllXipavYc2BCiauL
gNEE2JSlnh9GKD+MeKNG1DMMsRQUy52CEAwjwGbGkM5bhOM6xPq2aM4chxLsFzkevPvAPkdhnYIZ
hxjcL0Z77kU4afcVwMoYtT5ksh+KBJcAIIH11odU7/1Og1YBRB649JZ6BnKGGE488Ak4SksdAAAw
BADAEAAAQwBgeUudopZzNydbZVHzjxG75F4O9mPFaKnsUhOT+G+KWvjsnYx5+RI74CtIYCxDcpIz
UaQCxgin2EigdInLxJpkPI2NEn43zL8XbnIHRYAJWhaxRRpmMYi3VMSGivgiEjcvMotK7AqTdilJ
kn91Akx1XAWAcWOI1xnzJR3eUhFPVwnXe3h5SWfZR/P//pKMCbr0NSbvuy6SKd2qCP0nNGAKMJYh
UV0nfs1bC1IsrDIm9FJkNT6KmimQdODwDDGdeXnvTGmNp+Dz3MwaK8seSqzbwjeNwOEZIoct95xA
U3K0kAU8k+FVkvl1KhhHgMNa6iK6N09cPkn6w0N+fSCFGlO/5raBF76/MrTgCgQBDjqG2IUgzqxq
ckWIcBeROJa1k4itMGlN8PY1ReTtholJMswnaWPbNO4NeLcjYL4ANTg+/yGzCDcYcmSA/5BySAJB
ADBkWbMDBAEuMUMAAAwBADAEAMAQAABDAAAMAQAwBAAAMAQAwBAAAEMAAAwBADAEAMAQAABDAAAM
AQAwBAAAMAQAwBAAmAF8rxO1/0d357q/5iyi55EyUKJu6b3SJUkGY3mhufjmzooqWns3wOVkCJN8
xURD8X0mGllRs+88oQppJ6pENRc/uLMcwA8wxO0oVUQ0mLhp3gWzwy4H5fXL5pIfLtg1sb+66+7D
eMLNuIvlZNMV2FePBzm52ry6WNpQxCnVDJLeNbdQyM2J2iFKqYAZSvWC14pNG8f8dA9GrTHy2hNE
hOFGAncH3fwj/EKMpLbB5oK2OqCTjUiU4OXqxHd1MZ52/8O/ligUODUtq9c7dOTaXmhMx+x2ojpy
rq0QaZVTVxLipv1gHQtuaqTMuGKu6oye1N6BSNaB2WCRgjFynPoYovWAKq5UF8uOJcUmgUr8GjCC
M8G6sg7p+G4hTA0bvhPgtCz1vICpdm9IXTifpdIdsJ6BIKxGtXdQUEi6YAwlJzuGmM7R9pG7M+eH
9nrQIIFn1mvtTIup+XpixWpkJ3Rzebb3Yu+goXmUBioyu41RBAwxFocvMvaaOdONOa/5T3uwibR7
GoQrOy2mFB+XvCpoRxytcRAUGi3BzTVZCR2wV9lrOlIhDCMnhIX3fld6gddtQS+/nMSCDRvBenu/
X1s2e7346wMFywA44jEEAI58DAFDgO3iIrhyfU1LHQAAMAQAwBAAAEMAAAwBgNXhvA/Ze5nN+Rzv
PKz7hwU8Z/a5Gm/rEafrTp1sEspXx638QCzbDKn4/DqVZxzGcopxbqq9IKs8+AYZ9Kmp++m3m5O/
f1tt89Mpuki95j+kzGOg9im5h6Ucy0p2ZFxM1MkmIVlxDwOxeoYm4/PrNKV4igfbCyRrCOJnwBpP
xtvNad7gtgxLSZw2Q5I9kHk6MvUw5oeTK8mSkkywLCNeKUVJUlWykcXTesJX+gAP7IOe4jYAVT7F
BRgiYz1QrnVokQoHas7wE5q1Ip1CUdNvTxByubSEZmrXjdDxGN3lAxOkbZGLCT3cEgyRSZNCZh6T
XKT1KnIlL8mAtkyF4kiyTEKpLv9RurxsNJyFzAB5ePE/Wi0rtEOojOuLWSGFsuMkkfkHLkvkQVYX
T3LG4qP1oaKk8ZGUJ/RiyGwHAO5cy7eGXL+9BpQsedhqpIunZZunVIlLj3SeYZ6JEbl8ukwZfh9C
eSlZxsKk+ohUlJLmJYjNTkop5GLFTx6T29plqpSIkUl4gmNIZ4fIfhyW5PaSzU9z0T3M/USpUD+2
EcvqUxXLFk8J7SWIOK14N9jeVHcuq5tvoKQgRnsnxc1/AsDX7yeGsjnzcYlnB75+B1agyCpJjxcP
XYPMnJZafa1Y665NOz8+bA9fuv/SC68beQVDAMBK5x5/8D/+f/T2H9+6+cP9D9ghAOAK6GNvmrOn
fu+La1vq7laK/T5tbIPEWCDbWL3Z2oTtlmX3T9/MdiTulvWbKl4Fe+nzNuTtWlYIP+u3Jw/cwvQP
3dv6X7Na9TuHHbzNbv/Zi3P76+f1R4d/ZFedJxTZ11xFT+0Vuxm69veNZvukq80QRK+5g3uueBWN
0J3p6kL4Gdtn3H8y3d6YKvrc+ier1+hSrjz2+TsNQc7a37/1E794+/CGm/dbd72G6VaUHScUHzKc
Bvd6IO7GSvfdzyagN1v8cAstMhCXbpm3wtZ6z/3g4q2zHUF2f+fd8b/9O7fuH3gc8fyH+I+k9cHB
3HEo7TjtcBIrMUUADtWNr7uNYrr4BWuV5Vb73BJRVtym6rFv7caP/Qji/t158OjttRjib1wdfWY6
ua+zNptFD3Fl7VFkXQc5yeL1sG2xTLsWNcjhu5X//sNUyEdfXm0M8fXRorbSzK1Io7EqjW1CFxDj
Ce2aGwi0zkVZcYblr9y/fauxP7y/J1+88+aKdoiuJoidxwI2MRMRd/ggnAnGoSjB5VU00z8lXvjh
XrE6M8rW/njr4W/fuLGapR54+izqQYw9rpiLwY46aq223ZTBOaF4Hr2sO9exxO7++26U3vcFm6Cx
oXrdFntDvPCjO6Kb7j0Xv/Q/vHJofgT+Q4yfjX4GSptmU84pb2zj59Dxq6GYAqY3MYnk6IR6NS8g
g8UHEWLtWlaIyDg7yUfZkI+UN9797Se78ydv//U3bhy+CtPeqW94rhAY8xyU3t5jfOaHb+8UrJuf
/Bc3Vmmzad/26tkjAosbKhMIss44cv/Fh2498fbr6xAE32UBx8Hs1fpYrA8BADAEAMAQAABDAAAM
AQAwBACOkSHE/nXPCkF+moocKbYD7rhqAMBGxxAZk/spyQFgmwwhIrPPYHPGT3eHRu77ABL8l7Dx
G6GnIEc/bZeFMNnaCKIP6S8AwIER97DT7EgpmTckx/UUCeEFWH9UJKM+UGyOQVpnT3M3uz6EsEUm
sAWGUJkCxHchj2wX7/gTk5kN5eN7kcsgAgBshCG9a80C25oK7Y0YRQY1JppkzwDAwloW67xlmVld
1dvTkBeBMAJGE2BTlnp+GKH8MOKNGlHPMMRSUCx3CkIwjACbGUNk7/yROZewvi2aM8frBPsVuozi
0Y05b1yVtA4xuF+M9tyLsJSTEgAYxqj1IZN8UPjRMEcFDGO99SHVW7/ToFUAkQcuvaWewYx+ZGGE
A0dsqQMAAIYAABgCAGAIACxvqVPUcu7mZKssav4xYpfcy8F+rBgt1V4h6Sdo30EG9WHvZMzLl/0B
M2vAXAzJfT87Uc4oI6kykj37ljd4gU9yKI3z3bAERYC5tSxiizTMYhBvqYgNFfFFJG5eZBaV2BUm
7VKSAv5BvoHNjCFeZ8y7YG+piNvLR9Z7eHlJZ9lH8//+UqhZidi38Fy1EoH2FlW4nBxAMmBehkTk
M3XNWwtS/PpPxsaJCkHuX+zLOCe6AHztCCzBEPLkrEhgw9PwN41WpKjmY3szVnXfPwLAzAyRw5Z7
akgIVnbICsHOxaF4ZbJpoF0Bi2lZVDhNKoO52MhyEhn88E2VQYFOsVWWjzsAMBND7EIQZ1Y1uSJE
uItIHM3GScRWmLS2d/vSIvJ2w8SMyXjS8LZp3BsAUYApOD7/IbUSD4ZcBsB/SDkqrW8QBDgxhlQa
4CAIcGoMAQAwBADAEAAAQwAADAEAMAQAwBAAAMAQAABDAAAMAQAwBADAEAAAQwAADAEAMAQAwBAA
AMAQAABDAGAG8L1O1P4f3Z1r4Z8FkTJQom7pvdIlSQZj+ZVNxm9uQ+hsbiaw9laAS8sQJvlKhGdW
atTsO0+oQtqJKmnNxNdtcDY3EANwGKJiBImKm7Y/nYMynbKTU3PJDxfsWtOV77r7MJ5wM+5iOdl0
BfbV40FOrjYve782N14nFrMfR8L6A6dnhyilgsGEKVutALVxzE/3YNQaI689QUQYbmRxd9DNP1a6
WbzmyC5oqwM62YhECV6uTnxHj/Rqw2Lm6w+cGkP6B59Q3XfhuucITxUoJjqhq+hQk1Eqo+D0wToW
vK+REdm+IimtSvd3oNPaVF+cstE0FC8wJJT0YAhpzQ8raiIu2WmTQCV+DdjBmWBdWQddUG57dTBn
hRHkRC31uPXR0qTprHWvrRdMPLm9c7wrHk8QVqNiitj4OYIM54yh5CTHkE7BUOzCXosxyrwKNKwg
gWfWa82t/uQoMnLqq6uRtb1zee7CIneQmJdQyuEwRhEwxCrhGZ2mCdWNOa/5T3uwUbV7GoQrOy2m
FB+XvCq4ZkpvH+ug0GgJbq5e5qqfl9CR2nSmzVD9gcuOhfd+V3qBN27BO0w9Y27AJrHe3u/Xls1e
L/7qQMEqAI54DAGAIx9DwBBgy7gIrlxfz1IHAAAMAQAwBADAEAAAQwBgdfD3IRHH5gkYB7Odx/XY
YX7kvdqy0GzEslra4MK76sukfBsms2szCIL7C3We4dP1JyG9GCZjp0pO+qbs/b90in5TnTeGUtQ9
hvapRQ8LEKQ0lMrrPBCrOD4vU44qnuLB9gLJ+icTLVB6MUzZTpX4D5ZNpaPuS8iQeEfX918k3Z5m
Qx0KlT48OT6WLCl+QIzl1PqPhBzfsKs9aopbAXTgCl0rGRtIikjnsiUOyMWFLathyJh+M7MEL9bs
+Qaj1XrCptiL+cg+B0OMzin96shk9cLHJklsW1stU6ZZrE4JKRNROWgHjSEQ7f+fZAYMJU49N9mb
KSf69cW1GD0p3WaD/fNCo0xxloMRy0S9i9XKZjnppZil+Fi2JKc0rORmh4zMusSfm5xW70tqhxh7
I9YddkFLj/zR0b6sNJq3WlsRi/mUR7lsg102XE1bSeRPtISzRodrWCllmbAORKRSOlbFL85/rckg
GttgtG69N4ArMiLwe81CunNZ9prsR/vu/cl23ofYGc4hy7PofQjJuvch/mRfTfGR9yE8O9P2FYxI
1N/VtViD8Qup9Icfa9b/thdfv58YBoS8+LXsyTAEX52cHEVWSXq8eOgaZOa0pmbyD/zahLRL4MP2
8KX7L73wupFYMAQArHzu8Qdfeef+23/87/3wh/sfa1rqALBB3P6ZN83ZrfsfHb54zhB3K8V+nza2
xVQskG2X3mxtovlu2N2O6ZvZjsTdsn5TxatgL33ehrxdywqJFKe8gKDcWAZ8Y/zDt9k/+oW32K+n
3j04R646Tyiyp7mKntordiN0uz8jy1CoRNK1CKLX3L09V7yKRujOdHUh8eK0/2TcYoJQIxNar7Ov
2JXHfm5PkDPz8+ytB4/ePrTh5v3WgrnN6Hx2MHccXvcXDCpspGkumX1wt8IQvdnih1to9ECspzB6
zVZ77gcXO36cnYvz3Z853vn8gccRz3+I/0haHxzMHYfSTmfjJFZiigAcqhtfd4/FdPF6nZse4J15
qmu02u3HvnVnRwzh/7314Bdvr8OQYNtnHX2OKSK0zFGDXFl7FFnXOU6yeD1sW4xv18GbTm5FzHwh
HbqpfvbDVMhv/MWVxpDeNUjBwOtTxjgf2Y0wSmOb0AWItVC7qtAw8SViLbx+/4VbxgZx/m6+8NYb
a2lZBS0S9jRagxDHBBW6qdjqkP/Guy8+ubM9jILVHp/81Ntv3FjJDlG+A1xV1uCu7sW9VqnN+dlY
uTqVxTvOWvTostxSWY/mOIgJYrYuV9Zttdfv/z+3zs35/vjki3fevHHYKsTeh/QOYpWd2hL8tPe4
0To/4L5xzXSX58hWbOaFyFG9D2FN77RrUSGBE2CuAXC3wCrwE5zKYJ1Jjmffe9uc3fr4KzcOXvy0
d+qlTQYfHVvpH4YmBPQWH+MzP9xz5IlPrsCPqd/26tkjAssPYuMJspY9cv+3xZPPv/PGGgTBd1nA
cTB7tT4W60MAAAwBADAEAMAQAABDAAAMAYBjZIizcZwYsbUF+WkqcqQwFLuZAZdsDJExuZ+SHAC2
yRCipksnc8ZPd4d2z9IugAT/JWz8RugpyNFP22VhtkJl2Yk+pL8AAAdG3MOO8ThkfRe57kSE8AL6
jcNltwGzTOUYpHX2NHezs/ufSuy+DGyAIVSmAMmsTzLp+BOTmR33ZTQLGUQAgI0wpN+vusC2pkJ7
I0aRYSckk+wZAFhYy8o4nUoEVPX2nhOSkggYTYBNWer5YYTyw4g3akQ9wxBLQbHcKQjBMAJsZgzp
/LO1/oGlc9G4LXNduLFf5Lqp6AKJ+aLuPZ+1DjEk84vRnnsRjsA5InBpMWp9yCQfFH40zFEBw1hv
fUj11u/Dbi8h8sClt9QzkDPEcOKBT8BRWuoAAIAhAACGAAAYAgDLW+oUtZx7B9s1FjX/GLFL7uXA
nLfHSrVXgklh83FkUB/2Tob5AMfMGjAXQ3Lfz06UM8pIqoxkz77lDV68kxxK43w3LEERYG4ti9gi
DbMYxFsqYkNFfBGJmxeZRSV2hUm7lKSAfxNeK4IZwLxjiNcZ8y7YWyri9vKR9R5eXtJZ9tH8v78U
alYi9i28e9XX3ga5gEEEmJkhA92wdKWPnO+AC4VRxsaJCkHuX+zLTASB1/vAMgwxHXP514IUPQ1/
01w2Tj5F9+EjACzDEDlsuacENljZIcsFu0BjKkwj55lfAICklkWF06SSpC+MlB0jrBUTBI8RZ5kb
lEAQYBGG2IUgzqxqckWIcBeROAqOk4itMGnypfalReTthokZE/Gk4W3TdGd4IQJMx/H5D6mVeDDk
MgD+QyoUKwJBADCk1vaYKTYAHD9DAAAMAQAwBADAEAAAQwAADAEAMAQAADAEAMAQAABDAAAMAQAw
BADAEAAAQwAADAEAMAQAADAEAMAQAJgBfK8Ttf9Hd+c6uMbi6e5fH8q5aNffm+u7Q/t/qj42Xiy/
ILYWifpn8g4u5ssAwBAL7Qibd60eKriih7LUSukhXiTybxKpzKYYuvI6ADgMURGC2Gumr+36eK36
iJodNMtgH0XpLqwNbWO0ZyyliR6MCNopWXjJvPx7afey7usdFGuro/qY7CYBwLNDlFJBt2qv7aXR
SCQj0P6CPSh+XTcSqnWbxk3qphT7g69A6T6B6uN0ybTNX7B4KpY1r3eqwlxv828SAEP6DrgTDR25
1lzUwalIqWm606iUiuoyymdF+9NIrk0XK4oHusOHCrN2K+sVqyOZYAABogzREcnQ46RFCyvCcZWl
j6FUjV0dC7QDn7bWSCJrnSkQAAYt9SlGuN/Jm4mmlKB3MfRUgrinaiBrWzEAqBxDTOdq+9jdWW2H
aw0CPTDxxKx6x4qIGcpDlXCHjEjWsWL9rDG0AENaVkSwdVTYRWMn2GB70E4yM31kJN/r+HnKeGdv
7RAldJhM2Pz7yri1UREzI1lhDCxADEew9zvmXgHs/Q4Al8xSPyAwggDbsEMAAABDAAAMAYBTskOA
k8QFO7+OMQQAoGUBwJFrWRHH5iZAll3jOcnUoQo2zVDqvj4DEasqU1w8Cx5wvtsGp7Lrr5Mtt/UN
L6vc+gYVtxn3ATLTIvwHyU406BT9pjp2yFz3T+3jjB7GZOScJUXCT1JQtbmKZ8E0KLqZ7Prr5D6T
psY1BPErzgqU8QZzqsR/9P0m1TrqvrSWevMs2k6EJO9yvGt9v9Y9v30TyiTTxtBPluZApQ9Pjite
lkYcqEhBPWXxSD3lfqMVKRuklwKl9X8SX5ksSzMyhPco5jR2rQ9iaWjRBpQzCf6SkBMJ2t6llV+m
LsmF60kJDZsOQxC/9AsnaL3vsq5FtFdpaxtTrmW6f5eU7XHGtDJJh7YjOqMptSBXHV+8iw3usu2K
ZKPhjDMDSlNVNDDskEDKqETyVu2cbbxZ1eVDS4302MZ7qjIRprDv8lIlZgnkOrrVMdohzvwFb+Wa
vnfuIWQ+Ko185gcZQpgQ+xmWWlpytr7GqcrpMuVqna5Csdmj8NqKBKEZc6SVCCKlFEUzY9Obo7wq
GEPyuookKd3huZ3SYhHtKbUjuUlgDjTihYhJQ31ew+I/ENGt2rDGZgyBgcrbehargnFNx30pwepp
jJG6/Ml/BpkGs0mE9+PEMfMaQ7Tp1jFpMFzv8W5kLmv6gA6CHDtFllTZLpOWNX4eBtg2prywOckn
jC8XAQAMAQAwBAA2bocAwBh0H2Bd3z5D7PfS/e/CV3/xhSBzzA1WLvsQpQtJat/NDMan0g+4srFs
C7JXhiPWh4TtZj9ml8ENkf+xS2J9CdaHTBHjcCHIHHODlcs+ROlCEhohcENrxoKzohuLF+N9d1+7
PiRsN2/BSbgCJPiCILK+BOtD4j2muyykXxxiLrrP03naNAP15l72YXKcvlhlEchx41Gm3WSiIeUh
752KTOFsrK+sNnxdG+wx3WUhZhEIu7ikQMmlZHDMU5ZFIllG6qGFVhGdsYYssua2TV1ouRFCFtkh
2VjbWR+Svj37RTZF7n3p7xFkjSFQp6mXxj7IJxfUrdCxa2Ynrg9J1rvyfk71g6JwfQgVjZGH1kiL
DQe5zHLqQ5jpbTkkI6t/J6wPGYoRmulAnaUeN7rl1joYknV61FILOkgUynF1Fz5yfUhQTmSvE/OM
szMcEgwptbQii0A2RBCSKxDE14rK40drRTMqr4M6lqmLXI0g14+QIY7S76ot5pe3kCG2HmRe8S9b
9lG+kKTyhUjx8pRZrK1geUft+hBmPCVuNLWixV8fMmFxzyXBFaifpwWsD6kEvss6OYqskvR4AYac
GKSsM/Qr0s6EB8/efOTP3Xz2AbQsAAjN9sc/eOIb7emz1+5dQMsCANZd33xUfudNQxDx+nfee/Tm
7U2NIY3/cm1/aZ+9KhbYOjY3iZXjmrz3eb4dZ+WstnqlCmjegH5IUL+uDStcvrObU25uyt61cs+U
++jd0k0ktWSbffPPP/jgXuT6T92Vdy82MobsGkG3Au83d3hqr+xTGXrsTpwmtEGRpGsRpKkSq9kK
DI23h4rWrzvT1ffYdmD+3ergWSovjYiU7nWe8+tWDz/6uW+/eU+cmd/s+I03/0g+eut764mM/z5E
d92FbhtI2XFC8SFDuA3O+0Sl2aX2XG+FIdqr9koEqQoZr4qbZ6XHlHawdrr+D//Gg3tnd3Z0OBfn
u7/YUTxz/sz/8qnPr2+HKOU/EqWNntSfaqezcRKrUaJxaBlVqzpo10lh18vcrRqQ/SLeLabjPPf0
L8qfe/2e2JFg4O+NL37u0VvX12WI9jmioy2bbHPdKl1DXFl7FLEKxHpjWH13PbJdU3erY49VZ+ym
pfDjV85Lo559dOXplccQrQs6+7Ctm+emjTql91a5FpvHqiNJfZc8sV3Td6u0COyQcPpgsbZ67Z3f
+egnn338zNge6b+zp2/Q/bdeXd0O0dUEsfNYR4V1Va12RNDLZKwH7lb50ym5qvQzb8vR5Mbu79lP
PHh7b3M0ClV4vHXtpX9FOy53VprL8uY3ygRfKVf3sg3Zal3bYo9SWyBIMOuXr23FuKO1DhO7d+tG
caviPC2lupSl9R2N1+/c//CFj5kZrE7tao/qmU999O7dV9d7WA/ZQeTll3bYNcTuqF/a/bufgWp+
vfxyH9Ce7gNfblK83KTSbeKmEXeXXmpDu2v7Xy9tRPHqq7S/15fXqIFpG3PwQ2xLm5aLtWvpPb4c
3C3LoHkq4mW33O6xdj+8lGXlj8Ov/OD97/9r//eNHzqWx6eviVd+9IO/3d7+Spj21UlpX6yOwTQ5
AQw+h/xIdYDHeP3sgy/qZoL37GM3rr86wXRbwlKfc2pmbERgeQtoPEGWx8Wd7/7OC89e/anP3KDv
vvnqFloMXy4CR8FsfLkIAJsEGAIAYAgAgCEAAIYAABgCAFvCgP+QOvj7ZnaO1t1IItyx0V6hyD7O
1O/K2YbEnO7yHQTbDZ7cKCQjm1PzW41vCZ/wo8H30kvfz1jfH8BWGTIZkf0vKbYNOYWCavf0dI5e
cJs+sk2qv9l2bJvfcPc0J0iKeJKoHw1ZdD/jfH8AR6BlEZHZZ68546e7Q+sfoQsgwX8JG9/PT5g/
SouLG2Kd4ZhdHymVQzDuecNWrE513boM+gDrxMbPaIQ7A+C4xhDbU7rOQ+IORFi0nSSbHUylSI0C
xDfLjstWRHfhm5+HOcioxsaVv6ZqIpEoRsz8xlFsg/b0/RDIctkYQmX6U9SBCJeeRKea6o1rlbhs
Dh0ZXaPD98kU6xYidIuNOYmb87hhvYBM8v0BbIshvf+QAq98JMq4VRKcV7bGmULVHnHmlGDHC0i5
7w/gaCx1OSw3skK8KGlbyySjPIGKyBeNEeyCRIkoA55ochnTSbrIvNQMEdlJX4qr75Ip6alRhIo4
5UxEyZT7KVmhClHFSCFrdKxYKnh1uvQMkf0bCOY3w/q2CB2IyMAoJc8KMGminan1VhEVynJ/JCRD
DxyiwHFbcjLWZtP527AvRDKe1jw/KqN8fwAbwaj1IZN8UBzEHKnMgepd12CIOCg24gu3VJE/DEEO
CFntGBc4eTukTkuvizFbUbPlMGLaCyw5DeDLRQAAQwAADAEAMAQAVrTUo6s57GfpNZZp8JEFBW8E
nAUdmfUe/WdW3meNubUc3RfrI749AYAkQ3Jz/BPlLPdZUmxdBv9Ghbry2bvI/FoO9tm8t5YDAObQ
soit+TCLQbylIjZUxBeRuHmRWVRiV5i0S0mS/KPIWqwqPo5KBwDZMcTrjHkX7C0VcXvsyCISLy/p
rCJp/ucrLEJ1y8mBMuTJrjJpVUMMIsDMDBnout0PrqTbYRcKY/S7XVk8Mgyv5RjU7QBgPENMx1z8
wWBgNYjEb6q3ceKBcgQPAWAuhshhyz0lisFKEFkusolJrW4yS5anAYCltaxSBUWGu/dQdhjwdxzi
60oS5MsQBNwAVmCIt7yB3PUhIvzlLiJxLGsnEVth0prg7YsOSoo6p12XUcFajtQFAKjH8fkPGbOW
Azh2wH9IOSrXfIMgwIkxRKy3hQkAhgAAAIYAABgCAGAIAIAhAACGAAAYAgBgCACAIQAAhgAAAIYA
ABgCAGAIAIAhAACGAAAYAgBgCACAIQBwIuB7naj9P7o770+Ev4i+vRQJ4OnaX9q7vju0/ycrlAtz
8rQRB5MAwCwMYSKvmDyq0ftMqOCKdouZkqcOaw0ASzJExQjSC6Dp+ruxQCse3h80T6dagnVZ2OTt
GUtpomuPCdop1ebZR++HpG5gUiAMsKAdopQKumV7zQwnylWJ9hfsQfHrupFxrds0blI3pdgfPF2K
JVM2qm7rpq3OxmpnswOAJRjSi5eOXGslMzgVKTVNdxqVUlFdSPmscH46yTKjgoaqBRyKIXo+Idvr
OyprR/cxlBppsSeSYQQBFrTUpxjhHgGUmXRKSXoXQ89KEAwlwHJjiOl+bS88oj9WfUqd5xSLodSE
7l9hFAEOpmVFBFtHhX1/XbNge9BOsnYSqjMonIzclJ6IK5YskoJf0kXVBYCxuHLM+9oqjdeFJ4L1
9n6/dszNpvH6AwBDYJcDYAhwQrgIrlw/EksdAAAwBADAEAAAQwAADAGA1cHmsoyP2eYVIknzvwmQ
scOiXjSpK0Q4lShIOBCxvamBWO69FscXGefwA5V0qhWUSzWe4ft4fm4UtCWxBx6vH8+DTtFvKmMI
fwbSa3BDF3tY2sks9dUgXoky8chFLMrOv9fC+E6N6ypJ2XKb/4sJkryLjiCsdOml8evn5FHpqPvS
McQ2T/PfvtXSVFjYTTn1D6O2IFmacUEmsjRXObVpaD7hc7OSkbrLyqrKGfq6rGJP85a4OEMML6yW
NUqZmQa5FBOXb/tRNZbz5esM/4Mdhhn1MgSdqloFqS/ElglRxBBZ8nTk4uOIW1w5I0se6XB2nV1Q
yNVqOaLKu28GdVlNVpLRujMli2RhHrDUN9YX15kXTtWGI5ZmJ+cs1Jf4yuamwTJ82suhGDIkfzyP
6gqfGENotWFwtZKTve48NZYjKkSjc7V1kvFKUmC6H5UitCiujnzom+1QaEaCUKng0yqVnM72boJf
SiE3VOFjGUO6UZ3akdeo7u7hYI+4uLyyiAOx3FveN0R+ZsJGnGZVuY3Lb7s9l2PaLKi7uRC0Khtq
/Aoc9HFvC1dOd/g8PZCcEjyX0jvq6/f11hjiq5OTosgWNNjLaKkDlwNyUvCsetaXPvjgjec/9jUw
BAACneq5Dz64+KoQZ18X4qfO5dsX264utCzgkHjw1cc//a1X37q3Oz3f/X3j9Vfee+zWlQdHYqlz
/yF2mx1mI6lYINvEvdl8hG1iZfdv39CWC1vYIz5avHJ20bd77pvN8XWhtep5fmFb7zs5Og/c21KJ
VU+5O/RPa7N/9qdvXJzHAs5uXPsnn9++pb7fajrcOV1FT+0Vu936PrXn4KDPT22IIG7NViJpoqH9
LfH7M111f61M+bvh67Dw5pn5VeHPjWcySUivP/PYp/7lh+60BDnrmNGFvvHq5z79689sckcHX8vS
7WaH/a7TqqWBck9t9KDn8pxEaS3Elnbt2eyWpcMVK+pGXc8vOrJduY49s9xYN/3hPbjytz793rc/
uCvOz1paxI7v/Efflo/8re0pXJ7/EP+RGB8gEXcgwVNV2Q1zNyOZm91iS8+djRrewbiNkqOemrwN
8nNPn335wS+/09od+b/zt3/5wZfPHr6+VYZonyNxrwapJmuZo2Zp1aXlcIP7+w55byxs14jnFxVz
3eJGyeQ3XRv98KOaSd2vfSSe2uwYEtNJ04agS5nOn47eW+Wb3wpxZTtEV29QP6Fd0wTRulB701M2
1H/tznfvvvgPbgqjUGX/bj174+53339tU7Lie/pU1e2tBfyijRgw1AK0H3ROrISImNzKMR7jW/1P
qu8N8R+Klz7487973ihTZ+cidrzy7PW77+7jbtcOYf1ExQSUUm4no7RDN3jzSLdZWbxiO10zG1zF
ezRt56T2Uy/KpuueYDyTGSbHX33rK/dufOamsTmEe3z86ecf/ODum5t8dxh7H+K7l9Xc12333kN3
j011U+rmqP2Zd1U8lX8oDWsL70N0tmKs5SLtOnh/NqF1Bqn4S5DOlXDgpth/bn11tJjFE8X1mw8+
uOdeeuqhh18eHDnWE6Bp3/aWNhmcfGykZ5gmhDM9xs++f/Gvtxmd/fQffOyVIr3qWP2H6FIdCgTZ
Akf0VILMg1eF+NX/9+Jf/eN7H7v2exs0PGYdQwBgC+w+kKUOAAAYAgBgCACAIQAAhgAAGAIAR8MQ
Yv+6Z4UgP01FjhSG0shqAMBGx5DoPrFTkgPANhlCRGZrvuaMn+4Ojdz3AST4L2HjN0JPQY5+2i4L
YbK1EUQf0l8AgAMj+tVJ53HI+i9yfFCREF6AdUzVbcAsUzkGaZ09zd3snN39CUMMsDZDqEwB4ruQ
RxyLOP7EZNz1CD/KIFRC7QI2yZB+w/MC25oK7Y0YRQY1JppkzwDAwlpWiQM/Od7IbnSmuggYTYBN
Wer5YYTyw4g3akQ9wxBLQbHcKQjBMAJsZgyRvQNI5jfCepJozhyHEuwXSX7oA/schXX5ZRxicL8Y
7bkX4aTdVwArY9T6kMl+KBJcAoAEjmiNIYkyL7IAcIkt9QzkDDGceOATcJSWOgAAYAgAgCEAAIYA
wPKWOkUt525Otsqi5h8jdsm9HDyv936p7Ipx6i7s140UtfDZOxnz8iU8YJ4NGM+Q3PezEyWLMrIp
I9nzb3nJu0ByKE343XB/kKAIMF3LIrZIwywG8ZaK2FARX0Ti5kVmUYldYdIuJUnyT4qhC6MAdgBT
xhCvM+adrrdUxO/lg/UeXl7SWfbR/L+/FGpWESkm77suX3srl3zzQQtoAkxkyECny695a0GKe2kZ
E3oZiHOSGv2L/QpxJ1ghwEwMMR1z+deCFD0Nf1O5jcNXF86jLoEdwFwMkcOWe0r4gpUdslxIE1pW
N5kly9MAwNJaVqlKIkn6AwFlx4hwZKDImlsbLrMEATeAFRhiF4I4s6rJFSHCXUTiWNZOIrbCpDXB
29cUkbcbJianXZdR0tS2adwbcA8wRYA6HJ//kGkyDoYcJ+A/pMLiJhAEAEOK5gUOmxYAQwAAAEMA
AAwBADAEAMAQAABDAAAMAQAwBADAEAAAQwAAAEMAAAwBADAEAMAQAABDAAAMAQAwBADAEAA4GfC9
TtT+H92d6/6S8FbRq+aKCq6zdN0v7V3fHdr/kxVKlDi0kH+9lf7A6TCECaZiF9TozMOUOib/XowI
HXR9SQAwN0NUSJCg9+9/adVH1OygWQb7KEp3YW2oMpzTbkoTXXsyr1mpLKJTl1hJALCMHaKUynTa
exk0csjYs79gD4pf1400a92mcZO6KcX+4OtVfjLtZdaEtFe04Y3GYAIsyZBewnRsZNE2QKd6a+1I
uNGaoqaFjcFKz+UYZKadKwCwNEP0fBrKXvtRWSu7j1En4CpGNDYG4oECi1rqJSJZZBq3ClAugy6G
no8gMEKARccQ0wPbjnhEl6z6lDrPKRZDqVxxdXXAKAIsqGVFBTs1RmiWxB60k1U73dSZDl53z1NG
h5g2wEkWWh3mSl8ShhFgXmx873eIPNAKAvZ+B4CjtNRXBkYQYDt2CAAAYAgAgCEAAIYAACx14Ehx
0Z9dxxgCACczhrSOYnf/9h5jHdex5kfnZt05zO9l1jhbF33+A246bZ2LIg7E8u/ucMVTUG7jBr7C
F3xQafuMgrYM7tO/n/4JkLTpT1fL6ppFDjxhQyJ7MC05J0H6ihAvdiB+ccSBWP7dHa548oNtr1VK
EL/SLDc5GMO/n+4JtEwhceIM6R6C01/sW5CR5jC9CPUPgz05WRK/OOMcoj1FcfFz1DM2iJdBzhDD
qWbLH8r1C2ndnSbUYtuWeq9rRbuYyU+++CHacrNDvJxPfpKdf2Hxk+oZtCNTiA4oUoFyLevu5uLo
eFDKEGckl6nnQmvcNjePsg+XCh8LFfXeJOuKL49YVru2c9rd1O7/YjOg06mSTdHlJJmJAhSNIb6y
S2XNdwDOyHImFVSnFbkFip/WaVrRluTkJou4R2HvHz7Pdkhw7BDeGiRO0RwfoWX1T2bfiHKQDrQQ
Sxajniwr+NDDpWlHOU6PHdbH5OBluQWFYUu4GlFSYmoIZZtMSnlcPQ9tkyCmHam4nqN6FaptDYwh
EYpIq6pKR5+ldhw21+RBBmWShQUVRxyIZW6yOxy6eBPMszO6UBH5vUoHhQXZ2wszjR/XLxFDrkDp
PB0MTkhuwN5MAGsMgS0ol8smv5SWOnCZIKfNXpzmJBfGEAAAQwAAWhZwWJgvS65f9vvEGAIApWPI
hPUhNLsd562joAFLsXglR3JFRDw7mnl9yEDx/XKQOdeHsJvwHyyJ/g2lHGjO5htvrA8ZnrNIrA+Z
u+n8dRQDa1CKV3IkV0TEs6Mg/1x1Zyg+uIfp60NYu0mvut13WX7jRpqzoSrWh4xdHzL7m6TYV0iz
FFLQB4zge/H6EFkycE67Z1nSlgMly9qubI5GPDJLvXZ9yMwNspFv7kuXvRSvDynXkEJ1R87WluFt
kRzbEpde75ppfYhcTIJp9iRlXyVS7FOmMiWHZHnGQ+04Zn0I8a/oxjbW4BqTk9SyRq8PWewbdarW
fUckKRBmKu4CJjWFTF2oWh/SxYs0BdnQXIyo4QSGxB9Z2fqQpSDrS51n5Uc/lbbIHi4LKXxysCn6
iUFna4fIZgB+NelkV4rMsz5kqTmO+VWsKoIssOxlQAObtQFSie1tUWk1j24B0IJjyKj1IUtpq6mF
C5mIVSs/BmJZcZlrfYjbeqnbmLQ+pLwp/BjkP+RsHtdPhCFYH3JCwPqQGbQs4FJTZNXkl8MOAS4x
pJw0x5FJ/72nzv6lTz7x8HMPoGUBgGePfO3f/Did707Odv88fv3a9d/9/KXSsh7C5+/AaDz47y7+
xh/+Vw9+8P7+x/6fH733/Xf/6yd+4rF3fmXmkl56eQtjSOOqXNtf2mevigW27sxNYiWYV3XRezpX
G/LYaaq+jh9q1lg6WrEgQteGvF2HC2BnSnQ3LLT39FKNESm9f7h27Hji4sd3kvV4/Ge+eu/islnq
u2bSXWt4tAlO7ZV9KkOP3YnT0jYoknQ9gqxYIdMirGG8igURujNdVQA7U7YoHTzHeGMEmejm0Xp1
eO+PXr9zZs7D473f/M57n3js1veO3zDxlSzddijKdD9a2XFC8SFDuI3Oe6GO7s0l3Xc/m8JK9dFT
alTSjQZPRol6l9uRxxsbcnd2x/ne9sgcxTPnt/7uf/bQq8fMEGcuSyn/kSht9KT+lI8zyk2stieS
STFba9BWSe1Oz12AOQuei/L7spEazHnR352/9srLn7r51GcvA0O0zxEdfY4pIphBfZArm8BqWm1E
vSqqUXG7MqXKDPh6RPfkWyrTrLarH3300aUYQ7Qu6Oz9tjKU0Uad0nurXG/2dpU+zsc0Y7uWDCEq
YtQHSlbZ363P3v7E/bt3XrskdoiuJoidxzoOqCOmyfCt6ZIotgnMmXKMx94KTc91NXjsP/5v3moU
qb3dET2Kj73/2//+u+JPXRpLnRvb5R2uscet9tsn0krplSZVc9rVmjWqLJtHH34Y2pHoaFHamYsx
Z87kTEEmBq/95+ITNx9c3G3o0Nkl/fHxX/iH116+If7K8Xc8V119qW0x1c9AadN0yjl1G1wZG175
04n82uXstusJ2jVkQvaCCLF2HS6gpKi8ud89ZZUzfi7eOP/+Nz/zpK9+PfHs89/6wd9987Ubl+KZ
TfvqpLTxFRiyASVsaDJAj8zi+uMffKENOPvpr1+7d+1iidof6be9evaIwLI22DSCJIaSt85/9YXP
PH7z6Uce+Z137350cblaDV8uAkfBbqwPAYCtW+oAAIAhAACGAAAYAgBgCACsjqj/EOd3BfztK83e
GOFGp+GGfgmPF/xivxdcSQ7+Nk/OdvbhDZodDcN904XncqN1EsD3mIrXhtWYFtzVGDgoQyYjsism
xbaipVBQUx4vRLBnrizJIbbPbuh6wAmSIp6E3O0JpQg3AKd4Q5DtNkCQS6ZlEZHZeK8546e7Q/Po
+wAS/Jew8f38hPmjtLi4m8ZaLztmJ0hK5SDzXI3Wqa5bDzcztU51ElQEKy7vGNJ2nZL1xY7XKeK9
vXRdUXUbMMvkKEB8mJA5okjvUqfEFeQQKH9dx88SpXbNjubrOmGTJEXmfkykkWQEtsuQQn9CfBfy
yPbioU4hB8TfqYIcrEQ0h7z7JklCDBCKQubE6+CVFKez74GABEhyCRjS26LD+4f7atRAL15hyqzV
38qlIpX5/gCOylKXwyIhKySHItYslUtcQk+hiOkyqNgUFFtZs4JUdJIuMi81Q0R20pfi6ru0alZy
FKE8p2IpZcr/kyzWsVi5BYIv64gapsJocekZIvs3EMx9hPVt0Zw5Lxxk4JDStwJMmmhnmvJ4Ue5K
L/B3Qdwf2aDjtuRkbOC/hF3IkCX0dCZhhxwrRq0PmeyHYpZiZsyhtiTCO8ADY731IdVvDKnI6jgy
VL7RAzlgh4zT0otV/bmKmi0HWZ8tWHIawJeLAACGAAAYAgBgCACsaKlHV3PY72wrv4T1vwb03wjw
LxnF4HoPvnpjeC2Hu0bEWzGCmVpgJENykjNRpHKfJeXXZZgz+1luwVqO4GNk/vlxyy5QBJigZRFb
82EWg3hLRWyoiC8icfMis6jErjBpl5Jk+SeLSUp1XAWAcWOI1xnbRSJtn0sythqQn0fW9jkrTfh6
Er7CIqZuJVfMUlIfK0L/CQ2YAoxlSKYf96+5a0FksbBGl3bIQrVM8Bf7kHTg8AwxnXl570xpjYeG
1aGh73azDJOEt9vAoRkihy33lMAGK0Fkudxn12XkDH2MI8BhLXVjfhdxg6Q/PJAYHkYoJvuywYh7
AEGAg44hdiGIM6uaXBEi3EUkzlIMJxFbYdLka7ZWiLzdSK0YEUVrOdwb8G5HwHwBanB8/kNmEW4w
5MgA/yEVOhWBIAAYsqzZAYIAl5ghAACGAAAYAgBgCACAIQAAhgAAGAIAABgCAGAIAIAhAACGAAAY
AgBgCACAIQAAhgAAGAIAABgCAGAIAMwAvteJ2v+ju3PdX3MX0SvngtJdVCXGLrYPV+mrsFDdR2MF
9Sl318aXDwBlDGFiqbhkZvaZCAk0giAFcTSLpuMpwQ9gYYaokCARMux763bgaP7fdeMNi7pxRIgu
rP/Ry7d/YHnYK92IoFg+bXBTlDBpupSWPP3leXgLAKEdopRKdshKa+0wR7V6Ty/S7aGN04m87i55
B83iaUMNHeGlakcwI/G6zTIo3UuQygwApjKkFyxtVRdl+vXmLKPV6AGNR7XC3Rz6vLQXriOZ6pTa
1VWQD34YOYDlGKJTcq1EsSWuVPySbo/mEOalo0nHmzYYQYBFLPWsPd1ZGiqzR6ROXWqVK3OIkM2E
i4Iyygx7AJh7DDEdr+1/4z2x1lokDPk+kfJ7dKOrqdRAZMNzZUSKs+Y9RhFgaS0rIsAZO6SXz/ag
eWw7SphLkYNwZVwNaXGu8a1NPomYeDkCzIQl9n5fXjyV81IEZLj8WG/v92vH3nIwOoCjG0MA4PKM
IWAIsFVcBFeur2upAwAAhgAAGAIAYAgAgCEAsDqc9yF7L7NRn+PUOUE3FztX685hJsRKCOoWRGRn
eUe3yTqny43Gj5RGBY0xunhZ5cGX5e81E/VHv93cB27rZ2+LTtFF6jX/IcUew+4a9e1q4phr9jAX
QSIlNJC5iOyMBvkXrXOi3FT8SGnk1mfm4knWEMTm7zcTY4Pbbs6tsPqx25rDUfdxjyFhD2K6Durp
s3QbpUoIxCMdMVtFWVSuHEwqi0obWfz87SnHVWstUMICoBVqey3SWH7/IvsxZPm6yQK9IRtRzlwu
UzTzySYJuSyR9YUyNreWqD+tMXC0tb7YBJM5QySVV4JMfD6UL91oCRmpLZxK6kyh0UOyQGTloFG2
TyYrTTfZGILTzABKj18zKsmXXMuShV1V+8C6scb8WmdsGVn4YDJfamQp74qMsmrTTRZL8jD34qNx
qvuRYMiY1pDb0WKrC59LXwyGlLIGHCtypdqOHCxXJokTnaU5dZaMeh9Ck7QcMb3ICYX3k59jSstI
upRSLEiQufkcMite/8LbOpExpLNDrJac0JfNZfcw78jgZN2qciKj92di+LLfRBvILsg1iE/hK4MS
O2Rk8b02W9d8tlrk61apdjMjrJ9+iWd8JMDX7ycGkhOCDzsC4ut3YBWKrJL0ePHQNcjMaanV14q1
7tq0c+PD9vCl+y+98LqRVjAEAKxs7nDxG9fv3n/7j2/d+PH+F+wQAOB48Pz7b5vTW/c/Wt9S5/5D
mAcRtvFOLJBt597sb625V49ui/fN7Efi7kG/qeJVuEc+a0PermWFBJmynWFYFCUC/y+JDA69r8z3
/8tfvcd+PvXx19eQmKvOE4rsma6ip/aK3dm32ShRu4/cbvq7FYLoNXeHzxWvohG6M11dSJCpEIx2
9sl02/APZ3DYLuXBE8/8cjdsnO3/eeuVR2+vYbh5v7XxqiPMRu3Muwd39MGiu4MKG2mU6Bmjt8IQ
vdnih1toxECsBm96q65WnvvRlbNzcb77E/Z45/NPvXtwXcvzH+I/Eu7doz3l44xyEysxRQBOHXql
TNvnlqDfSurx7b/53TfEjhTB31sPfvHKemNI69NJ55s3rZxYZzjb3gdx5V1Mm/2Glcr7X4n3MPXt
qgtuOu+Gbx387I/OU0G/8fQb640hxgVOnYCZXarNZu27EabxgbBxgujV9oY3hm+tGTSxXQd7hW0N
IeL1737u6TNjfzh/N19468AECTx9quq21kelQvU72a9T6aUHMJXy/zUcJcoHtRZNXhPPffxH541y
tbdD2uOTH//2jRsr2iGsW62YgDIupvrESjt025gfj85P0EoGaiVBeOOVySlzvML8wDilRqOYeUjn
aSkVTk8ekiPv3PsHjwtjfzSd+Yt33rxx+HrE3ocwZ7P91Jbgp71/EKX7PqmTOaX9WXdVMZW/vIj2
3NXrFl/yPoQ1vdOuBaWw6Ug2o6XYSxAvfxFzaRzU6sCN9uD597o3Irc+/sqNVURm2jv10iaDj48j
maXI92QrPMb2rfrZVfHOjZXabNp3WS+/9HJRvJdAkE3gJZF/YEMEES8fusZ/+70HPyl/4hOv/9O/
tlab4bss4ChGv9X6WKwPAQAwBADAEAAAQwAADAEAMAQAjpEhxP51zwpB8c3minKkMJRGVgMANjqG
yJjcT0kOANtkCBGZffqaM366OzRy3weQ4L+Ejd8IPQU5+mm7LITJ1kYQfUh/AQAOjLiHHcdtSOBx
ioTwAvq9zGW3AbNM5RikdfY0d7PrQ+Z1cwUAIxlCZQoQ34U8FFvp+BOL+RaT7lEGoRJqF7BJhvTb
ohfY1qX7v8coMqgx0SR7BgAW1rJY5y3LzOqq3n7QH2cYAaMJsClLPT+MUH4Y8UaNqGcYYikoljsF
IRhGgM2MIZ23iNY/sHQuGv9mrkMJ9osCp188ujHnjauS1iEG94vRnnsRTtp9BbAyRq0PmeSDwo+G
OSpgGOutD6leYjjsLxciD1x6Sz0DOUMMJx74BBylpQ4AABgCAGAIAIAhALC8pU5Ry7mbk62yqPnH
iF1yLwf7sWK0VM9ZObE45uPIoD7snUx3FtQDAMYzJPf97EQ5y0mqjGTPv+Xt6UA2LJ+mP2vfOoIi
wMxaFrFFGmYxiLdUxIaK+CISNy8yi0rsCpN2KUkV/+okHbQAZh9DvM6YL+nwlor4vXyw3sPLSzrL
Ppr/95dCzSoi2t2CE5IxosTTGJ2QJAYRYAGGDPTE/Jq3FqS465ax0aFCkPsX+7JaqQOAyQwxHXP5
14IUPQ1/U736FA+UJQQESYCFGCKHLfeUwAYrO2S5YCe0rOwaXMrlS2AJsJSWVaqnyNA8oOwwYK2Y
IDg1WuQqIvO8BUGABRhiF4I4s6rJFSHCXUTirJhyErEVJq0d3c7IRt5umJgxAU8a3jaNW1OwBJiC
4/MfUivxYMhlAPyHlEMSCAKAIUXzAvPHBoDjZwgAgCEAAIYAABgCAGAIAIAhAACGAAAAhgAAGAIA
YAgAgCEAAIYAABgCAGAIAIAhAACGAAAAhgAAGAIAM4DvdaL2/+juXPfX3EX0yrmgdBdVibGL7f1V
+m09hvKzJQPAYRjCRF8JSxSV2WciJNAIgoSXdFkq8AM4JENUSJCISO5iqbb7bv7fdeUNi7pxRIgu
rP9hkoUHloe94hapBc+J/epKNmWBMMAh7BClVLITV1prhzl7sdai17BUe2jjdCKvu0veQbN42ki/
jvJS8GzZL231QZYxACyqZfUalY4pPiqrCWmV15J2rOgPfV7aC9dRW6cvIX4ZDxE4DENioqYV77uH
O2mVuKSbbr47hHl1AVmp10yXKykZAOa21KM2s+JWimr/1+no8UutcmUOkTkoEz5EvyaKLiwZAGa1
Q8xwwUYN1f5whU9rnevDlQo69DYf3Z7FJdmGp4cGZmsoFc8DABZkiI4IsJ3r1VEJ1N1LFNO5mxzs
KGEuRQ5OHjpKHj9bL0eRrzsAzIAl9n6HrAKzyxT2fgeAo7TUxwAjCACGAMACuAiuXN+QpQ4AABgC
AGAIAIAhAACGAMDqcOay9l5mZa372M7tunOY7IPWukTvKpVw2ulElMUlU9YHqOPi3bh99xO0xQTF
hxFFJFlYSSe7SK51zyXdfNQHSJFu4Hir0in6Tb3mP6TdP3UEaR+dezAyNoEgTCCkfyEesTuj2vwj
4HdArBY+iSLFD7QeOYdEdkGuzf81BMk0nwxqEDZwolUlidNmCGvf3fPYNZzpuSgcJLqLS3ljln6f
mypKhpWf5zG68hjp8qkgmUjULkhNSwlfqj62wHyN5bL1o0Gl38T4SlYKDsoQOwY3HGF9mNO9mdMB
SZipEaWjHpRyax7J6mTay1mOU99kIrUcL+vj1ElZWuNlxdLP9yIVY73vsjhDJLnPMHicMn5rtEj7
MS0hS8l+MKO6B0m1j5LkrBGrSqf9/6PMAMlMnFE1PknjIzWGyIy4VwngjDIih3ox6RsC5SJXfiey
troL9LUDw3Z8RJDh/cZjiKH2BUMKNNJEJy6jz2nqZNayj0WWlk5iGxJSqrfKwcunPSRUo+B9COWV
kpj8SCnFTAShOXWl+mTmTmj2jA9FrMFq0VHdz3bsEE8j6bWsQNmidtROBY9+sGTG94GMZTe3Vld0
WWRL/uLipzWAmwm/qfZc1uUzXK0gRnvLI1v1UmJ4jSFhVL5MGJyOXlUWkl+/Y40hcGC968BJL4eW
ddDZGWAdyAnBhxKFL33wnae/83nxtSNhCAAcDNfFZ9/5C7/7VSHuia8+flN+7DUwBAAsP27Sj18W
v2l+3dubH3/wP3/hxnYsde4/hHkQsTaSigWy7dybvUa1jWa3eN/a5g7rbRWf9raiwj3yWRvydi2+
uW4zM9HvQM62Ro5HCTPo66sWbbPn7so/uRcL+Pl/euPlG5uw1JXQkQ3UVfTUXrE7IWq+N3WXYb+n
6cYIstZW8SrVlO0ld498VlM98ua0djfW1+Gz9KNESvc6z9nx4Ktnn/zW/bfvnZnfzvG3/vhbN8/+
j9V2dPC1LG29dnQbUCvussPrfYNBhY00zSWzYSM2DC0iSD6tHtER5OsxtPufLq7cBNXqqbvyytn5
jg7n4jxxvLv7U//XY6+soXB5/kP8R8K9e7Sn2ulsnMRqWDROHtrrWUJpnJeRqYeiS5+b2WZ2KdXq
6b95Yzd4iB0Rhv70/W9/+bGnrq/JkGBr6ai7hOQG0i1z1GCbgyBjCDKyXVPKpB6OwkOX068+fOWj
8si//9H9p1YdQ7Qu6Oz9YdlQxmwIvxthGh8ImxfUIyPxuHbVevBu9brP6rU7X7l3+5EnzozNkft7
8pkX6d33Dz/963v6rCUI8zByZH35pRznVGp8UgNR1sPOtnj/uU8/oL3N0ShUseNf/b33769Uv6tR
K6RiAsp4GOkTK+3QbZt9tToOx6C88crsdObcpfP+4t9tNErMEA1CFxxK3ji/982PP9n+OBfu8a9/
5sWPvvJvXaz1EGLvQ3oXs8pObQl+av2l6b5P6p6CYoor82G7MXFcryOteR/Cmt5p1+GbcxOzB+JM
PirfV7Hv0th9H7K424tv/gx94L4Sefxjv/YfXJR3EEszZPTjni0ecBB6ZiLotR/jc3flj5tJXqG+
/uDmq3VD6NKW+uipmRkjAosPnhMIcgiF6/37956XP/XEs7d/9d33X91Ai13Bp7vAMTAb60MAYJMA
QwAADAEAMAQAwBAAAEMAYKsM8beOq97agvw0FTlSGEojqwEAGx1DZEzupyQHgG0yhIjMvofNGT/d
HRq57wNI8F/Cxm+EnoIc/bRdFsJkayOIPqS/AAAHRnSvk3YbdRm6CzGuRITwAqwDpm4DZpnKMUjr
7GnuZkej9nUHgKUYQmUKkKScZiQdf2Ix32KewwMZhA56RACAVRjSe2IpsK2p0N6IUWRQY6JJ9gwA
LKxlCTlsPcvxRvagP84wAkYTYFOWen4Yofww4o0aUc8wxFJQLHcKQjCMAJsZQzqnEXvbmjv6Mn4m
mjPHrwT7FfoL59GNOW9clbQOMbhfjN5XCY8g4MUCWA2j1odM8kHhR8McFTCMbfjCLZPrQasAIg9c
eks9AzlDDCce+AQcpaUOAAAYAgBgCACAIQCwvKVOUcu5m5Otsqj5x4hdci8H+7Fi1F7nwdIe2iCK
WvjsnQxLg5k1YC6G5L6fnShnlJFUGcueeMH84+H2EEtjozhpJCgCzK1lEVukYRaDeEtFbKiILyJx
8yKzqMSuMGmXkiT5Zy+MEW9QAlhkDIl227Jb9sEXbQh3xUa43sPLSzrLPpr/95dkbNyQAzLua2+D
lMAgAszMkIHeWLrSR853wIXCKGNCn9PwvA+zaIhKYAWwIENMx1z+tSBFT8PfNFqavbEJ8g+syRA5
bLmnhoRgZYcsNxASGlO2DmPSAMB0LYsKp0klSV8mKSuu1ooJguWIEWZMGgCYxhC7EMSZVU2uCBHu
IhJnxZSTiK0wafKl9qUFJUW92TWiSWTzSRreJkqQBnQBpuD4/IfUSjwYchkA/yHlkASCAGBIte0x
T2wAOH6GAAAYAgBgCACAIQAAhgAAGAIAYAgAAGAIAIAhAACGAAAYAgBgCACAIQAAhgAAGAIAYAgA
AGAIAIAhADAD+F4nav+P7s61YGfKhtjI7ILSXQolxq659xfrt9WpzW98+QAwwBAm88qV073Yqcx2
EyGBRhAkvDQmS/ADWIohKkmQCBl2kVU7cDT/7waAhkXdOCJEF9b/EGwscg4sD3vFHxZYsX0Unru2
F7T5NQtvAdghXBSVCnpiX/XRWju02Yu1Fr2GpdpDG6cTed1d8g6axdNG0nVsMHHpwqI4Wag+QLFS
AGA2hvQSlSRIo23ltBo9oPE0YmsOfV7aC9faZ6wZKezg0qT1stBQtYAlGaKL5KrIElYqfkm3R3MI
89JuUp2pkhm3stVRGEGAeS31YoKo9n9dbi5rOxBoc4hItwkvM+yVHuArhhJgzjHE9Li24812wYn+
XfG0yu/RVSvRKiXYNjw6P+DMJRQZGRhFgBm1rLTk2iAdFTrdvUtRmse2owQ3G3RgRPR5xKug+bDi
RtEZDmTuBwBKseDe7xBPYD5hwt7vAHApLPUKYAQBoGUBwIK4CK5ch5YFAJsCGAIAYAgAgCEAAIYA
wKHBZ3tbJ7MDLsg7L+uxw/zoM046XbdFl9WlKpYtNxU/KH7I+24bGmbnXI/cVJ1n+FirCFOCLGg3
J7S/fzpFv6nO+xBpHpXMP+DdX/SwAEH6jGXP4FSMsrpUxbLlpuIHxcdr6fdCYXYUr529QLKGIGG1
pPOQB9qN/2CRKh11X0KGsAbePZC22yK3g4k+pcP0LAUSIgfrI8eVW5ZMFuRFVdcP1HZySqMvojmk
bAA6rMyJzDt1Z4RYbJCYlSDk6hGHIyYvPi/rcjxxp7V/TqvMNhit4JK+L/Bipc44yRAK+2FZ+Kho
fQ3V1frmFrVB3g2Wy59zpdztR3KaRP1MF9dWPFUlyUykk7fUM814DM0jF+1lZJmmUkaS6jFZFlMw
LugyE0PmqiQ5RcGQpimGLI2VhpDZSqjMqLZcWmzSgmr6iUkxVjM1t4irNY9+yzrWskwr7j+llFuU
JpqYkE6WIM63vf3sXziPm3o/QN2PhXoZ6lW/pBZtY5S86Rh6v5EqN/8+xG2iud6H8Fzbczmi3bxW
IZmN4dxuKvRg2MK3vfj6/cQwIORLTHIcN0Pw1cnJUWSVpKdghwCXAnLsu8PhtIvhC5947EubsEMA
YHt49oP37+0Oj994+DUwBAA8s+Ps/Xf6H7f+1y/cWJch3H+I3cyH7cOiYoFsH/dmY2u2u5XdmH0z
uzq4m8+vUoFU8SrcHJ+1obtrWMk9undr9nB1A0R/TQnPN4bmIsEqcUj8o1+4uOdcePzHP75Y0Q5R
Qkf2MVTRU3vFbn7Y7MKo3Ufe5ac2QxC97rbwymuYeIiN0J3p6nsUwbMRTPDtkwkbxPmh7c79h6XH
9Zuf+rkPDEHOzLWP7r/32DMP1rXUdbuLYbuT4X4f0ZYGyj210f1BhY00zSWthdjQxkBar83Q+pBw
BB8zbOXGGz0m5aL45jOPvveju+L8rKUHO7717ZsPP1iNId4On55bj/ZUO52Nk1iNEo3Tgh4RMgMx
M89m4LmtsfPx7Zs//e074nx3Fvu7e//LTzy3CkOCPaV19DmmmqxljlqrVWfpUQ9EkNiOwnp48Bnf
rjmdUqc3TB5IuRj+3Y/y4b//4YfrjCHG902dgBnKmJF6N8I0zg9AkDJLoVzEJ7RrgWqZqJHWA93i
Mnjt7oPnbxnFKvx7/BE6f30tO2S4LUMB0/qYth+95NttFwwzY0aigz/jizff/d8/+3irWJ0Jfnzy
k3ffP+h8Vs7TZ5Fp2NrjNrFN1LkCBUHmqG2Zna5jid2b1pnWUF4o9wB+6Ib7onjwz9RbxvYQ7fGJ
G+/ev3/gdyKx9yG9O1kzQ8890bpezpXu59i7OXSl/Vl3VTGVf5i5JH0k70NY0zvtWnCT2n1uwnN2
n4ji+zJmoXqV/uWb/8Znv9H/uPkT3175jeFyXTJciRzJEJrvyVZ5jLd/5oN7Z+fi7MaN11dps2lf
LurZIwKHGETHEmQNfPH8wWcfuvXEvXvrEATfZQHHwWz4oAKATQIMAQAwBADAEAAAQwAADAGArTKE
2L/uWSHIT1ORI4Wh2M0MuGRjiIzJ/ZTkALBNhhA1XTqZM366OzRy3weQ4L+Ejd8IPQU5+mm7LITJ
1kYQfUh/AQAOjJSHncbjENuV1PEmIoQXYD0ddRswy1SOQVpnT3M3uz5kC/5LADAkoxO52+lTTjOS
jj8xmd5xP+HOQAYRAGAjDOk9qRTY1lRob8QoMqgx0SR7BgAW1rJY5y3LzOqq3p7kgMiHETCaAJuy
1PPDCOWHEW/UiHqGIZaCYrlTEIJhBNjMGNL5tGv9A0vnovHX5bq9Y78ocKLBoxtzvqWN8bMrmV+M
9tyLUO/3DwDmwqj1IZN8UPjRMEcFDGO99SHXqtkxaBVA5IFLb6lnMJ8nyWV91wLAspY6AABgCACA
IQAAhgDA8pY6RS3n3sF2jUXNP0bskns52I8Vo6XaKyT9BDLuv529k2E+wDGzBszFkNz3sxPljDKS
KiPZs295gxf4JIfSON8NS1AEmFvLIrZIwywG8ZaK2FARX0Ti5kVmUYldYdIuJSngH+Qb2MwY4nXG
vAv2loq4vXxkvYeXl3SWfTT/7y+FmpWIfQvPVSsRaG9RhcvJASQD5mVIRD5T17y1IMWv/2RsnKgQ
5P7FvoxzogvA147AEgwhT86KBDY8DX/TaEWKaj62N2NV9/0jAMzMEDlsuaeGhGBlh6wQ7Fwcilcm
mwbaFbCYlkWF06QymIuNLCeRwQ/fVBkU6BRbZfm4AwAzMcQuBHFmVZMrQoS7iMTRbJxEbIVJa3u3
Ly0ibzdMzJiMJw1vm8a9ARAFmILj8x9SK/FgyGUA/IeUo9L6BkGAE2NIpQEOggCnxhAAAEMAAAwB
ADAEAMAQAABDAAAMAQAADAEAMAQAwBAAAEMAAAwBADAEAMAQAABDAAAMAQAADAEAMAQAZgDf60Tt
/9HduRbOmb3QR2YXlE7FK4e/WL+pjtDZHFVY38QNOUlY5dfbIgA4OoYwaVKenLILcUEVYqqkRUrY
ZakKJVin6BPLQMVuFAAGGKKKCGLIsIus2oGj+X/XFSvBxhHT95v+uv83emB52CsxWee5WlK2A0WX
ifbpqnl9+oy6onipADBkhyilgi5ZuxeU1trpePcCpnth3Yvc/tDG6YRPd5e8g2bxtBFiHenWFUvk
/xL7TKLxmhsSvD72lrQpPFcqAPhalu50kiRBRCBKXt+rVV71Ua08N4c+L+2F66wKpZNKU6QubZjS
OlTLwAmgjiFleoZySVBsU3TK0F5kzSHMqwuImzcqXkZEJ+Ms2LFDxQx5XjjIApRZ6kUEMSKlMvNA
OnWpVa7MISK2JjwxPg3a5kGItWyUTlrrMEKAIjvEGCFKeRcSYqh1bvRQKuz01f5/3Z7FZdKGi1R4
8CuWlwlRTq7ZsUJhGAGGGKLTkutFEgmlvjV9bUaaWQjNpcjBySNXBTeM/1JKRePpJoQXp4MbGSoV
OHUsuPc7pA6YT5iw9zsAXApLvQIYQQBoWQCwJC6CK9ehZQHAlgCGAAAYAgBgCACAIQBwaDizvXsv
s3Zui3mRpc4JurnYuVp3DhPhZMZ8rKcK6S9QH69LKoeLCZzkJopnZ36u5FarrDGSsWINyy/UeYZP
V4vcZrVP3alSPJRO0W/qteCRRxphd42LYfPDXLOHqQRxMpOJsoL4XbReDgZqEyQbKL4/o4gQ8tLK
GiMZK3Gz9gLJGoJkqiW9GKwD6EtIhFY66r6EY0iiB6JO8vaPKYw9T78i/cyYQMhIQTIhGLKomJri
c5IpKxtDJkV6NeHLE289d/QUNwJoRpkbxxAZ9kCyH0PkGg+u0+/ipTPZqnmaQyLpEySIP69My6mS
PF29HRW6IJpSLxbqj0cyRFJ5DchRDuapN0WZ4KpzThVkomr5XjEVTHLUvcTtk3x8WSl3sjEEFzID
8nqhXHMc2ZyWJQu7qvaBdYdGEZMzPjCSWf3HiUhyMIPCZNnUtTQothMqOlQqauZh7nkx5NTB7dQs
9XFGw+wKcXFdyE5m1VSHwsksmVGywviUmtkoGELGtQ7VPBoI/VwY9T6EYoe5dKy6OkgpRWRSqDrZ
QPFB/O7CoQiysEU8MvQU4Hzb29khZA327qx7sou9D/FeZ7CZgpL3IUxtGfc+JF28zClaTMkMXuQU
3GWMobEH0J3LitaU8eYjmY3hNGIq9HDYwLe9+Pr9xDBpjDtFhuCrk5OjyCpJjxcPXYPMnNbUzLXi
mZvatAvgw/bwpUd+9IXXjcBCywIAT0YffWv3761/8kWMIQAQ4PYj33hnf3zv7938P//+GvxkY4jr
bqPbzIftw6JigWwf92afT7Ytld2tfTO7OrAt4/V6xUc3m1fh5visDb3tvoruMchNeQH2oSvh+caI
hKoVdue48pd+k/1aYxy56jyhyB7oKnpqr3ibsGv3kXf5qc0QpNtAfs3io5vNq2iE7kyPuMdYcdp/
MsI8dXYhFXr4LuW5Rx80BDkzvy8+/+iVgxtu3m8trJ8N4br1iPnaCAYVNtIo0TNGb4UherPFF2wX
rpfh7OjQxfWrP/etPTXOzsX57q893hG3PvnaWmNIsHmt59aDud2IPVWV3fp2M9vithuQbtA3m16t
QdTo0EX58di//ZbYEcP/u/Otx66sxJBgT2kdfY6pJmuZo1Zt1RJBXNlxCNtIuIYgy7VrvkHWa66/
+KfPEyF/8sxaY4jWBZ29CpwUKNWlbbTWxvnBxrHeENL5TakUvMXaVevxocvijd958ckzY4Pwv1u3
3359PTtEVxPEzmMdFdRKNFlasS+w6dXR7Bf7unj6+p3GBmkUrOZ48ye+feOwtbgatUIqJqA6HwMq
6J5brWtb7DHV0TFfcNsjCG+8Mj5zp46qJErMI0sq9PB4890Xf0l0ytbueOuFt988MEGi70OU51qW
vfPQ1vVs99gU9zfbTXe5c/l6O5bxuu9DFBupC96HsKZ32rXoHlXggdhxPx+N4vsyDnwXr9Bmz773
tjm7+fd/9sbhy5/21Ykqd34ogC30D0MTAnqDj/HZ9368Gz+e/N++cGON0qd9dFL8ngMEOYo5iiGC
rGiPvPDKjXVKx5eLwPEz+0CWOgAAYAgAgCEAAIYAABgCAGAIABwNQ4j9654Vgvw0FTlSGDrvjnUA
sPoYImNyPyU5AGyTIURNl07mjJ/uDo3c9wEk+C9h4zdCT0GOftouC2GytRFEH9JfAIADI+5hx3Eb
EnicIiG8gH77TtltwCxTOQZpnT3N3ez6EDr5PfqBTTCEyhQgvgt5xDmB409MRt0XOEcZhEqoXcAm
GdJvf15gW1OhvRGjyKDGRJPsGQBYWMsScth6luON7H7T9PIIGE2ATVnq+WGE8sOIN2pEPcNw97IU
yz30P4thBNjMGCJ7LxrM4Z45tR7a+EjDvOcG3jl4dGPOG5eJrUMMyfxitOdehHq/fwAwF0atD5nH
z9IY52rAiWK99SHVawyH/eVC5IFLb6lnMJ8nyUXchQLAgSx1AADAEAAAQwAADAGA5S11ilrOvYPt
Gouaf4zYJfdysB8rRku171eYQ/EuZdxpeZCGOlfnADAHQ3Lfz06UM8pIqoxkb7/lJel/hEKyMI3z
PTEAzKdlEVukYRaDeEtFbKiILyJx8yKzqMSuMGmXkpTzD2IOrD+GeJ0x74K9pSLCXbERrvfw8pLO
so/m//2lULMSqdcjMsGVXJouKdgFzMuQqGDGr3lrQYpf/8nYAFEhyP2LfZmJIPC1I7AMQ0zHXP61
IEVPw980lwaVT2E/rpSgCLAAQ+Sw5Z7TgSgpy7KAZ3V0iafB9yzA0loWFU6TSpL+QEDZMYKkf4mm
rLmVmUEJ9gewDEPsQhBnVjW5IkS4i0gczcZJxFaYNPlS+9Ii8nbDxNxb8xQskpdJ3cpNYy8AwGgc
n/+QWokHQy4D4D+kQrEiEAQAQ2ptj5liA8DxMwQAwBAAAEMAAAwBADAEAMAQAABDAAAAQwAADAEA
MAQAwBAAAEMAAAwBADAEAMAQAABDAAAAQwAADAGAGcD3OlH7f3R3rgU7UzaER29DtBLxdfYqHZRF
rLThuMom2q/7T6/9N3UaVTXglBnCxFK5tNkLk0qL3MySNlBaIq5ya6/SaUAMYBRDVJIgTKbMsNB1
w9oSSAg22CifbrofUJwYqv8Tfa7Nv1rt87Zl9ak0K8wrRJkA1XNEiz7PSKGVoxUAO0QpFXSzgfyo
ttNWQV++v+YeugTmh0rF8H5FyrKpFM+xrXRTR93IfhOwP9VOzU0CW0yXUaJcAIgypBcXHdO7tL0S
nhppM7l4So1Sg9pNk9pP6RbALykVVtoPEIYU7vW+DO3WGgCGGKIHJDibjxaOcDo/vLRKDaaOVUCV
1CYzZ1BSawDIW+rVBFFuhx1Vzvy0OiqqamDjSR3WRgV5VRKkpFwAY4jXS9tOVanSEaS3BqL5DI0H
fWqlOqmNlaiUy0nRGBcqy6owmz6BcmsNAINaVk5glIrJohbaTeweEsaBG1EHRUcqEokei2sC7PxY
cN1EjpYLACGOa+93pete9EH8LwvWU4WvHVU76ar3FwrvOoATY0idxIMewMkxBLj0uAiuXN+KpQ4A
ABgCAGAIAIAhAACGAMDq4HNZrZPZ9CtE61bWnHUe12OHWcBcrQ9ky4IHvN+2wUO19GMl4xun8Lbh
ipzvhtk5BQblUqVneJ7/PpmtIAX1jD23yI3v4tMp+k3lDJEDz1d6Z9Q+tehhHvTSN5QtC6YC0g3W
0o+VjE9ePUWRL+swO4q0qHOBZA1BWP7kVVB69Yw9t8iN7+NXOuq+fAxhPWLTLiScX7J9TrY3k3ka
zTSMyLpsKf8Yqegpm1iyorSOn+OkiJYXPo+RfYFysI9aHJTX+/fBXzlsjdIM4d1G13e5PbScb4So
f66Fw87kJy6rS+vqObJt5AIt4VLBSy63RGGnMhfR4K18l9U0o3Tq7f6Ka88+5eXBySIrrZ/i+Mz2
WrDfLKju7v/FzID9TSZb5CSNjxRDopo81fcIdPA2rbV+auO3Ijpfp1mbnSwevj1Bj6SIUyHZIvLg
esOm7RBn7iPya56Rf9S4scpDIlmmldRWTo6oCY3KmQLhl2MqT+JUWXK1QKOoIggtz5UVCLKmijVt
tJJyErupOJsTGEPITAy6KkBGIaB2wDYarHuYW1Ap/wZDdjNus9ohplCSpfGnFu+2IS+3Pa/Mf7g+
tmWdJJEKnCyunPbtnx6K3qeuOZDHv35fby4LX52cHEWOQTnctqUOXGZMeV90QH3jSx988MbzH/va
xix1AFgf169f/8Onn/jq1/9QfP2rf+GZn/yT6+suMRQPYRABtmUZP3H9v/j+D3cn7wvx8vffvf29
R3//7wnx0stbsNS5/xC7kw6zkVQskG2r3uxFom00u+n7hjZVSPpDOWgdYluGR/fO79qQt2tF7nbj
MLMFvvafoEht1u+cqa4Si+LBi+//+G54+ee//nv/yRYsdSV0ZCd0FT21V+z26drbcJ3vrK42RBCx
+p7v0eJ5xZxN6mtFk+fePRi2597/39657LhRRGG4ggjlBQjBMMCERAlC7BBIZJsFG3a15lV4Blbw
ArwBYkPtWPEISOyiBAUIE43GSCQbiggF2112161v1VePvi/xuN1dXW236+9zTrmrjv9dJifrj44e
XDxHcq/ee/P04flOICd2lX3+7tmHP539s5BIXQsnvUaRQ8BNy6GDy188NXxpaYo8IGJvWxYkkCXS
/Mb6GOJwaj0VfYFJprtwXz/94tuHG0msd4919Hx5ee3d66vf5o7Ug4lHlc3FYS8lToaO1LeqaqfQ
XUzLXOwkWmO8sf5pw4pZW0f2kv8+e0P++tXlZmld83jy+/3X3749p0J0qJGKSdorGru2M1I3aWUJ
7XCB8/XqZhOTf15VKguLu7HyhEzijT747966VcEX4vtZbYjWLS72yTmnRZldZxuVL36yw5njEN05
a0neeW116bcdBHUnZOyOlk8vfnj19pmNOyofp7d+eXpxd+Y4RHcWSNmPBZ0MhhpJ+oF5sLGjrimi
W1U7skyePxH3PzfnW4dqG3eEzyfitVcePb07x3f1UjIK6dABVaYdCK83hdeFeirPWbtyna7jTq+V
UnHvYlzEF0iYRmyfXi9Vz+B8dP7Xi/dvKLF3uA7PJ1/eMZ+dP5rpywryhzhJOmyedJuLw1t0vVmb
rNlzZJWIvP2lOf2zxiHVybCj/Cup8zrsh1PFtx4mfNFznKfVn+uvP7hx4q566+zO42/On8/XVvrd
29v29JHHYzHxV5/IZaqv8ea/nxQH+vhy9WA1SSjULlIfvAMmoyCMrZE+ApmIPy5+XN06fefm6uf1
49XcZ4zxIXAUymZ8CMAiQSEAKAQAhQCgEAAUArBUhRjnr7/UEpOei65VjSbeajLfBsBCbUhyjtg+
uwMsUyHGGDvj4G7JXdw87dr9YYMR7itRlt81ehPVGO67r0LYassC4rDlsAJgYpJTnRRTIUs/e4iT
UkRUJRkRcj8Bs6yqMdrXm1o8ylnSkAIKYEqFmHYOkDuPb9xspZdPLJVbrD4liYwKACxEIfLg6zSL
pm2SEWkyohPTK54BGNnLErI5eu6R9Ks2JUm6ANYEFhWp15sRU29GAquRzK1gnD1MqnYTbcGMwGJs
yD5pxDa2LsOFQ26L3ZKXV8J5VWYE9TYaJxn1PiWJTYjh5sUoloMCgiwWMBtZ40N65aAIi9FHBc0s
JRdum3bdGBXQ5OHKR+o1yAFKeOXQExxlpA4AKAQAhQCgEIDxI3WTjJz3fbKdImr3ZsT97kEN5c2K
yXi93N3IcIfiN8jo/Ti/ydgfX2wydIBBFFJ3/2zPdmZqWqpMVR//om/ct5Lap7z/17tvWCIRGNrL
Ms4gDTsYJBgqUm4V6UEkfl3GDiopR5gUQ0kq9RdbkC7I5CJATxsSXIzdS3AwVET4Izbi8R5BXdIb
9rH7v10lU3ZD+g07cK1E5L3V6cDewoJMYFCFiPpLsLsuGAvS+potUxajQ0M2sZQSRsgQhcAoCrEX
5vZ3C5rkYvzaZMc4Judme9QB4yhENkfuVU0xGtkh2zfZWo/JpN9MxT6YDhjZy2rroMioLzYxnERG
L8JQpVE/VWqV2VYJIFch5UAQr1e1ckSI8AeReCOmvJ2cESZF7F38aGEqm3qqpVcG3rb23UwTu8Vy
BUA2x5c/pGuLRyFXAfKHtEcaBAIopFW/wPClAY5fIQAoBACFAKAQABQCgEIAUAgAoBAAFAKAQgBQ
CAAKAUAhACgEAIUAoBAAQCEAKARgAK4xShWyyJwA4Ch2c/fDhgDgZQGgEADiEFhQHHKlP10pi5f5
qqFvI7qCkTpeFgBxCAAKASBSB5gPInXoR+dsFTkxvsnrGMjbzf9EKAT6CSSj+XXuYTJ5mZLydjPE
ITAj8tiOhUJgSh/r+D4RCoGrrKr+xyIOgewARHZrgOYYMoJFnwiFQB8n33S4TMujMCHhJ0Ih0E8m
S85NnHEsSW8vzOycZThbMvOHjSEcO35TB6iDviwAFAKAQgBQCMDU0JcFHVDbP3qoynSbbV6pAY7v
H1VpFAJDomeuS0/+ifGyIOdCrFRxQVd2+fCiXBOU2/xTh1XFa2FXBhvianocP1VzU+3YEBjAP9r7
J+5y8bJcUyxppe0qZ6PdZbtGhBt2u4QVZx4/VbOorx0bAj2Nh/V1tEq0MV3pDemqcjpdTA9yfJ16
A118NWwIZMQBtQ7KpuX65bTbkFVtL0Dtiu7HHwAUApleVq2MrCZ03J512yC85iCtj0+kDrOJJLQN
ZZtViYLe6tZmRPU/vur7QbEhkOFrqaLROz6Ns6r0coqlTTvWu4ctlzYjwYZtTF0eJP/4OlFzJ1eM
e3thOs/sGMHLAsCGAGBDAFAIAAoBQCEAKAQAhQCgEAAUAgBp/gc1OlF+dh01uAAAAABJRU5ErkJg
gg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-05-12 12:02:31 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-011.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 11.1 Active drug versus placebo: Anger, SMDs</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxMAAAWwCAMAAAAR3OwYAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-05-12 12:02:31 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-012.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 12.1 Active drug versus placebo: Psychotic symptoms, SMDs</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwUAAAMACAMAAABCdjv4AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-05-12 12:02:31 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-014.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison 14.1 Active drug versus placebo: Depression, SMDs</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxMAAATgCAMAAAC7Je9bAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2010-05-12 12:02:32 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-015.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 15.1 Active drug versus placebo: Anxiety, SMDs</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxoAAAPACAMAAACFO/8pAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2010-05-12 12:02:32 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-016.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 16.1 Active drug versus placebo: General psychiatric pathology, SMDs</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxoAAAMACAMAAACU0+GdAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2010-05-12 12:02:32 +0100" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-017.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 8.1 Active drug versus placebo: Mental health status, SMDs</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxMAAALgCAMAAADY9dphAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2010-05-12 12:02:32 +0100" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-018.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 18.1 Active treatment versus placebo: Attrition, RRs</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAt8AAAeQCAMAAAAi4snoAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2010-05-12 12:02:31 +0100" MODIFIED_BY="[Empty name]" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAX8AAAQyCAIAAADP2GglAABRz0lEQVR42u2dv04kybL/SzrOMcbA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2010-05-12 12:02:31 +0100" MODIFIED_BY="[Empty name]" NO="11" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAAEZCAMAAAC0DjydAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2010-05-12 15:06:43 +0100" MODIFIED_BY="Chris Champion" NO="12" REF_ID="CMP-011.01" SETTINGS="SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 11.1 Active drug versus placebo: Anger, SMDs</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-05-12 15:07:10 +0100" MODIFIED_BY="Chris Champion">
<APPENDIX ID="APP-01" MODIFIED="2010-05-11 12:58:57 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-06-30 21:08:05 +0100" MODIFIED_BY="[Empty name]">ASSIA search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-11 12:58:57 +0100" MODIFIED_BY="[Empty name]">
<P>We searched Applied Social Sciences Index and Abstracts (1987 to September 2009):</P>
<P>((personality near disorder*) or ((antisocial* near disorder*) or (avoidant* near disorder*) or (bordeline* near disorder*))<BR/>or ((dependent* near disorder*) or (histrionic* near disorder*) or (narcissistic* near disorder*)) or ((obsessive* near disorder*) or (compulsive* near disorder*) or (paranoid* near disorder*)) or (((passive* near disorder*) or (aggress* near disorder*) or (sadomasochistic* near disorder*)) or (schizo* near disorder*)) or (((passive* and disorder*) or (aggress* and disorder*) or (sadomasochistic* and disorder*)) or ((schizo* and disorder*) or (paranoid* and disorder*) or (compulsive* and disorder*)) or ((obsessive* and disorder*) or (narcissistic and disorder*) or (histrionic* and disorder*))) or (((personality and disorder*) or (antisocial* and disorder*) or (avoidant* and disorder*)) or ((borderline* and disorder*) or (dependent* and disorder*)))) and ((AB=randomi* or TI=randomi*) or (DE=(randomi?ed controlled trials) or AB=(double* blind*) or TI=(double* blind*)) or (DE=(double blind studies) or (single* near blind*)))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-05-11 12:58:56 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-06-30 21:06:09 +0100" MODIFIED_BY="[Empty name]">BIOSIS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-11 12:58:56 +0100" MODIFIED_BY="[Empty name]">
<P>We searched BIOSIS (1985 to 16 September 2009) using the phrase:</P>
<P>((((al: ((personality and disorder))) or al: ((antisocial and behaviour))) or al: ((antisocial and behavior)) or (((al: ((self and defeating))) or al: ((parano* and person*))) or al: ((gender and identity)) or ((al: ((asocial or antisocial* or dissocial* or psychopath* or sadist* or sociopath*))) and al: ((person*)) and or (al: ((moral and insanity)) or ((al: ((psychopath* or sociopath* or dissocial* or sadis* or schizotypal self-defeating or borderline or avoidant or dependent or depressive))) and<BR/>al: (person*) or ((al: ((histrionic or multi-impulsive or multiple or narcissistic or passive-aggressive))) and al: (person*) and ((al: ((randomi* or crossover or random-assignment))) or al: (((singl* or doubl* or tripl*or trebl*) and (mask* or blind*)))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-01-13 17:00:46 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-07-01 15:01:19 +0100" MODIFIED_BY="[Empty name]">COPAC search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-13 17:00:46 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Consortium of University Research Libraries joint catalogue in September 2009 using the phrase:</P>
<P>randomi* OR ((double OR single OR triple OR treble) and blind) OR prospective OR (clinical and trial)</P>
<P>We then downloaded results into a Procite5 database and searched again using the terms:<BR/>(antisocial* OR asocial* OR avoidant OR borderline OR dependent OR depressive OR dissocial OR dissocial* OR histrionic OR moral OR multi-impulsive OR multiple* OR narcissistic OR parano* OR passive-aggressive OR psychopath* OR sadis* OR schizotypal OR self-defeating OR sociopath*)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-01-13 17:00:47 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-06-30 21:15:06 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-13 17:00:47 +0000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (Cochrane library) 2009, issue 3, using the phrase:</P>
<P>[(antisocial-personality-disorder*:me OR personality-disorders*:me OR sexual-and-gender-disorders*:me OR multiple-personality-disorder*:me OR paraphilias*:me) OR (multi-impulsive and personality) OR (parano* NEAR person*) OR (asocial* NEAR person) OR (dissocial* NEAR person) OR (psychopath* NEAR person) OR (sadist* NEAR person) OR (sociopath* NEAR person*) OR (moral NEAR insanity) OR ((personality and disorder*) and ((((avoidant OR multiimpulsive)<BR/>OR narcissistic) OR self-defeating) OR personality)]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2010-05-11 12:58:51 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2008-06-30 20:37:13 +0100" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-11 12:58:51 +0100" MODIFIED_BY="[Empty name]">
<P>We searched CINHAL 1982 to September 2009 using the phrase:</P>
<P>1 exp Personality Disorders/<BR/>2 exp Antisocial Personality Disorder/<BR/>3 exp Borderline Personality Disorder/<BR/>4 exp Compulsive Personality Disorder/<BR/>5 exp Dependent Personality Disorder/<BR/>6 exp Impulse Control Disorders/<BR/>7 exp Passive-Aggressive Personality Disorder/<BR/>8 (histrionic$ adj2 person$).tw.<BR/>9 (parano$ adj2 person$).tw.<BR/>10 (schizo$ adj3 person$).tw.<BR/>11 ((asocial$ or antisocial$ or dissocial$ or psychopath$ or sadist$ or sociopath$) adj2 person$).tw.<BR/>12 psychopath.tw.<BR/>13 sociopath.tw.<BR/>14 (moral adj2 insanity).tw.<BR/>15 dyssocial.tw.<BR/>16 (DSM and (Axis and II)).tw.<BR/>17 or/1-16<BR/>18 randomi$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>19 clin$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>20 trial$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>21 (clin$ adj3 trial$).mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>22 singl$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>23 doubl$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>24 tripl$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>25 trebl$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>26 mask$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>27 blind$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>28 (22 or 23 or 24 or 25) and (26 or 27)<BR/>29 crossover.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>30 random$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>31 allocate$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>32 assign$.mp. [mp=title, subject heading word, abstract, instrumentation]<BR/>33 (random$ adj3 (allocate$ or assign$)).mp.<BR/>34 Random Assignment/<BR/>35 exp Clinical Trials/<BR/>36 exp Meta Analysis/<BR/>37 33 or 29 or 28 or 21 or 18 or 34 or 35 or 36<BR/>38 17 and 37</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2010-05-11 12:58:45 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2008-07-01 14:50:45 +0100" MODIFIED_BY="[Empty name]">DISSERTATION ABSTRACTS INTERNATIONAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-11 12:58:45 +0100" MODIFIED_BY="[Empty name]">
<P>We searched Dissertation Abstracts International using the term "Borderline Personality Disorder" (1861 to September 2009) and then read through the titles of the dissertations that were found.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2010-05-11 12:58:44 +0100" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2008-06-30 20:40:02 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-11 12:58:44 +0100" MODIFIED_BY="[Empty name]">
<P>We searched EMBASE (1980 to 37th week 2009) using the phrase:</P>
<P>1 exp Personality Disorder/<BR/>2 exp Borderline State/<BR/>3 exp Character Disorder/<BR/>4 exp Compulsive Personality Disorder/<BR/>5 exp DELUSION/<BR/>6 exp Dependent Personality Disorder/<BR/>7 exp DEPERSONALIZATION/<BR/>8 exp JEALOUSY/<BR/>9 exp KLEPTOMANIA/<BR/>10 exp Multiple Personality/<BR/>11 exp NARCISSISM/<BR/>12 exp PSYCHOPATHY/<BR/>13 exp SCHIZOIDISM/<BR/>14 exp SOCIOPATHY/<BR/>15 (antisoci$ adj2 person$).tw.<BR/>16 (aggres$ adj2 person$).tw.<BR/>17 (border$ adj2 person$).tw.<BR/>18 histrion$ person$.tw.<BR/>19 paranoid person$.tw.<BR/>20 (passive adj2 aggressive).tw.<BR/>21 ((asocial$ or antisocial$ or dissocial$ or psychopath$ or sadist$ or sociopath$) adj person$).tw.<BR/>22 (moral adj2 insan$).tw.<BR/>23 dyssocial.tw.<BR/>24 (DSM and (Axis and II)).tw.<BR/>25 or/1-24<BR/>26 clin$.tw.<BR/>27 trial$.tw.<BR/>28 (clin$ adj3 trial$).tw.<BR/>29 singl$.tw.<BR/>30 doubl$.tw.<BR/>31 trebl$.tw.<BR/>32 tripl$.tw.<BR/>33 blind$.tw.<BR/>34 mask$.tw.<BR/>35 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.<BR/>36 randomi$.tw.<BR/>37 random$.tw.<BR/>38 allocat$.tw.<BR/>39 assign$.tw.<BR/>40 (random$ adj3 (allocat$ or assign$)).tw.<BR/>41 crossover.tw.<BR/>42 41 or 40 or 36 or 35 or 28<BR/>43 exp Randomized Controlled Trial/<BR/>44 exp Double Blind Procedure/<BR/>45 exp Crossover Procedure/<BR/>46 exp Single Blind Procedure/<BR/>47 exp RANDOMIZATION/<BR/>48 43 or 44 or 45 or 46 or 47 or 42<BR/>49 25 and 48</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2010-05-11 12:58:42 +0100" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2008-06-30 09:03:43 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-11 12:58:42 +0100" MODIFIED_BY="[Empty name]">
<P>We searched Medline 1966 to 11 September 2009 using the phrase:</P>
<P>1 exp Personality Disorders/<BR/>2 exp Antisocial Personality Disorder/<BR/>3 exp Borderline Personality Disorder/<BR/>4 exp Compulsive Personality Disorder/<BR/>5 exp Dependent Personality Disorder/<BR/>6 exp Histrionic Personality Disorder/<BR/>7 exp Hysteria/<BR/>8 exp Paranoid Personality Disorder/<BR/>9 exp Passive-Aggressive Personality Disorder/<BR/>10 exp Schizoid Personality Disorder/<BR/>11 exp Schizotypal Personality Disorder/<BR/>12 ((asocial$ or antisocial$ or dissocial$ or psychopath$ or sadist$ or sociopath$) adj2 person$).tw.<BR/>13 psychopath.tw.<BR/>14 sociopath$.tw.<BR/>15 (moral adj2 insanity).tw.<BR/>16 (DSM and (axis and II)).tw.<BR/>17 or/1-16<BR/>18 randomized controlled trial.pt.<BR/>19 controlled clinical trial.pt.<BR/>20 randomized controlled trials.sh.<BR/>21 random allocation.sh.<BR/>22 double blind method.sh.<BR/>23 single-blind method.sh.<BR/>24 or/18-23<BR/>25 (animal not human).sh.<BR/>26 24 not 25<BR/>27 clinical trial.pt.<BR/>28 exp clinical trials/<BR/>29 (clin$ adj25 trial$).ti,ab.<BR/>30 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>31 Placebos.sh.<BR/>32 placebo$.ti,ab.<BR/>33 random$.ti,ab.<BR/>34 research design.sh.<BR/>35 or/27-34<BR/>36 35 not 25<BR/>37 36 not 26<BR/>38 comparative study.sh.<BR/>39 exp evaluation studies/<BR/>40 follow up studies.sh.<BR/>41 prospective studies.sh.<BR/>42 (control$ or prospectiv$ or volunteer$).ti,ab.<BR/>43 or/38-42<BR/>44 43 not 25<BR/>45 44 not (26 or 37)<BR/>46 26 or 37 or 45<BR/>47 17 and 46</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2009-10-07 12:36:17 +0100" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2008-07-02 09:50:19 +0100" MODIFIED_BY="[Empty name]">NATIONAL CRIMINAL JUSTICE REFERENCE SERVICE ABSTRACTS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-10-07 12:36:17 +0100" MODIFIED_BY="[Empty name]">
<P>We searched NCJRS 1970 to July 2008 using the phrase:</P>
<P>(randomi* OR double blind) and (antisocial* OR asocial* OR avoidant OR borderline OR dependent OR depressive OR<BR/>dissocial OR dissocial* OR histrionic OR moral OR multiimpulsive OR multiple* OR narcissistic OR parano* OR passiveaggressive OR psychopath* OR sadis* OR schizotypal OR selfdefeating OR sociopath*)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-10" MODIFIED="2010-01-13 17:00:47 +0000" MODIFIED_BY="[Empty name]" NO="10">
<TITLE MODIFIED="2008-06-30 21:04:45 +0100" MODIFIED_BY="[Empty name]">PsycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-13 17:00:47 +0000" MODIFIED_BY="[Empty name]">
<P>We searched PsycINFO 1872 to 2nd week September 2009 using the phrase:</P>
<P>1 Personality Disorders/<BR/>2 exp Antisocial Personality Disorder/<BR/>3 exp Avoidant Personality Disorder/<BR/>4 exp Borderline Personality Disorder/<BR/>5 exp Dependent Personality Disorder/<BR/>6 exp Histrionic Personality Disorder/<BR/>7 exp Narcissistic Personality Disorder/<BR/>8 exp Obsessive Compulsive Personality Disorder/<BR/>9 exp Paranoid Personality Disorder/<BR/>10 exp Passive Aggressive Personality Disorder/<BR/>11 exp Sadomasochistic Personality/<BR/>12 exp Schizoid Personality Disorder/<BR/>13 exp Schizotypal Personality Disorder/<BR/>14 (personality adj disorders).tw.<BR/>15 (antisocial adj personality).tw.<BR/>16 (avoidant adj personality).tw.<BR/>17 (borderline adj personality).tw.<BR/>18 (dependent adj personality).tw.<BR/>19 (histrionic adj (personality and disorder)).tw.<BR/>20 (narcissistic adj personality).tw.<BR/>21 (obsessive adj (compulsive and personality)).tw.<BR/>22 (paranoid adj personality).tw.<BR/>23 (passive adj (aggressive and personality)).tw.<BR/>24 (sadomasochistic adj personality).tw.<BR/>25 (schizoid adj personality).tw.<BR/>26 (schizotypal adj personality).tw.<BR/>27 or/1-26<BR/>28 randomi$.tw.<BR/>29 singl$.tw.<BR/>30 doubl$.tw.<BR/>31 trebl$.tw.<BR/>32 tripl$.tw.<BR/>33 blind$.tw.<BR/>34 mask$.tw.<BR/>35 (or/29-32) adj3 (or/33-34)<BR/>36 clin$.tw.<BR/>37 trial$.tw.<BR/>38 (clin$ adj3 trial$).tw.<BR/>39 placebo$.tw.<BR/>40 exp PLACEBO/<BR/>41 crossover.tw.<BR/>42 exp Treatment Effectiveness Evaluation/<BR/>43 exp Mental Health Program Evaluation/<BR/>44 random$.tw.<BR/>45 assign$.tw.<BR/>46 allocate$.tw.<BR/>47 (random$ adj3 (assign$ or allocate$)).tw.<BR/>48 27 or 35 or 38 or 39 or 40 or 41 or 42 or 43 or 47<BR/>49 27 and 48</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-11" MODIFIED="2008-07-02 10:05:21 +0100" MODIFIED_BY="[Empty name]" NO="11">
<TITLE MODIFIED="2008-07-02 10:02:53 +0100" MODIFIED_BY="[Empty name]">SIGLE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-02 10:05:21 +0100" MODIFIED_BY="[Empty name]">
<P>We searched SIGLE 1980 to April 2006 using the phrase: </P>
<P>((randomisation) OR (randomised) OR (randomisee) OR (randomises) OR (randomize) OR (randomized) OR (randomly)<BR/>OR ((double AND blind) OR double-blind OR double* blind* OR randomi?ed controlled trials)) AND ((psychopath* OR sociopath* OR dissocial OR sadis* OR schizotypal OR selfdefeating OR borderline OR avoidant OR dependent OR depressive OR histrionic OR multi-impulsive OR multiple OR narcissistic OR passive-aggressive) AND (person*) OR <BR/>(antisocial AND behaviour) OR (personality AND disorder*) OR (gender AND identity) OR (parano* AND person*) OR<BR/>(self AND defeating) OR ((asocial* OR antisocial* OR dissocial* OR psychopath* OR sadist* OR sociopath*) AND person*) OR (moral AND insanity))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-12" MODIFIED="2010-01-13 17:00:47 +0000" MODIFIED_BY="[Empty name]" NO="12">
<TITLE MODIFIED="2008-06-30 21:07:29 +0100" MODIFIED_BY="[Empty name]">SOCIOLOGICAL ABSTRACTS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-13 17:00:47 +0000" MODIFIED_BY="[Empty name]">
<P>We searched SOCIOLOGICAL ABSTRACTS 1963 to September 2009 using the phrase:</P>
<P>((personality near disorder*) or ((antisocial* near disorder*) or (avoidant* near disorder*) or (bordeline* near disorder*)) or ((dependent* near disorder*) or (histrionic* near disorder*) or (narcissistic* near disorder*)) or ((obsessive* near disorder*) or (compulsive* near disorder*) or (paranoid* near disorder*)) or (((passive* near disorder*) or (aggress* near disorder*) or (sadomasochistic* near disorder*)) or (schizo* near disorder*)) or (((passive* and disorder*) or (aggress* and disorder*) or (sadomasochistic* and disorder*)) or ((schizo* and disorder*) or (paranoid* and disorder*) or (compulsive* and disorder*)) or ((obsessive* and disorder*) or (narcissistic and disorder*) or (histrionic* and disorder*))) or (((personality and disorder*) or (antisocial* and disorder*) or (avoidant* and disorder*)) or ((borderline* and disorder*)<BR/>or (dependent* and disorder*)))) and ((AB=randomi* or TI=randomi*) or (DE=(randomi?ed controlled trials) or AB=(double* blind*) or TI=(double* blind*)) or (DE=(double blind studies) or (single* near blind*)))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-13" MODIFIED="2010-01-13 17:00:47 +0000" MODIFIED_BY="[Empty name]" NO="13">
<TITLE MODIFIED="2008-07-01 14:54:48 +0100" MODIFIED_BY="[Empty name]">WEB OF SCIENCE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-13 17:00:47 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Web of Science 1981 to 12 September 2009 using the phrase:</P>
<P>(double blind OR randomi*) AND ((passive-aggressive OR psychopath* OR sociopath* OR dissocial OR sadis* OR schizotypal OR self-defeating OR borderline OR avoidant OR dependent OR depressive OR parano* OR asocial* OR antisocial* OR dissocial* OR psychopath* OR sadist* OR sociopath* OR histrionic OR multi-impulsive OR multiple* OR narcissistic) AND personality*) OR ((moral AND insanity) OR (self AND defeating) OR (gender AND identity) OR (personality AND disorder) OR (antisocial AND behaviour))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-14" MODIFIED="2010-05-12 15:07:10 +0100" MODIFIED_BY="Chris Champion" NO="14">
<TITLE MODIFIED="2010-05-12 15:07:10 +0100" MODIFIED_BY="Chris Champion">Summary of findings: haloperidol vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:32 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>Haloperidol for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> haloperidol</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect</B>
<BR/>
<B>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants</B>
<BR/>
<B>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Haloperidol</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B>
<BR/>Borderline Syndrome Index (BSI)<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity in the control groups was<BR/>
<B>20.08 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity in the intervention groups was<BR/>
<B>0.30 standard deviations higher</B>
<BR/>(0.22 lower to 0.82 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>58<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the control groups was<BR/>
<B>0 </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the intervention groups was<BR/>
<B>0.37 standard deviations lower</B>
<BR/>(0.74 lower to 0 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>114<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>Barrett Impulsiveness Scale (BIS)<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity ranged across control groups from<BR/>
<B>103.06 to 237.74 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the intervention groups was<BR/>
<B>0.07 standard deviations higher</B>
<BR/>(0.3 lower to 0.43 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>114<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>SCL-90-R-hostility. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger ranged across control groups from<BR/>
<B>0.97 to 1.05 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the intervention groups was<BR/>
<B>0.46 standard deviations lower</B>
<BR/>(0.84 to 0.09 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>114<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B>
<BR/>SCL-90-paranoid ideation. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms ranged across control groups from<BR/>
<B>0.98 to1.00 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the intervention groups was<BR/>
<B>0.44 standard deviations lower</B>
<BR/>(1.09 lower to 0.2 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>114<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>BDI. Scale from: 0 to 63.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression ranged across control groups from<BR/>
<B>13.04 to 14.88 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>0.09 standard deviations lower</B>
<BR/>(0.87 lower to 0.68 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>114<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B>
<BR/>SCL-90-R-anxiety. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety ranged across control groups from<BR/>
<B>1.00 to 1.07 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the intervention groups was<BR/>
<B>0.06 standard deviations higher</B>
<BR/>(0.68 lower to 0.79 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>114<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B>
<BR/>SCL-90-R global severity index. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology ranged across control groups from<BR/>
<B>0.84 to 0.87 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the intervention groups was<BR/>
<B>0.08 standard deviations lower</B>
<BR/>(0.71 lower to 0.54 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>114<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B>
<BR/>GAS. Scale from: 0 to 100.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status ranged across control groups from<BR/>
<B>48.16 to 58.43 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status in the intervention groups was<BR/>
<B>0.16 standard deviations higher</B>
<BR/>(0.77 lower to 1.08 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>114<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>111 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>128 per 1000</B>
<BR/>(50 to 324)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.15 </B>
<BR/>(0.45 to 2.92)</P>
</TD>
<TD VALIGN="TOP">
<P>130<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Final value in controls<BR/>
<SUP>2</SUP> Small sample size<BR/>
<SUP>3</SUP> Single study effect only, publication bias cannot be excluded<BR/>
<SUP>4</SUP> Two study effects only, publication bias cannot be excluded</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-15" MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]" NO="15">
<TITLE MODIFIED="2010-05-09 23:34:46 +0100" MODIFIED_BY="[Empty name]">Summary of 
findings
: thiothixene vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>Thiothixene for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> thiothixene</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect<BR/>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants<BR/>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence<BR/>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Thiothixene</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B>
<BR/>Schedule of Interviewing Schizotypal Personalities, borderline score<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity in the control groups was<BR/>
<B>4.1812 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity in the intervention groups was<BR/>
<B>0.28 standard deviations higher</B>
<BR/>(0.28 lower to 0.83 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>HSCL-90-interpersonal sensitivity. Scale from: 0 to 4.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the control groups was<BR/>
<B>0.6209 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the intervention groups was<BR/>
<B>0.18 standard deviations lower</B>
<BR/>(0.74 lower to 0.37 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>SCL-90-hostility. Scale from: 0 to 4.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the control groups was<BR/>
<B>0.6769 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the intervention groups was<BR/>
<B>0.07 standard deviations lower</B>
<BR/>(0.63 lower to 0.48 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B>
<BR/>Schedule of Interviewing Schizotypal Personalities (SIB)-suspicious/paranoid score<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the control groups was<BR/>
<B>1.8654 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the intervention groups was<BR/>
<B>0.19 standard deviations higher</B>
<BR/>(0.37 lower to 0.75 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>SCL-90-depression. Scale from: 0 to 4.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the control groups was<BR/>
<B>1.5065 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>0.12 standard deviations higher</B>
<BR/>(0.43 lower to 0.68 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B>
<BR/>GAS. Scale from: 0 to 100.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status in the control groups was<BR/>
<B>71.92 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status in the intervention groups was<BR/>
<B>0.06 standard deviations higher</B>
<BR/>(0.5 lower to 0.61 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>attrition<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>115 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>291 per 1000</B>
<BR/>(85 to 998)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 2.53 </B>
<BR/>(0.74 to 8.68)</P>
</TD>
<TD VALIGN="TOP">
<P>50<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>low</B>
<SUP>3,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Final value in controls<BR/>
<SUP>2</SUP> SMD calculated on basis of post mean and pre mean SD, might overestimate the treatment effect<BR/>
<SUP>3</SUP> Small sample size<BR/>
<SUP>4</SUP> Effect estimate had to be calculated by using the SD of the pre-treatment means. This may have led to an overestimation of effect sizes, as the pre-SDs are commonly smaller than post-SDs.<BR/>
<SUP>5</SUP> Single study effect only, publication bias cannot be excluded</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-16" MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]" NO="16">
<TITLE MODIFIED="2010-05-09 22:55:48 +0100" MODIFIED_BY="[Empty name]">Sum
m
ary of findings
: flupenthixol decanoate vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>Flupenthixol decanoate for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> flupenthixol decanoate</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect<BR/>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants<BR/>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence<BR/>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Flupenthixol decanoate</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B>
<BR/>suicidal act during treatment<BR/>Follow-up: mean 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>789 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>387 per 1000</B>
<BR/>(205 to 726)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.49 </B>
<BR/>(0.26 to 0.92)</P>
</TD>
<TD VALIGN="TOP">
<P>37<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: mean 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>158 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>223 per 1000</B>
<BR/>(57 to 858)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.41 </B>
<BR/>(0.36 to 5.43)</P>
</TD>
<TD VALIGN="TOP">
<P>37<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Small sample size<BR/>
<SUP>2</SUP> Single study effect only, publication bias cannot be excluded</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-17" MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]" NO="17">
<TITLE MODIFIED="2010-05-09 22:53:06 +0100" MODIFIED_BY="[Empty name]">Summary
 of findings
: aripiprazole vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>Aripiprazole for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> aripiprazole</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect<BR/>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants<BR/>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence<BR/>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Aripiprazole</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>SCL-90-R-interpersonal sensitivity<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the control groups was<BR/>
<B>64.2 points (Z-transformed score)</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the intervention groups was<BR/>
<B>0.77 standard deviations lower</B>
<BR/>(1.33 to 0.2 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>52<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>STAXI-anger out<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the control groups was<BR/>
<B>20.7 points (Z-transformed score)</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the intervention groups was<BR/>
<B>1.84 standard deviations lower</B>
<BR/>(2.49 to 1.18 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>52<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B>
<BR/>self-injury during treatment<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>269 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>78 per 1000</B>
<BR/>(19 to 336)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.29 </B>
<BR/>(0.07 to 1.25)</P>
</TD>
<TD VALIGN="TOP">
<P>52<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>SCL-90-R-hostility<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the control groups was<BR/>
<B>73.1 points (Z-transformed score)</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the intervention groups was<BR/>
<B>1.14 standard deviations lower</B>
<BR/>(1.73 to 0.55 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>52<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B>
<BR/>SCL-90-R-paranoid ideation<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the control groups was<BR/>
<B>68.3 points (Z-transformed score)</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the intervention groups was<BR/>
<B>1.05 standard deviations lower</B>
<BR/>(1.64 to 0.47 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>52<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>Ham-D. Scale from: 0 to 50.<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the control groups was<BR/>
<B>18.8 points </B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>1.25 standard deviations lower</B>
<BR/>(1.85 to 0.65 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>52<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B>
<BR/>HARS. Scale from: 0 to 56.<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the control groups was<BR/>
<B>19.5 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the intervention groups was<BR/>
<B>0.73 standard deviations lower</B>
<BR/>(1.29 to 0.17 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>52<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B>
<BR/>SCL-90-R-global severity index<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the control groups was<BR/>
<B>69.4 points (Z-transformed score)</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the intervention groups was<BR/>
<B>1.27 standard deviations lower</B>
<BR/>(1.87 to 0.67 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>52<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B> - not reported</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Final value in controls<BR/>
<SUP>2</SUP> Small sample size<BR/>
<SUP>3</SUP> Single study effect only, publication bias cannot be excluded</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-18" MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]" NO="18">
<TITLE MODIFIED="2010-05-09 22:55:23 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: olanzapine vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="34">
<TR>
<TD COLSPAN="7">
<P>
<B>olanzapine compared to for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> olanzapine<BR/>
<B>Comparison: </B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect</B>
<BR/>
<B>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants</B>
<BR/>
<B>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Olanzapine</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B>
<BR/>Zan-BPD-total score. Scale from: 0 to 36.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity ranged across control groups from<BR/>
<B>-6.19 to -6.69 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity in the intervention groups was<BR/>
<B>0.15 standard deviations lower</B>
<BR/>(0.41 lower to 0.1 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>596<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>The mean avoidance of abandonment in the intervention groups was<BR/>
<B>0.01 standard deviations lower</B>
<BR/>(0.22 lower to 0.21 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>631<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems I</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems I in the intervention groups was<BR/>
<B>0.10 standard deviations lower</B>
<BR/>(0.31 lower to 0.12 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>340<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems II</B>
<BR/>Zan-BPD-unstable interpersonal relationships. Scale from: 0 to 4.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>See comment<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>291<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mean baseline change difference between groups was -0.2 (greater change in controls, 95% CI -0.31 to 0.12)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>The mean identity disturbance in the intervention groups was<BR/>
<B>0.06 standard deviations lower</B>
<BR/>(0.21 lower to 0.1 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>631<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity I</B>
<BR/>behavioural reports of numbers of episodes of impulsivity/aggressive behaviour<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity I in the control groups was<BR/>
<B>6.12 points</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity I in the intervention groups was<BR/>
<B>0.04 standard deviations lower</B>
<BR/>(0.54 lower to 0.47 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity II</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>340<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mean baseline change difference between groups was -0.18 (95% CI -0.40 to 0.03)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity III</B>
<BR/>Zan-BPD-impulsivity that are self-damaging. Scale from: 0 to 4.<BR/>Follow-up: median 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>See comment<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>291<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mean baseline change difference between groups was -0.10 (95% CI -0.40 to 0.20)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation I</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>The mean suicidal ideation I in the intervention groups was<BR/>
<B>0.29 standard deviations higher</B>
<BR/>(0.07 to 0.5 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>340<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation II</B>
<BR/>high suicidality according to OAS-M<BR/>Follow-up: mean 21 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>417 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>500 per 1000</B>
<BR/>(209 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.20 </B>
<BR/>(0.5 to 2.88)</P>
</TD>
<TD VALIGN="TOP">
<P>24<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour I</B>
<BR/>behavioural reports of numbers of episodes of self-injuring behaviour/suicide attempts<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean suicidal behaviour i in the control groups was<BR/>
<B>0.88 points</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean suicidal behaviour I in the intervention groups was<BR/>
<B>0.15 standard deviations higher</B>
<BR/>(0.36 lower to 0.65 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour II</B>
<BR/>Zan-BPD-suicidal or self-mutilating behaviour. Scale from: 0 to 4.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>See comment<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>291<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mean baseline change difference between groups was -0.2 (95% CI -0.20 to 0.00)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour III</B>
<BR/>high suicidality according to OAS-M<BR/>Follow-up: mean 21 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>417 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>500 per 1000</B>
<BR/>(209 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.20 </B>
<BR/>(0.5 to 2.88)</P>
</TD>
<TD VALIGN="TOP">
<P>24<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>The mean affective instability in the intervention groups was<BR/>
<B>0.16 standard deviations lower</B>
<BR/>(0.32 to 0.01 lower)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>631<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>The mean chronic feelings of emptiness in the intervention groups was<BR/>
<B>0.03 standard deviations lower</B>
<BR/>(0.22 lower to 0.16 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>631<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the intervention groups was<BR/>
<B>0.27 standard deviations lower</B>
<BR/>(0.43 to 0.12 lower)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>631<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the intervention groups was<BR/>
<B>0.18 standard deviations lower</B>
<BR/>(0.34 to 0.03 lower)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>631<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression I</B>
<BR/>Ham-D. Scale from: 0 to 50.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression I ranged across control groups from<BR/>
<B>15.4 to 15.8 points</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression I in the intervention groups was<BR/>
<B>0.37 standard deviations lower</B>
<BR/>(0.8 lower to 0.07 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>84<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression II</B>
<BR/>MADRS. Scale from: 0 to 60.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>See comment<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>596<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mean baseline change difference was 0.39 (95% CI -0.20 to 0.97)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety I</B>
<BR/>HARS. Scale from: 0 to 56.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety I in the control groups was<BR/>
<B>19.93 points</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety I in the intervention groups was<BR/>
<B>0.23 standard deviations lower</B>
<BR/>(0.74 lower to 0.28 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety II</B>
<BR/>SCL-90-R-anxiety. Scale from: 0 to 4.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>See comment<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>274<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mean baseline change difference was -0.22 (95% CI -0.41 to -0.03)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B>
<BR/>SCL-90-R-global severity index. Scale from: 0 to 4.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology ranged across control groups from<BR/>
<B>-0.53 to -0.56 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the intervention groups was<BR/>
<B>0.21 standard deviations lower</B>
<BR/>(0.53 lower to 0.1 higher)<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>557<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status I</B>
<BR/>CGI-S. Scale from: 0 to 7.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status I in the control groups was<BR/>
<B>3.97 points</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status I in the intervention groups was<BR/>
<B>0.03 standard deviations lower</B>
<BR/>(0.53 lower to 0.48 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status II</B>
<BR/>GAF. Scale from: 0 to 100.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>See comment<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>596<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mean baseline change difference was 1.52 (95% CI -0.75 to 3.79)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: mean 16 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>389 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>377 per 1000</B>
<BR/>(280 to 502)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.97 </B>
<BR/>(0.72 to 1.29)</P>
</TD>
<TD VALIGN="TOP">
<P>767<BR/>(6 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Change value in controls<BR/>
<SUP>2</SUP> SMD on basis of change scores<BR/>
<SUP>3</SUP> Small sample size<BR/>
<SUP>4</SUP> Final value in controls</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-19" MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]" NO="19">
<TITLE MODIFIED="2010-05-09 22:59:32 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: ziprasidone vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>Ziprasidone for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> ziprasidone</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect<BR/>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants<BR/>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence<BR/>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Ziprasidone</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B>
<BR/>Clinical Global Impression scale for use in borderline patients-global. Scale from: 1 to 7.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity in the control groups was<BR/>
<B>4.3 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity in the intervention groups was<BR/>
<B>0.47 standard deviations lower</B>
<BR/>(0.98 lower to 0.05 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B>
<BR/>CGI-BPD-abandonment. Scale from: 1 to 7.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean avoidance of abandonment in the control groups was<BR/>
<B>4.53 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean avoidance of abandonment in the intervention groups was<BR/>
<B>0.08 standard deviations lower</B>
<BR/>(0.58 lower to 0.43 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>CGI-BPD-unstable relationships. Scale from: 1 to 7.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the control groups was<BR/>
<B>4.5 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the intervention groups was<BR/>
<B>0.12 standard deviations lower</B>
<BR/>(0.63 lower to 0.38 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B>
<BR/>CGI-BPD-identity disturbance. Scale from: 1 to 7.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean identity disturbance in the control groups was<BR/>
<B>5.03 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean identity disturbance in the intervention groups was<BR/>
<B>0.38 standard deviations lower</B>
<BR/>(0.9 lower to 0.13 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>CGI-BPD-impulsivity. Scale from: 1 to 7.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the control groups was<BR/>
<B>3.96 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the intervention groups was<BR/>
<B>0.03 standard deviations higher</B>
<BR/>(0.48 lower to 0.53 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B>
<BR/>CGI-BPD-recurrent suicidal ideation. Scale from: 1 to 7.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean suicidal ideation in the control groups was<BR/>
<B>3.13 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean suicidal ideation in the intervention groups was<BR/>
<B>0.27 standard deviations lower</B>
<BR/>(0.78 lower to 0.23 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
<BR/>CGI-BPD-affective instability. Scale from: 1 to 7.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean affective instability in the control groups was<BR/>
<B>30 30</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean affective instability in the intervention groups was<BR/>
<B>0.10 standard deviations lower</B>
<BR/>(0.61 lower to 0.41 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B>
<BR/>CGI-BPD-chronic feelings of emptiness. Scale from: 1 to 7.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean chronic feelings of emptiness in the control groups was<BR/>
<B>4.4 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean chronic feelings of emptiness in the intervention groups was<BR/>
<B>0.18 standard deviations higher</B>
<BR/>(0.32 lower to 0.69 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>CGI-BPD-inappropriate anger. Scale from: 1 to 7.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the control groups was<BR/>
<B>3.56 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the intervention groups was<BR/>
<B>0.08 standard deviations higher</B>
<BR/>(0.43 lower to 0.58 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B>
<BR/>CGI-BPD-transient paranoia or dissociation. Scale from: 1 to 7.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the control groups was<BR/>
<B>2.23 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the intervention groups was<BR/>
<B>0.23 standard deviations lower</B>
<BR/>(0.74 lower to 0.28 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>Ham-D. Scale from: 0 to 50.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the control groups was<BR/>
<B>16.07 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>0.30 standard deviations lower</B>
<BR/>(0.81 lower to 0.21 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B>
<BR/>HARS. Scale from: 0 to 56.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the control groups was<BR/>
<B>16.53 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the intervention groups was<BR/>
<B>0.12 standard deviations lower</B>
<BR/>(0.63 lower to 0.39 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B>
<BR/>SCL-90-R-GSI. Scale from: 0 to 4.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the control groups was<BR/>
<B>2.39 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the intervention groups was<BR/>
<B>0.41 standard deviations lower</B>
<BR/>(0.92 lower to 0.1 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>467 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>565 per 1000</B>
<BR/>(346 to 929)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.21 </B>
<BR/>(0.74 to 1.99)</P>
</TD>
<TD VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Final value in controls<BR/>
<SUP>2</SUP> Very high attrition (&gt;50%), unclear how participants were selected from eligible patients<BR/>
<SUP>3</SUP> Small sample size<BR/>
<SUP>4</SUP> Single study effect only, publication bias cannot be excluded</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-20" MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]" NO="20">
<TITLE MODIFIED="2010-05-09 23:02:26 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: carbamazepine vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>Carbamazepine for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> carbamazepine</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect<BR/>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants<BR/>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence<BR/>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Carbamazepine</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>SCL-90-interpersonal sensitivity. Scale from: 0 to 4.<BR/>Follow-up: mean 32 days</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the control groups was<BR/>
<B>11.0 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the intervention groups was<BR/>
<B>0.54 standard deviations lower</B>
<BR/>(1.46 lower to 0.38 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>status quo or worsened after treatment according to Acting out scale<BR/>Follow-up: mean 32 days</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>800 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>704 per 1000</B>
<BR/>(424 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.88 </B>
<BR/>(0.53 to 1.46)</P>
</TD>
<TD VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>SCL-90-hostility<BR/>Follow-up: mean 32 days</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the control groups was<BR/>
<B>8.33 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the intervention groups was<BR/>
<B>0.34 standard deviations lower</B>
<BR/>(1.25 lower to 0.57 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B>
<BR/>SCL-90-paranoid ideation<BR/>Follow-up: mean 32 days</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the control groups was<BR/>
<B>9.22 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the intervention groups was<BR/>
<B>0.58 standard deviations lower</B>
<BR/>(1.5 lower to 0.35 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>SCL-90-depression<BR/>Follow-up: mean 32 days</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the control groups was<BR/>
<B>22.6 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>0.66 standard deviations lower</B>
<BR/>(1.59 lower to 0.27 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B>
<BR/>SCL-90-anxiety<BR/>Follow-up: mean 32 days</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the control groups was<BR/>
<B>17.44 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the intervention groups was<BR/>
<B>0.51 standard deviations lower</B>
<BR/>(1.43 lower to 0.41 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B>
<BR/>SCL-90-GSI<BR/>Follow-up: mean 32 days</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the control groups was<BR/>
<B>125.11 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the intervention groups was<BR/>
<B>0.57 standard deviations lower</B>
<BR/>(1.49 lower to 0.36 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B>
<BR/>GAS. Scale from: 0 to 100.<BR/>Follow-up: mean 32 days</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status in the control groups was<BR/>
<B>60.1 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status in the intervention groups was<BR/>
<B>0.34 standard deviations higher</B>
<BR/>(0.57 lower to 1.25 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>19<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: mean 32 days</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 5 </B>
<BR/>(0.27 to 92.62)</P>
</TD>
<TD VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Final value in controls<BR/>
<SUP>2</SUP> Small sample size<BR/>
<SUP>3</SUP> Single study effect only, publication bias cannot be excluded</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-21" MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]" NO="21">
<TITLE MODIFIED="2010-05-09 23:05:39 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: valproate semisodium vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="27">
<TR>
<TD COLSPAN="7">
<P>
<B>Valproate semisodium for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> valproate semisodium</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect<BR/>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants<BR/>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence<BR/>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Valproate semisodium</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>SCL-90-R-interpersonal sensitivity. Scale from: 0 to 4.<BR/>Follow-up: mean 24 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the control groups was<BR/>
<B>2.2 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the intervention groups was<BR/>
<B>1.04 standard deviations lower</B>
<BR/>(1.85 to 0.23 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: 10 to 24 weeks</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the intervention groups was<BR/>
<B>0.62 standard deviations lower</B>
<BR/>(1.48 lower to 0.24 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>46<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B>
<BR/>Overt Aggression Scale-Modified (OAS-M)-suicidality<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean suicidal ideation in the control groups was<BR/>
<B>0.3 points</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean suicidal ideation in the intervention groups was<BR/>
<B>0.52 standard deviations higher</B>
<BR/>(0.63 lower to 1.67 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>16<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger I</B>
<BR/>OAS-M-irritability. Scale from: 0 to 10.<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>16<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger II</B>
<BR/>SCL-90-R-hostility. Scale from: 0 to 4.<BR/>Follow-up: mean 24 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: 10 to 24 weeks</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>0.66 standard deviations lower</B>
<BR/>(1.31 to 0.01 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>46<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B>
<BR/>CGI-I score of 3 or more (i.e. minimally improved to very much worse)<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>1000 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>640 per 1000</B>
<BR/>(370 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.64 </B>
<BR/>(0.37 to 1.11)</P>
</TD>
<TD VALIGN="TOP">
<P>16<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: 10 to 24 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>714 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>557 per 1000</B>
<BR/>(286 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.78 </B>
<BR/>(0.4 to 1.53)</P>
</TD>
<TD VALIGN="TOP">
<P>46<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Final value in controls<BR/>
<SUP>2</SUP> Small sample size<BR/>
<SUP>3</SUP> Single study effect only, publication bias cannot be excluded<BR/>
<SUP>4</SUP> Two study effects only, publication bias cannot be excluded<BR/>
<SUP>5</SUP> Unclear how study participants were chosen out of eligible patients; very high attrition rate (&gt; 50%)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-22" MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]" NO="22">
<TITLE MODIFIED="2010-05-09 23:08:46 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: lamotrigine vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="27">
<TR>
<TD COLSPAN="7">
<P>
<B>Lamotrigine for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> lamotrigine</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect<BR/>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants<BR/>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence<BR/>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Lamotrigine</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B>
<BR/>Zan-BPD-total score. Scale from: 0 to 36.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity in the control groups was<BR/>
<B>-6.6 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity in the intervention groups was<BR/>
<B>0.43 standard deviations lower</B>
<BR/>(1.2 lower to 0.34 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>27<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity I</B>
<BR/>STAXI-anger out. Scale from: 8 to 32.<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity I in the control groups was<BR/>
<B>23.2 points</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity I in the intervention groups was<BR/>
<B>1.62 standard deviations lower</B>
<BR/>(2.54 to 0.69 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>27<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity II</B>
<BR/>Zan-BPD-impulsivity that are self-damaging. Scale from: 0 to 4.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity II in the control groups was<BR/>
<B>-0.1 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity II in the intervention groups was<BR/>
<B>1.41 standard deviations lower</B>
<BR/>(2.27 to 0.55 lower)<SUP>5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>27<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
<BR/>Zan-BPD-affective instability. Scale from: 0 to 4.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean affective instability in the control groups was<BR/>
<B>-0.8 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean affective instability in the intervention groups was<BR/>
<B>0.61 standard deviations lower</B>
<BR/>(1.39 lower to 0.17 higher)<SUP>5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>27<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>STAXI-trait anger. Scale from: 10 to 40.<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the control groups was<BR/>
<B>27.9 points</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the intervention groups was<BR/>
<B>1.69 standard deviations lower</B>
<BR/>(2.62 to 0.75 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>27<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: 8 to 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>333 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>246 per 1000</B>
<BR/>(73 to 826)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.74 </B>
<BR/>(0.22 to 2.48)</P>
</TD>
<TD VALIGN="TOP">
<P>54<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,6</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Change score in controls<BR/>
<SUP>2</SUP> Small sample size<BR/>
<SUP>3</SUP> Single study effect only, publication bias cannot be excluded<BR/>
<SUP>4</SUP> Final value in controls<BR/>
<SUP>5</SUP> SMD on basis of change scores<BR/>
<SUP>6</SUP> Two study effects only, publication bias cannot be excluded</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-23" MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]" NO="23">
<TITLE MODIFIED="2010-05-09 23:14:52 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: topiramate vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="27">
<TR>
<TD COLSPAN="7">
<P>
<B>Topiramate for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> topiramate</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect</B>
<BR/>
<B>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants</B>
<BR/>
<B>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Topiramate</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>SCL-90-R-interpersonal sensitivity<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the control groups was<BR/>
<B>66.9 points (Z-transformed score)</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the intervention groups was<BR/>
<B>0.91 standard deviations lower</B>
<BR/>(1.46 to 0.35 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>56<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>STAXI-anger-out<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity ranged across control groups from<BR/>
<B>22.6 to 24.8 points (Z-transformed scores)</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the intervention groups was<BR/>
<B>3.36 standard deviations lower</B>
<BR/>(4.44 to 2.27 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>71<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger I</B>
<BR/>outcome was measured on different scales in different studies<BR/>Follow-up: 8 to 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger I in the intervention groups was<BR/>
<B>3.00 standard deviations lower</B>
<BR/>(3.64 to 2.36 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>85<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger II</B>
<BR/>STAXI-trait anger. Scale from: 10 to 40.<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger II in the control groups was<BR/>
<B>27.6 points</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger II in the intervention groups was<BR/>
<B>0.65 standard deviations lower</B>
<BR/>(1.27 to 0.03 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>42<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B>
<BR/>SCL-90-R-paranoid ideation<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the control groups was<BR/>
<B>71.1 points (Z-transformed score)</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the intervention groups was<BR/>
<B>0.49 standard deviations lower</B>
<BR/>(1.02 lower to 0.05 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>56<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>SCL-90-R-depression<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the control groups was<BR/>
<B>72.7 points (Z-transformed)</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>0.51 standard deviations lower</B>
<BR/>(1.04 lower to 0.02 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>56<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B>
<BR/>SCL-90-R-anxiety<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the control groups was<BR/>
<B>69.8 points (Z-transformed score)</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the intervention groups was<BR/>
<B>1.40 standard deviations lower</B>
<BR/>(1.99 to 0.81 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>56<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B>
<BR/>SCL-90-R-global severity index<BR/>Follow-up: mean 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the control groups was<BR/>
<B>70.1 points (Z-transformed score)</B>
<SUP>4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the intervention groups was<BR/>
<B>1.19 standard deviations lower</B>
<BR/>(1.76 to 0.61 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>56<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: 8 to 10 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>98 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>54 per 1000</B>
<BR/>(14 to 212)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.55 </B>
<BR/>(0.14 to 2.16)</P>
</TD>
<TD VALIGN="TOP">
<P>133<BR/>(3 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Two study effects only, publication bias cannot be excluded<BR/>
<SUP>2</SUP> Small sample size<BR/>
<SUP>3</SUP> Single study effect only, publication bias cannot be excluded<BR/>
<SUP>4</SUP> Final value in controls</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-24" MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]" NO="24">
<TITLE MODIFIED="2010-05-09 23:17:59 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: amitriptyline vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:33 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>Amitriptyline for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> amitriptyline</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect</B>
<BR/>
<B>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants</B>
<BR/>
<B>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Amitriptyline</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>SCL-90-interpersonal sensitivity. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the control groups was<BR/>
<B>1.74 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the intervention groups was<BR/>
<B>0.39 standard deviations lower</B>
<BR/>(0.92 lower to 0.13 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>Barratt Impulsiveness Scale. Scale from: 30 to 120.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the control groups was<BR/>
<B>103.06 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the intervention groups was<BR/>
<B>0.12 standard deviations lower</B>
<BR/>(0.64 lower to 0.4 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>SCL-90-hostility. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the control groups was<BR/>
<B>1.39 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the intervention groups was<BR/>
<B>0.26 standard deviations lower</B>
<BR/>(0.78 lower to 0.26 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B>
<BR/>SCL-90-paranoid ideation. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the control groups was<BR/>
<B>1.44 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the intervention groups was<BR/>
<B>0.43 standard deviations lower</B>
<BR/>(0.96 lower to 0.09 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>BDI. Scale from: 0 to 63.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the control groups was<BR/>
<B>23.04 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>0.59 standard deviations lower</B>
<BR/>(1.12 to 0.06 lower)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B>
<BR/>SCL-90-anxiety. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the control groups was<BR/>
<B>1.54 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the intervention groups was<BR/>
<B>0.15 standard deviations lower</B>
<BR/>(0.67 lower to 0.37 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B>
<BR/>SCL-90-global severity index. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the control groups was<BR/>
<B>1.35 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the intervention groups was<BR/>
<B>0.34 standard deviations lower</B>
<BR/>(0.87 lower to 0.18 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B>
<BR/>GAS. Scale from: 0 to 100.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status in the control groups was<BR/>
<B>48.16 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status in the intervention groups was<BR/>
<B>0.27 standard deviations higher</B>
<BR/>(0.25 lower to 0.79 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>57<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>34 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>33 per 1000</B>
<BR/>(2 to 501)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.97 </B>
<BR/>(0.06 to 14.74)</P>
</TD>
<TD VALIGN="TOP">
<P>59<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Final value in controls<BR/>
<SUP>2</SUP> Small sample size<BR/>
<SUP>3</SUP> Single study effect only, publication bias cannot be excluded</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-25" MODIFIED="2010-05-12 12:02:34 +0100" MODIFIED_BY="[Empty name]" NO="25">
<TITLE MODIFIED="2010-05-09 23:20:51 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: fluoxetine vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:34 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluoxetine for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> fluoxetine</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect<BR/>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants<BR/>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence<BR/>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Fluoxetine</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>OAS-M-aggression<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the control groups was<BR/>
<B>7.45 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the intervention groups was<BR/>
<B>0.59 standard deviations lower</B>
<BR/>(1.5 lower to 0.31 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B>
<BR/>OAS-M-suicidality<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean suicidal ideation in the control groups was<BR/>
<B>1 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean suicidal ideation in the intervention groups was<BR/>
<B>0.44 standard deviations higher</B>
<BR/>(0.46 lower to 1.33 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B>
<BR/>OAS-M-autoagrression<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean self-mutilating behaviour in the control groups was<BR/>
<B>6.55 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean self-mutilating behaviour in the intervention groups was<BR/>
<B>0.03 standard deviations higher</B>
<BR/>(0.85 lower to 0.92 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>Profile of Mood States (POMS)-anger<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the control groups was<BR/>
<B>44.89 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the intervention groups was<BR/>
<B>0.65 standard deviations lower</B>
<BR/>(1.53 lower to 0.22 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>22<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B>
<BR/>dissociative experiences scales<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean dissociation in the control groups was<BR/>
<B>12.66 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean dissociation in the intervention groups was<BR/>
<B>0.42 standard deviations higher</B>
<BR/>(0.47 lower to 1.32 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>BDI. Scale from: 0 to 63.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression ranged across control groups from<BR/>
<B>6 to 13.91 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>0.12 standard deviations higher</B>
<BR/>(1.13 lower to 1.36 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>42<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B>
<BR/>STAI-trait<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the control groups was<BR/>
<B>96.18 points</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the intervention groups was<BR/>
<B>0.15 standard deviations higher</B>
<BR/>(0.73 lower to 1.03 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B>
<BR/>GAS/GAF. Scale from: 0 to 100.<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status ranged across control groups from<BR/>
<B>59.3 to 82.6 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status in the intervention groups was<BR/>
<B>0.40 standard deviations higher</B>
<BR/>(0.27 lower to 1.07 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>42<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>3,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>154 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>251 per 1000</B>
<BR/>(51 to 1000)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.63 </B>
<BR/>(0.33 to 8.11)</P>
</TD>
<TD VALIGN="TOP">
<P>25<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Final value in controls<BR/>
<SUP>2</SUP> High overall attrition rate (20%), analysis refers to completers only<BR/>
<SUP>3</SUP> Small sample size<BR/>
<SUP>4</SUP> Single study effect only, publication bias cannot be excluded<BR/>
<SUP>5</SUP> Effect based on a two study estimates only</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-26" MODIFIED="2010-05-12 12:02:34 +0100" MODIFIED_BY="[Empty name]" NO="26">
<TITLE MODIFIED="2010-05-09 23:23:15 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: fluvoxamine vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:34 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>Fluvoxamine for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> fluvoxamine</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect<BR/>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants<BR/>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence<BR/>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Fluvoxamine</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>Borderline Personality Disorder Severity Index-impulsivity<BR/>Follow-up: 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the control groups was<BR/>
<B>0.73 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the intervention groups was<BR/>
<B>0.05 standard deviations lower</B>
<BR/>(0.68 lower to 0.59 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>38<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B>
<BR/>BPDSI-rapid mood shifts<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean affective instability in the control groups was<BR/>
<B>5.83 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean affective instability in the intervention groups was<BR/>
<B>0.64 standard deviations lower</B>
<BR/>(1.3 lower to 0.01 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>38<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>BPDSI-anger<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the control groups was<BR/>
<B>2.49 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the intervention groups was<BR/>
<B>0.37 standard deviations lower</B>
<BR/>(1.01 lower to 0.28 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>38<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: mean 6 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>111 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>50 per 1000</B>
<BR/>(4 to 505)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.45 </B>
<BR/>(0.04 to 4.55)</P>
</TD>
<TD VALIGN="TOP">
<P>38<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Final value in controls<BR/>
<SUP>2</SUP> Small sample size<BR/>
<SUP>3</SUP> Single study effect only, publication bias cannot be excluded</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-27" MODIFIED="2010-05-12 12:02:34 +0100" MODIFIED_BY="[Empty name]" NO="27">
<TITLE MODIFIED="2010-05-09 23:25:58 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: phenelzine sulfate vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:34 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>Phenelzine sulfate for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> phenelzine sulfate</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect</B>
<BR/>
<B>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants</B>
<BR/>
<B>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Phenelzine sulfate</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B>
<BR/>Borderline Syndrome Index<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity in the control groups was<BR/>
<B>20.08 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean BPD severity in the intervention groups was<BR/>
<B>0.15 standard deviations lower</B>
<BR/>(0.65 lower to 0.35 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>62<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B>
<BR/>Atypical Depression Inventory (ADDS)-rejection sensitivity<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the control groups was<BR/>
<B>0.73 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean interpersonal problems in the intervention groups was<BR/>
<B>0.24 standard deviations higher</B>
<BR/>(0.26 lower to 0.74 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>62<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>Barrett Impulsiveness Scale (BIS)<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the control groups was<BR/>
<B>237.74 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the intervention groups was<BR/>
<B>0.00 standard deviations lower</B>
<BR/>(0.5 lower to 0.5 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>62<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B>
<BR/>SCL-90-hostility. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the control groups was<BR/>
<B>1.04 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anger in the intervention groups was<BR/>
<B>0.34 standard deviations lower</B>
<BR/>(0.84 lower to 0.17 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>62<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B>
<BR/>SCL-90-paranoid ideation. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the control groups was<BR/>
<B>1.18 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean psychotic symptoms in the intervention groups was<BR/>
<B>0.28 standard deviations lower</B>
<BR/>(0.78 lower to 0.22 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>62<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>BDI. Scale from: 0 to 63.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the control groups was<BR/>
<B>19.54 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>0.34 standard deviations lower</B>
<BR/>(0.84 lower to 0.16 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>62<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B>
<BR/>SCL-90-anxiety. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the control groups was<BR/>
<B>1.18 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean anxiety in the intervention groups was<BR/>
<B>0.14 standard deviations lower</B>
<BR/>(0.65 lower to 0.36 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>62<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B>
<BR/>SCL-90-global severity index. Scale from: 0 to 4.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the control groups was<BR/>
<B>1.16 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean general psychiatric pathology in the intervention groups was<BR/>
<B>0.23 standard deviations lower</B>
<BR/>(0.73 lower to 0.27 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>62<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B>
<BR/>GAS. Scale from: 0 to 100.<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status in the control groups was<BR/>
<B>58.43 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean mental health status in the intervention groups was<BR/>
<B>0.14 standard deviations higher</B>
<BR/>(0.36 lower to 0.64 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>62<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>176 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>106 per 1000</B>
<BR/>(32 to 341)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.60 </B>
<BR/>(0.18 to 1.94)</P>
</TD>
<TD VALIGN="TOP">
<P>72<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Final value in controls<BR/>
<SUP>2</SUP> Small sample size<BR/>
<SUP>3</SUP> Single study effect only, publication bias cannot be excluded</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-28" MODIFIED="2010-05-12 12:02:34 +0100" MODIFIED_BY="[Empty name]" NO="28">
<TITLE MODIFIED="2010-05-09 23:28:37 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: mianserin vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:34 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="26">
<TR>
<TD COLSPAN="7">
<P>
<B>Mianserin for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> mianserin</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect<BR/>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants<BR/>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence<BR/>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Mianserin</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B>
<BR/>self-harm during treatment<BR/>Follow-up: mean 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>690 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>690 per 1000</B>
<BR/>(490 to 973)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.00 </B>
<BR/>(0.71 to 1.41)</P>
</TD>
<TD VALIGN="TOP">
<P>58<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: mean 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>276 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>414 per 1000</B>
<BR/>(199 to 861)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.50 </B>
<BR/>(0.72 to 3.12)</P>
</TD>
<TD VALIGN="TOP">
<P>58<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Small sample size<BR/>
<SUP>2</SUP> Single study effect only, publication bias cannot be excluded</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-29" MODIFIED="2010-05-12 12:02:34 +0100" MODIFIED_BY="[Empty name]" NO="29">
<TITLE MODIFIED="2010-05-09 23:30:43 +0100" MODIFIED_BY="[Empty name]">Summary of findings
: omega-3 fatty acids vs. placebo</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-12 12:02:34 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="27">
<TR>
<TD COLSPAN="7">
<P>
<B>Omega-3 fatty acids for borderline personality disorder</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with borderline personality disorder<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> omega-3 fatty acids</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Illustrative comparative risks* (95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Relative effect<BR/>(95% CI)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>No of Participants<BR/>(studies)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Quality of the evidence<BR/>(GRADE)</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Assumed risk</P>
</TD>
<TD VALIGN="TOP">
<P>Corresponding risk</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Omega-3 fatty acids</B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BPD severity</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Avoidance of abandonment</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interpersonal problems</B> - not reported</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Identity disturbance</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Impulsivity</B>
<BR/>Modified Overt Aggresion Scale (MOAS), total<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the control groups was<BR/>
<B>12.9 final value in controls</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean impulsivity in the intervention groups was<BR/>
<B>0.47 standard deviations lower</B>
<BR/>(1.28 lower to 0.34 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>27<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidal ideation</B>
<BR/>OAS-M-suicidality subscale score of 1 or higher (at least slight suicidal tendencies)<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>704 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>366 per 1000</B>
<BR/>(197 to 669)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.52 </B>
<BR/>(0.28 to 0.95)</P>
</TD>
<TD VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Suicidial behaviour</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Self-mutilating behaviour</B>
<BR/>self-harm during treatment<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>259 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>319 per 1000</B>
<BR/>(132 to 769)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 1.23 </B>
<BR/>(0.51 to 2.97)</P>
</TD>
<TD VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Affective instability</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Chronic feelings of emptiness</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anger</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Psychotic symptoms</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Dissociation</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>no remission (i.e. at least 50% reduction of depressive pathology as ass BDI)<BR/>Follow-up: mean 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>852 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>409 per 1000</B>
<BR/>(239 to 690)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.48 </B>
<BR/>(0.28 to 0.81)</P>
</TD>
<TD VALIGN="TOP">
<P>49<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Depression</B>
<BR/>MADRS. Scale from: 0 to 60.<BR/>Follow-up: mean 8 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the control groups was<BR/>
<B>8 points</B>
<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean depression in the intervention groups was<BR/>
<B>0.34 standard deviations lower</B>
<BR/>(1.15 lower to 0.46 higher)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>27<BR/>(1 study)</P>
</TD>
<TD VALIGN="TOP">
<P>+OOO<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Anxiety</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>General psychiatric pathology</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mental health status</B> - not measured</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not measured</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Attrition</B>
<BR/>lost after randomisation<BR/>Follow-up: 8 to 12 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>216 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>132 per 1000</B>
<BR/>(45 to 387)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.61 </B>
<BR/>(0.21 to 1.79)</P>
</TD>
<TD VALIGN="TOP">
<P>79<BR/>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>++OO<BR/>
<B>low</B>
<SUP>2,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<SUP>1</SUP> Final value in controls<BR/>
<SUP>2</SUP> Small sample size<BR/>
<SUP>3</SUP> Single study effect only, publication bias cannot be excluded<BR/>
<SUP>4</SUP> Concomitant psychotropic treatment was allowed without any restrictions and could be changed anytime<BR/>
<SUP>5</SUP> Findings based on two study estimates only</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>